{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-001","record":{"id":"src-001","title":"SEC EDGAR submissions record for Chrome Holding Co. (CIK 0001804591)","url":"https://data.sec.gov/submissions/CIK0001804591.json","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"","locator":"Registrant metadata, former names and filing index","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"corporate_registry","publisher_type":"regulator"},"reading":"SEC EDGAR submissions record for Chrome Holding Co. (CIK 0001804591), U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-002","record":{"id":"src-002","title":"23andMe Holding Co. Form 8-K reporting the Chapter 11 filing (event of March 21, 2025)","url":"https://www.sec.gov/Archives/edgar/data/1804591/000119312525060817/d933650d8k.htm","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2025-03-24","locator":"Items 1.03, 5.02 and 8.01","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"company_statement","publisher_type":"regulator"},"reading":"23andMe Holding Co. Form 8-K reporting the Chapter 11 filing (event of March 21, 2025), U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-003","record":{"id":"src-003","title":"Exhibit 99.1 to the Form 8-K of March 24, 2025: list of filing subsidiaries","url":"https://www.sec.gov/Archives/edgar/data/1804591/000119312525060817/d933650dex991.htm","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2025-03-24","locator":"Exhibit 99.1","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"company_statement","publisher_type":"regulator"},"reading":"Exhibit 99.1 to the Form 8-K of March 24, 2025: list of filing subsidiaries, U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-004","record":{"id":"src-004","title":"23andMe Holding Co. definitive proxy statement for the 2024 annual meeting","url":"https://www.sec.gov/Archives/edgar/data/1804591/000114036124033309/ny20030770x2_def14a.htm","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2024-07","locator":"Schedule 14A: directors, officers, ownership and compensation","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"company_statement","publisher_type":"regulator"},"reading":"23andMe Holding Co. definitive proxy statement for the 2024 annual meeting, U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-005","record":{"id":"src-005","title":"Schedule 13D Amendment No. 13 filed by Anne Wojcicki and affiliates regarding 23andMe Holding Co.","url":"https://www.sec.gov/Archives/edgar/data/1804591/000114036125022544/xslSCHEDULE_13D_X01/primary_doc.xml","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2025-06","locator":"Items 4-6","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"regulatory_record","publisher_type":"regulator"},"reading":"Schedule 13D Amendment No. 13 filed by Anne Wojcicki and affiliates regarding 23andMe Holding Co., U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-006","record":{"id":"src-006","title":"23andMe Holding Co. Form 8-K on the resignation of the independent directors (event of September 17, 2024)","url":"https://www.sec.gov/Archives/edgar/data/1804591/000119312524221081/d894676d8k.htm","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2024-09","locator":"Item 5.02 and resignation letter","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"company_statement","publisher_type":"regulator"},"reading":"23andMe Holding Co. Form 8-K on the resignation of the independent directors (event of September 17, 2024), U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-007","record":{"id":"src-007","title":"23andMe Holding Co. Form 8-K on the closing of the business combination (event of June 16, 2021)","url":"https://www.sec.gov/Archives/edgar/data/1804591/000119312521194255/d187358d8k.htm","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2021-06","locator":"Items 2.01, 5.02 and beneficial ownership table","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"company_statement","publisher_type":"regulator"},"reading":"23andMe Holding Co. Form 8-K on the closing of the business combination (event of June 16, 2021), U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-008","record":{"id":"src-008","title":"23andMe Holding Co. Form 8-K on the name change to Chrome Holding Co. (event of August 14, 2025)","url":"https://www.sec.gov/Archives/edgar/data/1804591/000095014225002208/eh250668029_8k.htm","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2025-08","locator":"Items 5.03 and 8.01","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"company_statement","publisher_type":"regulator"},"reading":"23andMe Holding Co. Form 8-K on the name change to Chrome Holding Co. (event of August 14, 2025), U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-009","record":{"id":"src-009","title":"Schedule 13D filed by Zentree Investments Limited and Richard Magides regarding 23andMe Holding Co. (March 2025)","url":"https://www.sec.gov/Archives/edgar/data/1804591/000121465925004427/xslSCHEDULE_13D_X01/primary_doc.xml","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2025-03","locator":"Cover page and Items 3-5","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"regulatory_record","publisher_type":"regulator"},"reading":"Schedule 13D filed by Zentree Investments Limited and Richard Magides regarding 23andMe Holding Co. (March 2025), U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-010","record":{"id":"src-010","title":"Schedule 13D Amendment No. 12 filed by Anne Wojcicki and affiliates regarding 23andMe Holding Co.","url":"https://www.sec.gov/Archives/edgar/data/1804591/000114036125007990/xslSCHEDULE_13D_X01/primary_doc.xml","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2025-03","locator":"Items 4-6","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"regulatory_record","publisher_type":"regulator"},"reading":"Schedule 13D Amendment No. 12 filed by Anne Wojcicki and affiliates regarding 23andMe Holding Co., U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-011","record":{"id":"src-011","title":"VG Acquisition Corp. annual report on Form 10-K for 2020","url":"https://www.sec.gov/Archives/edgar/data/1804591/000119312521092793/d119190d10k.htm","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2021-03","locator":"Items 1, 10, 12 and 13","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"company_statement","publisher_type":"regulator"},"reading":"VG Acquisition Corp. annual report on Form 10-K for 2020, U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-012","record":{"id":"src-012","title":"Disclosure statement for the joint plan of Chrome Holding Co. and its debtor affiliates, Exhibit 99.2 to Form 8-K","url":"https://www.sec.gov/Archives/edgar/data/1804591/000119312525182189/d60496dex992.htm","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2025-08","locator":"Exhibit 99.2","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"court_record","publisher_type":"regulator"},"reading":"Disclosure statement for the joint plan of Chrome Holding Co. and its debtor affiliates, Exhibit 99.2 to Form 8-K, U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-013","record":{"id":"src-013","title":"Corporate registry source · src-013","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"corporate_registry","publisher_type":"corporate"},"reading":"Corporate registry source · src-013"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-014","record":{"id":"src-014","title":"Corporate registry source · src-014","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"corporate_registry","publisher_type":"corporate"},"reading":"Corporate registry source · src-014"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-015","record":{"id":"src-015","title":"Chrome Holding Co. Form 8-K on confirmation of the plan (December 2025)","url":"https://www.sec.gov/Archives/edgar/data/1804591/000119312525308060/d12373d8k.htm","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2025-12","locator":"Items 1.03 and 9.01; plan as confirmed","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"company_statement","publisher_type":"regulator"},"reading":"Chrome Holding Co. Form 8-K on confirmation of the plan (December 2025), U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-016","record":{"id":"src-016","title":"Order confirming the modified fifth amended joint plan, Exhibit 2.1 to Form 8-K","url":"https://www.sec.gov/Archives/edgar/data/1804591/000119312525308060/d12373dex21.htm","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2025-12-01","locator":"Exhibit 2.1, findings and decretal paragraphs","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"court_record","publisher_type":"regulator"},"reading":"Order confirming the modified fifth amended joint plan, Exhibit 2.1 to Form 8-K, U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-017","record":{"id":"src-017","title":"Chrome Holding Co. Form 8-K on the Lemonaid stock purchase agreement (event of September 10, 2025)","url":"https://www.sec.gov/Archives/edgar/data/1804591/000095014225002422/eh250675856_8k.htm","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2025-09","locator":"Item 1.01","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"company_statement","publisher_type":"regulator"},"reading":"Chrome Holding Co. Form 8-K on the Lemonaid stock purchase agreement (event of September 10, 2025), U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-018","record":{"id":"src-018","title":"Memorandum opinion on the sale of the debtors' assets to TTAM Research Institute","url":"https://www.moeb.uscourts.gov/sites/moeb/files/opinions/25-40976_BK_01_23andMe.pdf","publisher":"U.S. Bankruptcy Court, E.D. Mo.","date":"","locator":"Case No. 25-40976, related to Doc. 30","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"court_record","publisher_type":"government"},"reading":"Memorandum opinion on the sale of the debtors' assets to TTAM Research Institute, U.S. Bankruptcy Court, E.D. Mo."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-019","record":{"id":"src-019","title":"Plan Administration Trust's motion to approve the stipulation with the signatory governmental claimants, with the stipulation","url":"https://ag.ny.gov/sites/default/files/settlements-agreements/chrome-holding-co-settlement-2026.pdf","publisher":"Office of the New York State Attorney General (copy of a court filing)","date":"2026-07-14","locator":"Case No. 25-40976","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"court_record","publisher_type":"government"},"reading":"Plan Administration Trust's motion to approve the stipulation with the signatory governmental claimants, with the stipulation, Office of the New York State Attorney General (copy of a court filing)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-020","record":{"id":"src-020","title":"Schedule 13G filed by Farallon Partners, L.L.C. and affiliates regarding 23andMe Holding Co. (June 2025)","url":"https://www.sec.gov/Archives/edgar/data/1804591/000090883425000202/xslSCHEDULE_13G_X01/primary_doc.xml","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2025-06","locator":"Cover pages","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"regulatory_record","publisher_type":"regulator"},"reading":"Schedule 13G filed by Farallon Partners, L.L.C. and affiliates regarding 23andMe Holding Co. (June 2025), U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-021","record":{"id":"src-021","title":"Schedule 13D Amendment No. 2 filed by Zentree Investments Limited and Richard Magides (March 2025)","url":"https://www.sec.gov/Archives/edgar/data/1804591/000121465925005213/xslSCHEDULE_13D_X01/primary_doc.xml","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2025-03","locator":"Cover page and Items 3-5","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"regulatory_record","publisher_type":"regulator"},"reading":"Schedule 13D Amendment No. 2 filed by Zentree Investments Limited and Richard Magides (March 2025), U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-022","record":{"id":"src-022","title":"23andMe Holding Co. Form 8-K on the appointment of three independent directors (October 2024)","url":"https://www.sec.gov/Archives/edgar/data/1804591/000119312524246528/d887736d8k.htm","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2024-10","locator":"Item 5.02","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"company_statement","publisher_type":"regulator"},"reading":"23andMe Holding Co. Form 8-K on the appointment of three independent directors (October 2024), U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-023","record":{"id":"src-023","title":"23andMe press release on three new independent directors, Exhibit 99.1","url":"https://www.sec.gov/Archives/edgar/data/1804591/000119312524246528/d887736dex991.htm","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2024-10-29","locator":"Exhibit 99.1","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"company_statement","publisher_type":"regulator"},"reading":"23andMe press release on three new independent directors, Exhibit 99.1, U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-024","record":{"id":"src-024","title":"Corporate registry source · src-024","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"corporate_registry","publisher_type":"corporate"},"reading":"Corporate registry source · src-024"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-025","record":{"id":"src-025","title":"State Bar of California attorney profile no. 96667","url":"https://apps.calbar.ca.gov/attorney/Licensee/Detail/96667","publisher":"State Bar of California","date":"","locator":"Attorney profile and licence history","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"regulatory_record","publisher_type":"regulator"},"reading":"State Bar of California attorney profile no. 96667, State Bar of California"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-026","record":{"id":"src-026","title":"Revlon, Inc. Form 10-K/A for 2022, Exhibit 32.4 certification","url":"https://www.sec.gov/Archives/edgar/data/890547/000088792123000009/rev-202210xkaxex324.htm","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2023","locator":"Exhibit 32.4","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"company_statement","publisher_type":"regulator"},"reading":"Revlon, Inc. Form 10-K/A for 2022, Exhibit 32.4 certification, U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-027","record":{"id":"src-027","title":"GLEIF LEI record 529900FU5IIBCXYHHX25","url":"https://api.gleif.org/api/v1/lei-records/529900FU5IIBCXYHHX25","publisher":"Global Legal Entity Identifier Foundation","date":"2026-10-16","locator":"LEI record","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"corporate_registry","publisher_type":"registry_operator"},"reading":"GLEIF LEI record 529900FU5IIBCXYHHX25, Global Legal Entity Identifier Foundation"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-028","record":{"id":"src-028","title":"Schedule 13D Amendment No. 9 filed by Anne Wojcicki and affiliates regarding 23andMe Holding Co.","url":"https://www.sec.gov/Archives/edgar/data/1804591/000095017025024862/xslSCHEDULE_13D_X01/primary_doc.xml","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2025","locator":"Items 4-6","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"regulatory_record","publisher_type":"regulator"},"reading":"Schedule 13D Amendment No. 9 filed by Anne Wojcicki and affiliates regarding 23andMe Holding Co., U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-029","record":{"id":"src-029","title":"Written statement of Joseph Selsavage for the U.S. Senate Judiciary Committee hearing \"23 and You\"","url":"https://www.judiciary.senate.gov/download/06/30/2026/2025-06-11_-testimony_-selsavagepdf","publisher":"U.S. Senate Committee on the Judiciary","date":"2025-06-11","locator":"Statement","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"company_statement","publisher_type":"government"},"reading":"Written statement of Joseph Selsavage for the U.S. Senate Judiciary Committee hearing \"23 and You\", U.S. Senate Committee on the Judiciary"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-030","record":{"id":"src-030","title":"Other source · src-030","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"other","publisher_type":"corporate"},"reading":"Other source · src-030"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-031","record":{"id":"src-031","title":"Court record source · src-031","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"court_record","publisher_type":"corporate"},"reading":"Court record source · src-031"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-032","record":{"id":"src-032","title":"Court record source · src-032","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"court_record","publisher_type":"corporate"},"reading":"Court record source · src-032"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-033","record":{"id":"src-033","title":"Media source · src-033","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-033"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-034","record":{"id":"src-034","title":"Memorandum opinion on the landlord's lease-rejection claim against ChromeCo, Inc.","url":"https://www.moeb.uscourts.gov/sites/moeb/files/opinions/25-40976_BK_01_Chrome.pdf","publisher":"U.S. Bankruptcy Court, E.D. Mo.","date":"","locator":"Case No. 25-40976","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"court_record","publisher_type":"government"},"reading":"Memorandum opinion on the landlord's lease-rejection claim against ChromeCo, Inc., U.S. Bankruptcy Court, E.D. Mo."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-035","record":{"id":"src-035","title":"Chrome Holding Co. annual report on Form 10-K for the fiscal year ended March 31, 2025","url":"https://www.sec.gov/Archives/edgar/data/1804591/000162828025030786/mehcq-20250331.htm","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2025","locator":"Items 1, 1A, 3, 7, 8 and notes","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"company_statement","publisher_type":"regulator"},"reading":"Chrome Holding Co. annual report on Form 10-K for the fiscal year ended March 31, 2025, U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-036","record":{"id":"src-036","title":"Court page listing the cases associated with Chrome Holding Co.","url":"https://www.moeb.uscourts.gov/sites/moeb/files/Chrome_Holding_Associated_Cases.pdf","publisher":"U.S. Bankruptcy Court, E.D. Mo.","date":"","locator":"Associated cases list","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"court_record","publisher_type":"government"},"reading":"Court page listing the cases associated with Chrome Holding Co., U.S. Bankruptcy Court, E.D. Mo."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-037","record":{"id":"src-037","title":"Other source · src-037","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"other","publisher_type":"nonprofit"},"reading":"Other source · src-037"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-038","record":{"id":"src-038","title":"Media source · src-038","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-038"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-039","record":{"id":"src-039","title":"Court record source · src-039","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"court_record","publisher_type":"corporate"},"reading":"Court record source · src-039"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-040","record":{"id":"src-040","title":"Court record source · src-040","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"court_record","publisher_type":"corporate"},"reading":"Court record source · src-040"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-041","record":{"id":"src-041","title":"Pennsylvania Attorney General statement supporting the proposed sale","url":"https://www.attorneygeneral.gov/taking-action/ag-sunday-supports-proposed-sale-of-23andme-that-would-protect-consumers-dna-and-data/","publisher":"Office of the Pennsylvania Attorney General","date":"","locator":"Press release","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"other","publisher_type":"government"},"reading":"Pennsylvania Attorney General statement supporting the proposed sale, Office of the Pennsylvania Attorney General"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-042","record":{"id":"src-042","title":"GLEIF full-text search for \"23andMe\"","url":"https://api.gleif.org/api/v1/lei-records?filter[fulltext]=23andMe&page[size]=20","publisher":"Global Legal Entity Identifier Foundation","date":"2026-10-16","locator":"Search result","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"corporate_registry","publisher_type":"registry_operator"},"reading":"GLEIF full-text search for \"23andMe\", Global Legal Entity Identifier Foundation"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-043","record":{"id":"src-043","title":"Media source · src-043","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-043"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-044","record":{"id":"src-044","title":"Colorado Attorney General announcement of the multistate settlement of bankruptcy claims","url":"https://coag.gov/2026/attorney-general-phil-weiser-announces-multistate-settlement-of-bankruptcy-claims-against-23andme-over-genetic-data-breach/","publisher":"Colorado Department of Law","date":"2026-07-14","locator":"Press release","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"other","publisher_type":"government"},"reading":"Colorado Attorney General announcement of the multistate settlement of bankruptcy claims, Colorado Department of Law"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-045","record":{"id":"src-045","title":"Company statement source · src-045","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"company_statement","publisher_type":"corporate"},"reading":"Company statement source · src-045"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-046","record":{"id":"src-046","title":"Other source · src-046","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"other","publisher_type":"corporate"},"reading":"Other source · src-046"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-047","record":{"id":"src-047","title":"Court information page for the Chrome Holding Co. case","url":"https://www.moeb.uscourts.gov/chrome-holding-co-information","publisher":"U.S. Bankruptcy Court, E.D. Mo.","date":"","locator":"Case information page","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"court_record","publisher_type":"government"},"reading":"Court information page for the Chrome Holding Co. case, U.S. Bankruptcy Court, E.D. Mo."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-048","record":{"id":"src-048","title":"Hearing calendar of Judge Brian C. Walsh for the Chrome Holding Co. case","url":"https://files.moeb.uscourts.gov/pdfs/hearingdates/BCW11EM-23ANDME.pdf","publisher":"U.S. Bankruptcy Court, E.D. Mo.","date":"","locator":"Hearing dates","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"court_record","publisher_type":"government"},"reading":"Hearing calendar of Judge Brian C. Walsh for the Chrome Holding Co. case, U.S. Bankruptcy Court, E.D. Mo."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-049","record":{"id":"src-049","title":"Court record source · src-049","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"court_record","publisher_type":"corporate"},"reading":"Court record source · src-049"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-050","record":{"id":"src-050","title":"Research source · src-050","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"research","publisher_type":"corporate"},"reading":"Research source · src-050"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-051","record":{"id":"src-051","title":"Court record source · src-051","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"court_record","publisher_type":"corporate"},"reading":"Court record source · src-051"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-052","record":{"id":"src-052","title":"Court record source · src-052","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"court_record","publisher_type":"corporate"},"reading":"Court record source · src-052"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-053","record":{"id":"src-053","title":"Companies House search for Lemonaid Health Limited","url":"https://find-and-update.company-information.service.gov.uk/search/companies?q=LEMONAID+HEALTH+LIMITED","publisher":"Companies House (UK)","date":"","locator":"Search result","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"corporate_registry","publisher_type":"registry_operator"},"reading":"Companies House search for Lemonaid Health Limited, Companies House (UK)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-054","record":{"id":"src-054","title":"Companies House register of persons with significant control: company 12561320","url":"https://find-and-update.company-information.service.gov.uk/company/12561320/persons-with-significant-control","publisher":"Companies House (UK)","date":"","locator":"PSC register","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"corporate_registry","publisher_type":"registry_operator"},"reading":"Companies House register of persons with significant control: company 12561320, Companies House (UK)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-055","record":{"id":"src-055","title":"Schedule 13G filed by VG Acquisition Sponsor LLC and the Virgin entities regarding VG Acquisition Corp.","url":"https://www.sec.gov/Archives/edgar/data/1804591/000095010321002318/dp146166_sc13g.htm","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2021-02","locator":"Cover pages and Item 4","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"regulatory_record","publisher_type":"regulator"},"reading":"Schedule 13G filed by VG Acquisition Sponsor LLC and the Virgin entities regarding VG Acquisition Corp., U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-056","record":{"id":"src-056","title":"Adversary complaint of the State of Arizona and other states against 23andMe, Inc. (Adv. No. 25-04035)","url":"https://ag.ny.gov/sites/default/files/court-filings/the-state-of-arizona-et-al-v-23andme-inc-complaint-2025.pdf","publisher":"Office of the New York State Attorney General (copy of a court filing)","date":"2025-06-09","locator":"Doc. 1","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"court_record","publisher_type":"government"},"reading":"Adversary complaint of the State of Arizona and other states against 23andMe, Inc. (Adv. No. 25-04035), Office of the New York State Attorney General (copy of a court filing)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-057","record":{"id":"src-057","title":"Chrome Holding Co. Form 10-K/A for the fiscal year ended March 31, 2025 (Part III)","url":"https://www.sec.gov/Archives/edgar/data/1804591/000119312525165458/d97426d10ka.htm","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2025","locator":"Items 10-13","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"company_statement","publisher_type":"regulator"},"reading":"Chrome Holding Co. Form 10-K/A for the fiscal year ended March 31, 2025 (Part III), U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-058","record":{"id":"src-058","title":"Schedule 13G filed by Zentree Investments Limited and Richard Magides regarding 23andMe Holding Co. (November 2024)","url":"https://www.sec.gov/Archives/edgar/data/1804591/000121465924018797/x1111241sc13g.htm","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2024-11","locator":"Cover pages","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"regulatory_record","publisher_type":"regulator"},"reading":"Schedule 13G filed by Zentree Investments Limited and Richard Magides regarding 23andMe Holding Co. (November 2024), U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-059","record":{"id":"src-059","title":"Schedule 13D Amendment No. 9 regarding Virgin Galactic Holdings, Inc. filed by the Virgin entities","url":"https://www.sec.gov/Archives/edgar/data/1706946/000095015723001115/sc13da.htm","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2023-11-03","locator":"Items 2 and 5, Schedule A","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"regulatory_record","publisher_type":"regulator"},"reading":"Schedule 13D Amendment No. 9 regarding Virgin Galactic Holdings, Inc. filed by the Virgin entities, U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-060","record":{"id":"src-060","title":"Media source · src-060","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-060"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-061","record":{"id":"src-061","title":"Company statement source · src-061","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"company_statement","publisher_type":"corporate"},"reading":"Company statement source · src-061"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-062","record":{"id":"src-062","title":"Lattice Semiconductor Corporation definitive proxy statement for 2026","url":"https://www.sec.gov/Archives/edgar/data/855658/000114036126010150/ny20060701x1_def14a.htm","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2026","locator":"Director biographies","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"company_statement","publisher_type":"regulator"},"reading":"Lattice Semiconductor Corporation definitive proxy statement for 2026, U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-063","record":{"id":"src-063","title":"Company statement source · src-063","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"company_statement","publisher_type":"corporate"},"reading":"Company statement source · src-063"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-064","record":{"id":"src-064","title":"Court record source · src-064","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"court_record","publisher_type":"corporate"},"reading":"Court record source · src-064"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-065","record":{"id":"src-065","title":"Court record source · src-065","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"court_record","publisher_type":"corporate"},"reading":"Court record source · src-065"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-066","record":{"id":"src-066","title":"Company statement source · src-066","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"company_statement","publisher_type":"corporate"},"reading":"Company statement source · src-066"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-067","record":{"id":"src-067","title":"Company statement source · src-067","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"company_statement","publisher_type":"nonprofit"},"reading":"Company statement source · src-067"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-068","record":{"id":"src-068","title":"Other source · src-068","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"other","publisher_type":"corporate"},"reading":"Other source · src-068"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-069","record":{"id":"src-069","title":"Form D notice of Xfund 3, L.P.","url":"https://www.sec.gov/Archives/edgar/data/1763789/000176378919000001/xslFormDX01/primary_doc.xml","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2019-04-17","locator":"Items 1-3 and signature","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"regulatory_record","publisher_type":"regulator"},"reading":"Form D notice of Xfund 3, L.P., U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-070","record":{"id":"src-070","title":"Company statement source · src-070","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"company_statement","publisher_type":"unknown"},"reading":"Company statement source · src-070"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-071","record":{"id":"src-071","title":"Companies House officers register: company 12561320","url":"https://find-and-update.company-information.service.gov.uk/company/12561320/officers","publisher":"Companies House (UK)","date":"","locator":"Officers register","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"corporate_registry","publisher_type":"registry_operator"},"reading":"Companies House officers register: company 12561320, Companies House (UK)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-072","record":{"id":"src-072","title":"California Attorney General press release on the suit against Chrome Holding Co.","url":"https://oag.ca.gov/news/press-releases/attorney-general-bonta-sues-chrome-holding-co-formerly-known-23andme-over-2023","publisher":"California Department of Justice","date":"","locator":"Press release","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"other","publisher_type":"government"},"reading":"California Attorney General press release on the suit against Chrome Holding Co., California Department of Justice"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-073","record":{"id":"src-073","title":"Summary of the joint investigation of 23andMe by the privacy commissioners of Canada and the UK","url":"https://www.priv.gc.ca/en/opc-news/news-and-announcements/2025/bg_23andme_250617/","publisher":"Office of the Privacy Commissioner of Canada","date":"2025-06-17","locator":"Investigation summary","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"regulatory_record","publisher_type":"regulator"},"reading":"Summary of the joint investigation of 23andMe by the privacy commissioners of Canada and the UK, Office of the Privacy Commissioner of Canada"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-074","record":{"id":"src-074","title":"Penalty notice to 23andMe, Inc.","url":"https://ico.org.uk/media2/kclbljpo/23andme-penalty-notice.pdf","publisher":"Information Commissioner's Office (UK)","date":"2025-06-05","locator":"Penalty notice, Parts I-F","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"regulatory_record","publisher_type":"regulator"},"reading":"Penalty notice to 23andMe, Inc., Information Commissioner's Office (UK)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-075","record":{"id":"src-075","title":"Complaint of the People of the State of California against Chrome Holding Co. and others","url":"https://oag.ca.gov/system/files/attachments/press-docs/People%20v%20Chrome%20Holding%20fka%2023andMe%20et%20al.%20-%20Stamped%20Complaint.pdf","publisher":"California Department of Justice (copy of a court filing)","date":"","locator":"Complaint","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"court_record","publisher_type":"government"},"reading":"Complaint of the People of the State of California against Chrome Holding Co. and others, California Department of Justice (copy of a court filing)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-076","record":{"id":"src-076","title":"Court record source · src-076","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"court_record","publisher_type":"corporate"},"reading":"Court record source · src-076"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-077","record":{"id":"src-077","title":"Letter of the FTC Chairman to the U.S. Trustee on the 23andMe sale","url":"https://www.ftc.gov/system/files/ftc_gov/pdf/23andme-letter-ferguson.pdf","publisher":"U.S. Federal Trade Commission","date":"2025-03-31","locator":"Letter","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"regulatory_record","publisher_type":"regulator"},"reading":"Letter of the FTC Chairman to the U.S. Trustee on the 23andMe sale, U.S. Federal Trade Commission"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-078","record":{"id":"src-078","title":"Court record source · src-078","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"court_record","publisher_type":"nonprofit"},"reading":"Court record source · src-078"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-079","record":{"id":"src-079","title":"Second amended disclosure statement, Exhibit 99.4 to Form 8-K","url":"https://www.sec.gov/Archives/edgar/data/1804591/000095014225002625/eh250683952_ex9904.htm","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2025-09","locator":"Exhibit 99.4","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"court_record","publisher_type":"regulator"},"reading":"Second amended disclosure statement, Exhibit 99.4 to Form 8-K, U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-080","record":{"id":"src-080","title":"Court record source · src-080","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"court_record","publisher_type":"corporate"},"reading":"Court record source · src-080"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-081","record":{"id":"src-081","title":"Companies House register of persons with significant control: Boots UK Limited (00928555)","url":"https://find-and-update.company-information.service.gov.uk/company/00928555/persons-with-significant-control","publisher":"Companies House (UK)","date":"","locator":"PSC register","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"corporate_registry","publisher_type":"registry_operator"},"reading":"Companies House register of persons with significant control: Boots UK Limited (00928555), Companies House (UK)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-082","record":{"id":"src-082","title":"SEC EDGAR submissions record for AJAX I (CIK 0001824963)","url":"https://data.sec.gov/submissions/CIK0001824963.json","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"","locator":"Registrant metadata","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"corporate_registry","publisher_type":"regulator"},"reading":"SEC EDGAR submissions record for AJAX I (CIK 0001824963), U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-083","record":{"id":"src-083","title":"Press release on the planned merger of 23andMe with VG Acquisition Corp., Exhibit 99.1","url":"https://www.sec.gov/Archives/edgar/data/1804591/000095010321001779/dp145636_ex9901.htm","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2021-02-04","locator":"Exhibit 99.1","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"company_statement","publisher_type":"regulator"},"reading":"Press release on the planned merger of 23andMe with VG Acquisition Corp., Exhibit 99.1, U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-084","record":{"id":"src-084","title":"Other source · src-084","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"other","publisher_type":"corporate"},"reading":"Other source · src-084"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-085","record":{"id":"src-085","title":"Court record source · src-085","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"court_record","publisher_type":"corporate"},"reading":"Court record source · src-085"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-086","record":{"id":"src-086","title":"Other source · src-086","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"other","publisher_type":"nonprofit"},"reading":"Other source · src-086"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-087","record":{"id":"src-087","title":"Colorado Secretary of State business entity record (ID 20161206900)","url":"https://www.coloradosos.gov/biz/BusinessEntityDetail.do?quitButtonDestination=BusinessEntityResults&fileId=20161206900","publisher":"Colorado Secretary of State","date":"","locator":"Entity detail","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"corporate_registry","publisher_type":"registry_operator"},"reading":"Colorado Secretary of State business entity record (ID 20161206900), Colorado Secretary of State"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-088","record":{"id":"src-088","title":"Court opinions collection for Case No. 4:25-bk-40976","url":"https://www.govinfo.gov/app/details/USCOURTS-moeb-4_25-bk-40976","publisher":"U.S. Government Publishing Office (GovInfo)","date":"","locator":"Collection details","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"court_record","publisher_type":"government"},"reading":"Court opinions collection for Case No. 4:25-bk-40976, U.S. Government Publishing Office (GovInfo)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-089","record":{"id":"src-089","title":"Other source · src-089","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"other","publisher_type":"corporate"},"reading":"Other source · src-089"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-090","record":{"id":"src-090","title":"Getty Images Holdings, Inc. Form 8-K on board changes (July 2026)","url":"https://www.sec.gov/Archives/edgar/data/1898496/000121390026080021/ea0298703-8k_getty.htm","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2026-07","locator":"Item 5.02","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"company_statement","publisher_type":"regulator"},"reading":"Getty Images Holdings, Inc. Form 8-K on board changes (July 2026), U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-091","record":{"id":"src-091","title":"SEC EDGAR full-text search for Form 3 filings naming Walper","url":"https://efts.sec.gov/LATEST/search-index?q=%22Walper%22&forms=3","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"","locator":"Search result list","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"corporate_registry","publisher_type":"regulator"},"reading":"SEC EDGAR full-text search for Form 3 filings naming Walper, U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-092","record":{"id":"src-092","title":"Form 3 initial statement of beneficial ownership of Thomas B. Walper (23andMe Holding Co.)","url":"https://www.sec.gov/Archives/edgar/data/1804591/000162828025014984/xslF345X02/wk-form3_1743021328.xml","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2025-03","locator":"Form 3","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"regulatory_record","publisher_type":"regulator"},"reading":"Form 3 initial statement of beneficial ownership of Thomas B. Walper (23andMe Holding Co.), U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-093","record":{"id":"src-093","title":"Other source · src-093","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"other","publisher_type":"corporate"},"reading":"Other source · src-093"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-094","record":{"id":"src-094","title":"Other source · src-094","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"other","publisher_type":"corporate"},"reading":"Other source · src-094"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-095","record":{"id":"src-095","title":"Other source · src-095","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"other","publisher_type":"corporate"},"reading":"Other source · src-095"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-096","record":{"id":"src-096","title":"Other source · src-096","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"other","publisher_type":"corporate"},"reading":"Other source · src-096"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-097","record":{"id":"src-097","title":"Other source · src-097","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"other","publisher_type":"corporate"},"reading":"Other source · src-097"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-098","record":{"id":"src-098","title":"Other source · src-098","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"other","publisher_type":"corporate"},"reading":"Other source · src-098"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-099","record":{"id":"src-099","title":"VG Acquisition Corp. Form 8-K on the shareholder vote on the business combination (June 2021)","url":"https://www.sec.gov/Archives/edgar/data/1804591/000119312521189041/d156286d8k.htm","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2021-06","locator":"Item 5.07","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"company_statement","publisher_type":"regulator"},"reading":"VG Acquisition Corp. Form 8-K on the shareholder vote on the business combination (June 2021), U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-100","record":{"id":"src-100","title":"Other source · src-100","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"other","publisher_type":"corporate"},"reading":"Other source · src-100"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-101","record":{"id":"src-101","title":"Other source · src-101","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"other","publisher_type":"corporate"},"reading":"Other source · src-101"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-102","record":{"id":"src-102","title":"NPI registry record for Lemonaid Community Pharmacy, Inc.","url":"https://npiregistry.cms.hhs.gov/api/?version=2.1&organization_name=LEMONAID+COMMUNITY+PHARMACY","publisher":"Centers for Medicare & Medicaid Services (NPPES)","date":"","locator":"Provider record","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"corporate_registry","publisher_type":"registry_operator"},"reading":"NPI registry record for Lemonaid Community Pharmacy, Inc., Centers for Medicare & Medicaid Services (NPPES)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-103","record":{"id":"src-103","title":"Other source · src-103","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"other","publisher_type":"corporate"},"reading":"Other source · src-103"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-104","record":{"id":"src-104","title":"Company statement source · src-104","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"company_statement","publisher_type":"nonprofit"},"reading":"Company statement source · src-104"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-105","record":{"id":"src-105","title":"SEC EDGAR submissions record for Ansys, Inc. (CIK 0001013462)","url":"https://data.sec.gov/submissions/CIK0001013462.json","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"","locator":"Registrant metadata and recent filings","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"corporate_registry","publisher_type":"regulator"},"reading":"SEC EDGAR submissions record for Ansys, Inc. (CIK 0001013462), U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-106","record":{"id":"src-106","title":"Ansys, Inc. definitive proxy statement for 2025","url":"https://www.sec.gov/Archives/edgar/data/1013462/000110465925041176/tm252293-2_def14a.htm","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2025-04","locator":"Director biographies","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"company_statement","publisher_type":"regulator"},"reading":"Ansys, Inc. definitive proxy statement for 2025, U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-107","record":{"id":"src-107","title":"Minnesota Attorney General press release on the multistate settlement","url":"https://www.ag.state.mn.us/Office/Communications/2026/07/14_23andMe.asp","publisher":"Office of the Minnesota Attorney General","date":"2026-07-14","locator":"Press release","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"other","publisher_type":"government"},"reading":"Minnesota Attorney General press release on the multistate settlement, Office of the Minnesota Attorney General"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-108","record":{"id":"src-108","title":"Cardlytics, Inc. Form 4/A filed for Andre J. Fernandez","url":"https://www.sec.gov/Archives/edgar/data/0001666071/000162828026058613/wk-form4a_1787601884.xml","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2026-08-24","locator":"Form 4/A","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-17","source_type":"regulatory_record","publisher_type":"regulator"},"reading":"Cardlytics, Inc. Form 4/A filed for Andre J. Fernandez, U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-109","record":{"id":"src-109","title":"Company statement source · src-109","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"company_statement","publisher_type":"media"},"reading":"Company statement source · src-109"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-110","record":{"id":"src-110","title":"Media source · src-110","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-110"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-111","record":{"id":"src-111","title":"Media source · src-111","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"corporate"},"reading":"Media source · src-111"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"sources","id":"src-112","record":{"id":"src-112","title":"Media source · src-112","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-112"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-id-edgar","record":{"id":"c-id-edgar","kind":"fact","text":"The SEC's EDGAR registrant record for Central Index Key 0001804591 names the company Chrome Holding Co., incorporated in Delaware, with employer identification number 871240344, a fiscal year ending March 31 and the industry code 2834 (pharmaceutical preparations); at the time of retrieval it listed no trading symbols or exchanges.","source_ids":["src-001"],"entity_ids":["holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: The SEC's EDGAR registrant record for Central Index Key 0001804591 names the company Chrome Holding Co., incorporated in Delaware, with employer identification number 871240344, a fiscal year ending March 31 and the industry code 2834 (pharmaceutical preparations); at the time of retrieval it listed no trading symbols or exchanges."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-id-former-names","record":{"id":"c-id-former-names","kind":"fact","text":"EDGAR lists the registrant's earlier names as Bleecker Street Acquisition Corp. (March 6 to August 12, 2020), VG Acquisition Corp. (September 16, 2020 to June 17, 2021) and 23andMe Holding Co. (June 21, 2021 to August 4, 2025).","source_ids":["src-001","src-008"],"entity_ids":["holdco"],"qualification":"EDGAR's end date for the 23andMe Holding Co. name, August 4, 2025, is earlier than the August 14, 2025 effective date of the Delaware name change reported in the company's own Form 8-K.","response":"","outcome":""},"reading":"Fact: EDGAR lists the registrant's earlier names as Bleecker Street Acquisition Corp. (March 6 to August 12, 2020), VG Acquisition Corp. (September 16, 2020 to June 17, 2021) and 23andMe Holding Co. (June 21, 2021 to August 4, 2025)."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-id-rename","record":{"id":"c-id-rename","kind":"fact","text":"On and effective August 14, 2025, 23andMe Holding Co. filed a certificate of amendment with the Delaware Secretary of State changing its name to Chrome Holding Co.; the company's Form 8-K said the change did not affect stockholders' rights and made no other change to the certificate of incorporation.","source_ids":["src-008"],"entity_ids":["holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: On and effective August 14, 2025, 23andMe Holding Co. filed a certificate of amendment with the Delaware Secretary of State changing its name to Chrome Holding Co.; the company's Form 8-K said the change did not affect stockholders' rights and made no other change to the certificate of incorporation."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-id-trademark-names","record":{"id":"c-id-trademark-names","kind":"fact","text":"The August 2025 disclosure statement explains that, in connection with the sale to TTAM and as contemplated by the purchase agreement and the sale order, the debtors whose names contained the 23andMe trademark stopped using it: 23andMe Holding Co. became Chrome Holding Co., 23andMe, Inc. became ChromeCo, Inc., and 23andMe Pharmacy Holdings, Inc. became Chrome Pharmacy Holdings, Inc.","source_ids":["src-012"],"entity_ids":["holdco","inc","pharmacy-holdings","ttam"],"qualification":"","response":"","outcome":""},"reading":"Fact: The August 2025 disclosure statement explains that, in connection with the sale to TTAM and as contemplated by the purchase agreement and the sale order, the debtors whose names contained the 23andMe trademark stopped using it: 23andMe Holding Co. became Chrome Holding Co., 23andMe, Inc. became ChromeCo, Inc., and 23andMe Pharmacy Holdings, Inc. became Chrome Pharmacy Holdings, Inc."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-id-addresses","record":{"id":"c-id-addresses","kind":"fact","text":"The company's Form 8-K of March 24, 2025 gives its principal executive office as 870 Market Street, Room 415, San Francisco, replacing the former address at 223 N. Mathilda Avenue, Sunnyvale, California; in 2026 the Wind-Down Debtor's service address in the bankruptcy case was 490 Post St., Suite 500 PMB 2065, San Francisco.","source_ids":["src-002","src-019"],"entity_ids":["holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: The company's Form 8-K of March 24, 2025 gives its principal executive office as 870 Market Street, Room 415, San Francisco, replacing the former address at 223 N. Mathilda Avenue, Sunnyvale, California; in 2026 the Wind-Down Debtor's service address in the bankruptcy case was 490 Post St., Suite 500 PMB 2065, San Francisco."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-id-listing","record":{"id":"c-id-listing","kind":"fact","text":"After the June 2021 merger the company's Class A common stock and warrants traded on The Nasdaq Global Select Market under the symbols ME and MEUSW; by March 2025 its Class A common stock was registered on The Nasdaq Capital Market under the symbol ME.","source_ids":["src-007","src-002"],"entity_ids":["holdco","nasdaq"],"qualification":"","response":"","outcome":""},"reading":"Fact: After the June 2021 merger the company's Class A common stock and warrants traded on The Nasdaq Global Select Market under the symbols ME and MEUSW; by March 2025 its Class A common stock was registered on The Nasdaq Capital Market under the symbol ME."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-id-delisting","record":{"id":"c-id-delisting","kind":"fact","text":"Nasdaq's Listing Qualifications Department notified the company on March 24, 2025 that, following the Chapter 11 filing, its securities would be delisted; the delisting took effect on March 31, 2025 and the stock then traded over the counter. As of July 25, 2025 Chrome Holding Co. had about 25,431,244 Class A and 2,110,250 Class B shares outstanding.","source_ids":["src-012"],"entity_ids":["holdco","nasdaq"],"qualification":"","response":"","outcome":""},"reading":"Fact: Nasdaq's Listing Qualifications Department notified the company on March 24, 2025 that, following the Chapter 11 filing, its securities would be delisted; the delisting took effect on March 31, 2025 and the stock then traded over the counter. As of July 25, 2025 Chrome Holding Co. had about 25,431,244 Class A and 2,110,250 Class B shares outstanding."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-id-15-12g","record":{"id":"c-id-15-12g","kind":"fact","text":"The most recent filing in the registrant's EDGAR record at retrieval is a Form 15-12G dated December 4, 2025, the form used to give notice of the termination of a class of securities' registration under the Securities Exchange Act.","source_ids":["src-001"],"entity_ids":["holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: The most recent filing in the registrant's EDGAR record at retrieval is a Form 15-12G dated December 4, 2025, the form used to give notice of the termination of a class of securities' registration under the Securities Exchange Act."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-id-gleif","record":{"id":"c-id-gleif","kind":"fact","text":"The GLEIF record for legal entity identifier 529900FU5IIBCXYHHX25 (entity status active, registration issued and fully corroborated) gives the legal name Chrome Holding Co. and the previous legal name 23andMe Holding Co., registration number 6006171 at registration authority RA000602 in the jurisdiction of Delaware, a legal address c/o Corporation Service Company, 251 Little Falls Drive, Wilmington, Delaware, and a headquarters address still recorded as 223 N. Mathilda Avenue, Sunnyvale.","source_ids":["src-027","src-008","src-007"],"entity_ids":["holdco","csc"],"qualification":"GLEIF records the entity's creation as 2021-06-15 22:00 UTC and the legal-name change as effective 2025-09-11 22:00 UTC; these recording timestamps do not match the dates in the company's SEC filings exactly (domestication on June 16, 2021; name change effective August 14, 2025).","response":"","outcome":""},"reading":"Fact: The GLEIF record for legal entity identifier 529900FU5IIBCXYHHX25 (entity status active, registration issued and fully corroborated) gives the legal name Chrome Holding Co. and the previous legal name 23andMe Holding Co., registration number 6006171 at registration authority RA000602 in the jurisdiction of Delaware, a legal address c/o Corporation Service Company, 251 Little Falls Drive, Wilmington, Delaware, and a headquarters address still recorded as 223 N. Mathilda Avenue, Sunnyvale."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-id-gleif-search","record":{"id":"c-id-gleif-search","kind":"fact","text":"A GLEIF full-text search for \"23andMe\" run on October 16, 2026 returned two records: Chrome Holding Co. and an unrelated Italian company in liquidation, FG2 23andMe S.r.l.; no LEI record for 23andMe, Inc. or ChromeCo, Inc. appeared.","source_ids":["src-042"],"entity_ids":["holdco","inc"],"qualification":"A search result describes what the register returned on that date; it does not prove that no other identifier exists.","response":"","outcome":""},"reading":"Fact: A GLEIF full-text search for \"23andMe\" run on October 16, 2026 returned two records: Chrome Holding Co. and an unrelated Italian company in liquidation, FG2 23andMe S.r.l.; no LEI record for 23andMe, Inc. or ChromeCo, Inc. appeared."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-id-agg-holdco","record":{"id":"c-id-agg-holdco","kind":"fact","text":"A company-data aggregator's copy of the Delaware register lists 23ANDME HOLDING CO. as a Delaware domestic corporation, company number 6006171, with Incorporating Services, Ltd (3500 S DuPont Hwy, Dover) as registered agent; the page does not show the Chrome Holding Co. name and withholds the incorporation date.","source_ids":["src-013"],"entity_ids":["holdco","isl"],"qualification":"The aggregator says it is not the primary source; the Delaware register itself was not retrieved. The company number matches the GLEIF record.","response":"","outcome":""},"reading":"Fact: A company-data aggregator's copy of the Delaware register lists 23ANDME HOLDING CO. as a Delaware domestic corporation, company number 6006171, with Incorporating Services, Ltd (3500 S DuPont Hwy, Dover) as registered agent; the page does not show the Chrome Holding Co. name and withholds the incorporation date."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-id-agg-inc","record":{"id":"c-id-agg-inc","kind":"fact","text":"The same aggregator lists 23ANDME, INC. as a Delaware corporation, company number 4150436, with the same registered agent; it names 23andMe Holding Co. (shown with a California jurisdiction) as parent company and lists eight branch registrations in other states, some already under the name ChromeCo, Inc., including Utah, Massachusetts, Arizona and Colorado.","source_ids":["src-014"],"entity_ids":["inc","holdco","isl"],"qualification":"Aggregator data, not the primary register; the Delaware and other state registers were not retrieved, apart from Colorado's record of the branch.","response":"","outcome":""},"reading":"Fact: The same aggregator lists 23ANDME, INC. as a Delaware corporation, company number 4150436, with the same registered agent; it names 23andMe Holding Co. (shown with a California jurisdiction) as parent company and lists eight branch registrations in other states, some already under the name ChromeCo, Inc., including Utah, Massachusetts, Arizona and Colorado."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-id-agg-pharmacy","record":{"id":"c-id-agg-pharmacy","kind":"fact","text":"The aggregator also lists 23ANDME PHARMACY HOLDINGS, INC. as a Delaware domestic corporation, company number 7632876, with Incorporating Services, Ltd as registered agent and 23andMe Holding Co. as parent company; the page does not show the Chrome Pharmacy Holdings name.","source_ids":["src-024"],"entity_ids":["pharmacy-holdings","holdco","isl"],"qualification":"Aggregator data, not the primary register.","response":"","outcome":""},"reading":"Fact: The aggregator also lists 23ANDME PHARMACY HOLDINGS, INC. as a Delaware domestic corporation, company number 7632876, with Incorporating Services, Ltd as registered agent and 23andMe Holding Co. as parent company; the page does not show the Chrome Pharmacy Holdings name."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-id-colorado","record":{"id":"c-id-colorado","kind":"fact","text":"Colorado's Secretary of State records ChromeCo, Inc., a Delaware corporation registered in Colorado as a foreign corporation on March 24, 2016 under ID 20161206900, as Withdrawn: it relinquished its authority to do business in Colorado on August 6, 2026. The record gives its principal office as 490 Post St., PMP 2065 Room 500, San Francisco.","source_ids":["src-087"],"entity_ids":["inc"],"qualification":"","response":"","outcome":""},"reading":"Fact: Colorado's Secretary of State records ChromeCo, Inc., a Delaware corporation registered in Colorado as a foreign corporation on March 24, 2016 under ID 20161206900, as Withdrawn: it relinquished its authority to do business in Colorado on August 6, 2026. The record gives its principal office as 490 Post St., PMP 2065 Room 500, San Francisco."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-spac-blank-check","record":{"id":"c-spac-blank-check","kind":"fact","text":"VG Acquisition Corp. (VGAC) was a blank check company incorporated in the Cayman Islands on February 19, 2020 to effect a business combination; it completed its initial public offering on October 6, 2020, selling 50,855,000 units at $10.00 each, including units sold to the underwriters on October 16, 2020 under their over-allotment option.","source_ids":["src-011"],"entity_ids":["holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: VG Acquisition Corp. (VGAC) was a blank check company incorporated in the Cayman Islands on February 19, 2020 to effect a business combination; it completed its initial public offering on October 6, 2020, selling 50,855,000 units at $10.00 each, including units sold to the underwriters on October 16, 2020 under their over-allotment option."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-spac-sponsor-chain","record":{"id":"c-spac-sponsor-chain","kind":"fact","text":"VGAC's 2020 annual report states that its sponsor, VG Acquisition Sponsor LLC, held all 12,623,750 founder shares, 99.29% of the Class B ordinary shares and 19.86% of all ordinary shares, and that before the business combination only holders of founder shares could vote on the election of directors. Corvina Holdings Limited, a British Virgin Islands company wholly owned by Virgin Group Holdings Limited, was the sponsor's sole managing member and manager; Virgin Group Holdings was owned by Sir Richard Branson, who could appoint and remove its management and so may indirectly control its voting and disposition decisions and be deemed the indirect beneficial owner of the sponsor's shares.","source_ids":["src-011"],"entity_ids":["holdco","vgac-sponsor","corvina","vghl","branson"],"qualification":"","response":"","outcome":""},"reading":"Fact: VGAC's 2020 annual report states that its sponsor, VG Acquisition Sponsor LLC, held all 12,623,750 founder shares, 99.29% of the Class B ordinary shares and 19.86% of all ordinary shares, and that before the business combination only holders of founder shares could vote on the election of directors. Corvina Holdings Limited, a British Virgin Islands company wholly owned by Virgin Group Holdings Limited, was the sponsor's sole managing member and manager; Virgin Group Holdings was owned by Sir Richard Branson, who could appoint and remove its management and so may indirectly control its voting and disposition decisions and be deemed the indirect beneficial owner of the sponsor's shares."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-spac-13g","record":{"id":"c-spac-13g","kind":"fact","text":"A Schedule 13G for December 31, 2020, filed jointly by VG Acquisition Sponsor LLC (a Cayman Islands company at 65 Bleecker Street, New York), Corvina Holdings Limited, Virgin Group Holdings Limited (both British Virgin Islands companies at Craigmuir Chambers, Road Town, Tortola) and Sir Richard Branson, reports the sponsor's 12,623,750 Class B shares as 19.86% of VGAC's ordinary shares.","source_ids":["src-055"],"entity_ids":["vgac-sponsor","corvina","vghl","branson","holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: A Schedule 13G for December 31, 2020, filed jointly by VG Acquisition Sponsor LLC (a Cayman Islands company at 65 Bleecker Street, New York), Corvina Holdings Limited, Virgin Group Holdings Limited (both British Virgin Islands companies at Craigmuir Chambers, Road Town, Tortola) and Sir Richard Branson, reports the sponsor's 12,623,750 Class B shares as 19.86% of VGAC's ordinary shares."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-spac-officers","record":{"id":"c-spac-officers","kind":"fact","text":"Before the merger VGAC's chief executive officer and director was Josh Bayliss and its chief financial officer and director was Evan Lovell, both in office since the company's formation in February 2020; Teresa Briggs, James B. Lockhart III and Douglas R. Brown were its other directors. When the business combination closed each of VGAC's officers and directors ceased serving the company, although Lovell was among those elected to the combined company's board.","source_ids":["src-011","src-007"],"entity_ids":["holdco","bayliss","lovell","briggs","lockhart","brown"],"qualification":"","response":"","outcome":""},"reading":"Fact: Before the merger VGAC's chief executive officer and director was Josh Bayliss and its chief financial officer and director was Evan Lovell, both in office since the company's formation in February 2020; Teresa Briggs, James B. Lockhart III and Douglas R. Brown were its other directors. When the business combination closed each of VGAC's officers and directors ceased serving the company, although Lovell was among those elected to the combined company's board."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-spac-bayliss","record":{"id":"c-spac-bayliss","kind":"fact","text":"According to VGAC's 2020 annual report, Josh Bayliss had been chief executive officer of the Virgin Group since 2011 and its general counsel from 2005 to 2011, was also chief executive officer and a director of the sister blank check companies VGAC II and VGAC III, and was a director of Virgin Group Holdings Limited, Corvina Holdings Limited, Virgin Investments Limited, Virgin Entertainment Holdings, Inc. and Virgin Red Limited.","source_ids":["src-011"],"entity_ids":["bayliss","holdco","vgac-ii","vgac-iii","vghl","corvina","virgin-investments","virgin-entertainment","virgin-red"],"qualification":"","response":"","outcome":""},"reading":"Fact: According to VGAC's 2020 annual report, Josh Bayliss had been chief executive officer of the Virgin Group since 2011 and its general counsel from 2005 to 2011, was also chief executive officer and a director of the sister blank check companies VGAC II and VGAC III, and was a director of Virgin Group Holdings Limited, Corvina Holdings Limited, Virgin Investments Limited, Virgin Entertainment Holdings, Inc. and Virgin Red Limited."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-spac-lovell","record":{"id":"c-spac-lovell","kind":"fact","text":"According to the same report, Evan Lovell had been the Virgin Group's chief investment officer since 2012, was a founding partner of the Virgin Green Fund from 2008 to 2012, worked at TPG Capital from 1998 to 2008, was chief financial officer and a director of VGAC II and VGAC III, and sat on boards including that of Virgin Galactic, from 2017.","source_ids":["src-011"],"entity_ids":["lovell","holdco","vgac-ii","vgac-iii","virgin-green-fund","tpg","virgin-galactic"],"qualification":"","response":"","outcome":""},"reading":"Fact: According to the same report, Evan Lovell had been the Virgin Group's chief investment officer since 2012, was a founding partner of the Virgin Green Fund from 2008 to 2012, worked at TPG Capital from 1998 to 2008, was chief financial officer and a director of VGAC II and VGAC III, and sat on boards including that of Virgin Galactic, from 2017."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-spac-briggs","record":{"id":"c-spac-briggs","kind":"fact","text":"Teresa Briggs, an independent VGAC director from its initial public offering and chair of its audit committee, had been Vice Chair and West Region and San Francisco Managing Partner of Deloitte LLP from June 2011 to April 2019 and Managing Partner, Silicon Valley from 2006 to 2011, and served on the boards of Snowflake, ServiceNow, DocuSign and JAND, Inc. (Warby Parker).","source_ids":["src-011"],"entity_ids":["briggs","holdco","deloitte-llp","snowflake","servicenow","docusign","jand"],"qualification":"","response":"","outcome":""},"reading":"Fact: Teresa Briggs, an independent VGAC director from its initial public offering and chair of its audit committee, had been Vice Chair and West Region and San Francisco Managing Partner of Deloitte LLP from June 2011 to April 2019 and Managing Partner, Silicon Valley from 2006 to 2011, and served on the boards of Snowflake, ServiceNow, DocuSign and JAND, Inc. (Warby Parker)."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-spac-lockhart","record":{"id":"c-spac-lockhart","kind":"fact","text":"James B. Lockhart III, an independent VGAC director from its initial public offering, had been Vice Chairman of the private equity firm WL Ross & Co. LLC from 2009 through 2018 and earlier Director of the Federal Housing Finance Agency, Director of its predecessor, the Office of Federal Housing Enterprise Oversight, and a member of the Troubled Asset Relief Program's Financial Stability Oversight Board; he had also served on the board of Virgin Money Holdings (UK).","source_ids":["src-011"],"entity_ids":["lockhart","holdco","wl-ross","virgin-money"],"qualification":"","response":"","outcome":""},"reading":"Fact: James B. Lockhart III, an independent VGAC director from its initial public offering, had been Vice Chairman of the private equity firm WL Ross & Co. LLC from 2009 through 2018 and earlier Director of the Federal Housing Finance Agency, Director of its predecessor, the Office of Federal Housing Enterprise Oversight, and a member of the Troubled Asset Relief Program's Financial Stability Oversight Board; he had also served on the board of Virgin Money Holdings (UK)."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-spac-brown","record":{"id":"c-spac-brown","kind":"fact","text":"Douglas R. Brown, an independent VGAC director from its initial public offering, founded AquaVenture Holdings in December 2006 and chaired it from January 2007 until its acquisition by Culligan in March 2020, served as chief executive officer of AquaVenture and of Seven Seas Water Corporation, was chief executive officer of Ionics, Incorporated from 2003 to 2005, spent 17 years at Advent International and was an operating partner of Element Partners.","source_ids":["src-011"],"entity_ids":["brown","holdco","aquaventure","seven-seas","ionics","advent","element-partners"],"qualification":"","response":"","outcome":""},"reading":"Fact: Douglas R. Brown, an independent VGAC director from its initial public offering, founded AquaVenture Holdings in December 2006 and chaired it from January 2007 until its acquisition by Culligan in March 2020, served as chief executive officer of AquaVenture and of Seven Seas Water Corporation, was chief executive officer of Ionics, Incorporated from 2003 to 2005, spent 17 years at Advent International and was an operating partner of Element Partners."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-spac-announcement","record":{"id":"c-spac-announcement","kind":"fact","text":"VGAC and 23andMe announced their merger agreement on February 4, 2021. The joint release said the combination valued 23andMe at an enterprise value of about $3.5 billion and was expected to deliver up to $759 million of gross proceeds, from up to $509 million in VGAC's trust account and a concurrent $250 million private placement (PIPE) at $10.00 per share; Sir Richard Branson and Anne Wojcicki were each investing $25 million in the PIPE, existing 23andMe shareholders would own 81% of the combined company, and Wojcicki called Branson an early investor in 23andMe.","source_ids":["src-083"],"entity_ids":["holdco","inc","branson","wojcicki"],"qualification":"These were the expected terms at signing; the amounts actually raised at closing differed after shareholder redemptions.","response":"","outcome":""},"reading":"Fact: VGAC and 23andMe announced their merger agreement on February 4, 2021. The joint release said the combination valued 23andMe at an enterprise value of about $3.5 billion and was expected to deliver up to $759 million of gross proceeds, from up to $509 million in VGAC's trust account and a concurrent $250 million private placement (PIPE) at $10.00 per share; Sir Richard Branson and Anne Wojcicki were each investing $25 million in the PIPE, existing 23andMe shareholders would own 81% of the combined company, and Wojcicki called Branson an early investor in 23andMe."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-spac-vote","record":{"id":"c-spac-vote","kind":"fact","text":"At VGAC's extraordinary general meeting on June 10, 2021, at which about 54.71% of the ordinary shares were represented, shareholders approved the business combination with 23andMe (30,391,593 votes for, 3,265,415 against and 1,121,337 abstentions), the transfer to Delaware with the change of name to 23andMe Holding Co., and the creation of Class B common stock carrying ten votes per share (29,496,733 for and 4,019,644 against).","source_ids":["src-099"],"entity_ids":["holdco","inc"],"qualification":"","response":"","outcome":""},"reading":"Fact: At VGAC's extraordinary general meeting on June 10, 2021, at which about 54.71% of the ordinary shares were represented, shareholders approved the business combination with 23andMe (30,391,593 votes for, 3,265,415 against and 1,121,337 abstentions), the transfer to Delaware with the change of name to 23andMe Holding Co., and the creation of Class B common stock carrying ten votes per share (29,496,733 for and 4,019,644 against)."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-spac-board-elect","record":{"id":"c-spac-board-elect","kind":"fact","text":"At the same meeting the holders of VGAC's 12,713,750 Class B ordinary shares voted, with none against, to elect Roelof Botha, Patrick Chung, Richard Scheller, Neal Mohan, Peter Taylor, Anne Wojcicki and Evan Lovell as directors of the combined company.","source_ids":["src-099"],"entity_ids":["holdco","botha","chung","scheller","mohan","taylor","wojcicki","lovell"],"qualification":"","response":"","outcome":""},"reading":"Fact: At the same meeting the holders of VGAC's 12,713,750 Class B ordinary shares voted, with none against, to elect Roelof Botha, Patrick Chung, Richard Scheller, Neal Mohan, Peter Taylor, Anne Wojcicki and Evan Lovell as directors of the combined company."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-spac-closing","record":{"id":"c-spac-closing","kind":"fact","text":"On June 16, 2021 VGAC deregistered in the Cayman Islands, was domesticated as a Delaware corporation and changed its name to 23andMe Holding Co.; the same day its wholly owned subsidiary Chrome Merger Sub, Inc. merged into 23andMe, Inc., which survived as a wholly owned subsidiary of 23andMe Holding Co. The merger agreement was dated February 4, 2021 and amended on February 13 and March 25, 2021.","source_ids":["src-007"],"entity_ids":["holdco","inc","chrome-merger-sub"],"qualification":"","response":"","outcome":""},"reading":"Fact: On June 16, 2021 VGAC deregistered in the Cayman Islands, was domesticated as a Delaware corporation and changed its name to 23andMe Holding Co.; the same day its wholly owned subsidiary Chrome Merger Sub, Inc. merged into 23andMe, Inc., which survived as a wholly owned subsidiary of 23andMe Holding Co. The merger agreement was dated February 4, 2021 and amended on February 13 and March 25, 2021."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-spac-same-registrant","record":{"id":"c-spac-same-registrant","kind":"fact","text":"The listed company that later filed for Chapter 11 as 23andMe Holding Co. is therefore the former VG Acquisition Corp.: its post-merger filings define it as \"23andMe Holding Co. (formerly known as VG Acquisition Corp.)\", while the genetic-testing business founded in 2006 is 23andMe, Inc., its subsidiary and accounting predecessor.","source_ids":["src-007","src-075","src-012"],"entity_ids":["holdco","inc"],"qualification":"","response":"","outcome":""},"reading":"Fact: The listed company that later filed for Chapter 11 as 23andMe Holding Co. is therefore the former VG Acquisition Corp.: its post-merger filings define it as \"23andMe Holding Co. (formerly known as VG Acquisition Corp.)\", while the genetic-testing business founded in 2006 is 23andMe, Inc., its subsidiary and accounting predecessor."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-spac-pipe","record":{"id":"c-spac-pipe","kind":"fact","text":"At signing, PIPE investors subscribed for 25,000,000 Class A shares at $10.00 per share, for gross proceeds of $250,000,000; one of them was an affiliate of VG Acquisition Sponsor LLC, which subscribed for 2,500,000 shares, and the Anne Wojcicki Foundation bought 2,500,000 shares in the PIPE. Holders of 16,667,061 VGAC Class A shares redeemed them. Immediately after closing there were 92,655,484 Class A shares, 313,759,355 Class B shares and 25,065,665 warrants outstanding.","source_ids":["src-007"],"entity_ids":["holdco","vgac-sponsor","aw-foundation"],"qualification":"","response":"","outcome":""},"reading":"Fact: At signing, PIPE investors subscribed for 25,000,000 Class A shares at $10.00 per share, for gross proceeds of $250,000,000; one of them was an affiliate of VG Acquisition Sponsor LLC, which subscribed for 2,500,000 shares, and the Anne Wojcicki Foundation bought 2,500,000 shares in the PIPE. Holders of 16,667,061 VGAC Class A shares redeemed them. Immediately after closing there were 92,655,484 Class A shares, 313,759,355 Class B shares and 25,065,665 warrants outstanding."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-spac-proceeds","record":{"id":"c-spac-proceeds","kind":"fact","text":"According to the declaration of the chief restructuring officer filed on the first day of the Chapter 11 case, the 2021 merger with VGAC generated about $592 million of gross proceeds.","source_ids":["src-031"],"entity_ids":["holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: According to the declaration of the chief restructuring officer filed on the first day of the Chapter 11 case, the 2021 merger with VGAC generated about $592 million of gross proceeds."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ctl-dual-class","record":{"id":"c-ctl-dual-class","kind":"fact","text":"23andMe Holding Co. had two classes of common stock: Class A, with one vote per share and listed until March 2025, and Class B, with ten votes per share, which was not listed, could be converted into Class A one-for-one at the holder's option and converted automatically on most transfers.","source_ids":["src-004","src-012"],"entity_ids":["holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: 23andMe Holding Co. had two classes of common stock: Class A, with one vote per share and listed until March 2025, and Class B, with ten votes per share, which was not listed, could be converted into Class A one-for-one at the holder's option and converted automatically on most transfers."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ctl-2021","record":{"id":"c-ctl-2021","kind":"fact","text":"Immediately after the June 16, 2021 merger, the closing Form 8-K reported Anne Wojcicki as beneficial owner of 102,453,219 Class A shares counting her convertible Class B stock (25.21%) and of 98,702,638 Class B shares held through ABeeC 2.0, LLC (24.29%), together 30.67% of the total voting power; the other large holders were ABeeC 2.0, LLC itself (30.56% of the vote), Glaxo Group Limited (12.28%), entities affiliated with G Squared Equity Management LP (9.44%) and entities affiliated with FMR LLC (7.79%).","source_ids":["src-007"],"entity_ids":["wojcicki","abeec","holdco","glaxo-group","g-squared","fmr"],"qualification":"","response":"","outcome":""},"reading":"Fact: Immediately after the June 16, 2021 merger, the closing Form 8-K reported Anne Wojcicki as beneficial owner of 102,453,219 Class A shares counting her convertible Class B stock (25.21%) and of 98,702,638 Class B shares held through ABeeC 2.0, LLC (24.29%), together 30.67% of the total voting power; the other large holders were ABeeC 2.0, LLC itself (30.56% of the vote), Glaxo Group Limited (12.28%), entities affiliated with G Squared Equity Management LP (9.44%) and entities affiliated with FMR LLC (7.79%)."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ctl-2024-wojcicki","record":{"id":"c-ctl-2024-wojcicki","kind":"fact","text":"The 2024 proxy statement reports that on July 1, 2024 ABeeC 2.0, LLC held 98,633,827 Class B shares, 59.24% of that class and 49.20% of the total vote. The Anne Wojcicki Revocable Trust U/A/D 9/2/09 was the LLC's sole member and Anne Wojcicki its sole trustee, and the LLC, the trust and Wojcicki shared power to vote and dispose of those shares; counting 10,880,319 Class A shares, including 2,500,000 held by the Anne Wojcicki Foundation, Wojcicki held 49.75% of the total voting power.","source_ids":["src-004"],"entity_ids":["abeec","aw-trust","wojcicki","aw-foundation","holdco"],"qualification":"Share counts are before the 1-for-20 reverse stock split completed on October 16, 2024.","response":"","outcome":""},"reading":"Fact: The 2024 proxy statement reports that on July 1, 2024 ABeeC 2.0, LLC held 98,633,827 Class B shares, 59.24% of that class and 49.20% of the total vote. The Anne Wojcicki Revocable Trust U/A/D 9/2/09 was the LLC's sole member and Anne Wojcicki its sole trustee, and the LLC, the trust and Wojcicki shared power to vote and dispose of those shares; counting 10,880,319 Class A shares, including 2,500,000 held by the Anne Wojcicki Foundation, Wojcicki held 49.75% of the total voting power."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ctl-2024-holders","record":{"id":"c-ctl-2024-holders","kind":"fact","text":"The same table lists the other holders of more than 5% on July 1, 2024: GSK plc, whose indirect subsidiary Glaxo Group Limited held 39,660,487 Class B shares (23.82% of the class, 19.78% of the vote); entities affiliated with Sequoia Capital with 17,818,440 Class B shares (10.70%, 8.89% of the vote), over which Douglas M. Leone and Roelof Botha, as directors and stockholders of SC US (TTGP), Ltd., exercised voting and investment discretion; The Vanguard Group with 22,554,104 Class A shares (6.64%, 1.13% of the vote); and NewView Capital Fund I, L.P. with 19,455,681 Class A shares (5.73%, 0.97% of the vote).","source_ids":["src-004"],"entity_ids":["gsk","glaxo-group","sc-us-ttgp","botha","vanguard","newview","holdco"],"qualification":"Share counts are before the 1-for-20 reverse stock split completed on October 16, 2024.","response":"","outcome":""},"reading":"Fact: The same table lists the other holders of more than 5% on July 1, 2024: GSK plc, whose indirect subsidiary Glaxo Group Limited held 39,660,487 Class B shares (23.82% of the class, 19.78% of the vote); entities affiliated with Sequoia Capital with 17,818,440 Class B shares (10.70%, 8.89% of the vote), over which Douglas M. Leone and Roelof Botha, as directors and stockholders of SC US (TTGP), Ltd., exercised voting and investment discretion; The Vanguard Group with 22,554,104 Class A shares (6.64%, 1.13% of the vote); and NewView Capital Fund I, L.P. with 19,455,681 Class A shares (5.73%, 0.97% of the vote)."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ctl-13d-filings","record":{"id":"c-ctl-13d-filings","kind":"fact","text":"ABeeC 2.0, LLC, the trust and Anne Wojcicki filed their first Schedule 13D on the company on June 25, 2021 and twelve amendments between April 17, 2024 and March 11, 2025, followed by Amendment No. 13 reporting events of May and June 2025.","source_ids":["src-005"],"entity_ids":["abeec","aw-trust","wojcicki","holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: ABeeC 2.0, LLC, the trust and Anne Wojcicki filed their first Schedule 13D on the company on June 25, 2021 and twelve amendments between April 17, 2024 and March 11, 2025, followed by Amendment No. 13 reporting events of May and June 2025."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ctl-2025-early","record":{"id":"c-ctl-2025-early","kind":"fact","text":"Schedule 13D amendments of February and March 2025 report that ABeeC 2.0, LLC, a manager-managed Delaware company whose filings were signed by its manager Ryan Batenchuk, owned 4,931,692 Class B shares, 69.4% of the class at January 31, 2025 and 69.5% at March 6, 2025, convertible into about 20% of the Class A stock. Wojcicki's total beneficial ownership was 5,651,888 Class A-equivalent shares (22.4%) in February and 5,659,700 (21.9%) in March 2025.","source_ids":["src-028","src-010","src-005"],"entity_ids":["abeec","batenchuk","aw-trust","wojcicki","holdco"],"qualification":"The filings state that Wojcicki disclaims beneficial ownership of the shares held by the LLC and by the Anne Wojcicki Foundation except to the extent of her pecuniary interest.","response":"","outcome":""},"reading":"Fact: Schedule 13D amendments of February and March 2025 report that ABeeC 2.0, LLC, a manager-managed Delaware company whose filings were signed by its manager Ryan Batenchuk, owned 4,931,692 Class B shares, 69.4% of the class at January 31, 2025 and 69.5% at March 6, 2025, convertible into about 20% of the Class A stock. Wojcicki's total beneficial ownership was 5,651,888 Class A-equivalent shares (22.4%) in February and 5,659,700 (21.9%) in March 2025."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ctl-awf-holding","record":{"id":"c-ctl-awf-holding","kind":"fact","text":"The Anne Wojcicki Foundation, a 501(c)(3) non-profit organization in Los Altos, California, held 125,000 Class A shares in 2025; Wojcicki, its President and Chairman of the Board, shared power to vote and dispose of them.","source_ids":["src-005"],"entity_ids":["aw-foundation","wojcicki","holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: The Anne Wojcicki Foundation, a 501(c)(3) non-profit organization in Los Altos, California, held 125,000 Class A shares in 2025; Wojcicki, its President and Chairman of the Board, shared power to vote and dispose of them."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ctl-conversion","record":{"id":"c-ctl-conversion","kind":"fact","text":"On June 9, 2025 ABeeC 2.0, LLC gave notice converting all its 4,931,692 Class B shares into the same number of Class A shares, and the company confirmed the conversion on June 11, 2025. Amendment No. 13 then reported Wojcicki as beneficial owner of 5,722,832 Class A shares, 22% of that class: 62,530 held directly, 603,610 options vesting within sixty days, the LLC's 4,931,692 shares and the foundation's 125,000.","source_ids":["src-005"],"entity_ids":["abeec","wojcicki","aw-foundation","holdco"],"qualification":"The percentages are based on 25,431,244 Class A shares outstanding on June 11, 2025; Wojcicki disclaims beneficial ownership of the LLC's and the foundation's shares except to the extent of her pecuniary interest.","response":"","outcome":""},"reading":"Fact: On June 9, 2025 ABeeC 2.0, LLC gave notice converting all its 4,931,692 Class B shares into the same number of Class A shares, and the company confirmed the conversion on June 11, 2025. Amendment No. 13 then reported Wojcicki as beneficial owner of 5,722,832 Class A shares, 22% of that class: 62,530 held directly, 603,610 options vesting within sixty days, the LLC's 4,931,692 shares and the foundation's 125,000."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ctl-2025-july","record":{"id":"c-ctl-2025-july","kind":"fact","text":"After the conversion, the July 2025 annual-report amendment shows Anne Wojcicki with 5,736,063 Class A shares on July 1, 2025, 22.56% of the class and 12.33% of the total vote, and no Class B shares; ABeeC 2.0, LLC held 4,931,692 Class A shares (19.39%, 10.60% of the vote), Zentree Investments Limited 3,699,236 (14.55%, 7.95%) and Farallon Capital Partners, L.P. 1,270,908 (5.00%, 2.73%). The other directors held no shares.","source_ids":["src-057"],"entity_ids":["wojcicki","abeec","zentree","farallon","holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: After the conversion, the July 2025 annual-report amendment shows Anne Wojcicki with 5,736,063 Class A shares on July 1, 2025, 22.56% of the class and 12.33% of the total vote, and no Class B shares; ABeeC 2.0, LLC held 4,931,692 Class A shares (19.39%, 10.60% of the vote), Zentree Investments Limited 3,699,236 (14.55%, 7.95%) and Farallon Capital Partners, L.P. 1,270,908 (5.00%, 2.73%). The other directors held no shares."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ctl-zentree-13g","record":{"id":"c-ctl-zentree-13g","kind":"fact","text":"Zentree Investments Limited, a Cayman Islands company with an address c/o Zentree Investment Management Pte Ltd in Singapore, and its director Richard Magides first reported a stake on Schedule 13G as passive investors: 878,813 Class A shares (5.02%) on November 8, 2024, of which Zentree held 20,000 and Magides 858,813.","source_ids":["src-058"],"entity_ids":["zentree","magides","zentree-im","holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: Zentree Investments Limited, a Cayman Islands company with an address c/o Zentree Investment Management Pte Ltd in Singapore, and its director Richard Magides first reported a stake on Schedule 13G as passive investors: 878,813 Class A shares (5.02%) on November 8, 2024, of which Zentree held 20,000 and Magides 858,813."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ctl-zentree-13d","record":{"id":"c-ctl-zentree-13d","kind":"fact","text":"On Schedule 13D Zentree and Richard Magides reported 2,639,190 Class A shares (13.0%) on March 12, 2025, bought by Magides with $9,340,639 of personal funds for his part, and 3,699,236 shares (18.2%) on March 28, 2025, of which Zentree held 566,643 and Magides 3,132,593. They stated that they sought a voice for minority investors, to prevent a sale of the company at an unreasonable price, more prudent cost management and equal rights for Class A and Class B shares.","source_ids":["src-009","src-021"],"entity_ids":["zentree","magides","holdco"],"qualification":"The stated purposes are the filers' own; the filings report no agreements with other persons.","response":"","outcome":""},"reading":"Fact: On Schedule 13D Zentree and Richard Magides reported 2,639,190 Class A shares (13.0%) on March 12, 2025, bought by Magides with $9,340,639 of personal funds for his part, and 3,699,236 shares (18.2%) on March 28, 2025, of which Zentree held 566,643 and Magides 3,132,593. They stated that they sought a voice for minority investors, to prevent a sale of the company at an unreasonable price, more prudent cost management and equal rights for Class A and Class B shares."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ctl-farallon","record":{"id":"c-ctl-farallon","kind":"fact","text":"Farallon Partners, L.L.C., the general partner of funds including Farallon Capital Partners, L.P., reported on Schedule 13G as a passive investor shared voting and dispositive power over 1,231,241 Class A shares (6% of the class) for an event date of June 13, 2025.","source_ids":["src-020"],"entity_ids":["farallon","holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: Farallon Partners, L.L.C., the general partner of funds including Farallon Capital Partners, L.P., reported on Schedule 13G as a passive investor shared voting and dispositive power over 1,231,241 Class A shares (6% of the class) for an event date of June 13, 2025."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ctl-avey","record":{"id":"c-ctl-avey","kind":"attributed","text":"Co-founder Linda Avey wrote on the social network X on March 26, 2025, as reported by a news outlet, that her time at the company was cut short in 2009 when Anne Wojcicki convinced the board that she should run it, that Wojcicki afterwards \"architected a majority vote for herself that eliminated board governance\", and that the 2024 board resignations came as no surprise.","source_ids":["src-112"],"entity_ids":["avey","wojcicki","inc"],"qualification":"This is Avey's personal account in a social-media post, carried by one news report; it is not a finding about the company's governance.","response":"The news report said 23andMe did not immediately respond to the outlet's request for comment; no response by Wojcicki to the post was found in the retained record.","outcome":""},"reading":"Attributed: Co-founder Linda Avey wrote on the social network X on March 26, 2025, as reported by a news outlet, that her time at the company was cut short in 2009 when Anne Wojcicki convinced the board that she should run it, that Wojcicki afterwards \"architected a majority vote for herself that eliminated board governance\", and that the 2024 board resignations came as no surprise."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-founding","record":{"id":"c-gov-founding","kind":"fact","text":"23andMe, Inc. was founded in 2006 by Anne Wojcicki, Linda Avey and Paul Cusenza as the first direct-to-consumer genetic testing company; by the time of the bankruptcy filing its research platform held data from over 15 million customers, according to the August 2025 disclosure statement.","source_ids":["src-012"],"entity_ids":["inc","wojcicki","avey","cusenza"],"qualification":"","response":"","outcome":""},"reading":"Fact: 23andMe, Inc. was founded in 2006 by Anne Wojcicki, Linda Avey and Paul Cusenza as the first direct-to-consumer genetic testing company; by the time of the bankruptcy filing its research platform held data from over 15 million customers, according to the August 2025 disclosure statement."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-wojcicki-roles","record":{"id":"c-gov-wojcicki-roles","kind":"fact","text":"Anne Wojcicki joined the board of 23andMe, Inc. in 2006, co-founded it that year and was its chief executive officer from 2010. She was elected to the board of 23andMe Holding Co. when the business combination closed and was appointed its chair effective June 16, 2021; in July 2024 she held the combined positions of chair and chief executive officer, and she was a non-independent director.","source_ids":["src-004","src-057","src-007"],"entity_ids":["wojcicki","inc","holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: Anne Wojcicki joined the board of 23andMe, Inc. in 2006, co-founded it that year and was its chief executive officer from 2010. She was elected to the board of 23andMe Holding Co. when the business combination closed and was appointed its chair effective June 16, 2021; in July 2024 she held the combined positions of chair and chief executive officer, and she was a non-independent director."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-wojcicki-background","record":{"id":"c-gov-wojcicki-background","kind":"fact","text":"Company filings describe Wojcicki's earlier work as a healthcare analyst at Passport Capital, LLC (2004–2006), Andor Capital Management (2001–2002), Ardsley Partners (1999–2000) and Investor AB (1996–1999). They list her as a board member of Zipline, Inc. and the Kaiser Permanente Bernard J. Tyson School of Medicine, a co-founder and board member of the Breakthrough Prize in Life Sciences, a board member of the Foundation for the National Institutes of Health from 2008 to 2016, a director of the blank check company AJAX I from 2020 to 2021 and a director of Cazoo Group Ltd. until 2022.","source_ids":["src-057","src-030"],"entity_ids":["wojcicki","passport","andor","ardsley","investor-ab","zipline","kp-school","breakthrough-prize","fnih","ajax","cazoo"],"qualification":"An aggregator dates the end of her Cazoo seat to February 27, 2023, later than the filings' 2022.","response":"","outcome":""},"reading":"Fact: Company filings describe Wojcicki's earlier work as a healthcare analyst at Passport Capital, LLC (2004–2006), Andor Capital Management (2001–2002), Ardsley Partners (1999–2000) and Investor AB (1996–1999). They list her as a board member of Zipline, Inc. and the Kaiser Permanente Bernard J. Tyson School of Medicine, a co-founder and board member of the Breakthrough Prize in Life Sciences, a board member of the Foundation for the National Institutes of Health from 2008 to 2016, a director of the blank check company AJAX I from 2020 to 2021 and a director of Cazoo Group Ltd. until 2022."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-wojcicki-pay","record":{"id":"c-gov-wojcicki-pay","kind":"fact","text":"In fiscal 2024 (to March 31, 2024) Wojcicki's base salary was raised from $64,480 to $66,560 on January 1, 2024 to comply with California minimum salary rules; the summary compensation table reports her fiscal-2024 compensation as $7,363,723, almost all of it stock options valued at $7,298,723.","source_ids":["src-004"],"entity_ids":["wojcicki","holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: In fiscal 2024 (to March 31, 2024) Wojcicki's base salary was raised from $64,480 to $66,560 on January 1, 2024 to comply with California minimum salary rules; the summary compensation table reports her fiscal-2024 compensation as $7,363,723, almost all of it stock options valued at $7,298,723."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-board-2021","record":{"id":"c-gov-board-2021","kind":"fact","text":"Effective June 16, 2021 the board also appointed Valerie Montgomery Rice as a Class II director and chair of its compensation committee.","source_ids":["src-007"],"entity_ids":["montgomery-rice","holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: Effective June 16, 2021 the board also appointed Valerie Montgomery Rice as a Class II director and chair of its compensation committee."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-lovell-end","record":{"id":"c-gov-lovell-end","kind":"fact","text":"Evan Lovell served as a Class III director until his death in June 2023, according to the 2024 proxy statement, which notes that his employer's policies prevented him from accepting compensation for board service; the board had nine members until June 2023 and eight in July 2024, divided into three classes.","source_ids":["src-004"],"entity_ids":["lovell","holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: Evan Lovell served as a Class III director until his death in June 2023, according to the 2024 proxy statement, which notes that his employer's policies prevented him from accepting compensation for board service; the board had nine members until June 2023 and eight in July 2024, divided into three classes."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-board-2024","record":{"id":"c-gov-board-2024","kind":"fact","text":"In July 2024 the board's eight directors were Roelof Botha, Patrick Chung, Sandra Hernández, Neal Mohan, Valerie Montgomery Rice, Richard Scheller, Peter Taylor and Anne Wojcicki; Peter Taylor, an independent director since 2021 who chaired the audit committee, and Wojcicki were nominated for re-election as Class III directors until 2027. KPMG LLP was proposed for ratification as auditor for the fiscal year ending March 31, 2025.","source_ids":["src-004"],"entity_ids":["botha","chung","hernandez","mohan","montgomery-rice","scheller","taylor","wojcicki","holdco","kpmg"],"qualification":"","response":"","outcome":""},"reading":"Fact: In July 2024 the board's eight directors were Roelof Botha, Patrick Chung, Sandra Hernández, Neal Mohan, Valerie Montgomery Rice, Richard Scheller, Peter Taylor and Anne Wojcicki; Peter Taylor, an independent director since 2021 who chaired the audit committee, and Wojcicki were nominated for re-election as Class III directors until 2027. KPMG LLP was proposed for ratification as auditor for the fiscal year ending March 31, 2025."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-botha","record":{"id":"c-gov-botha","kind":"fact","text":"Roelof Botha joined the 23andMe, Inc. board in 2017 and the holding company's board at the 2021 merger as an independent director; he had worked at the venture capital firm Sequoia Capital since 2003, as a Managing Member of Sequoia Capital Operations, LLC since 2007.","source_ids":["src-004"],"entity_ids":["botha","inc","holdco","sequoia-ops"],"qualification":"","response":"","outcome":""},"reading":"Fact: Roelof Botha joined the 23andMe, Inc. board in 2017 and the holding company's board at the 2021 merger as an independent director; he had worked at the venture capital firm Sequoia Capital since 2003, as a Managing Member of Sequoia Capital Operations, LLC since 2007."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-chung","record":{"id":"c-gov-chung","kind":"fact","text":"Patrick Chung joined the 23andMe, Inc. board in 2009 and the holding company's board at the 2021 merger; he had been Managing General Partner of Xfund since 2015, and the 2024 proxy attributes to him beneficial ownership of 1,141,824 Class B shares held by Xfund 2, L.P. and Xfund 2A, L.P.","source_ids":["src-004"],"entity_ids":["chung","inc","holdco","xfund"],"qualification":"","response":"","outcome":""},"reading":"Fact: Patrick Chung joined the 23andMe, Inc. board in 2009 and the holding company's board at the 2021 merger; he had been Managing General Partner of Xfund since 2015, and the 2024 proxy attributes to him beneficial ownership of 1,141,824 Class B shares held by Xfund 2, L.P. and Xfund 2A, L.P."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-scheller","record":{"id":"c-gov-scheller","kind":"fact","text":"Richard Scheller joined the 23andMe, Inc. board in 2019 and the holding company's board at the 2021 merger as a non-independent director; he had been Chief Scientific Officer and Head of Therapeutics of 23andMe, Inc. from 2015 until his retirement in 2019 and was Senior Advisor and Chairman of R&D of BridgeBio Pharma, Inc.","source_ids":["src-004"],"entity_ids":["scheller","inc","holdco","bridgebio"],"qualification":"","response":"","outcome":""},"reading":"Fact: Richard Scheller joined the 23andMe, Inc. board in 2019 and the holding company's board at the 2021 merger as a non-independent director; he had been Chief Scientific Officer and Head of Therapeutics of 23andMe, Inc. from 2015 until his retirement in 2019 and was Senior Advisor and Chairman of R&D of BridgeBio Pharma, Inc."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-mohan","record":{"id":"c-gov-mohan","kind":"fact","text":"Neal Mohan joined the 23andMe, Inc. board in 2017 and the holding company's board at the 2021 merger; he was chief executive officer of YouTube, Inc.","source_ids":["src-004"],"entity_ids":["mohan","inc","holdco","youtube"],"qualification":"","response":"","outcome":""},"reading":"Fact: Neal Mohan joined the 23andMe, Inc. board in 2017 and the holding company's board at the 2021 merger; he was chief executive officer of YouTube, Inc."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-hernandez","record":{"id":"c-gov-hernandez","kind":"fact","text":"Sandra Hernández was appointed to the holding company's board in November 2021; she had been president and chief executive officer of the California Health Care Foundation since 2014.","source_ids":["src-004"],"entity_ids":["hernandez","holdco","chcf"],"qualification":"","response":"","outcome":""},"reading":"Fact: Sandra Hernández was appointed to the holding company's board in November 2021; she had been president and chief executive officer of the California Health Care Foundation since 2014."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-montgomery-rice","record":{"id":"c-gov-montgomery-rice","kind":"fact","text":"Valerie Montgomery Rice, appointed to the board in June 2021, is the sixth president, and the dean, of Morehouse School of Medicine and the first woman to lead the institution.","source_ids":["src-004"],"entity_ids":["montgomery-rice","holdco","morehouse"],"qualification":"","response":"","outcome":""},"reading":"Fact: Valerie Montgomery Rice, appointed to the board in June 2021, is the sixth president, and the dean, of Morehouse School of Medicine and the first woman to lead the institution."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-officers-2024","record":{"id":"c-gov-officers-2024","kind":"fact","text":"The fiscal-2024 named executive officers were Anne Wojcicki (chief executive officer), Joseph Selsavage (chief financial and accounting officer, permanent in that post from May 2024), William Richards (Head of Therapeutics Discovery and an executive officer from August 8, 2023 until August 23, 2024), Kathy Hibbs (former Chief Administrative Officer) and Kenneth Hillan (former Chief Therapeutics Officer). On July 1, 2024 the ten current directors and executive officers as a group held 59.44% of the total voting power.","source_ids":["src-004","src-057"],"entity_ids":["wojcicki","selsavage","richards","hibbs","hillan","holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: The fiscal-2024 named executive officers were Anne Wojcicki (chief executive officer), Joseph Selsavage (chief financial and accounting officer, permanent in that post from May 2024), William Richards (Head of Therapeutics Discovery and an executive officer from August 8, 2023 until August 23, 2024), Kathy Hibbs (former Chief Administrative Officer) and Kenneth Hillan (former Chief Therapeutics Officer). On July 1, 2024 the ten current directors and executive officers as a group held 59.44% of the total voting power."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-officer-pay","record":{"id":"c-gov-officer-pay","kind":"fact","text":"The 2024 summary compensation table reports fiscal-2024 total compensation of $2,133,227 for Selsavage, $1,461,868 for Richards and $2,119,783 for Hibbs.","source_ids":["src-004"],"entity_ids":["selsavage","richards","hibbs","holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: The 2024 summary compensation table reports fiscal-2024 total compensation of $2,133,227 for Selsavage, $1,461,868 for Richards and $2,119,783 for Hibbs."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-hibbs-gc","record":{"id":"c-gov-hibbs-gc","kind":"fact","text":"A 2019 legal directory profile lists Kathy L. Hibbs as General Counsel of 23andMe in Mountain View, California.","source_ids":["src-110"],"entity_ids":["hibbs","inc"],"qualification":"","response":"","outcome":""},"reading":"Fact: A 2019 legal directory profile lists Kathy L. Hibbs as General Counsel of 23andMe in Mountain View, California."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-related-party","record":{"id":"c-gov-related-party","kind":"fact","text":"The 2024 proxy reports two related-party arrangements in fiscal 2024: the company treated Glaxo Group Limited as a holder of 5% or more because of an exclusive drug-discovery collaboration with a GSK affiliate from July 2018 to July 2023, amended in October 2023 into a non-exclusive licence to de-identified aggregate data; and 23andMe, Inc. paid director Richard Scheller $120,000 in fiscal 2024 under a consulting agreement in force from April 1, 2019 and extended by amendments to March 31, 2024.","source_ids":["src-004"],"entity_ids":["holdco","glaxo-group","gsk","scheller","inc"],"qualification":"","response":"","outcome":""},"reading":"Fact: The 2024 proxy reports two related-party arrangements in fiscal 2024: the company treated Glaxo Group Limited as a holder of 5% or more because of an exclusive drug-discovery collaboration with a GSK affiliate from July 2018 to July 2023, amended in October 2023 into a non-exclusive licence to de-identified aggregate data; and 23andMe, Inc. paid director Richard Scheller $120,000 in fiscal 2024 under a consulting agreement in force from April 1, 2019 and extended by amendments to March 31, 2024."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-twf","record":{"id":"c-gov-twf","kind":"fact","text":"In January 2024 the company entered into a five-year research services agreement with the Troper Wojcicki Foundation to build lung-cancer research cohorts from its phenotype and genotype data, with $5.4 million of fees under the first statement of work; the company treated the foundation as a related party because Susan Wojcicki, a sister of Anne Wojcicki, was then a director and officer of it. Revenue under the agreement was $0.7 million in fiscal 2025, with $1.4 million deferred at March 31, 2025.","source_ids":["src-057"],"entity_ids":["holdco","twf","susan-wojcicki","wojcicki"],"qualification":"","response":"","outcome":""},"reading":"Fact: In January 2024 the company entered into a five-year research services agreement with the Troper Wojcicki Foundation to build lung-cancer research cohorts from its phenotype and genotype data, with $5.4 million of fees under the first statement of work; the company treated the foundation as a related party because Susan Wojcicki, a sister of Anne Wojcicki, was then a director and officer of it. Revenue under the agreement was $0.7 million in fiscal 2025, with $1.4 million deferred at March 31, 2025."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-special-committee","record":{"id":"c-gov-special-committee","kind":"fact","text":"In March 2024 the board formed a Special Committee of independent directors with power to review strategic transactions, including any proposal from Wojcicki, because she and her affiliates, who held about 49% of the total voting power, could have interests different from those of other stockholders; the committee engaged Wells Fargo Securities, LLC as financial adviser and Dechert LLP as legal adviser.","source_ids":["src-012"],"entity_ids":["holdco","wojcicki"],"qualification":"","response":"","outcome":""},"reading":"Fact: In March 2024 the board formed a Special Committee of independent directors with power to review strategic transactions, including any proposal from Wojcicki, because she and her affiliates, who held about 49% of the total voting power, could have interests different from those of other stockholders; the committee engaged Wells Fargo Securities, LLC as financial adviser and Dechert LLP as legal adviser."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-go-private-2024","record":{"id":"c-gov-go-private-2024","kind":"fact","text":"In April 2024 Wojcicki disclosed in a Schedule 13D amendment that she was considering a proposal to take the company private, conditioned on approval by the Special Committee and a majority of unaffiliated shareholders, and that she wished to keep control and would not support an alternative transaction. On July 29, 2024 she proposed to buy all shares she and her affiliates did not own for $0.40 each, without committed financing; on August 2, 2024 the Special Committee rejected the proposal because it offered no premium to the market price, lacked committed financing and was conditional, and asked her to withdraw her opposition to third-party offers.","source_ids":["src-031","src-012"],"entity_ids":["wojcicki","holdco"],"qualification":"The $0.40 offer preceded the 1-for-20 reverse stock split of October 16, 2024 and equalled $8.00 per share after it.","response":"","outcome":""},"reading":"Fact: In April 2024 Wojcicki disclosed in a Schedule 13D amendment that she was considering a proposal to take the company private, conditioned on approval by the Special Committee and a majority of unaffiliated shareholders, and that she wished to keep control and would not support an alternative transaction. On July 29, 2024 she proposed to buy all shares she and her affiliates did not own for $0.40 each, without committed financing; on August 2, 2024 the Special Committee rejected the proposal because it offered no premium to the market price, lacked committed financing and was conditional, and asked her to withdraw her opposition to third-party offers."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-resignations","record":{"id":"c-gov-resignations","kind":"fact","text":"On September 17, 2024 all seven independent directors resigned with immediate effect: Roelof Botha, Patrick Chung, Sandra Hernández, Neal Mohan, Valerie Montgomery Rice, Richard Scheller and Peter J. Taylor, who between them made up the audit, compensation and special committees. In their letter they said they differed with Wojcicki on the company's strategic direction and that, given that difference and her concentrated voting power, resigning was in the best interest of stockholders; they also said they had not received an actionable proposal from her and did not expect one.","source_ids":["src-006","src-050","src-079","src-012"],"entity_ids":["botha","chung","hernandez","mohan","montgomery-rice","scheller","taylor","wojcicki","holdco"],"qualification":"","response":"According to a bankruptcy-data summary of the case, Wojcicki told employees in a memo that she was surprised and disappointed by the resignations.","outcome":"On October 28, 2024 the board was enlarged from one to four members with three new independent directors, who became the new Special Committee on November 2, 2024."},"reading":"Fact: On September 17, 2024 all seven independent directors resigned with immediate effect: Roelof Botha, Patrick Chung, Sandra Hernández, Neal Mohan, Valerie Montgomery Rice, Richard Scheller and Peter J. Taylor, who between them made up the audit, compensation and special committees. In their letter they said they differed with Wojcicki on the company's strategic direction and that, given that difference and her concentrated voting power, resigning was in the best interest of stockholders; they also said they had not received an actionable proposal from her and did not expect one."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-sole-director","record":{"id":"c-gov-sole-director","kind":"fact","text":"After the resignations Wojcicki was the company's sole director. In early September 2024 she had said she was open to third-party proposals, but in late September she amended her Schedule 13D to say she remained committed to acquiring the company and would not consider third-party takeover proposals; Wells Fargo ended its engagement with the Special Committee in October 2024.","source_ids":["src-012"],"entity_ids":["wojcicki","holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: After the resignations Wojcicki was the company's sole director. In early September 2024 she had said she was open to third-party proposals, but in late September she amended her Schedule 13D to say she remained committed to acquiring the company and would not consider third-party takeover proposals; Wells Fargo ended its engagement with the Special Committee in October 2024."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-new-board","record":{"id":"c-gov-new-board","kind":"fact","text":"On October 28, 2024 the board was enlarged from one to four members with the appointment of three independent directors: Jim Frankola (Class I, term to the 2025 annual meeting) and Andre Fernandez and Mark Jensen (Class II, to 2026). All three joined the audit and compensation committees, Fernandez chairing audit and Jensen compensation, and Jensen was designated Lead Independent Director; on November 2, 2024 they also became the Special Committee, which then engaged Moelis & Company and Goodwin Procter LLP. Each received $1 million in cash for service to the 2025 annual meeting, $800,000 at once and $20,000 a month, in place of the previous director pay policy.","source_ids":["src-022","src-012"],"entity_ids":["frankola","fernandez","jensen","holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: On October 28, 2024 the board was enlarged from one to four members with the appointment of three independent directors: Jim Frankola (Class I, term to the 2025 annual meeting) and Andre Fernandez and Mark Jensen (Class II, to 2026). All three joined the audit and compensation committees, Fernandez chairing audit and Jensen compensation, and Jensen was designated Lead Independent Director; on November 2, 2024 they also became the Special Committee, which then engaged Moelis & Company and Goodwin Procter LLP. Each received $1 million in cash for service to the 2025 annual meeting, $800,000 at once and $20,000 a month, in place of the previous director pay policy."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-jensen","record":{"id":"c-gov-jensen","kind":"fact","text":"Mark Jensen had been an executive of Deloitte & Touche LLP until retiring in 2012, as U.S. Managing Partner for audit and enterprise risk services in the technology industry and for its venture capital services group, and earlier chief financial officer of Redleaf Group and Managing Partner of Arthur Andersen LLP's Silicon Valley office; in October 2024 he was a director and audit committee chair of Lattice Semiconductor Corporation.","source_ids":["src-023"],"entity_ids":["jensen","deloitte-touche","redleaf","arthur-andersen","lattice"],"qualification":"","response":"","outcome":""},"reading":"Fact: Mark Jensen had been an executive of Deloitte & Touche LLP until retiring in 2012, as U.S. Managing Partner for audit and enterprise risk services in the technology industry and for its venture capital services group, and earlier chief financial officer of Redleaf Group and Managing Partner of Arthur Andersen LLP's Silicon Valley office; in October 2024 he was a director and audit committee chair of Lattice Semiconductor Corporation."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-jensen-lattice","record":{"id":"c-gov-jensen-lattice","kind":"fact","text":"Lattice Semiconductor's 2026 proxy statement says Mark Jensen had been its director since June 2013 and a director of Wolfspeed since May 2025, served on the board of Chrome Holding Co. (formerly 23andMe Holding Co.) from October 2024 to December 2025, and earlier sat on the boards of Exabeam, Unwired Planet, Control4 and ForeScout Technologies.","source_ids":["src-062"],"entity_ids":["jensen","lattice","wolfspeed","holdco","exabeam","unwired-planet","control4","forescout"],"qualification":"","response":"","outcome":""},"reading":"Fact: Lattice Semiconductor's 2026 proxy statement says Mark Jensen had been its director since June 2013 and a director of Wolfspeed since May 2025, served on the board of Chrome Holding Co. (formerly 23andMe Holding Co.) from October 2024 to December 2025, and earlier sat on the boards of Exabeam, Unwired Planet, Control4 and ForeScout Technologies."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-fernandez","record":{"id":"c-gov-fernandez","kind":"fact","text":"Andre Fernandez had been chief financial officer of WeWork, Inc. from 2022 to 2023 (WeWork filed for Chapter 11 in November 2023, five months after he left), executive vice president and chief financial officer of NCR Corporation from 2018 to 2020 and president and chief executive officer of CBS Radio Inc. from 2015 to 2017; in 2025 he was a principal of the consulting firm Domain Americas LLC and a director of Cardlytics, Inc. and Blackstone Infrastructure Strategies L.P., and had served on the boards of FaZe Holdings (2022–2024) and Sachem Acquisition Corp. (2021–2022).","source_ids":["src-057","src-023"],"entity_ids":["fernandez","wework","ncr","cbs-radio","domain-americas","cardlytics","blackstone-bis","faze","sachem"],"qualification":"","response":"","outcome":""},"reading":"Fact: Andre Fernandez had been chief financial officer of WeWork, Inc. from 2022 to 2023 (WeWork filed for Chapter 11 in November 2023, five months after he left), executive vice president and chief financial officer of NCR Corporation from 2018 to 2020 and president and chief executive officer of CBS Radio Inc. from 2015 to 2017; in 2025 he was a principal of the consulting firm Domain Americas LLC and a director of Cardlytics, Inc. and Blackstone Infrastructure Strategies L.P., and had served on the boards of FaZe Holdings (2022–2024) and Sachem Acquisition Corp. (2021–2022)."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-frankola","record":{"id":"c-gov-frankola","kind":"fact","text":"Jim Frankola had been chief financial officer of Cloudera, Inc. from 2012 to 2021 and of Yodlee, Inc. from 2010 to 2012, and earlier of Ariba, Inc.; in October 2024 he was a director and audit committee chair of Ansys, Inc. and a director of Skillsoft Corp. Ansys's 2025 proxy statement, which describes him as an independent director since 2021, lists his service on the 23andMe board from 2024.","source_ids":["src-023","src-106"],"entity_ids":["frankola","cloudera","yodlee","ariba","ansys","skillsoft","holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: Jim Frankola had been chief financial officer of Cloudera, Inc. from 2012 to 2021 and of Yodlee, Inc. from 2010 to 2012, and earlier of Ariba, Inc.; in October 2024 he was a director and audit committee chair of Ansys, Inc. and a director of Skillsoft Corp. Ansys's 2025 proxy statement, which describes him as an independent director since 2021, lists his service on the 23andMe board from 2024."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-strategic-review","record":{"id":"c-gov-strategic-review","kind":"fact","text":"On January 28, 2025 the Special Committee announced that it was exploring strategic alternatives, including a sale of the company or its assets, a business combination, licensing or a restructuring. In the pre-bankruptcy marketing process run with Moelis the company approached 103 potential counterparties (51 strategic and 52 financial), held 90 introductory calls and signed about 42 confidentiality agreements; at the Special Committee's request Wojcicki again said she would consider third-party proposals.","source_ids":["src-031","src-012"],"entity_ids":["holdco","wojcicki"],"qualification":"","response":"","outcome":""},"reading":"Fact: On January 28, 2025 the Special Committee announced that it was exploring strategic alternatives, including a sale of the company or its assets, a business combination, licensing or a restructuring. In the pre-bankruptcy marketing process run with Moelis the company approached 103 potential counterparties (51 strategic and 52 financial), held 90 introductory calls and signed about 42 confidentiality agreements; at the Special Committee's request Wojcicki again said she would consider third-party proposals."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-feb-march-2025","record":{"id":"c-gov-feb-march-2025","kind":"fact","text":"On February 20, 2025 Wojcicki and New Mountain Capital L.L.C. jointly proposed to buy the shares they did not own for $2.53 each; it was the only indication of interest in the process that offered to acquire all of the company's equity out of court. On March 3, 2025 Wojcicki disclosed that New Mountain had withdrawn and that on March 2 she had proposed $0.41 per share plus $30 million of unsecured financing until closing; the Special Committee rejected that proposal.","source_ids":["src-012","src-031"],"entity_ids":["wojcicki","new-mountain","holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: On February 20, 2025 Wojcicki and New Mountain Capital L.L.C. jointly proposed to buy the shares they did not own for $2.53 each; it was the only indication of interest in the process that offered to acquire all of the company's equity out of court. On March 3, 2025 Wojcicki disclosed that New Mountain had withdrawn and that on March 2 she had proposed $0.41 per share plus $30 million of unsecured financing until closing; the Special Committee rejected that proposal."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-march-2025-final","record":{"id":"c-gov-march-2025-final","kind":"fact","text":"On March 6, 2025 Wojcicki offered $0.41 per share in cash plus three contingent value rights worth up to $2.53 per share in total if revenue milestones were met in fiscal 2026 to 2028, with financing for the company at 7% interest until closing. On March 10 she added a $20 million commitment to fund operations, kept the condition of approval by the Special Committee and by a majority of shares not held by her, her affiliates or rolling-over holders, and later told the committee it was her best and final offer; the committee rejected it.","source_ids":["src-012","src-010"],"entity_ids":["wojcicki","holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: On March 6, 2025 Wojcicki offered $0.41 per share in cash plus three contingent value rights worth up to $2.53 per share in total if revenue milestones were met in fiscal 2026 to 2028, with financing for the company at 7% interest until closing. On March 10 she added a $20 million commitment to fund operations, kept the condition of approval by the Special Committee and by a majority of shares not held by her, her affiliates or rolling-over holders, and later told the committee it was her best and final offer; the committee rejected it."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-restructuring-authority","record":{"id":"c-gov-restructuring-authority","kind":"fact","text":"As a bankruptcy filing approached, the board on March 7, 2025 extended the Special Committee's authority to all restructuring matters, including directing a Chapter 11 filing; on March 16 the committee directed counsel to review the company's governance, financial transactions and operations for possible claims against directors, officers, shareholders and other insiders; and on March 21 it approved the Chapter 11 filing and the sale-procedures motion, having concluded that none of the indications of interest, including Wojcicki's, was actionable out of court or in the company's best interest.","source_ids":["src-031","src-012"],"entity_ids":["holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: As a bankruptcy filing approached, the board on March 7, 2025 extended the Special Committee's authority to all restructuring matters, including directing a Chapter 11 filing; on March 16 the committee directed counsel to review the company's governance, financial transactions and operations for possible claims against directors, officers, shareholders and other insiders; and on March 21 it approved the Chapter 11 filing and the sale-procedures motion, having concluded that none of the indications of interest, including Wojcicki's, was actionable out of court or in the company's best interest."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-ceo-resignation","record":{"id":"c-gov-ceo-resignation","kind":"fact","text":"On March 21, 2025, by mutual agreement with the Special Committee, Wojcicki resigned as chief executive officer and president with effect from 5:00 p.m. Eastern Time on March 23, 2025, and stepped down as chair, remaining a Class III director. She also resigned as director and officer of 23andMe, Inc. and Lemonaid Health, Inc. and as an officer of 23andMe Pharmacy Holdings, Inc. and Lemonaid Pharmacy Holdings Inc.","source_ids":["src-002","src-012","src-031"],"entity_ids":["wojcicki","holdco","inc","lemonaid-health","pharmacy-holdings","lemonaid-pharmacy-holdings"],"qualification":"","response":"","outcome":""},"reading":"Fact: On March 21, 2025, by mutual agreement with the Special Committee, Wojcicki resigned as chief executive officer and president with effect from 5:00 p.m. Eastern Time on March 23, 2025, and stepped down as chair, remaining a Class III director. She also resigned as director and officer of 23andMe, Inc. and Lemonaid Health, Inc. and as an officer of 23andMe Pharmacy Holdings, Inc. and Lemonaid Pharmacy Holdings Inc."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-march-2025-appointments","record":{"id":"c-gov-march-2025-appointments","kind":"fact","text":"The same day the board appointed Mark Jensen chairman, Joseph Selsavage, the chief financial and accounting officer, interim chief executive officer and interim president from Wojcicki's departure, and Matthew Kvarda of Alvarez & Marsal North America, LLC, which had been retained as financial adviser in January 2025, chief restructuring officer from the filing date. It enlarged the board to five and appointed Thomas B. Walper as a Class III independent director and Special Committee member from the filing date, for $35,000 a month, of which $225,000 was payable upfront.","source_ids":["src-002","src-031"],"entity_ids":["jensen","selsavage","kvarda","alvarez-marsal","walper","holdco","wojcicki"],"qualification":"","response":"","outcome":""},"reading":"Fact: The same day the board appointed Mark Jensen chairman, Joseph Selsavage, the chief financial and accounting officer, interim chief executive officer and interim president from Wojcicki's departure, and Matthew Kvarda of Alvarez & Marsal North America, LLC, which had been retained as financial adviser in January 2025, chief restructuring officer from the filing date. It enlarged the board to five and appointed Thomas B. Walper as a Class III independent director and Special Committee member from the filing date, for $35,000 a month, of which $225,000 was payable upfront."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-investigation","record":{"id":"c-gov-investigation","kind":"fact","text":"On March 23, 2025 the Special Committee gave Walper its sole authority to conduct an independent investigation of the company's governance, financial transactions and operations to assess possible claims against insiders. Assisted by Goodwin and Paul, Weiss until mid-May 2025, he reviewed documents and interviewed management, current and former directors and Wojcicki. At the committee's insistence TTAM dropped from its bid the purchase of the estate's claims, including those against Wojcicki and former directors and officers, so that they were preserved for the estate.","source_ids":["src-012"],"entity_ids":["walper","holdco","wojcicki","ttam"],"qualification":"","response":"","outcome":""},"reading":"Fact: On March 23, 2025 the Special Committee gave Walper its sole authority to conduct an independent investigation of the company's governance, financial transactions and operations to assess possible claims against insiders. Assisted by Goodwin and Paul, Weiss until mid-May 2025, he reviewed documents and interviewed management, current and former directors and Wojcicki. At the committee's insistence TTAM dropped from its bid the purchase of the estate's claims, including those against Wojcicki and former directors and officers, so that they were preserved for the estate."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-guidelines","record":{"id":"c-gov-guidelines","kind":"fact","text":"The Special Committee also approved guidelines governing communications between Wojcicki and the company's management, subject to oversight by the committee and senior management.","source_ids":["src-012"],"entity_ids":["holdco","wojcicki"],"qualification":"","response":"","outcome":""},"reading":"Fact: The Special Committee also approved guidelines governing communications between Wojcicki and the company's management, subject to oversight by the committee and senior management."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-board-2025","record":{"id":"c-gov-board-2025","kind":"fact","text":"In July 2025 the board had five directors: Jim Frankola, Andre Fernandez, Mark Jensen, Thomas Walper and Anne Wojcicki, who sat on no committee and had served as chief executive officer and president until March 2025.","source_ids":["src-057"],"entity_ids":["frankola","fernandez","jensen","walper","wojcicki","holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: In July 2025 the board had five directors: Jim Frankola, Andre Fernandez, Mark Jensen, Thomas Walper and Anne Wojcicki, who sat on no committee and had served as chief executive officer and president until March 2025."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-walper","record":{"id":"c-gov-walper","kind":"fact","text":"The company describes Thomas Walper as a bankruptcy and restructuring lawyer who was a partner of Munger, Tolles & Olson LLP until 2025 and, between partnership terms, head of corporate restructuring at Plainfield Asset Management, a $5 billion investment firm in Greenwich, Connecticut. His Form 3 shows him as a director of 23andMe Holding Co. from March 23, 2025, owning no securities of the company.","source_ids":["src-057","src-092"],"entity_ids":["walper","munger","plainfield","holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: The company describes Thomas Walper as a bankruptcy and restructuring lawyer who was a partner of Munger, Tolles & Olson LLP until 2025 and, between partnership terms, head of corporate restructuring at Plainfield Asset Management, a $5 billion investment firm in Greenwich, Connecticut. His Form 3 shows him as a director of 23andMe Holding Co. from March 23, 2025, owning no securities of the company."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-walper-getty","record":{"id":"c-gov-walper-getty","kind":"fact","text":"On July 20, 2026 Getty Images Holdings, Inc. appointed Thomas Walper a Class I director under an independent director agreement paying $50,000 a month; an EDGAR full-text search shows Form 3 filings by him for two issuers only, 23andMe Holding Co. (event March 23, 2025) and Getty Images Holdings (event July 20, 2026).","source_ids":["src-090","src-091"],"entity_ids":["walper","getty","holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: On July 20, 2026 Getty Images Holdings, Inc. appointed Thomas Walper a Class I director under an independent director agreement paying $50,000 a month; an EDGAR full-text search shows Form 3 filings by him for two issuers only, 23andMe Holding Co. (event March 23, 2025) and Getty Images Holdings (event July 20, 2026)."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-selsavage","record":{"id":"c-gov-selsavage","kind":"fact","text":"Joseph Selsavage had been chief financial and accounting officer since August 2022 and interim chief executive officer since March 2025. He was earlier chief financial officer of Lemonaid Health, Inc. from 2020, a consultant at Red Eclipse Consulting (2018–2020), chief financial officer of Metromile, Inc. (2015–2018), vice president and chief financial officer of Hotwire.com, part of Expedia, Inc. (2001–2015), and controller of the International Brotherhood of Teamsters (1993–2001).","source_ids":["src-057"],"entity_ids":["selsavage","holdco","lemonaid-health","red-eclipse","metromile","hotwire"],"qualification":"An aggregator also lists him as chief executive of Lemonaid Health and ends his Lemonaid posts in 2025; the company's filings give only the chief financial officer post from 2020.","response":"","outcome":""},"reading":"Fact: Joseph Selsavage had been chief financial and accounting officer since August 2022 and interim chief executive officer since March 2025. He was earlier chief financial officer of Lemonaid Health, Inc. from 2020, a consultant at Red Eclipse Consulting (2018–2020), chief financial officer of Metromile, Inc. (2015–2018), vice president and chief financial officer of Hotwire.com, part of Expedia, Inc. (2001–2015), and controller of the International Brotherhood of Teamsters (1993–2001)."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-selsavage-titles","record":{"id":"c-gov-selsavage-titles","kind":"fact","text":"Selsavage signed the company's Form 8-K of August 15, 2025 as interim chief executive officer and chief financial and accounting officer, and its Form 8-K of December 4, 2025 as chief executive officer and chief financial and accounting officer.","source_ids":["src-008","src-015"],"entity_ids":["selsavage","holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: Selsavage signed the company's Form 8-K of August 15, 2025 as interim chief executive officer and chief financial and accounting officer, and its Form 8-K of December 4, 2025 as chief executive officer and chief financial and accounting officer."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-gov-kvarda","record":{"id":"c-gov-kvarda","kind":"fact","text":"Matthew Kvarda, chief restructuring officer from March 2025, is a Managing Director of Alvarez & Marsal North America, LLC with more than 30 years of restructuring experience, including interim chief financial officer roles at Revlon, TEAM, Inc. and Jacuzzi Brands. He held no shares and received no compensation directly from the company: under its engagement letter the company paid A&M $1,300 per hour of his service, with $750,000 of incentive compensation due on a Chapter 11 plan or a sale of all or a substantial portion of the assets. As interim chief financial officer of Revlon Consumer Products Corporation he signed a Sarbanes-Oxley certification of its 2022 annual report amendment on April 21, 2023.","source_ids":["src-057","src-026"],"entity_ids":["kvarda","alvarez-marsal","revlon","team-inc","jacuzzi","holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: Matthew Kvarda, chief restructuring officer from March 2025, is a Managing Director of Alvarez & Marsal North America, LLC with more than 30 years of restructuring experience, including interim chief financial officer roles at Revlon, TEAM, Inc. and Jacuzzi Brands. He held no shares and received no compensation directly from the company: under its engagement letter the company paid A&M $1,300 per hour of his service, with $750,000 of incentive compensation due on a Chapter 11 plan or a sale of all or a substantial portion of the assets. As interim chief financial officer of Revlon Consumer Products Corporation he signed a Sarbanes-Oxley certification of its 2022 annual report amendment on April 21, 2023."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-br-company-account","record":{"id":"c-br-company-account","kind":"fact","text":"In its August 2025 disclosure statement the company says that on October 1, 2023 a threat actor posted online a claim to hold 23andMe users' profile information. Its investigation with outside incident-response experts found that the actor had logged into about 0.1% of user accounts whose usernames and passwords had been reused from other, previously compromised websites, and, through those accounts, had reached information that users had chosen to share in the DNA Relatives and Connections features, so that personal information of about seven million customers was accessed without authorisation, generally ancestry information and, for a subset of accounts, genetics-based health information.","source_ids":["src-012"],"entity_ids":["holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: In its August 2025 disclosure statement the company says that on October 1, 2023 a threat actor posted online a claim to hold 23andMe users' profile information. Its investigation with outside incident-response experts found that the actor had logged into about 0.1% of user accounts whose usernames and passwords had been reused from other, previously compromised websites, and, through those accounts, had reached information that users had chosen to share in the DNA Relatives and Connections features, so that personal information of about seven million customers was accessed without authorisation, generally ancestry information and, for a subset of accounts, genetics-based health information."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-br-senate","record":{"id":"c-br-senate","kind":"fact","text":"Testifying to the Senate Judiciary Committee on June 11, 2025, interim chief executive Joseph Selsavage said the company learned in October 2023 that a threat actor had accessed about 14,000 accounts through credential stuffing and, through them, limited profile information of more than 6 million users who had opted into DNA Relatives. He said the company disabled affected accounts and the DNA Relatives feature, forced password resets for all users, engaged cybersecurity firms, notified law enforcement, regulators and customers, made two-step verification mandatory, and regretted the incident, which he named as one of the causes of the bankruptcy.","source_ids":["src-029"],"entity_ids":["selsavage","holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: Testifying to the Senate Judiciary Committee on June 11, 2025, interim chief executive Joseph Selsavage said the company learned in October 2023 that a threat actor had accessed about 14,000 accounts through credential stuffing and, through them, limited profile information of more than 6 million users who had opted into DNA Relatives. He said the company disabled affected accounts and the DNA Relatives feature, forced password resets for all users, engaged cybersecurity firms, notified law enforcement, regulators and customers, made two-step verification mandatory, and regretted the incident, which he named as one of the causes of the bankruptcy."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-br-regulator-scope","record":{"id":"c-br-regulator-scope","kind":"fact","text":"The Privacy Commissioner of Canada and the UK Information Commissioner, who investigated jointly, found that the attack began on April 29, 2023 and that over five months the hacker gained access to more than 18,000 customer accounts. 23andMe told them that almost 7 million customers were affected worldwide, including almost 320,000 in Canada and 155,600 in the UK; accessible data included information on health, race and ethnicity, relatives, date of birth, sex at birth and gender, much of it derived from DNA, and, through DNA Relatives, information about thousands of genetic relatives of each accessed account holder.","source_ids":["src-073"],"entity_ids":["inc"],"qualification":"","response":"","outcome":""},"reading":"Fact: The Privacy Commissioner of Canada and the UK Information Commissioner, who investigated jointly, found that the attack began on April 29, 2023 and that over five months the hacker gained access to more than 18,000 customer accounts. 23andMe told them that almost 7 million customers were affected worldwide, including almost 320,000 in Canada and 155,600 in the UK; accessible data included information on health, race and ethnicity, relatives, date of birth, sex at birth and gender, much of it derived from DNA, and, through DNA Relatives, information about thousands of genetic relatives of each accessed account holder."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-br-regulator-chronology","record":{"id":"c-br-regulator-chronology","kind":"fact","text":"The regulators' chronology records that in July 2023 the hacker logged into one free account more than a million times in a day, briefly taking the platform down, and later tried to start profile transfers in 400 accounts, which 23andMe investigated without recognising a wider breach; that in August 2023 a claim of stolen data of more than 10 million users, sent through the customer-service portal and repeated on Reddit, was dismissed by 23andMe as a hoax; and that in October 2023 the stolen data was advertised for sale on Reddit and 23andMe confirmed the breach.","source_ids":["src-073"],"entity_ids":["inc"],"qualification":"","response":"","outcome":""},"reading":"Fact: The regulators' chronology records that in July 2023 the hacker logged into one free account more than a million times in a day, briefly taking the platform down, and later tried to start profile transfers in 400 accounts, which 23andMe investigated without recognising a wider breach; that in August 2023 a claim of stolen data of more than 10 million users, sent through the customer-service portal and repeated on Reddit, was dismissed by 23andMe as a hoax; and that in October 2023 the stolen data was advertised for sale on Reddit and 23andMe confirmed the breach."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-br-regulator-safeguards","record":{"id":"c-br-regulator-safeguards","kind":"fact","text":"The two commissioners found that 23andMe lacked safeguards appropriate to the sensitivity of the data: multi-factor authentication was optional and used, with single sign-on, by fewer than 22% of customers, which 23andMe said it chose to avoid friction for users; passwords needed only eight characters; reused compromised passwords were not checked; raw DNA data had no extra protection; detection and logging failed to flag the attack; and after the breach it took four days to end all sessions and reset passwords and about a month to disable raw DNA downloads and make multi-factor authentication mandatory. The Privacy Commissioner of Canada held that 23andMe contravened Principle 4.7 of PIPEDA, and the UK Commissioner that it infringed Articles 5(1)(f) and 32(1) of the UK GDPR.","source_ids":["src-073"],"entity_ids":["inc"],"qualification":"","response":"23andMe informed both offices of security improvements implemented since the breach, many corresponding to concerns raised in the investigation.","outcome":"The Canadian Commissioner found the safeguards issue well-founded and resolved in light of those improvements.","adverse_subject_ids":["inc"]},"reading":"Fact: The two commissioners found that 23andMe lacked safeguards appropriate to the sensitivity of the data: multi-factor authentication was optional and used, with single sign-on, by fewer than 22% of customers, which 23andMe said it chose to avoid friction for users; passwords needed only eight characters; reused compromised passwords were not checked; raw DNA data had no extra protection; detection and logging failed to flag the attack; and after the breach it took four days to end all sessions and reset passwords and about a month to disable raw DNA downloads and make multi-factor authentication mandatory. The Privacy Commissioner of Canada held that 23andMe contravened Principle 4.7 of PIPEDA, and the UK Commissioner that it infringed Articles 5(1)(f) and 32(1) of the UK GDPR."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-br-regulator-notice","record":{"id":"c-br-regulator-notice","kind":"fact","text":"The commissioners also found 23andMe's breach notifications incomplete: its reports to them omitted known information, in particular about raw DNA data, and its notices to individuals did not fully describe the data involved or say that some of it had been posted for sale; holders of directly accessed accounts were notified only in January 2024, more than a month after the forensic analysis identified them. The Canadian Commissioner found contraventions of section 10.1 of PIPEDA and of the breach regulations, and the UK Commissioner breaches of Articles 33(3) and 34 of the UK GDPR.","source_ids":["src-073"],"entity_ids":["inc"],"qualification":"On timing, the Canadian Commissioner accepted that the report to the regulator was made as soon as feasible, and the UK Commissioner accepted 23andMe's explanation for not reporting within 72 hours.","response":"23andMe told both offices of improvements to its breach-notification process.","outcome":"The Canadian Commissioner found the notification issue well-founded and resolved."},"reading":"Fact: The commissioners also found 23andMe's breach notifications incomplete: its reports to them omitted known information, in particular about raw DNA data, and its notices to individuals did not fully describe the data involved or say that some of it had been posted for sale; holders of directly accessed accounts were notified only in January 2024, more than a month after the forensic analysis identified them. The Canadian Commissioner found contraventions of section 10.1 of PIPEDA and of the breach regulations, and the UK Commissioner breaches of Articles 33(3) and 34 of the UK GDPR."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-br-ico-penalty","record":{"id":"c-br-ico-penalty","kind":"fact","text":"On June 5, 2025 the UK Information Commissioner served a penalty notice, addressed to 23andMe, Inc. and 23andMe Holding Co., requiring 23andMe, Inc. to pay £2,310,000 for infringing Articles 5(1)(f) and 32(1) of the UK GDPR between May 25, 2018 and December 31, 2024. The Commissioner found that the attacker had obtained personal data of 155,592 UK customers over at least five months, including health and genetic data, that the data was offered for sale on online forums in August and October 2023 in posts indicating customers were targeted by racial and ethnic background, and that the seriousness was aggravated by the late detection and the incomplete notifications.","source_ids":["src-074"],"entity_ids":["inc","holdco"],"qualification":"","response":"23andMe argued in written and oral representations in April 2025 that, given its deteriorating finances, no monetary penalty should be imposed because it would deplete funds available to compensate claimants in the United States, Canada and the UK.","outcome":"The Commissioner reduced the penalty from the £4,593,750 proposed in the notice of intent, taking into account the parent company's finances, but rejected waiving it; the notice allowed an appeal to the First-tier Tribunal within 28 days, and the retained record does not show whether an appeal was brought.","adverse_subject_ids":["inc"]},"reading":"Fact: On June 5, 2025 the UK Information Commissioner served a penalty notice, addressed to 23andMe, Inc. and 23andMe Holding Co., requiring 23andMe, Inc. to pay £2,310,000 for infringing Articles 5(1)(f) and 32(1) of the UK GDPR between May 25, 2018 and December 31, 2024. The Commissioner found that the attacker had obtained personal data of 155,592 UK customers over at least five months, including health and genetic data, that the data was offered for sale on online forums in August and October 2023 in posts indicating customers were targeted by racial and ethnic background, and that the seriousness was aggravated by the late detection and the incomplete notifications."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-br-ico-amount","record":{"id":"c-br-ico-amount","kind":"fact","text":"The Commissioner calculated the penalty from the higher statutory maximum of £17.5 million, applying a turnover adjustment of 20%, because 23andMe Holding Co.'s projected turnover for its 2025 financial year was expected near the lower end of the £100–250 million band, and a seriousness adjustment of 60%, which gave £2,100,000; a 10% increase for aggravating factors brought it to £2,310,000, about 2.3% of the projected turnover. He noted the parent's accumulated deficit of $2.4 billion and $79.4 million of unrestricted cash at December 31, 2024, but made no further reduction for financial hardship because the company was using Chapter 11 to sell its business and intended to keep operating.","source_ids":["src-074"],"entity_ids":["inc","holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: The Commissioner calculated the penalty from the higher statutory maximum of £17.5 million, applying a turnover adjustment of 20%, because 23andMe Holding Co.'s projected turnover for its 2025 financial year was expected near the lower end of the £100–250 million band, and a seriousness adjustment of 60%, which gave £2,100,000; a 10% increase for aggravating factors brought it to £2,310,000, about 2.3% of the projected turnover. He noted the parent's accumulated deficit of $2.4 billion and $79.4 million of unrestricted cash at December 31, 2024, but made no further reduction for financial hardship because the company was using Chapter 11 to sell its business and intended to keep operating."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-br-regulatory-inquiries","record":{"id":"c-br-regulatory-inquiries","kind":"fact","text":"Before the bankruptcy, according to the disclosure statement, the Federal Trade Commission served a civil investigative demand about the incident in March 2024, attorneys general of 42 states and the District of Columbia opened a multistate investigation, and 12 foreign regulators made inquiries, including the joint Canadian and UK investigation begun in June 2024, which conducted three employee interviews; a UK firm also made a pre-arbitration demand on behalf of 3,720 UK customers.","source_ids":["src-012"],"entity_ids":["holdco"],"qualification":"","response":"","outcome":"","adverse_subject_ids":["holdco"]},"reading":"Fact: Before the bankruptcy, according to the disclosure statement, the Federal Trade Commission served a civil investigative demand about the incident in March 2024, attorneys general of 42 states and the District of Columbia opened a multistate investigation, and 12 foreign regulators made inquiries, including the joint Canadian and UK investigation begun in June 2024, which conducted three employee interviews; a UK firm also made a pre-arbitration demand on behalf of 3,720 UK customers."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-br-postpetition-regulators","record":{"id":"c-br-postpetition-regulators","kind":"fact","text":"After the bankruptcy filing the debtors reported, besides the UK penalty of £2,310,000 (about $3 million), a letter received on July 21, 2025 from the Spanish Data Protection Authority imposing a fine of 2,400,000 (about $2.8 million) over the incident, a civil investigative demand from the South Dakota Attorney General, and demand letters from shareholders about pre-bankruptcy conduct.","source_ids":["src-012"],"entity_ids":["holdco"],"qualification":"The disclosure statement prints the Spanish fine with a pound sign (£2,400,000); the Spanish decision itself was not retrieved.","response":"","outcome":""},"reading":"Fact: After the bankruptcy filing the debtors reported, besides the UK penalty of £2,310,000 (about $3 million), a letter received on July 21, 2025 from the Spanish Data Protection Authority imposing a fine of 2,400,000 (about $2.8 million) over the incident, a civil investigative demand from the South Dakota Attorney General, and demand letters from shareholders about pre-bankruptcy conduct."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-br-ca-allegations","record":{"id":"c-br-ca-allegations","kind":"attributed","text":"In a lawsuit announced on May 28, 2026, California's Attorney General alleges that a threat actor went undetected in 23andMe's systems for five months, using about 14,000 accounts accessed with credentials stolen in earlier breaches, including that of the partner genealogy site MyHeritage, and a coding error in the DNA Relatives feature to obtain data on nearly 7 million customers, including 855,541 Californians; that data of one million people was offered for sale on the dark web, advertised as belonging to Asian American and Pacific Islander and Jewish users; and that 23andMe told the public there was no security incident in its systems, downplayed the stolen data and blamed customers.","source_ids":["src-072"],"entity_ids":["holdco","california"],"qualification":"These are the Attorney General's allegations in a pending suit and press release; no court has ruled on them.","response":"The company's own account, given in its disclosure statement and in Senate testimony, attributes the access to reused passwords stolen from other websites and describes forced password resets, the temporary disabling of DNA Relatives and mandatory two-step verification after discovery.","outcome":"","adverse_subject_ids":["holdco"]},"reading":"Attributed: In a lawsuit announced on May 28, 2026, California's Attorney General alleges that a threat actor went undetected in 23andMe's systems for five months, using about 14,000 accounts accessed with credentials stolen in earlier breaches, including that of the partner genealogy site MyHeritage, and a coding error in the DNA Relatives feature to obtain data on nearly 7 million customers, including 855,541 Californians; that data of one million people was offered for sale on the dark web, advertised as belonging to Asian American and Pacific Islander and Jewish users; and that 23andMe told the public there was no security incident in its systems, downplayed the stolen data and blamed customers."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-br-ca-ransom","record":{"id":"c-br-ca-ransom","kind":"attributed","text":"California's complaint alleges that on October 7 and 8, 2023 the threat actor sent messages to three people, including Anne Wojcicki, then chief executive, and that between October 8 and 25, 2023 23andMe negotiated with the actor and paid $400,000 in cryptocurrency for a report of the vulnerabilities used and two more, destruction of the stolen data, deletion of posts about the breach and a cover story mitigating its severity, while its blog of October 6, 2023 said it had no indication of a security incident within its systems; the complaint says it is unknown whether the actor deleted any data.","source_ids":["src-076","src-075"],"entity_ids":["holdco","wojcicki","california"],"qualification":"These are the Attorney General's allegations; no court has found them proven, and the retained record contains no statement by the company or by Wojcicki answering the ransom allegation.","response":"No response by the company or the trust to the ransom allegation was found in the retained record; the trust's motion of May 31, 2026 to enforce the plan concerned whether California's claims were barred.","outcome":"","adverse_subject_ids":["holdco"]},"reading":"Attributed: California's complaint alleges that on October 7 and 8, 2023 the threat actor sent messages to three people, including Anne Wojcicki, then chief executive, and that between October 8 and 25, 2023 23andMe negotiated with the actor and paid $400,000 in cryptocurrency for a report of the vulnerabilities used and two more, destruction of the stolen data, deletion of posts about the breach and a cover story mitigating its severity, while its blog of October 6, 2023 said it had no indication of a security incident within its systems; the complaint says it is unknown whether the actor deleted any data."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-br-ca-warnings","record":{"id":"c-br-ca-warnings","kind":"attributed","text":"The complaint further alleges that 23andMe's engineers saw a suspicious spike in log-ins on July 6, 2023, with one actor making 1,300 log-in requests a minute from a single IP address, that its security team knew of the August 2023 Reddit post about stolen data two months before the October 1 date the company gives for its discovery, that the first dark-web post advertising its data appeared on August 11, 2023, and that it required multi-factor authentication only from November 6, 2023 and reset all passwords on October 10, 2023.","source_ids":["src-075"],"entity_ids":["holdco","california"],"qualification":"Allegations in the pending California complaint, which cites admissions by the company for the July and August events.","response":"","outcome":""},"reading":"Attributed: The complaint further alleges that 23andMe's engineers saw a suspicious spike in log-ins on July 6, 2023, with one actor making 1,300 log-in requests a minute from a single IP address, that its security team knew of the August 2023 Reddit post about stolen data two months before the October 1 date the company gives for its discovery, that the first dark-web post advertising its data appeared on August 11, 2023, and that it required multi-factor authentication only from November 6, 2023 and reset all passwords on October 10, 2023."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-st-litigation-scale","record":{"id":"c-st-litigation-scale","kind":"fact","text":"After the October 2023 disclosure the company faced more than 40 putative class actions, centralised as a multi-district action, arbitration claims asserted or threatened by about 35,000 claimants, and three class actions in Canadian courts, as well as government investigations in the United States and abroad; it settled some claims before the bankruptcy filing.","source_ids":["src-012"],"entity_ids":["holdco"],"qualification":"","response":"","outcome":"","adverse_subject_ids":["holdco"]},"reading":"Fact: After the October 2023 disclosure the company faced more than 40 putative class actions, centralised as a multi-district action, arbitration claims asserted or threatened by about 35,000 claimants, and three class actions in Canadian courts, as well as government investigations in the United States and abroad; it settled some claims before the bankruptcy filing."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-st-mdl","record":{"id":"c-st-mdl","kind":"fact","text":"On April 11, 2024 the Judicial Panel on Multidistrict Litigation centralised the federal class actions as MDL No. 3098 before Judge Edward M. Chen of the Northern District of California. On July 29, 2024 the parties signed a term sheet under which the company would pay $30.0 million to settle the claims of all affected U.S. persons, adopt cybersecurity business-practice measures and offer three years of privacy and monitoring services; on December 4, 2024 the MDL court granted preliminary conditional approval, excluding customers who had chosen arbitration. Nine similar suits were pending in California state courts, most brought by one firm, Potter Handy, LLP.","source_ids":["src-012"],"entity_ids":["holdco"],"qualification":"","response":"","outcome":"","adverse_subject_ids":["holdco"]},"reading":"Fact: On April 11, 2024 the Judicial Panel on Multidistrict Litigation centralised the federal class actions as MDL No. 3098 before Judge Edward M. Chen of the Northern District of California. On July 29, 2024 the parties signed a term sheet under which the company would pay $30.0 million to settle the claims of all affected U.S. persons, adopt cybersecurity business-practice measures and offer three years of privacy and monitoring services; on December 4, 2024 the MDL court granted preliminary conditional approval, excluding customers who had chosen arbitration. Nine similar suits were pending in California state courts, most brought by one firm, Potter Handy, LLP."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-st-march-2025","record":{"id":"c-st-march-2025","kind":"fact","text":"On March 21, 2025 the company settled with plaintiffs represented by Potter Handy, LLP in the California state actions and with arbitration claimants represented by Labaton Keller Sucharow, Levi & Korsinsky and Milberg Coleman Bryson Phillips Grossman; including earlier proposed settlements it had then agreed, subject to conditions, to pay a total of $37.5 million to settle claims of U.S. customers relating to the incident it had reported on October 10, 2023.","source_ids":["src-002"],"entity_ids":["holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: On March 21, 2025 the company settled with plaintiffs represented by Potter Handy, LLP in the California state actions and with arbitration claimants represented by Labaton Keller Sucharow, Levi & Korsinsky and Milberg Coleman Bryson Phillips Grossman; including earlier proposed settlements it had then agreed, subject to conditions, to pay a total of $37.5 million to settle claims of U.S. customers relating to the incident it had reported on October 10, 2023."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-st-class-agreements","record":{"id":"c-st-class-agreements","kind":"fact","text":"In the Chapter 11 case the debtors signed a U.S. Data Breach Class Settlement Agreement on August 4, 2025, allowing one class proof of claim with a minimum allowed amount of $30 million and capping cash distributions on it at $50 million, and a Canadian class settlement agreement in August 2025 capping distributions at $3.99 million.","source_ids":["src-012"],"entity_ids":["holdco"],"qualification":"The Canadian agreement was later replaced by an amended version of September 5, 2025 with a different cap (see the Canadian settlement).","response":"","outcome":""},"reading":"Fact: In the Chapter 11 case the debtors signed a U.S. Data Breach Class Settlement Agreement on August 4, 2025, allowing one class proof of claim with a minimum allowed amount of $30 million and capping cash distributions on it at $50 million, and a Canadian class settlement agreement in August 2025 capping distributions at $3.99 million."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-st-prelim-approvals","record":{"id":"c-st-prelim-approvals","kind":"fact","text":"On October 2, 2025 the bankruptcy court entered orders preliminarily approving three class settlements together: the Canadian breach settlement (Docket No. 1449), the U.S. breach settlement with the MDL class representatives (Docket No. 1450) and the Lemonaid tracking-pixel settlement (Docket No. 1451).","source_ids":["src-032"],"entity_ids":["holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: On October 2, 2025 the bankruptcy court entered orders preliminarily approving three class settlements together: the Canadian breach settlement (Docket No. 1449), the U.S. breach settlement with the MDL class representatives (Docket No. 1450) and the Lemonaid tracking-pixel settlement (Docket No. 1451)."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-st-arbitration","record":{"id":"c-st-arbitration","kind":"fact","text":"On November 17, 2025 the debtors and claimants represented by Labaton, Levi, Milberg and Tycko & Zavareei LLP signed the U.S. Data Breach Arbitration Agreement resolving about 32,000 arbitration claims arising from the incident; the bankruptcy court approved it on November 19, 2025 (Docket No. 1638).","source_ids":["src-032"],"entity_ids":["holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: On November 17, 2025 the debtors and claimants represented by Labaton, Levi, Milberg and Tycko & Zavareei LLP signed the U.S. Data Breach Arbitration Agreement resolving about 32,000 arbitration claims arising from the incident; the bankruptcy court approved it on November 19, 2025 (Docket No. 1638)."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-st-us-final","record":{"id":"c-st-us-final","kind":"fact","text":"The court-authorised settlement website for In re: 23andMe, Inc. Customer Data Security Breach Litigation, which covers about 6.4 million U.S. residents affected by the attack announced on October 6, 2023, states that the bankruptcy court granted final approval on January 30, 2026, approved a final settlement amount of $46.75 million on July 7, 2026, and that payments on approved claims were issued on September 29 and 30, 2026; the benefits included reimbursement of documented extraordinary losses up to $10,000 and five years of privacy and genetic monitoring.","source_ids":["src-084"],"entity_ids":["inc","holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: The court-authorised settlement website for In re: 23andMe, Inc. Customer Data Security Breach Litigation, which covers about 6.4 million U.S. residents affected by the attack announced on October 6, 2023, states that the bankruptcy court granted final approval on January 30, 2026, approved a final settlement amount of $46.75 million on July 7, 2026, and that payments on approved claims were issued on September 29 and 30, 2026; the benefits included reimbursement of documented extraordinary losses up to $10,000 and five years of privacy and genetic monitoring."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-st-news-july-2026","record":{"id":"c-st-news-july-2026","kind":"fact","text":"A news agency reported on July 7, 2026 that Judge Brian Walsh had approved the $46.75 million settlement as fair and equitable and in the best interest of the trust run by the bankruptcy administrator, and that the amount would be reduced by $14.29 million already disbursed, leaving an additional payout of $32.46 million.","source_ids":["src-043"],"entity_ids":["holdco"],"qualification":"News report of the hearing; the order itself was not retrieved.","response":"","outcome":""},"reading":"Fact: A news agency reported on July 7, 2026 that Judge Brian Walsh had approved the $46.75 million settlement as fair and equitable and in the best interest of the trust run by the bankruptcy administrator, and that the amount would be reduced by $14.29 million already disbursed, leaving an additional payout of $32.46 million."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-st-canada-suits","record":{"id":"c-st-canada-suits","kind":"fact","text":"In Canada, plaintiffs filed J.R. v. 23andMe Holding Co. & 23andMe, Inc. (Supreme Court of British Columbia, No. S237147) on October 20, 2023 and on September 18, 2024 a second action, J.R. and M.M. v. 23andMe Holding Co. et al. (No. S-246520), adding current and former directors and officers and the auditor KPMG LLP (United States) as defendants; a proposed class action filed in the Ontario Superior Court on November 24, 2023 was stayed by agreement on April 11, 2024 in favour of the British Columbia actions.","source_ids":["src-012","src-039"],"entity_ids":["holdco","inc","kpmg"],"qualification":"The chief restructuring officer's first-day declaration counts two Canadian class actions, one in Ontario and one in British Columbia; the disclosure statement counts three.","response":"","outcome":"","adverse_subject_ids":["holdco","inc"]},"reading":"Fact: In Canada, plaintiffs filed J.R. v. 23andMe Holding Co. & 23andMe, Inc. (Supreme Court of British Columbia, No. S237147) on October 20, 2023 and on September 18, 2024 a second action, J.R. and M.M. v. 23andMe Holding Co. et al. (No. S-246520), adding current and former directors and officers and the auditor KPMG LLP (United States) as defendants; a proposed class action filed in the Ontario Superior Court on November 24, 2023 was stayed by agreement on April 11, 2024 in favour of the British Columbia actions."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-st-canada-stay","record":{"id":"c-st-canada-stay","kind":"fact","text":"On June 5, 2025 the bankruptcy court entered a stipulated order temporarily staying the Canadian proceedings and extending the automatic stay to the directors and officers and to KPMG.","source_ids":["src-039"],"entity_ids":["holdco","kpmg"],"qualification":"","response":"","outcome":""},"reading":"Fact: On June 5, 2025 the bankruptcy court entered a stipulated order temporarily staying the Canadian proceedings and extending the automatic stay to the directors and officers and to KPMG."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-st-ccaa","record":{"id":"c-st-ccaa","kind":"fact","text":"The U.S. Chapter 11 cases of 23andMe Holding Co. and 23andMe, Inc. were recognised in Canada as foreign main proceedings under Part IV of the Companies' Creditors Arrangement Act on May 26, 2025, with Matthew Kvarda as foreign representative. On November 27, 2025 Justice Masuhara of the Supreme Court of British Columbia (No. S-253696), on Kvarda's application, recognised the U.S. order preliminarily approving the Canadian settlement and renamed the proceeding In the Matter of Chrome Holding Co. and ChromeCo, Inc.","source_ids":["src-038","src-039"],"entity_ids":["holdco","inc","kvarda"],"qualification":"","response":"","outcome":""},"reading":"Fact: The U.S. Chapter 11 cases of 23andMe Holding Co. and 23andMe, Inc. were recognised in Canada as foreign main proceedings under Part IV of the Companies' Creditors Arrangement Act on May 26, 2025, with Matthew Kvarda as foreign representative. On November 27, 2025 Justice Masuhara of the Supreme Court of British Columbia (No. S-253696), on Kvarda's application, recognised the U.S. order preliminarily approving the Canadian settlement and renamed the proceeding In the Matter of Chrome Holding Co. and ChromeCo, Inc."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-st-canada-settlement","record":{"id":"c-st-canada-settlement","kind":"fact","text":"Under the amended Canadian settlement of September 5, 2025, the class of customers resident in Canada between May 1 and October 1, 2023 who received breach notices has a single claim allowed at US$3,250,000, with distributions capped at that amount, in full settlement of the claims against 23andMe; the claims against the other defendants, the former directors and officers and KPMG LLP (United States), are to be dismissed with prejudice once the plan takes effect and the fund is paid. The settlement is not an admission of liability. Class counsel KND Complex Litigation's fee is 33%, and counsel expected about 64,000 eligible claimants to receive about CA$17.77 each from the ordinary-claims fund (the figure is printed \"CA$17. 77\" in the scanned notice); the final approval hearing was set for February 17, 2026.","source_ids":["src-039"],"entity_ids":["holdco","kpmg"],"qualification":"","response":"","outcome":""},"reading":"Fact: Under the amended Canadian settlement of September 5, 2025, the class of customers resident in Canada between May 1 and October 1, 2023 who received breach notices has a single claim allowed at US$3,250,000, with distributions capped at that amount, in full settlement of the claims against 23andMe; the claims against the other defendants, the former directors and officers and KPMG LLP (United States), are to be dismissed with prejudice once the plan takes effect and the fund is paid. The settlement is not an admission of liability. Class counsel KND Complex Litigation's fee is 33%, and counsel expected about 64,000 eligible claimants to receive about CA$17.77 each from the ordinary-claims fund (the figure is printed \"CA$17. 77\" in the scanned notice); the final approval hearing was set for February 17, 2026."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-st-cyber-insurers","record":{"id":"c-st-cyber-insurers","kind":"fact","text":"The company's cyber and liability insurance for May 1, 2023 to May 1, 2024 totalled $25 million in eroding limits: $15,000,000 from underwriters at Lloyd's under policy UMR B1510CY2300014, $5,000,000 from Allied World Specialty Insurance Company, and $2,500,000 each from Houston Casualty Company and Landmark American Insurance Company. Under a buyback and settlement motion filed on December 1, 2025 the insurers were to pay a lump sum of $16,525,759.63, the remaining limits after about $8,474,240.37 of defence costs paid from the Lloyd's layer, and take back the policies; the money was reserved for the covered breach and pixel settlements, and the insurers would become released parties.","source_ids":["src-032","src-016"],"entity_ids":["holdco","allied-world","houston-casualty","landmark"],"qualification":"","response":"","outcome":""},"reading":"Fact: The company's cyber and liability insurance for May 1, 2023 to May 1, 2024 totalled $25 million in eroding limits: $15,000,000 from underwriters at Lloyd's under policy UMR B1510CY2300014, $5,000,000 from Allied World Specialty Insurance Company, and $2,500,000 each from Houston Casualty Company and Landmark American Insurance Company. Under a buyback and settlement motion filed on December 1, 2025 the insurers were to pay a lump sum of $16,525,759.63, the remaining limits after about $8,474,240.37 of defence costs paid from the Lloyd's layer, and take back the policies; the money was reserved for the covered breach and pixel settlements, and the insurers would become released parties."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-st-states-claims","record":{"id":"c-st-states-claims","kind":"fact","text":"By the September 19, 2025 bar date for governmental claims, 42 state and District of Columbia claimants had filed proofs of claim seeking at least about $100 billion over the 2023 breach. On July 14, 2026 they signed a stipulation with the Plan Administration Trust and the Wind-Down Debtor allowing their claims at $150 million but limiting payment to $18 million in total, and barring the debtors for five years from direct consumer sales and from collecting or keeping personal information other than what the trust needs; the court hearing on approval was set for August 10, 2026.","source_ids":["src-019","src-107"],"entity_ids":["holdco","plan-trust"],"qualification":"The stipulation takes effect only on a final court order approving it; the retained record does not include the approval order.","response":"The stipulation records that the parties settled to avoid the cost, risk, burden and delay of litigation, preserving all defences and without admission of liability by any party.","outcome":"The trust's motion to approve the stipulation was set for hearing on August 10, 2026; the retained record does not include the court's ruling.","adverse_subject_ids":["holdco"]},"reading":"Fact: By the September 19, 2025 bar date for governmental claims, 42 state and District of Columbia claimants had filed proofs of claim seeking at least about $100 billion over the 2023 breach. On July 14, 2026 they signed a stipulation with the Plan Administration Trust and the Wind-Down Debtor allowing their claims at $150 million but limiting payment to $18 million in total, and barring the debtors for five years from direct consumer sales and from collecting or keeping personal information other than what the trust needs; the court hearing on approval was set for August 10, 2026."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-st-states-allocation","record":{"id":"c-st-states-allocation","kind":"fact","text":"Appendix A to the stipulation allots the $18 million among 41 states and the District of Columbia; the largest shares go to Texas ($1,266,860), Florida ($1,111,206), Indiana ($979,424), Connecticut ($887,729) and New York ($705,976), and the smallest to South Dakota ($149,339). California is not a signatory.","source_ids":["src-019"],"entity_ids":["holdco","texas"],"qualification":"","response":"","outcome":""},"reading":"Fact: Appendix A to the stipulation allots the $18 million among 41 states and the District of Columbia; the largest shares go to Texas ($1,266,860), Florida ($1,111,206), Indiana ($979,424), Connecticut ($887,729) and New York ($705,976), and the smallest to South Dakota ($149,339). California is not a signatory."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-st-states-release","record":{"id":"c-st-states-release","kind":"fact","text":"The mutual release in the states' stipulation covers the debtors, the trust and their officers, directors and affiliates for claims relating to the 2023 incident, but it expressly does not apply to the asset buyer, 23andMe Research Institute (formerly TTAM Research Institute).","source_ids":["src-019"],"entity_ids":["holdco","ttam","plan-trust"],"qualification":"","response":"","outcome":""},"reading":"Fact: The mutual release in the states' stipulation covers the debtors, the trust and their officers, directors and affiliates for claims relating to the 2023 incident, but it expressly does not apply to the asset buyer, 23andMe Research Institute (formerly TTAM Research Institute)."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-st-states-findings","record":{"id":"c-st-states-findings","kind":"attributed","text":"Announcing the settlement on July 14, 2026, the attorneys general of Colorado and Minnesota said that their multistate investigation found 23andMe's data security unreasonable, including a lack of protections against credential stuffing and of multi-factor authentication, rate limiting and monitoring, and that the company learned of the breach months after the data was publicly available, first denied it and then blamed consumers. They put the number affected at 6.9 million, including 140,517 in Colorado and 92,385 in Minnesota, said recovery was limited to $18 million because of the estate's finite funds, with $514,871 going to Minnesota, and noted that the buyer of the customer data, now 23andMe Research Institute, accepted strengthened protections, an advisory board and deletion rights.","source_ids":["src-107","src-044"],"entity_ids":["holdco","ttam"],"qualification":"These are the investigating states' conclusions as stated in press announcements of a negotiated settlement, not findings of a court.","response":"","outcome":""},"reading":"Attributed: Announcing the settlement on July 14, 2026, the attorneys general of Colorado and Minnesota said that their multistate investigation found 23andMe's data security unreasonable, including a lack of protections against credential stuffing and of multi-factor authentication, rate limiting and monitoring, and that the company learned of the breach months after the data was publicly available, first denied it and then blamed consumers. They put the number affected at 6.9 million, including 140,517 in Colorado and 92,385 in Minnesota, said recovery was limited to $18 million because of the estate's finite funds, with $514,871 going to Minnesota, and noted that the buyer of the customer data, now 23andMe Research Institute, accepted strengthened protections, an advisory board and deletion rights."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-st-ca-admin-claim","record":{"id":"c-st-ca-admin-claim","kind":"fact","text":"California said in the bankruptcy court that it might assert a material administrative claim against the debtors for an alleged violation of its Genetic Information Privacy Act when the sale to TTAM closed, and its representatives publicly stated an intention to seek administrative claims for civil penalties of more than $1 billion; the debtors disputed the claim and obtained procedures to estimate it.","source_ids":["src-012","src-079","src-016"],"entity_ids":["holdco","california","ttam"],"qualification":"","response":"The debtors stated that they disagree with California's alleged administrative claim and reserve all rights.","outcome":"The December 1, 2025 confirmation order forever barred California from asserting the California Administrative Claim against the debtors or their estates."},"reading":"Fact: California said in the bankruptcy court that it might assert a material administrative claim against the debtors for an alleged violation of its Genetic Information Privacy Act when the sale to TTAM closed, and its representatives publicly stated an intention to seek administrative claims for civil penalties of more than $1 billion; the debtors disputed the claim and obtained procedures to estimate it."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-st-ca-suit","record":{"id":"c-st-ca-suit","kind":"fact","text":"On May 27, 2026 the People of the State of California sued Chrome Holding Co. (formerly 23andMe Holding Co.), ChromeCo, Inc. (formerly 23andMe, Inc.) and Doe defendants in San Francisco Superior Court (No. CGC-26-636891) over the 2023 breach, seeking injunctive relief and civil penalties under the Genetic Information Privacy Act, the California Consumer Privacy Act, the Unfair Competition Law and the False Advertising Law, including $1,000 per Genetic Information Privacy Act violation and $2,500, or $7,500 if intentional, per Consumer Privacy Act violation.","source_ids":["src-075","src-076"],"entity_ids":["california","holdco","inc"],"qualification":"","response":"","outcome":"","adverse_subject_ids":["holdco","inc"]},"reading":"Fact: On May 27, 2026 the People of the State of California sued Chrome Holding Co. (formerly 23andMe Holding Co.), ChromeCo, Inc. (formerly 23andMe, Inc.) and Doe defendants in San Francisco Superior Court (No. CGC-26-636891) over the 2023 breach, seeking injunctive relief and civil penalties under the Genetic Information Privacy Act, the California Consumer Privacy Act, the Unfair Competition Law and the False Advertising Law, including $1,000 per Genetic Information Privacy Act violation and $2,500, or $7,500 if intentional, per Consumer Privacy Act violation."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-st-ca-enforcement-order","record":{"id":"c-st-ca-enforcement-order","kind":"fact","text":"On July 10, 2026 the bankruptcy court (Doc. 2333) granted in part the Plan Administration Trust's motion to enforce the plan and confirmation order and denied California's request for abstention: within 14 days California had to dismiss its state-court suit or drop its claims for monetary relief against Chrome Holding Co. and ChromeCo, Inc., which the plan injunction bars; the order does not bar the claims against the Doe defendants or non-monetary relief, and the trust's objection to California's proof of claim remained pending.","source_ids":["src-076","src-065"],"entity_ids":["holdco","inc","california","plan-trust"],"qualification":"The court described the monetary claims in the suit as essentially similar to those in the proof of claim California filed in the bankruptcy on September 4, 2025.","response":"The trust relied on the plan's exclusive-jurisdiction provision and injunction and argued that abstention was not available under the plan; the court held that the exclusive-jurisdiction provision did not support the motion but that the plan injunction bars the monetary claims.","outcome":"California filed a notice of appeal (Doc. 2364), docketed in the Court of Appeals as No. 26-3083 on October 14, 2026.","adverse_subject_ids":["holdco","inc"]},"reading":"Fact: On July 10, 2026 the bankruptcy court (Doc. 2333) granted in part the Plan Administration Trust's motion to enforce the plan and confirmation order and denied California's request for abstention: within 14 days California had to dismiss its state-court suit or drop its claims for monetary relief against Chrome Holding Co. and ChromeCo, Inc., which the plan injunction bars; the order does not bar the claims against the Doe defendants or non-monetary relief, and the trust's objection to California's proof of claim remained pending."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-st-ca-appeal-2026","record":{"id":"c-st-ca-appeal-2026","kind":"fact","text":"On October 14, 2026 the bankruptcy court docketed the transmission of the record to the Court of Appeals (No. 26-3083) on a notice of appeal filed by the People of the State of California (Doc. 2364); the docket entry does not name the order appealed.","source_ids":["src-065"],"entity_ids":["holdco","california"],"qualification":"","response":"","outcome":""},"reading":"Fact: On October 14, 2026 the bankruptcy court docketed the transmission of the record to the Court of Appeals (No. 26-3083) on a notice of appeal filed by the People of the State of California (Doc. 2364); the docket entry does not name the order appealed."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-finances","record":{"id":"c-ch-finances","kind":"fact","text":"The company's consolidated statements report revenue of $189.9 million in fiscal 2025 (to March 31, 2025), against $219.6 million in fiscal 2024 and $299.5 million in fiscal 2023, and net losses of $280.9 million, $666.7 million and $311.7 million; the fiscal-2024 loss included a goodwill impairment of $351.7 million, and fiscal 2025 included $61.4 million of restructuring costs. Revenue from GSK as a related party was $20.4 million, $12.0 million and $47.4 million in those years.","source_ids":["src-035"],"entity_ids":["holdco","gsk"],"qualification":"Amounts in the statements are in thousands of dollars and are rounded here to the nearest $0.1 million.","response":"","outcome":""},"reading":"Fact: The company's consolidated statements report revenue of $189.9 million in fiscal 2025 (to March 31, 2025), against $219.6 million in fiscal 2024 and $299.5 million in fiscal 2023, and net losses of $280.9 million, $666.7 million and $311.7 million; the fiscal-2024 loss included a goodwill impairment of $351.7 million, and fiscal 2025 included $61.4 million of restructuring costs. Revenue from GSK as a related party was $20.4 million, $12.0 million and $47.4 million in those years."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-revenue-fy25","record":{"id":"c-ch-revenue-fy25","kind":"fact","text":"Fiscal-2025 revenue fell 14%, mainly because of lower sales volume and prices of Personal Genome Service kits; it included $19.3 million recognised on receipt of a data use notice from GSK, almost all the revenue remaining under the 2023 amendment of the GSK data agreement, while telehealth revenue fell, partly because of the disposal of the UK subsidiary Lemonaid Health Limited in the second quarter of fiscal 2024.","source_ids":["src-035"],"entity_ids":["holdco","gsk","lemonaid-uk"],"qualification":"","response":"","outcome":""},"reading":"Fact: Fiscal-2025 revenue fell 14%, mainly because of lower sales volume and prices of Personal Genome Service kits; it included $19.3 million recognised on receipt of a data use notice from GSK, almost all the revenue remaining under the 2023 amendment of the GSK data agreement, while telehealth revenue fell, partly because of the disposal of the UK subsidiary Lemonaid Health Limited in the second quarter of fiscal 2024."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-balance-sheet","record":{"id":"c-ch-balance-sheet","kind":"fact","text":"At March 31, 2025 the company had $38.2 million of unrestricted cash (against $216.5 million a year earlier), total assets of $159.9 million, total liabilities of $186.6 million, including $113.5 million of liabilities subject to compromise in the bankruptcy, an accumulated deficit of $2.5 billion and negative stockholders' equity of $26.7 million. Management disclosed substantial doubt about its ability to continue as a going concern; the auditor was KPMG LLP of Santa Clara, auditor since 2020, whose report is dated June 11, 2025.","source_ids":["src-035"],"entity_ids":["holdco","kpmg"],"qualification":"Balance-sheet amounts are reported in thousands of dollars and rounded here.","response":"","outcome":""},"reading":"Fact: At March 31, 2025 the company had $38.2 million of unrestricted cash (against $216.5 million a year earlier), total assets of $159.9 million, total liabilities of $186.6 million, including $113.5 million of liabilities subject to compromise in the bankruptcy, an accumulated deficit of $2.5 billion and negative stockholders' equity of $26.7 million. Management disclosed substantial doubt about its ability to continue as a going concern; the auditor was KPMG LLP of Santa Clara, auditor since 2020, whose report is dated June 11, 2025."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-kpmg-fees","record":{"id":"c-ch-kpmg-fees","kind":"fact","text":"KPMG billed $3,398,206 for fiscal 2025, of which $3,338,206 for the audit and $60,000 for tax services, and $4,618,250 for fiscal 2024.","source_ids":["src-057"],"entity_ids":["kpmg","holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: KPMG billed $3,398,206 for fiscal 2025, of which $3,338,206 for the audit and $60,000 for tax services, and $4,618,250 for fiscal 2024."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-cutbacks","record":{"id":"c-ch-cutbacks","kind":"fact","text":"In November 2024 the company stopped developing all its therapeutics programmes, wound down clinical trials and cut about 200 employees, roughly 40% of its workforce.","source_ids":["src-012"],"entity_ids":["holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: In November 2024 the company stopped developing all its therapeutics programmes, wound down clinical trials and cut about 200 employees, roughly 40% of its workforce."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-causes","record":{"id":"c-ch-causes","kind":"fact","text":"The chief restructuring officer's first-day declaration says that although the business had generated more than $200 million of revenue a year for five years it had never recorded a net profit, and the disclosure statement attributes the filing to constrained access to capital after the 2021 merger, macroeconomic conditions, the breach and the litigation that followed. At the petition date the debtors had no funded debt; their unsecured claims came largely from the breach and from ordinary trade.","source_ids":["src-031","src-012"],"entity_ids":["holdco","kvarda"],"qualification":"","response":"","outcome":""},"reading":"Fact: The chief restructuring officer's first-day declaration says that although the business had generated more than $200 million of revenue a year for five years it had never recorded a net profit, and the disclosure statement attributes the filing to constrained access to capital after the 2021 merger, macroeconomic conditions, the breach and the litigation that followed. At the petition date the debtors had no funded debt; their unsecured claims came largely from the breach and from ordinary trade."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-nol","record":{"id":"c-ch-nol","kind":"fact","text":"The company had more than $1 billion of U.S. federal net operating losses, whose amount could be materially reduced by the plan transactions, and the court approved notice and hearing procedures for certain transfers of its common stock and for declarations of worthlessness to protect those tax attributes.","source_ids":["src-012"],"entity_ids":["holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: The company had more than $1 billion of U.S. federal net operating losses, whose amount could be materially reduced by the plan transactions, and the court approved notice and hearing procedures for certain transfers of its common stock and for declarations of worthlessness to protect those tax attributes."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-filing","record":{"id":"c-ch-filing","kind":"fact","text":"On March 23, 2025 23andMe Holding Co. and eleven subsidiaries filed voluntary Chapter 11 petitions in the U.S. Bankruptcy Court for the Eastern District of Missouri, jointly administered as In re 23andMe Holding Co., et al., Case No. 25-40976-357, and moved for a sale of their assets through a competitive auction under section 363 of the Bankruptcy Code, advised by Moelis & Company. The subsidiaries were 23andMe, Inc., Lemonaid Health, Inc., 23andMe Pharmacy Holdings, Inc. and Lemonaid Pharmacy Holdings Inc. (Delaware), Lemonaid Community Pharmacy, Inc. (Missouri), LPharm INS LLC, LPharm CS LLC and LPharm RX LLC (Delaware) and LPRXOne LLC, LPRXTwo LLC and LPRXThree LLC (Missouri).","source_ids":["src-002","src-003","src-012"],"entity_ids":["holdco","inc","lemonaid-health","pharmacy-holdings","lemonaid-pharmacy-holdings","lemonaid-community-pharmacy","lpharm-ins","lpharm-cs","lpharm-rx","lprxone","lprxtwo","lprxthree"],"qualification":"","response":"","outcome":"","adverse_subject_ids":["holdco","inc","lemonaid-health","pharmacy-holdings"]},"reading":"Fact: On March 23, 2025 23andMe Holding Co. and eleven subsidiaries filed voluntary Chapter 11 petitions in the U.S. Bankruptcy Court for the Eastern District of Missouri, jointly administered as In re 23andMe Holding Co., et al., Case No. 25-40976-357, and moved for a sale of their assets through a competitive auction under section 363 of the Bankruptcy Code, advised by Moelis & Company. The subsidiaries were 23andMe, Inc., Lemonaid Health, Inc., 23andMe Pharmacy Holdings, Inc. and Lemonaid Pharmacy Holdings Inc. (Delaware), Lemonaid Community Pharmacy, Inc. (Missouri), LPharm INS LLC, LPharm CS LLC and LPharm RX LLC (Delaware) and LPRXOne LLC, LPRXTwo LLC and LPRXThree LLC (Missouri)."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-debtor-structure","record":{"id":"c-ch-debtor-structure","kind":"fact","text":"The disclosure statement describes the debtor group: ChromeCo, Inc. (formerly 23andMe, Inc.), Lemonaid Health, Inc. and Chrome Pharmacy Holdings, Inc. were wholly owned by Chrome Holding Co.; Chrome Pharmacy Holdings wholly owned Lemonaid Pharmacy Holdings Inc., which wholly owned Lemonaid Community Pharmacy, Inc., LPharm RX LLC, LPharm INS LLC and LPharm CS LLC, which in turn wholly owned LPRXTwo LLC, LPRXThree LLC and LPRXOne LLC respectively. Lemonaid Health also had contractual relationships with four non-debtor professional medical corporations wholly owned by licensed providers.","source_ids":["src-012"],"entity_ids":["holdco","inc","lemonaid-health","pharmacy-holdings","lemonaid-pharmacy-holdings","lemonaid-community-pharmacy","lpharm-rx","lpharm-ins","lpharm-cs","lprxtwo","lprxthree","lprxone"],"qualification":"","response":"","outcome":""},"reading":"Fact: The disclosure statement describes the debtor group: ChromeCo, Inc. (formerly 23andMe, Inc.), Lemonaid Health, Inc. and Chrome Pharmacy Holdings, Inc. were wholly owned by Chrome Holding Co.; Chrome Pharmacy Holdings wholly owned Lemonaid Pharmacy Holdings Inc., which wholly owned Lemonaid Community Pharmacy, Inc., LPharm RX LLC, LPharm INS LLC and LPharm CS LLC, which in turn wholly owned LPRXTwo LLC, LPRXThree LLC and LPRXOne LLC respectively. Lemonaid Health also had contractual relationships with four non-debtor professional medical corporations wholly owned by licensed providers."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-related-cases","record":{"id":"c-ch-related-cases","kind":"fact","text":"The court's list of associated cases shows each subsidiary under its own number linked to the lead case No. 25-40976, including LPRXOne LLC (25-40975), ChromeCo, Inc. (25-40977), Chrome Pharmacy Holdings, Inc. (25-40978), Lemonaid Community Pharmacy, Inc. (25-40979), Lemonaid Health, Inc. (25-40980), Lemonaid Pharmacy Holdings Inc. (25-40981), LPharm CS LLC (25-40982), LPharm INS LLC (25-40983), LPharm RX LLC (25-40984), LPRXThree LLC (25-40985) and LPRXTwo LLC (25-40986).","source_ids":["src-036"],"entity_ids":["holdco","lprxone","inc","pharmacy-holdings","lemonaid-community-pharmacy","lemonaid-health","lemonaid-pharmacy-holdings","lpharm-cs","lpharm-ins","lpharm-rx","lprxthree","lprxtwo"],"qualification":"","response":"","outcome":""},"reading":"Fact: The court's list of associated cases shows each subsidiary under its own number linked to the lead case No. 25-40976, including LPRXOne LLC (25-40975), ChromeCo, Inc. (25-40977), Chrome Pharmacy Holdings, Inc. (25-40978), Lemonaid Community Pharmacy, Inc. (25-40979), Lemonaid Health, Inc. (25-40980), Lemonaid Pharmacy Holdings Inc. (25-40981), LPharm CS LLC (25-40982), LPharm INS LLC (25-40983), LPharm RX LLC (25-40984), LPRXThree LLC (25-40985) and LPRXTwo LLC (25-40986)."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-tax-ids","record":{"id":"c-ch-tax-ids","kind":"fact","text":"The confirmation order identifies the twelve debtors with the last four digits of their federal tax identification numbers: Chrome Holding Co. (0344), ChromeCo, Inc. (7371), Chrome Pharmacy Holdings, Inc. (4690), Lemonaid Community Pharmacy, Inc. (7330), Lemonaid Health, Inc. (6739), Lemonaid Pharmacy Holdings Inc. (6500), LPharm CS LLC (1125), LPharm INS LLC (9800), LPharm RX LLC (7746), LPRXOne LLC (3447), LPRXThree LLC (3852) and LPRXTwo LLC (1595), with a service address at 870 Market Street, Room 415, San Francisco.","source_ids":["src-016"],"entity_ids":["holdco","inc","pharmacy-holdings","lemonaid-community-pharmacy","lemonaid-health","lemonaid-pharmacy-holdings","lpharm-cs","lpharm-ins","lpharm-rx","lprxone","lprxthree","lprxtwo"],"qualification":"","response":"","outcome":""},"reading":"Fact: The confirmation order identifies the twelve debtors with the last four digits of their federal tax identification numbers: Chrome Holding Co. (0344), ChromeCo, Inc. (7371), Chrome Pharmacy Holdings, Inc. (4690), Lemonaid Community Pharmacy, Inc. (7330), Lemonaid Health, Inc. (6739), Lemonaid Pharmacy Holdings Inc. (6500), LPharm CS LLC (1125), LPharm INS LLC (9800), LPharm RX LLC (7746), LPRXOne LLC (3447), LPRXThree LLC (3852) and LPRXTwo LLC (1595), with a service address at 870 Market Street, Room 415, San Francisco."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-addresses-pharmacy","record":{"id":"c-ch-addresses-pharmacy","kind":"fact","text":"Court records list Lemonaid Community Pharmacy, Inc. at 7580 Watson Road, Shrewsbury, Missouri, and Lemonaid Pharmacy Holdings Inc., LPharm RX LLC, LPharm INS LLC, LPRXOne LLC and LPRXThree LLC at 1701 Macklind Ave., Suite 300, St. Louis; the federal NPI registry lists the pharmacy (NPI 1023626389, active, registered July 22, 2020) at 7580 Watson Rd, Saint Louis.","source_ids":["src-080","src-102"],"entity_ids":["lemonaid-community-pharmacy","lemonaid-pharmacy-holdings","lpharm-rx","lpharm-ins","lprxone","lprxthree"],"qualification":"The address list comes from an aggregator's copy of a court docket; the NPI record was last updated on its registration date.","response":"","outcome":""},"reading":"Fact: Court records list Lemonaid Community Pharmacy, Inc. at 7580 Watson Road, Shrewsbury, Missouri, and Lemonaid Pharmacy Holdings Inc., LPharm RX LLC, LPharm INS LLC, LPRXOne LLC and LPRXThree LLC at 1701 Macklind Ave., Suite 300, St. Louis; the federal NPI registry lists the pharmacy (NPI 1023626389, active, registered July 22, 2020) at 7580 Watson Rd, Saint Louis."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-dip","record":{"id":"c-ch-dip","kind":"fact","text":"On March 23, 2025 the company signed a binding term sheet with JMB Capital Partners Lending, LLC for a priming super-priority senior secured debtor-in-possession term loan of up to $35 million, which the court authorised on March 26, 2025 together with a $100,000 work fee and a $700,000 commitment fee. The loan agreement, approved on April 23 and signed on April 28, 2025 with all debtors as joint borrowers, was secured by substantially all their assets, bore 14.0% interest, matured on September 30, 2025 and gave immediate access to $10 million, with $25 million more on conditions; the company drew $10.0 million on May 5, 2025, the commitments were later raised to $60 million, and on July 14, 2025, at the closing of the sale to TTAM, the debtors repaid it in full and terminated it.","source_ids":["src-002","src-012","src-035"],"entity_ids":["holdco","jmb"],"qualification":"","response":"","outcome":""},"reading":"Fact: On March 23, 2025 the company signed a binding term sheet with JMB Capital Partners Lending, LLC for a priming super-priority senior secured debtor-in-possession term loan of up to $35 million, which the court authorised on March 26, 2025 together with a $100,000 work fee and a $700,000 commitment fee. The loan agreement, approved on April 23 and signed on April 28, 2025 with all debtors as joint borrowers, was secured by substantially all their assets, bore 14.0% interest, matured on September 30, 2025 and gave immediate access to $10 million, with $25 million more on conditions; the company drew $10.0 million on May 5, 2025, the commitments were later raised to $60 million, and on July 14, 2025, at the closing of the sale to TTAM, the debtors repaid it in full and terminated it."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-letters-of-credit","record":{"id":"c-ch-letters-of-credit","kind":"fact","text":"In April 2025 the landlord of the company's Sunnyvale facility drew in full on its letters of credit, $7.3 million of restricted cash.","source_ids":["src-035"],"entity_ids":["holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: In April 2025 the landlord of the company's Sunnyvale facility drew in full on its letters of credit, $7.3 million of restricted cash."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-advisers","record":{"id":"c-ch-advisers","kind":"fact","text":"The court approved the debtors' retention of Paul, Weiss and Carmody MacDonald, P.C. as co-counsel, Moelis & Company LLC as investment banker, Alvarez & Marsal North America, LLC and Matthew E. Kvarda as chief restructuring officer, Kroll Restructuring Administration LLC as claims and noticing agent, Deloitte Tax LLP for tax services, and Goodwin and Lewis Rice LLC as special counsel to the Special Committee.","source_ids":["src-012"],"entity_ids":["holdco","alvarez-marsal","kvarda","kroll"],"qualification":"","response":"","outcome":""},"reading":"Fact: The court approved the debtors' retention of Paul, Weiss and Carmody MacDonald, P.C. as co-counsel, Moelis & Company LLC as investment banker, Alvarez & Marsal North America, LLC and Matthew E. Kvarda as chief restructuring officer, Kroll Restructuring Administration LLC as claims and noticing agent, Deloitte Tax LLP for tax services, and Goodwin and Lewis Rice LLC as special counsel to the Special Committee."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-creditors-committee","record":{"id":"c-ch-creditors-committee","kind":"fact","text":"On April 3, 2025 the U.S. Trustee appointed an official committee of unsecured creditors consisting of Laboratory Corporation of America Holdings (with subsidiaries including National Genetics Institute), Workday, Inc., Telus International Services Limited, Jellyfish US Limited and three individual creditors; it retained Kelley Drye & Warren LLP, Stinson LLP and FTI Consulting, Inc.","source_ids":["src-012"],"entity_ids":["holdco","labcorp","workday","telus","jellyfish"],"qualification":"","response":"","outcome":""},"reading":"Fact: On April 3, 2025 the U.S. Trustee appointed an official committee of unsecured creditors consisting of Laboratory Corporation of America Holdings (with subsidiaries including National Genetics Institute), Workday, Inc., Telus International Services Limited, Jellyfish US Limited and three individual creditors; it retained Kelley Drye & Warren LLP, Stinson LLP and FTI Consulting, Inc."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-equity-committee","record":{"id":"c-ch-equity-committee","kind":"fact","text":"On July 15, 2025 the U.S. Trustee appointed an official equity committee of seven shareholders, including Esopus Creek Advisors, LLC, Farrallon Capital Management, LLC and Milestone Vimba Fund, L.P., which expected to retain Brown Rudnick LLP and Desai Law Firm LLC.","source_ids":["src-012"],"entity_ids":["holdco"],"qualification":"Four of the seven members are individual shareholders, who are not named here.","response":"","outcome":""},"reading":"Fact: On July 15, 2025 the U.S. Trustee appointed an official equity committee of seven shareholders, including Esopus Creek Advisors, LLC, Farrallon Capital Management, LLC and Milestone Vimba Fund, L.P., which expected to retain Brown Rudnick LLP and Desai Law Firm LLC."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-bar-dates","record":{"id":"c-ch-bar-dates","kind":"fact","text":"An order of April 30, 2025 set July 14, 2025 as the general bar date for claims, including breach-related claims, and September 19, 2025 for governmental claims. About 170,800 timely proofs of claim were filed and, by August 6, 2025, 46,530 more after the general bar date; the asserted total of all of them exceeded $7 trillion.","source_ids":["src-012"],"entity_ids":["holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: An order of April 30, 2025 set July 14, 2025 as the general bar date for claims, including breach-related claims, and September 19, 2025 for governmental claims. About 170,800 timely proofs of claim were filed and, by August 6, 2025, 46,530 more after the general bar date; the asserted total of all of them exceeded $7 trillion."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-creditors-list","record":{"id":"c-ch-creditors-list","kind":"fact","text":"Parties appearing in the case as creditors, according to an aggregator's copy of the docket, include Converge Technology Solutions, CoreWeave, GlaxoSmithKline Intellectual Property (No. 3) Limited, KR OP Tech, LLC, Laboratory Corporation of America Holdings, Oracle America, U.S. Bank Equipment Finance, the Missouri Department of Revenue, the claims buyers ASM Capital and Argo Partners, and the breach and pixel class plaintiffs; JMB Capital Partners Lending and Chubb also appeared as interested parties. The docket summary estimates more than 100,000 creditors and assets and liabilities each between $100,000,001 and $500 million.","source_ids":["src-065"],"entity_ids":["holdco","converge","kr-op-tech","labcorp","jmb"],"qualification":"An aggregator's summary of the court docket, not a court record itself.","response":"","outcome":""},"reading":"Fact: Parties appearing in the case as creditors, according to an aggregator's copy of the docket, include Converge Technology Solutions, CoreWeave, GlaxoSmithKline Intellectual Property (No. 3) Limited, KR OP Tech, LLC, Laboratory Corporation of America Holdings, Oracle America, U.S. Bank Equipment Finance, the Missouri Department of Revenue, the claims buyers ASM Capital and Argo Partners, and the breach and pixel class plaintiffs; JMB Capital Partners Lending and Chubb also appeared as interested parties. The docket summary estimates more than 100,000 creditors and assets and liabilities each between $100,000,001 and $500 million."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-plan-august","record":{"id":"c-ch-plan-august","kind":"fact","text":"The debtors filed their Joint Plan of Chrome Holding Co. and its Debtor Affiliates on August 15, 2025 with a disclosure statement signed by chief restructuring officer Matthew Kvarda. Under the plan the debtors' affairs would be wound down by a Plan Administrator, a Plan Administration Trust would hold the remaining assets for unsecured creditors and shareholders, and holders of the company's stock (Class 12, HoldCo Interests) would receive a share of the trust's Class B interests, with no estimate of their recovery.","source_ids":["src-012"],"entity_ids":["holdco","kvarda","plan-trust"],"qualification":"","response":"","outcome":""},"reading":"Fact: The debtors filed their Joint Plan of Chrome Holding Co. and its Debtor Affiliates on August 15, 2025 with a disclosure statement signed by chief restructuring officer Matthew Kvarda. Under the plan the debtors' affairs would be wound down by a Plan Administrator, a Plan Administration Trust would hold the remaining assets for unsecured creditors and shareholders, and holders of the company's stock (Class 12, HoldCo Interests) would receive a share of the trust's Class B interests, with no estimate of their recovery."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-ds-order","record":{"id":"c-ch-ds-order","kind":"fact","text":"On October 1, 2025 the court approved the disclosure statement and solicitation procedures, including procedures to determine California's claims, with a voting deadline of November 6, 2025; on November 14, 2025 the debtors filed a third amended plan, which modified the settlement with the breach arbitration claimants and dropped an alternative equity-sale structure, and the confirmation hearing was set for November 19, 2025.","source_ids":["src-045"],"entity_ids":["holdco","california"],"qualification":"","response":"","outcome":""},"reading":"Fact: On October 1, 2025 the court approved the disclosure statement and solicitation procedures, including procedures to determine California's claims, with a voting deadline of November 6, 2025; on November 14, 2025 the debtors filed a third amended plan, which modified the settlement with the breach arbitration claimants and dropped an alternative equity-sale structure, and the confirmation hearing was set for November 19, 2025."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-landlord-opinion","record":{"id":"c-ch-landlord-opinion","kind":"fact","text":"In a memorandum opinion of November 26, 2025 Judge Brian C. Walsh overruled the objection of KR OP Tech, LLC, the owner of a San Francisco building whose lease ChromeCo, Inc. rejected after its asset sale; the landlord's rejection-damages claim of about $9.7 million is reduced to about $5.6 million by the cap in section 502(b)(6), which the court held applies even if the debtor proves solvent. The court noted that creditors had filed claims with a face value in the trillions of dollars against about $200 million available to distribute, so that whether shareholders would receive anything was uncertain until claims were reconciled; that Classes 6, 7 and 12 had voted against the plan; and that the wind-down debtors would not receive a discharge, while the Lemonaid debtors would.","source_ids":["src-034"],"entity_ids":["holdco","inc","kr-op-tech"],"qualification":"","response":"","outcome":"On December 23, 2025 the landlord appealed the confirmation order to the U.S. District Court (Case No. 25-01805SEP), according to a case-tracking service."},"reading":"Fact: In a memorandum opinion of November 26, 2025 Judge Brian C. Walsh overruled the objection of KR OP Tech, LLC, the owner of a San Francisco building whose lease ChromeCo, Inc. rejected after its asset sale; the landlord's rejection-damages claim of about $9.7 million is reduced to about $5.6 million by the cap in section 502(b)(6), which the court held applies even if the debtor proves solvent. The court noted that creditors had filed claims with a face value in the trillions of dollars against about $200 million available to distribute, so that whether shareholders would receive anything was uncertain until claims were reconciled; that Classes 6, 7 and 12 had voted against the plan; and that the wind-down debtors would not receive a discharge, while the Lemonaid debtors would."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-confirmation","record":{"id":"c-ch-confirmation","kind":"fact","text":"The debtors filed the Modified Fifth Amended Joint Plan on November 28, 2025, and on December 1, 2025 the court confirmed it in Findings of Fact, Conclusions of Law and an Order (Docket No. 1662), amended on December 5, 2025 (Docket No. 1696). The breach classes (3, 4 and 5) and the pixel class (14) voted to accept, the Chrome commercial and other unsecured classes (6 and 7) and the shareholders (Class 12) voted to reject, and the court overruled the unresolved objections. The plan became effective on December 5, 2025.","source_ids":["src-015","src-016","src-019"],"entity_ids":["holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: The debtors filed the Modified Fifth Amended Joint Plan on November 28, 2025, and on December 1, 2025 the court confirmed it in Findings of Fact, Conclusions of Law and an Order (Docket No. 1662), amended on December 5, 2025 (Docket No. 1696). The breach classes (3, 4 and 5) and the pixel class (14) voted to accept, the Chrome commercial and other unsecured classes (6 and 7) and the shareholders (Class 12) voted to reject, and the court overruled the unresolved objections. The plan became effective on December 5, 2025."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-plan-trust","record":{"id":"c-ch-plan-trust","kind":"fact","text":"On the effective date the debtors' assets other than the Lemonaid interests vested in the Plan Administration Trust, with the Plan Administrator as its sole manager, director and officer, and the plan issued no new equity or securities. The trust's assets are the sale proceeds, the debtors' cash, retained causes of action, cyber-insurance proceeds and any excess in the professional-fee escrow; distributions follow a waterfall in which reserves and administrative and priority claims come first, then reserves for the breach and pixel settlements, then unsecured claims.","source_ids":["src-016"],"entity_ids":["holdco","plan-trust"],"qualification":"","response":"","outcome":""},"reading":"Fact: On the effective date the debtors' assets other than the Lemonaid interests vested in the Plan Administration Trust, with the Plan Administrator as its sole manager, director and officer, and the plan issued no new equity or securities. The trust's assets are the sale proceeds, the debtors' cash, retained causes of action, cyber-insurance proceeds and any excess in the professional-fee escrow; distributions follow a waterfall in which reserves and administrative and priority claims come first, then reserves for the breach and pixel settlements, then unsecured claims."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-shares-cancelled","record":{"id":"c-ch-shares-cancelled","kind":"fact","text":"On December 1, 2025 the company had 25,489,590 Class A and 2,110,250 Class B shares outstanding; on the effective date all its common stock, including shares issuable under equity awards, was cancelled, and holders became members of Class 12 entitled to a portion of the trust's Class B interests.","source_ids":["src-015"],"entity_ids":["holdco","plan-trust"],"qualification":"","response":"","outcome":""},"reading":"Fact: On December 1, 2025 the company had 25,489,590 Class A and 2,110,250 Class B shares outstanding; on the effective date all its common stock, including shares issuable under equity awards, was cancelled, and holders became members of Class 12 entitled to a portion of the trust's Class B interests."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-board-dissolved","record":{"id":"c-ch-board-dissolved","kind":"fact","text":"On the effective date the boards of the wind-down debtors were dissolved, their remaining directors and officers were dismissed, and the Plan Administrator became the sole officer, director and manager of the Chrome debtors.","source_ids":["src-016"],"entity_ids":["holdco","plan-trust"],"qualification":"","response":"","outcome":""},"reading":"Fact: On the effective date the boards of the wind-down debtors were dissolved, their remaining directors and officers were dismissed, and the Plan Administrator became the sole officer, director and manager of the Chrome debtors."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-plan-administrator","record":{"id":"c-ch-plan-administrator","kind":"fact","text":"The confirmation order appointed Thomas Walper, the independent director on the Special Committee, as initial Plan Administrator from the effective date, with power to represent the estates; the debtors had disclosed in the plan supplement that he is an insider of the debtors and how his compensation would be set. The order also approved Matthew Dundon as representative of general unsecured creditors and Alan Halperin as equity representative.","source_ids":["src-016"],"entity_ids":["walper","holdco","plan-trust"],"qualification":"","response":"","outcome":""},"reading":"Fact: The confirmation order appointed Thomas Walper, the independent director on the Special Committee, as initial Plan Administrator from the effective date, with power to represent the estates; the debtors had disclosed in the plan supplement that he is an insider of the debtors and how his compensation would be set. The order also approved Matthew Dundon as representative of general unsecured creditors and Alan Halperin as equity representative."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-excluded-parties","record":{"id":"c-ch-excluded-parties","kind":"fact","text":"The plan defines as Excluded Parties, who are not released and against whom the trust may bring claims, the Former CEO, defined as Anne Wojcicki in her capacity as a director of the holding company, shareholder and former chief executive; the debtors' former directors and officers who were not in office on the petition date; and the former Chief Security Officer who was not in office on that date. The plan states that the Former CEO is not an affiliate of the debtors.","source_ids":["src-016","src-045"],"entity_ids":["wojcicki","holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: The plan defines as Excluded Parties, who are not released and against whom the trust may bring claims, the Former CEO, defined as Anne Wojcicki in her capacity as a director of the holding company, shareholder and former chief executive; the debtors' former directors and officers who were not in office on the petition date; and the former Chief Security Officer who was not in office on that date. The plan states that the Former CEO is not an affiliate of the debtors."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-wojcicki-resolution","record":{"id":"c-ch-wojcicki-resolution","kind":"fact","text":"Paragraph 133 of the confirmation order, which resolved the discovery requests and plan objections of Anne Wojcicki, the Anne Wojcicki Foundation and entities they own or control including ABeeC 2.0, LLC (the Wojcicki Parties), treats them as having opted out of the plan's releases, except that ABeeC 2.0 and the foundation release claims for conduct between the petition date and the effective date. Their rights to indemnification, advancement of expenses and exculpation under law and Article VIII of the holding company's charter and bylaws are preserved, they may raise counterclaims in any trust suit but may not sue estate representatives first, and distributions on their Class 12 interests are not limited because of a disputed claim, though the trust may seek to withhold them. The asset buyer is neither a released nor a releasing party.","source_ids":["src-016"],"entity_ids":["wojcicki","aw-foundation","abeec","holdco","ttam","plan-trust"],"qualification":"","response":"","outcome":""},"reading":"Fact: Paragraph 133 of the confirmation order, which resolved the discovery requests and plan objections of Anne Wojcicki, the Anne Wojcicki Foundation and entities they own or control including ABeeC 2.0, LLC (the Wojcicki Parties), treats them as having opted out of the plan's releases, except that ABeeC 2.0 and the foundation release claims for conduct between the petition date and the effective date. Their rights to indemnification, advancement of expenses and exculpation under law and Article VIII of the holding company's charter and bylaws are preserved, they may raise counterclaims in any trust suit but may not sue estate representatives first, and distributions on their Class 12 interests are not limited because of a disputed claim, though the trust may seek to withhold them. The asset buyer is neither a released nor a releasing party."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-third-plan-buyer","record":{"id":"c-ch-third-plan-buyer","kind":"fact","text":"The third amended plan of November 14, 2025 defined the Chrome Purchaser as 23andMe Research Institute, formerly TTAM Research Institute, under the purchase agreement of June 13, 2025, and named ABeeC 2.0, LLC and the Anne Wojcicki Foundation as Chrome Purchaser Released Parties.","source_ids":["src-045","src-016"],"entity_ids":["ttam","abeec","aw-foundation","holdco"],"qualification":"The confirmation order later treated the Wojcicki Parties, including ABeeC 2.0 and the foundation, as having opted out of the releases (paragraph 133).","response":"","outcome":""},"reading":"Fact: The third amended plan of November 14, 2025 defined the Chrome Purchaser as 23andMe Research Institute, formerly TTAM Research Institute, under the purchase agreement of June 13, 2025, and named ABeeC 2.0, LLC and the Anne Wojcicki Foundation as Chrome Purchaser Released Parties."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-converge-reserve","record":{"id":"c-ch-converge-reserve","kind":"fact","text":"The confirmation order required the debtors to reserve $4,061,000 for the administrative claim of Converge Technology Solutions US LLC for unpaid invoices of May 1 to August 20, 2025 plus interest at 4.14%, preserving the right to contest it, and provided that the lease claim of KR OP Tech, LLC is not discharged although the landlord may not act against the debtor until plan distributions are made.","source_ids":["src-016"],"entity_ids":["holdco","converge","kr-op-tech"],"qualification":"","response":"","outcome":""},"reading":"Fact: The confirmation order required the debtors to reserve $4,061,000 for the administrative claim of Converge Technology Solutions US LLC for unpaid invoices of May 1 to August 20, 2025 plus interest at 4.14%, preserving the right to contest it, and provided that the lease claim of KR OP Tech, LLC is not discharged although the landlord may not act against the debtor until plan distributions are made."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-case-closing","record":{"id":"c-ch-case-closing","kind":"fact","text":"On January 21, 2026 the court closed all the Chapter 11 cases except that of Wind-Down Debtor Chrome Holding Co. (Docket No. 1843), where the remaining matters are administered.","source_ids":["src-019"],"entity_ids":["holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: On January 21, 2026 the court closed all the Chapter 11 cases except that of Wind-Down Debtor Chrome Holding Co. (Docket No. 1843), where the remaining matters are administered."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-cash-fees","record":{"id":"c-ch-cash-fees","kind":"fact","text":"A bankruptcy-data publisher's summary of the case reports that the debtors' November 2025 operating reports showed an ending cash balance of about $256.6 million, including about $17.8 million of professional-fee reserves, and that professional fees requested on a final basis totalled about $59.3 million, with the largest approved amounts going to Paul, Weiss ($25.99 million) as lead restructuring counsel, Alvarez & Marsal ($8.68 million) and Kelley Drye & Warren ($7.37 million) as counsel to the creditors' committee.","source_ids":["src-050"],"entity_ids":["holdco","alvarez-marsal"],"qualification":"Secondary summary of court filings; the operating reports and fee orders were not retrieved.","response":"","outcome":""},"reading":"Fact: A bankruptcy-data publisher's summary of the case reports that the debtors' November 2025 operating reports showed an ending cash balance of about $256.6 million, including about $17.8 million of professional-fee reserves, and that professional fees requested on a final basis totalled about $59.3 million, with the largest approved amounts going to Paul, Weiss ($25.99 million) as lead restructuring counsel, Alvarez & Marsal ($8.68 million) and Kelley Drye & Warren ($7.37 million) as counsel to the creditors' committee."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-admin-claims-2026","record":{"id":"c-ch-admin-claims-2026","kind":"fact","text":"The same summary reports three administrative expense applications filed on January 3, 2026: by 23andMe Research Institute for unliquidated amounts for unperformed obligations under the purchase agreement and unpaid transition-services payments, by Anne Wojcicki for indemnification of legal fees, and by a former executive for $102,500 of severance and reimbursement.","source_ids":["src-050"],"entity_ids":["ttam","wojcicki","holdco"],"qualification":"Secondary summary; the outcome of the applications is not reported in the retained record.","response":"","outcome":""},"reading":"Fact: The same summary reports three administrative expense applications filed on January 3, 2026: by 23andMe Research Institute for unliquidated amounts for unperformed obligations under the purchase agreement and unpaid transition-services payments, by Anne Wojcicki for indemnification of legal fees, and by a former executive for $102,500 of severance and reimbursement."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-wojcicki-application","record":{"id":"c-ch-wojcicki-application","kind":"fact","text":"In her application of January 3, 2026 (Doc. 1795), filed by Bryan Cave Leighton Paisner LLP, Anne Wojcicki asks the court to allow and pay as an administrative expense, under section 503(b), her indemnification expenses as a former director, officer and employee of the debtors, citing section V.E of the plan and paragraph 133(c)(i) of the confirmation order; the amount is unliquidated and continuing. She lists the proceedings concerned: two British Columbia class actions filed before the bankruptcy, the Special Committee's investigation, document and testimony requests from the U.S. House Oversight Committee, and an adversary proceeding in the bankruptcy court (No. 25-04043) in which she was among the defendants, as well as possible future claims of breach of fiduciary duty.","source_ids":["src-051","src-016"],"entity_ids":["wojcicki","holdco"],"qualification":"This is her application; the retained record does not show how the court ruled on it.","response":"","outcome":""},"reading":"Fact: In her application of January 3, 2026 (Doc. 1795), filed by Bryan Cave Leighton Paisner LLP, Anne Wojcicki asks the court to allow and pay as an administrative expense, under section 503(b), her indemnification expenses as a former director, officer and employee of the debtors, citing section V.E of the plan and paragraph 133(c)(i) of the confirmation order; the amount is unliquidated and continuing. She lists the proceedings concerned: two British Columbia class actions filed before the bankruptcy, the Special Committee's investigation, document and testimony requests from the U.S. House Oversight Committee, and an adversary proceeding in the bankruptcy court (No. 25-04043) in which she was among the defendants, as well as possible future claims of breach of fiduciary duty."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-pro-se-adversary","record":{"id":"c-ch-pro-se-adversary","kind":"fact","text":"That adversary proceeding, No. 4:25-ap-04043, was filed on July 17, 2025 by a self-represented individual against the holding company, 23andMe, Inc., the Lemonaid and pharmacy debtors, TTAM Research Institute, Anne Wojcicki and others; it was terminated on October 15, 2025 when the court granted a motion to dismiss and entered judgment. Wojcicki and TTAM were represented in it by the same lawyer of Bryan Cave Leighton Paisner LLP.","source_ids":["src-052"],"entity_ids":["holdco","inc","ttam","wojcicki"],"qualification":"The docket summary, from an aggregator, does not state what the suit alleged.","response":"","outcome":""},"reading":"Fact: That adversary proceeding, No. 4:25-ap-04043, was filed on July 17, 2025 by a self-represented individual against the holding company, 23andMe, Inc., the Lemonaid and pharmacy debtors, TTAM Research Institute, Anne Wojcicki and others; it was terminated on October 15, 2025 when the court granted a motion to dismiss and entered judgment. Wojcicki and TTAM were represented in it by the same lawyer of Bryan Cave Leighton Paisner LLP."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-converge-settlement","record":{"id":"c-ch-converge-settlement","kind":"attributed","text":"According to the case summary, Converge Technology Solutions sought $4.03 million as an administrative expense for cloud services in May to August 2025; the wind-down debtors disputed parts of it and argued that the invoices were liabilities assumed by TTAM under the purchase agreement, and on March 4, 2026 the trust and Converge settled for $6.11 million against combined claims of $32.37 million, with the trust preserving its right to seek reimbursement from 23andMe Research Institute.","source_ids":["src-050"],"entity_ids":["converge","ttam","plan-trust","holdco"],"qualification":"Secondary summary of filings; the settlement papers were not retrieved.","response":"According to the same summary, 23andMe Research Institute filed a reply disputing any preclusive effect on claims against it.","outcome":"The trust settled with Converge on March 4, 2026 for $6.11 million and kept the right to seek reimbursement from 23andMe Research Institute."},"reading":"Attributed: According to the case summary, Converge Technology Solutions sought $4.03 million as an administrative expense for cloud services in May to August 2025; the wind-down debtors disputed parts of it and argued that the invoices were liabilities assumed by TTAM under the purchase agreement, and on March 4, 2026 the trust and Converge settled for $6.11 million against combined claims of $32.37 million, with the trust preserving its right to seek reimbursement from 23andMe Research Institute."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-adversaries","record":{"id":"c-ch-adversaries","kind":"fact","text":"Besides the eleven jointly administered subsidiary cases, the lead case lists adversary proceedings including 23andMe Holding Co. et al. v. J.R. et al. (No. 4:25-ap-04011, April 14, 2025), NAAG Client States v. 23andMe Holding Co. (No. 4:25-ap-04035) and State of Texas v. 23andMe Holding Co. (No. 4:25-ap-04036), both of June 9, 2025, the self-represented suit No. 4:25-ap-04043 of July 17, 2025, and a 2026 suit by self-represented plaintiffs against 23andMe, Inc. (No. 4:26-ap-04016, April 9, 2026).","source_ids":["src-065"],"entity_ids":["holdco","inc","texas"],"qualification":"From an aggregator's copy of the docket.","response":"","outcome":""},"reading":"Fact: Besides the eleven jointly administered subsidiary cases, the lead case lists adversary proceedings including 23andMe Holding Co. et al. v. J.R. et al. (No. 4:25-ap-04011, April 14, 2025), NAAG Client States v. 23andMe Holding Co. (No. 4:25-ap-04035) and State of Texas v. 23andMe Holding Co. (No. 4:25-ap-04036), both of June 9, 2025, the self-represented suit No. 4:25-ap-04043 of July 17, 2025, and a 2026 suit by self-represented plaintiffs against 23andMe, Inc. (No. 4:26-ap-04016, April 9, 2026)."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-reyna","record":{"id":"c-ch-reyna","kind":"fact","text":"In January 2026 Judge Edward M. Chen of the Northern District of California denied a temporary restraining order, citing among other things the bankruptcy stay, in a suit by two self-represented plaintiffs against 23andMe, Inc. and Regeneron Pharmaceuticals, Inc. (No. 26-cv-00464-EMC); the plaintiffs, who were not 23andMe customers but say their data is linked to a relative's through DNA Relatives, described Regeneron as successor to 23andMe's genomic assets.","source_ids":["src-078"],"entity_ids":["inc","regeneron"],"qualification":"Regeneron did not acquire the assets; the sale was made to TTAM. The suit was later listed in the bankruptcy court as adversary proceeding No. 4:26-ap-04016.","response":"","outcome":""},"reading":"Fact: In January 2026 Judge Edward M. Chen of the Northern District of California denied a temporary restraining order, citing among other things the bankruptcy stay, in a suit by two self-represented plaintiffs against 23andMe, Inc. and Regeneron Pharmaceuticals, Inc. (No. 26-cv-00464-EMC); the plaintiffs, who were not 23andMe customers but say their data is linked to a relative's through DNA Relatives, described Regeneron as successor to 23andMe's genomic assets."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-hearing-calendar","record":{"id":"c-ch-hearing-calendar","kind":"fact","text":"The bankruptcy court's hearing calendar for Judge Brian C. Walsh, as retrieved in October 2026, lists in the Chrome Holding Co. case an omnibus claims-objection hearing on October 27, 2026, a status conference on November 3, 2026 and an estimation hearing on November 10, 2026; the court's case page refers to Kroll's website for the case documents.","source_ids":["src-048","src-047"],"entity_ids":["holdco","kroll"],"qualification":"","response":"","outcome":""},"reading":"Fact: The bankruptcy court's hearing calendar for Judge Brian C. Walsh, as retrieved in October 2026, lists in the Chrome Holding Co. case an omnibus claims-objection hearing on October 27, 2026, a status conference on November 3, 2026 and an estimation hearing on November 10, 2026; the court's case page refers to Kroll's website for the case documents."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ch-docket-oct-2026","record":{"id":"c-ch-docket-oct-2026","kind":"fact","text":"An aggregator's copy of the docket shows that in October 2026 the trust was pursuing its twenty-third omnibus objection to claims, supported by a declaration of Joseph Selsavage, while individual claimants were still litigating their claims.","source_ids":["src-065"],"entity_ids":["holdco","plan-trust","selsavage"],"qualification":"Docket summary only.","response":"","outcome":""},"reading":"Fact: An aggregator's copy of the docket shows that in October 2026 the trust was pursuing its twenty-third omnibus objection to claims, supported by a declaration of Joseph Selsavage, while individual claimants were still litigating their claims."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-sale-customer-data","record":{"id":"c-sale-customer-data","kind":"fact","text":"According to the bankruptcy court, the debtors held about 13 million customers' data at the time of the sale hearing, more than 80% of whom had consented to research, with data given to researchers de-identified; their consumer assets were saliva samples in biobanks and electronic data such as DNA test results, names and email addresses, and about 1.9 million customers had deleted their accounts since the Chapter 11 filing.","source_ids":["src-018"],"entity_ids":["holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: According to the bankruptcy court, the debtors held about 13 million customers' data at the time of the sale hearing, more than 80% of whom had consented to research, with data given to researchers de-identified; their consumer assets were saliva samples in biobanks and electronic data such as DNA test results, names and email addresses, and about 1.9 million customers had deleted their accounts since the Chapter 11 filing."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-sale-data-categories","record":{"id":"c-sale-data-categories","kind":"attributed","text":"The objecting states described the data offered to bidders as customers' biological samples, their genotype data, which may include the entire genome, and personal information such as profile, family-tree and phenotype data, which the debtors call Customer Data. Citing the purchase agreement, they said that on May 3, 2025 the business held, among other categories, 10,397,824 biobank-consented customers and 8,860,556 genotyped customers consented to research and biobanking, and biological samples and genetic information for over 15 million consumers.","source_ids":["src-056"],"entity_ids":["holdco"],"qualification":"Counts and characterisations as stated in the states' objection of June 9, 2025, citing the purchase agreement.","response":"","outcome":""},"reading":"Attributed: The objecting states described the data offered to bidders as customers' biological samples, their genotype data, which may include the entire genome, and personal information such as profile, family-tree and phenotype data, which the debtors call Customer Data. Citing the purchase agreement, they said that on May 3, 2025 the business held, among other categories, 10,397,824 biobank-consented customers and 8,860,556 genotyped customers consented to research and biobanking, and biological samples and genetic information for over 15 million consumers."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-sale-privacy-history","record":{"id":"c-sale-privacy-history","kind":"fact","text":"The court found that since 2007 every version of the company's privacy statement had warned that personal information could be sold in a merger, acquisition or sale of assets, with the statement continuing to apply to the buyer; the states pointed out that on June 8, 2022 the company removed an assurance that individual data would not be sold to third parties for research without explicit consent and added a provision covering bankruptcy.","source_ids":["src-018","src-056"],"entity_ids":["holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: The court found that since 2007 every version of the company's privacy statement had warned that personal information could be sold in a merger, acquisition or sale of assets, with the statement continuing to apply to the buyer; the states pointed out that on June 8, 2022 the company removed an assurance that individual data would not be sold to third parties for research without explicit consent and added a provision covering bankruptcy."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-sale-ftc-letter","record":{"id":"c-sale-ftc-letter","kind":"fact","text":"On March 31, 2025 Federal Trade Commission Chairman Andrew N. Ferguson wrote to the acting U.S. Trustee in the case that any bankruptcy sale or transfer of 23andMe users' personal information and biological samples, including those of 23andMe, Inc. and Lemonaid Health, would be subject to the company's privacy and data-security representations, consistent with section 363(b)(1), and that any purchaser should expressly agree to be bound by its privacy policies and applicable law; he noted Wojcicki's September 2024 pledge to maintain the privacy policy after any acquisition by her.","source_ids":["src-077"],"entity_ids":["holdco","inc","lemonaid-health","wojcicki"],"qualification":"","response":"","outcome":""},"reading":"Fact: On March 31, 2025 Federal Trade Commission Chairman Andrew N. Ferguson wrote to the acting U.S. Trustee in the case that any bankruptcy sale or transfer of 23andMe users' personal information and biological samples, including those of 23andMe, Inc. and Lemonaid Health, would be subject to the company's privacy and data-security representations, consistent with section 363(b)(1), and that any purchaser should expressly agree to be bound by its privacy policies and applicable law; he noted Wojcicki's September 2024 pledge to maintain the privacy policy after any acquisition by her."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-sale-regulators-letter","record":{"id":"c-sale-regulators-letter","kind":"fact","text":"In April 2025 the Canadian and UK privacy commissioners wrote to the U.S. Trustee that personal information of people in Canada and the UK had to be handled under their laws; they said they would give the approved purchaser their report of findings and were prepared to act if they found non-compliance.","source_ids":["src-073"],"entity_ids":["holdco","inc"],"qualification":"","response":"","outcome":""},"reading":"Fact: In April 2025 the Canadian and UK privacy commissioners wrote to the U.S. Trustee that personal information of people in Canada and the UK had to be handled under their laws; they said they would give the approved purchaser their report of findings and were prepared to act if they found non-compliance."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-sale-cpo","record":{"id":"c-sale-cpo","kind":"fact","text":"On April 29, 2025 the debtors, the U.S. Trustee, the creditors' committee and states that had opposed the debtors' proposed independent Customer Data Representative agreed to the appointment of a Consumer Privacy Ombudsman to report to the court on the sale of personal information, including genetic data; Neil M. Richards, a law professor at Washington University, was appointed on May 6, 2025 and filed his report on June 11, 2025 (Docket No. 718), which does not bind the court.","source_ids":["src-012"],"entity_ids":["holdco"],"qualification":"The stipulation was without prejudice to the debtors' position that an ombudsman was not required.","response":"","outcome":""},"reading":"Fact: On April 29, 2025 the debtors, the U.S. Trustee, the creditors' committee and states that had opposed the debtors' proposed independent Customer Data Representative agreed to the appointment of a Consumer Privacy Ombudsman to report to the court on the sale of personal information, including genetic data; Neil M. Richards, a law professor at Washington University, was appointed on May 6, 2025 and filed his report on June 11, 2025 (Docket No. 718), which does not bind the court."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-sale-senate-safeguards","record":{"id":"c-sale-senate-safeguards","kind":"fact","text":"Selsavage told the Senate committee that the company had barred bids from entities based in or controlled from countries of concern such as China, Cuba, Iran, North Korea, Russia and Venezuela, had itself asked for an independent Customer Data Representative, required all bidders to comply with its privacy policies, and stored genetic data separately from personal identifiers; on June 11, 2025 two bidders remained, Regeneron and TTAM Research Institute.","source_ids":["src-029"],"entity_ids":["selsavage","holdco","regeneron","ttam"],"qualification":"","response":"","outcome":""},"reading":"Fact: Selsavage told the Senate committee that the company had barred bids from entities based in or controlled from countries of concern such as China, Cuba, Iran, North Korea, Russia and Venezuela, had itself asked for an independent Customer Data Representative, required all bidders to comply with its privacy policies, and stored genetic data separately from personal identifiers; on June 11, 2025 two bidders remained, Regeneron and TTAM Research Institute."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-sale-bidding-procedures","record":{"id":"c-sale-bidding-procedures","kind":"fact","text":"The court entered bidding procedures on March 28, 2025 (Docket No. 125). Moelis contacted about 57 potential purchasers and the debtors received 32 indications of interest but named no stalking-horse bidder; an auction among seven qualified bidders, opened with a bid of $52 million, ran from May 14 to May 16, 2025.","source_ids":["src-012","src-018"],"entity_ids":["holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: The court entered bidding procedures on March 28, 2025 (Docket No. 125). Moelis contacted about 57 potential purchasers and the debtors received 32 indications of interest but named no stalking-horse bidder; an auction among seven qualified bidders, opened with a bid of $52 million, ran from May 14 to May 16, 2025."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-sale-regeneron","record":{"id":"c-sale-regeneron","kind":"fact","text":"On the third day of the auction the debtors judged the $256 million bid of Regeneron Pharmaceuticals, Inc. for the whole company except the Lemonaid business the highest and best, signed an asset purchase agreement with Regeneron on May 17, 2025, and announced Regeneron as successful bidder and TTAM Research Institute as backup bidder on May 19, 2025; according to the court, TTAM's backup bid was $146 million.","source_ids":["src-012","src-018","src-035"],"entity_ids":["regeneron","holdco","ttam"],"qualification":"","response":"","outcome":""},"reading":"Fact: On the third day of the auction the debtors judged the $256 million bid of Regeneron Pharmaceuticals, Inc. for the whole company except the Lemonaid business the highest and best, signed an asset purchase agreement with Regeneron on May 17, 2025, and announced Regeneron as successful bidder and TTAM Research Institute as backup bidder on May 19, 2025; according to the court, TTAM's backup bid was $146 million."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-sale-ttam-origin","record":{"id":"c-sale-ttam-origin","kind":"fact","text":"The court found that Anne Wojcicki created TTAM Research Institute soon after the Chapter 11 filing in order to buy the debtors' assets; TTAM is a non-profit public-benefit corporation, fully funded by Wojcicki and her affiliates, of which she is chief executive officer, president and one of three directors. Her Schedule 13D describes it as a California nonprofit public benefit corporation and her affiliate.","source_ids":["src-018"],"entity_ids":["wojcicki","ttam","holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: The court found that Anne Wojcicki created TTAM Research Institute soon after the Chapter 11 filing in order to buy the debtors' assets; TTAM is a non-profit public-benefit corporation, fully funded by Wojcicki and her affiliates, of which she is chief executive officer, president and one of three directors. Her Schedule 13D describes it as a California nonprofit public benefit corporation and her affiliate."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-sale-ttam-wins","record":{"id":"c-sale-ttam-wins","kind":"fact","text":"After the auction TTAM submitted higher offers, including one of $305 million. The court approved final-round procedures on June 6, 2025, and on June 13, 2025 the debtors chose TTAM as winning bidder at $305 million, with Regeneron as backup at $151 million. Under the Chrome Purchase Agreement signed that day TTAM agreed to buy substantially all the Chrome debtors' assets under section 363 for $302.5 million and to sponsor a plan to acquire the Lemonaid debtors for $2.5 million.","source_ids":["src-012","src-005"],"entity_ids":["ttam","holdco","regeneron","lemonaid-health"],"qualification":"","response":"","outcome":""},"reading":"Fact: After the auction TTAM submitted higher offers, including one of $305 million. The court approved final-round procedures on June 6, 2025, and on June 13, 2025 the debtors chose TTAM as winning bidder at $305 million, with Regeneron as backup at $151 million. Under the Chrome Purchase Agreement signed that day TTAM agreed to buy substantially all the Chrome debtors' assets under section 363 for $302.5 million and to sponsor a plan to acquire the Lemonaid debtors for $2.5 million."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-sale-newco","record":{"id":"c-sale-newco","kind":"fact","text":"On June 14, 2025 the debtors elected to carry out the sale as an equity sale: the assets and liabilities TTAM was buying would be transferred to a newly formed, wholly owned non-debtor subsidiary (NewCo) for a note of about $302.5 million, and the company would sell all of NewCo's equity to TTAM for about $302.5 million, so that no genetic data would be transferred directly to TTAM.","source_ids":["src-012","src-049"],"entity_ids":["holdco","ttam"],"qualification":"","response":"","outcome":""},"reading":"Fact: On June 14, 2025 the debtors elected to carry out the sale as an equity sale: the assets and liabilities TTAM was buying would be transferred to a newly formed, wholly owned non-debtor subsidiary (NewCo) for a note of about $302.5 million, and the company would sell all of NewCo's equity to TTAM for about $302.5 million, so that no genetic data would be transferred directly to TTAM."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-sale-ttam-terms","record":{"id":"c-sale-ttam-terms","kind":"fact","text":"The court described the terms: after closing TTAM would own NewCo, which would hold all customers' genetic data; it would operate in the same way, offer jobs to all employees, keep access to data limited to the same people and disclose genetic data to no new parties, and keep the privacy policy in force at the petition date, including deletion and research opt-out rights in perpetuity. Under Exhibit D to the agreement TTAM also agreed to comply with applicable laws even where its non-profit status might excuse it, to limits on future mergers, sales and bankruptcy transactions, not to share personal information with insurers, to form an independent consumer privacy advisory board within ninety days and to provide two years of identity-theft monitoring.","source_ids":["src-018"],"entity_ids":["ttam","holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: The court described the terms: after closing TTAM would own NewCo, which would hold all customers' genetic data; it would operate in the same way, offer jobs to all employees, keep access to data limited to the same people and disclose genetic data to no new parties, and keep the privacy policy in force at the petition date, including deletion and research opt-out rights in perpetuity. Under Exhibit D to the agreement TTAM also agreed to comply with applicable laws even where its non-profit status might excuse it, to limits on future mergers, sales and bankruptcy transactions, not to share personal information with insurers, to form an independent consumer privacy advisory board within ninety days and to provide two years of identity-theft monitoring."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-sale-states-objection","record":{"id":"c-sale-states-objection","kind":"attributed","text":"Attorneys general of more than 30 states and the District of Columbia objected to the sale. Some argued that selling the genetic data of more than 13 million customers violated state genetic-privacy statutes unless each customer first gave new opt-in consent, while acknowledging that a change of ownership structured as a purchase of the debtors' stock might be lawful without it; in their objection they also argued that the purchase agreements in effect sold the Customer Data free and clear despite describing its transfer as merely a change of ownership, and that a non-profit buyer should remain subject to state privacy laws.","source_ids":["src-012","src-056","src-049"],"entity_ids":["holdco","ttam","regeneron","california","texas"],"qualification":"These are the objecting states' arguments; the court overruled the remaining objections and approved the sale (see the court's ruling).","response":"The debtors maintained that the transaction complied with their privacy policies and applicable law, and later restructured it as the NewCo equity sale.","outcome":"The equity structure resolved the objections of 29 of the 34 objecting jurisdictions; at the June 2025 hearing only California, Kentucky, Tennessee, Texas and Utah still objected, and the court overruled them."},"reading":"Attributed: Attorneys general of more than 30 states and the District of Columbia objected to the sale. Some argued that selling the genetic data of more than 13 million customers violated state genetic-privacy statutes unless each customer first gave new opt-in consent, while acknowledging that a change of ownership structured as a purchase of the debtors' stock might be lawful without it; in their objection they also argued that the purchase agreements in effect sold the Customer Data free and clear despite describing its transfer as merely a change of ownership, and that a non-profit buyer should remain subject to state privacy laws."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-sale-states-suits","record":{"id":"c-sale-states-suits","kind":"fact","text":"On June 9, 2025 twenty-eight states and the District of Columbia, led by Arizona, filed an adversary proceeding (No. 25-04035) seeking a declaration on the debtors' rights to sell each customer's genetic material and data without express informed consent, and Texas filed its own (No. 25-04036); on June 18, 2025 the court denied Texas a preliminary injunction against the sale.","source_ids":["src-056","src-080","src-064"],"entity_ids":["holdco","inc","texas"],"qualification":"","response":"","outcome":"After the sale closed, Texas dismissed its suit on July 21, 2025 and the multistate plaintiffs filed a joint notice of dismissal on July 30, 2025; the multistate case was closed on July 31, 2025.","adverse_subject_ids":["holdco","inc"]},"reading":"Fact: On June 9, 2025 twenty-eight states and the District of Columbia, led by Arizona, filed an adversary proceeding (No. 25-04035) seeking a declaration on the debtors' rights to sell each customer's genetic material and data without express informed consent, and Texas filed its own (No. 25-04036); on June 18, 2025 the court denied Texas a preliminary injunction against the sale."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-sale-biodata-trust","record":{"id":"c-sale-biodata-trust","kind":"fact","text":"On June 18, 2025 the Global BioData Trust, also called CAVEAT, filed a motion for leave to file an amicus brief asking the court to recognise the company's genetic data as held in trust; the court overruled its objection with the states' on June 27, 2025.","source_ids":["src-012"],"entity_ids":["biodata-trust","holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: On June 18, 2025 the Global BioData Trust, also called CAVEAT, filed a motion for leave to file an amicus brief asking the court to recognise the company's genetic data as held in trust; the court overruled its objection with the states' on June 27, 2025."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-sale-opinion","record":{"id":"c-sale-opinion","kind":"fact","text":"After a contested sale hearing on June 18 and 20, 2025, Judge Brian C. Walsh issued a memorandum opinion on June 27, 2025 (Docket No. 908) granting the sale motion, approving the sale to TTAM and entering the sale order. He held that the debtors had to comply with state law when selling customers' personal and genetic data, rejecting their argument that section 363(b)(1) pre-empts such laws, but found that their privacy policies at the petition date authorised or did not prohibit a sale of personal information with the business, subject to customers' right to opt out.","source_ids":["src-018","src-012"],"entity_ids":["holdco","ttam"],"qualification":"","response":"","outcome":""},"reading":"Fact: After a contested sale hearing on June 18 and 20, 2025, Judge Brian C. Walsh issued a memorandum opinion on June 27, 2025 (Docket No. 908) granting the sale motion, approving the sale to TTAM and entering the sale order. He held that the debtors had to comply with state law when selling customers' personal and genetic data, rejecting their argument that section 363(b)(1) pre-empts such laws, but found that their privacy policies at the petition date authorised or did not prohibit a sale of personal information with the business, subject to customers' right to opt out."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-sale-opinion-newco","record":{"id":"c-sale-opinion-newco","kind":"fact","text":"The court concluded that transferring the genetic data with the rest of the business to NewCo, a wholly owned subsidiary, was not a transfer to a third party under California's genetic-privacy statute or to a person under the Kentucky, Tennessee, Texas and Utah statutes, and that the sale of NewCo's equity to TTAM required no consent either, because those laws do not regulate a change in ownership of a genetic testing company. It rejected Texas's argument that customers' property rights in their DNA were violated, Utah's purpose-limitation argument, California and Texas's arguments of a sub rosa plan and fraudulent transfer, and the argument of California, Tennessee and Texas that the sale breached 28 U.S.C. § 959(b), and found NewCo and TTAM good-faith purchasers.","source_ids":["src-018"],"entity_ids":["holdco","ttam","texas","california"],"qualification":"","response":"","outcome":""},"reading":"Fact: The court concluded that transferring the genetic data with the rest of the business to NewCo, a wholly owned subsidiary, was not a transfer to a third party under California's genetic-privacy statute or to a person under the Kentucky, Tennessee, Texas and Utah statutes, and that the sale of NewCo's equity to TTAM required no consent either, because those laws do not regulate a change in ownership of a genetic testing company. It rejected Texas's argument that customers' property rights in their DNA were violated, Utah's purpose-limitation argument, California and Texas's arguments of a sub rosa plan and fraudulent transfer, and the argument of California, Tennessee and Texas that the sale breached 28 U.S.C. § 959(b), and found NewCo and TTAM good-faith purchasers."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-sale-opinion-price","record":{"id":"c-sale-opinion-price","kind":"fact","text":"The court found that the $305 million transaction, including $302.5 million in cash, was nearly six times the opening auction bid and nearly $50 million above the highest bid at the original auction, set by a competitive process run by independent directors; even treating Wojcicki as an insider, she would not benefit unfairly because she was investing more than $300 million of her own funds and would end up owning a non-profit corporation, which limits her ability to recover the investment. It added that TTAM would remain subject to state genetic-privacy laws.","source_ids":["src-018"],"entity_ids":["holdco","ttam","wojcicki"],"qualification":"","response":"","outcome":""},"reading":"Fact: The court found that the $305 million transaction, including $302.5 million in cash, was nearly six times the opening auction bid and nearly $50 million above the highest bid at the original auction, set by a competitive process run by independent directors; even treating Wojcicki as an insider, she would not benefit unfairly because she was investing more than $300 million of her own funds and would end up owning a non-profit corporation, which limits her ability to recover the investment. It added that TTAM would remain subject to state genetic-privacy laws."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-sale-opinion-cpo","record":{"id":"c-sale-opinion-cpo","kind":"fact","text":"The court declined to impose the ombudsman's recommended conditions, including separate express consent from each customer, a protocol for the data of deceased customers and a fiduciary duty of TTAM to customers, and shortened the stays on the sale order under Rules 6004(h) and 6006(d) to 10 days. It summed up the transaction as Wojcicki's repurchase of a business she co-founded and ran, involving a sale of customer data only in a technical sense.","source_ids":["src-018"],"entity_ids":["holdco","wojcicki","ttam"],"qualification":"The ombudsman had been unable to conclude that the sale would not violate state genetic-privacy laws.","response":"","outcome":""},"reading":"Fact: The court declined to impose the ombudsman's recommended conditions, including separate express consent from each customer, a protocol for the data of deceased customers and a fiduciary duty of TTAM to customers, and shortened the stays on the sale order under Rules 6004(h) and 6006(d) to 10 days. It summed up the transaction as Wojcicki's repurchase of a business she co-founded and ran, involving a sale of customer data only in a technical sense."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-sale-pa-ag","record":{"id":"c-sale-pa-ag","kind":"fact","text":"On June 30, 2025 Pennsylvania Attorney General Dave Sunday announced that a group of attorneys general who had sued and objected supported the sale to TTAM, created by Wojcicki, for $305 million on the agreed conditions: no transfer of consumer DNA, with data kept in place under the same policies, protections and management; deletion rights with state oversight; and part of the price going to claims of the 7 million breach victims. The attorneys general said they still objected to consumer DNA ever being part of a bankruptcy auction.","source_ids":["src-041"],"entity_ids":["ttam","holdco","wojcicki"],"qualification":"","response":"","outcome":""},"reading":"Fact: On June 30, 2025 Pennsylvania Attorney General Dave Sunday announced that a group of attorneys general who had sued and objected supported the sale to TTAM, created by Wojcicki, for $305 million on the agreed conditions: no transfer of consumer DNA, with data kept in place under the same policies, protections and management; deletion rights with state oversight; and part of the price going to claims of the 7 million breach victims. The attorneys general said they still objected to consumer DNA ever being part of a bankruptcy auction."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-sale-appeals-stay","record":{"id":"c-sale-appeals-stay","kind":"fact","text":"California and CAVEAT appealed the sale order to the U.S. District Court for the Eastern District of Missouri on July 3, 2025. The bankruptcy court denied a stay pending appeal on July 7, the district court denied it on July 10, leaving an administrative stay until 11:59 p.m. on July 11, and the Eighth Circuit denied renewed stay requests on July 11, 2025; California's emergency motion to the Eighth Circuit had asked to stop the transfer of the genetic data and samples of about 1.8 million Californians to TTAM, set to begin that night.","source_ids":["src-012","src-085"],"entity_ids":["california","biodata-trust","holdco","ttam"],"qualification":"California withdrew its appeal in the Eighth Circuit on August 11, 2025, according to the disclosure statement.","response":"","outcome":""},"reading":"Fact: California and CAVEAT appealed the sale order to the U.S. District Court for the Eastern District of Missouri on July 3, 2025. The bankruptcy court denied a stay pending appeal on July 7, the district court denied it on July 10, leaving an administrative stay until 11:59 p.m. on July 11, and the Eighth Circuit denied renewed stay requests on July 11, 2025; California's emergency motion to the Eighth Circuit had asked to stop the transfer of the genetic data and samples of about 1.8 million Californians to TTAM, set to begin that night."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-sale-closing","record":{"id":"c-sale-closing","kind":"fact","text":"The sale order of June 27, 2025 (Docket No. 910) approved the sale free and clear of liens, claims and interests, with the assumption and assignment of contracts, and the sale closed at about 8:00 a.m. Eastern Time on July 14, 2025: the debtors sold substantially all their assets to 23andMe Research Institute, formerly TTAM Research Institute, for $302.5 million in cash plus TTAM's assumption of certain liabilities, keeping the Lemonaid telehealth business.","source_ids":["src-040","src-017","src-012"],"entity_ids":["holdco","ttam","lemonaid-health"],"qualification":"","response":"","outcome":""},"reading":"Fact: The sale order of June 27, 2025 (Docket No. 910) approved the sale free and clear of liens, claims and interests, with the assumption and assignment of contracts, and the sale closed at about 8:00 a.m. Eastern Time on July 14, 2025: the debtors sold substantially all their assets to 23andMe Research Institute, formerly TTAM Research Institute, for $302.5 million in cash plus TTAM's assumption of certain liabilities, keeping the Lemonaid telehealth business."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-sale-district-court","record":{"id":"c-sale-district-court","kind":"fact","text":"On September 29, 2026 Judge Cristian M. Stevens of the U.S. District Court for the Eastern District of Missouri dismissed the appeal of California, CAVEAT and an individual against the sale order (No. 4:25-CV-00999-CMS) for lack of bankruptcy appellate standing and, independently, as statutorily moot under section 363(m), because the sale had closed without a stay and the bankruptcy court's findings that NewCo and TTAM bought in good faith were not clearly erroneous; the appellants had not alleged fraud or collusion, and the $302.5 million price exceeded the opening bid by $250.5 million.","source_ids":["src-049"],"entity_ids":["california","biodata-trust","holdco","ttam"],"qualification":"","response":"","outcome":""},"reading":"Fact: On September 29, 2026 Judge Cristian M. Stevens of the U.S. District Court for the Eastern District of Missouri dismissed the appeal of California, CAVEAT and an individual against the sale order (No. 4:25-CV-00999-CMS) for lack of bankruptcy appellate standing and, independently, as statutorily moot under section 363(m), because the sale had closed without a stay and the bankruptcy court's findings that NewCo and TTAM bought in good faith were not clearly erroneous; the appellants had not alleged fraud or collusion, and the $302.5 million price exceeded the opening bid by $250.5 million."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-sale-buyer-entities","record":{"id":"c-sale-buyer-entities","kind":"fact","text":"Parties appearing in the bankruptcy case on the buyer's side include 23andMe Research Institute (formerly TTAM Research Institute), TTAM 2.0, LLC, 23andMe Employees LLC (formerly TTAM Employee Company), 23andMe Genomics LLC (formerly 23andMe PGS LLC) and 23andMe Research LLC (formerly TTAM Research Company, LLC); the court's party list also includes the U.S. Department of Justice's National Security Division. The same law firm, Bryan Cave Leighton Paisner LLP, represents the Institute and those LLCs as well as Anne Wojcicki, ABeeC 2.0, LLC, the revocable trust and the Anne Wojcicki Foundation.","source_ids":["src-065","src-088"],"entity_ids":["ttam","ttam-2","ttam-employees","ttam-genomics","ttam-research-llc","wojcicki","abeec","aw-trust","aw-foundation","holdco"],"qualification":"From docket party lists; the ownership of the four LLCs is not stated in the retained record.","response":"","outcome":""},"reading":"Fact: Parties appearing in the bankruptcy case on the buyer's side include 23andMe Research Institute (formerly TTAM Research Institute), TTAM 2.0, LLC, 23andMe Employees LLC (formerly TTAM Employee Company), 23andMe Genomics LLC (formerly 23andMe PGS LLC) and 23andMe Research LLC (formerly TTAM Research Company, LLC); the court's party list also includes the U.S. Department of Justice's National Security Division. The same law firm, Bryan Cave Leighton Paisner LLP, represents the Institute and those LLCs as well as Anne Wojcicki, ABeeC 2.0, LLC, the revocable trust and the Anne Wojcicki Foundation."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-sale-wojcicki-ttam-ceo","record":{"id":"c-sale-wojcicki-ttam-ceo","kind":"fact","text":"A 2026 conference speaker profile describes Anne Wojcicki as founder and chief executive officer of the 23andMe Research Institute.","source_ids":["src-068"],"entity_ids":["wojcicki","ttam"],"qualification":"Conference organiser's description; the bankruptcy court's finding that she created and leads TTAM is the documented basis.","response":"","outcome":""},"reading":"Fact: A 2026 conference speaker profile describes Anne Wojcicki as founder and chief executive officer of the 23andMe Research Institute."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-lem-acquisition","record":{"id":"c-lem-acquisition","kind":"fact","text":"In November 2021 23andMe acquired Lemonaid Health, Inc., an online platform offering telemedicine, laboratory and pharmacy fulfilment services in all 50 states and the District of Columbia, for $400 million in cash ($88.6 million) and Class A shares, under a merger agreement of October 21, 2021 among 23andMe Holding Co., two merger subsidiaries, Lemonaid Health, Inc. and Fortis Advisors LLC as representative of Lemonaid's shareholders; Lemonaid became a wholly owned subsidiary.","source_ids":["src-031","src-035","src-004"],"entity_ids":["holdco","lemonaid-health"],"qualification":"","response":"","outcome":""},"reading":"Fact: In November 2021 23andMe acquired Lemonaid Health, Inc., an online platform offering telemedicine, laboratory and pharmacy fulfilment services in all 50 states and the District of Columbia, for $400 million in cash ($88.6 million) and Class A shares, under a merger agreement of October 21, 2021 among 23andMe Holding Co., two merger subsidiaries, Lemonaid Health, Inc. and Fortis Advisors LLC as representative of Lemonaid's shareholders; Lemonaid became a wholly owned subsidiary."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-lem-uk-disposal","record":{"id":"c-lem-uk-disposal","kind":"fact","text":"The company disposed of its only foreign subsidiary, the UK company Lemonaid Health Limited, on August 1, 2023, according to its annual report. The UK register shows that the company (No. 12561320, incorporated April 17, 2020) is now called Boots Digital Health Limited, and that from August 1, 2023 Boots UK Limited (No. 00928555) has held 75% or more of its shares and votes; Boots UK's own person with significant control since April 6, 2016 is Alliance Boots Holdings Limited (No. 04452715).","source_ids":["src-035","src-053","src-054","src-081"],"entity_ids":["holdco","lemonaid-uk","boots-uk","alliance-boots"],"qualification":"The register does not name the U.S. group as owner for June 2021 to July 2023, when the company filed a statement that it had no registrable person; the annual report links the disposal date to the UK subsidiary without naming the buyer.","response":"","outcome":""},"reading":"Fact: The company disposed of its only foreign subsidiary, the UK company Lemonaid Health Limited, on August 1, 2023, according to its annual report. The UK register shows that the company (No. 12561320, incorporated April 17, 2020) is now called Boots Digital Health Limited, and that from August 1, 2023 Boots UK Limited (No. 00928555) has held 75% or more of its shares and votes; Boots UK's own person with significant control since April 6, 2016 is Alliance Boots Holdings Limited (No. 04452715)."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-lem-uk-officers","record":{"id":"c-lem-uk-officers","kind":"fact","text":"While the UK company belonged to the group, its directors were Ian Alexander Van Every, from April 17, 2020 to December 21, 2022, and Joseph Anthony Selsavage, the group's chief financial officer, from December 21, 2022 until August 1, 2023; Van Every had also been registered as a person with significant control of it from December 30, 2020 to June 4, 2021. Directors from Boots were appointed from August 1, 2023.","source_ids":["src-071","src-054"],"entity_ids":["lemonaid-uk","van-every","selsavage","boots-uk"],"qualification":"","response":"","outcome":""},"reading":"Fact: While the UK company belonged to the group, its directors were Ian Alexander Van Every, from April 17, 2020 to December 21, 2022, and Joseph Anthony Selsavage, the group's chief financial officer, from December 21, 2022 until August 1, 2023; Van Every had also been registered as a person with significant control of it from December 30, 2020 to June 4, 2021. Directors from Boots were appointed from August 1, 2023."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-lem-pixel-suit","record":{"id":"c-lem-pixel-suit","kind":"attributed","text":"A class action filed on June 30, 2023 in the Northern District of California, A.J., et al. v. Lemonaid Health Inc. and LMND Medical Group, Inc. d/b/a Lemonaid Health (No. 3:23-cv-03288, Judge Rita F. Lin), on behalf of visitors to the Lemonaid website between June 30, 2019 and July 14, 2025, alleges damages and seeks injunctive relief over the defendants' use of tracking pixels on the site; the defendants are the debtor Lemonaid Health, Inc. and the non-debtor LMND Medical Group, Inc., a California professional corporation.","source_ids":["src-032","src-012"],"entity_ids":["lemonaid-health","lmnd-medical"],"qualification":"These are the plaintiffs' allegations; no court ruled on their merits before the case was settled.","response":"","outcome":"","adverse_subject_ids":["lemonaid-health"]},"reading":"Attributed: A class action filed on June 30, 2023 in the Northern District of California, A.J., et al. v. Lemonaid Health Inc. and LMND Medical Group, Inc. d/b/a Lemonaid Health (No. 3:23-cv-03288, Judge Rita F. Lin), on behalf of visitors to the Lemonaid website between June 30, 2019 and July 14, 2025, alleges damages and seeks injunctive relief over the defendants' use of tracking pixels on the site; the defendants are the debtor Lemonaid Health, Inc. and the non-debtor LMND Medical Group, Inc., a California professional corporation."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-lem-pixel-settlement","record":{"id":"c-lem-pixel-settlement","kind":"fact","text":"Under a settlement agreement of September 16, 2025, the pixel class of all U.S. visitors to lemonaidhealth.com between June 30, 2019 and July 14, 2025 has a claim allowed at $3.25 million, filed against Lemonaid Health, Inc., Chrome Holding Co. and ChromeCo, Inc. but capped at $3.25 million in total, with Almeida Law Group LLC and Migliaccio & Rathod, LLP as class counsel; the confirmed plan treats these claims as Class 14, paid from a pixel settlement fund if the settlement receives final approval, and otherwise as other Lemonaid unsecured claims.","source_ids":["src-016","src-015"],"entity_ids":["lemonaid-health","holdco","inc"],"qualification":"","response":"","outcome":"The class voted to accept the plan, and the court preliminarily approved the settlement on October 2, 2025.","adverse_subject_ids":["lemonaid-health"]},"reading":"Fact: Under a settlement agreement of September 16, 2025, the pixel class of all U.S. visitors to lemonaidhealth.com between June 30, 2019 and July 14, 2025 has a claim allowed at $3.25 million, filed against Lemonaid Health, Inc., Chrome Holding Co. and ChromeCo, Inc. but capped at $3.25 million in total, with Almeida Law Group LLC and Migliaccio & Rathod, LLP as class counsel; the confirmed plan treats these claims as Class 14, paid from a pixel settlement fund if the settlement receives final approval, and otherwise as other Lemonaid unsecured claims."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-lem-ttam-stalking-horse","record":{"id":"c-lem-ttam-stalking-horse","kind":"fact","text":"Under the TTAM purchase agreement TTAM was obliged to sponsor a plan to buy the reorganised Lemonaid equity for $2.5 million, subject to higher or better offers; after the TTAM sale closed, the debtors marketed Lemonaid separately to several interested parties.","source_ids":["src-012"],"entity_ids":["ttam","lemonaid-health","holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: Under the TTAM purchase agreement TTAM was obliged to sponsor a plan to buy the reorganised Lemonaid equity for $2.5 million, subject to higher or better offers; after the TTAM sale closed, the debtors marketed Lemonaid separately to several interested parties."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-lem-spv-agreement","record":{"id":"c-lem-spv-agreement","kind":"fact","text":"On September 10, 2025 Chrome Holding Co., Lemonaid Health, Inc. and Chrome Pharmacy Holdings, Inc. agreed to sell all the shares of Lemonaid Health and of Chrome Pharmacy Holdings to Lemonaid SPV, Inc., a Delaware corporation, for $10 million in cash plus cure payments, with Bambumeta Ventures guaranteeing the price and a $2.5 million good-faith deposit; closing required confirmation and effectiveness of a plan and regulatory approvals for the transfer of pharmacy licences.","source_ids":["src-017"],"entity_ids":["holdco","lemonaid-health","pharmacy-holdings","lemonaid-spv","bambumeta"],"qualification":"","response":"","outcome":""},"reading":"Fact: On September 10, 2025 Chrome Holding Co., Lemonaid Health, Inc. and Chrome Pharmacy Holdings, Inc. agreed to sell all the shares of Lemonaid Health and of Chrome Pharmacy Holdings to Lemonaid SPV, Inc., a Delaware corporation, for $10 million in cash plus cure payments, with Bambumeta Ventures guaranteeing the price and a $2.5 million good-faith deposit; closing required confirmation and effectiveness of a plan and regulatory approvals for the transfer of pharmacy licences."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-lem-spv-investors","record":{"id":"c-lem-spv-investors","kind":"fact","text":"A press release of September 16, 2025, in which Chrome Holding Co. announced the stock purchase agreement with Bambu Ventures, says the SPV was formed in partnership with Innova Capital Partners; BambuMeta Ventures acted as lead sponsor and guarantor, eGateway Capital of Cincinnati as a lead sponsor, supported by Broadview Capital, Auctus Holding Ltd., Day Break Partners and others; Bambu's general partners Richard Hearn and Kyle Pretsch were to provide executive leadership, and Dylan Runne was to join Innova's principals on the board.","source_ids":["src-063"],"entity_ids":["lemonaid-spv","bambumeta","innova","egateway","broadview","auctus","day-break","hearn","pretsch","runne","lemonaid-health"],"qualification":"An announcement by the seller and the buyer's sponsors; the SPV's ownership is not documented in a register in the retained record.","response":"","outcome":""},"reading":"Fact: A press release of September 16, 2025, in which Chrome Holding Co. announced the stock purchase agreement with Bambu Ventures, says the SPV was formed in partnership with Innova Capital Partners; BambuMeta Ventures acted as lead sponsor and guarantor, eGateway Capital of Cincinnati as a lead sponsor, supported by Broadview Capital, Auctus Holding Ltd., Day Break Partners and others; Bambu's general partners Richard Hearn and Kyle Pretsch were to provide executive leadership, and Dylan Runne was to join Innova's principals on the board."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-lem-buyer-interview","record":{"id":"c-lem-buyer-interview","kind":"fact","text":"In a press interview published on October 22, 2025, Kyle Pretsch, chief operating officer of Lemonaid SPV Inc. and a general partner of Bambu Ventures, said the buyer was the SPV, owned with its own capital table, with Bambu Ventures as guarantor; the report compares the price of about $10 million with the $400 million 23andMe paid for Lemonaid in 2021.","source_ids":["src-033"],"entity_ids":["pretsch","lemonaid-spv","bambumeta"],"qualification":"","response":"","outcome":""},"reading":"Fact: In a press interview published on October 22, 2025, Kyle Pretsch, chief operating officer of Lemonaid SPV Inc. and a general partner of Bambu Ventures, said the buyer was the SPV, owned with its own capital table, with Bambu Ventures as guarantor; the report compares the price of about $10 million with the $400 million 23andMe paid for Lemonaid in 2021."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-lem-sale-approved","record":{"id":"c-lem-sale-approved","kind":"fact","text":"The confirmation order of December 1, 2025 approved the Lemonaid sale to Lemonaid SPV, Inc. under a stock purchase agreement filed as Docket No. 1292: after the Lemonaid debtors' discharge, the Lemonaid interests vest in the purchaser free and clear of liens and claims in exchange for the purchase price, and the court found the purchaser to be a good-faith buyer.","source_ids":["src-016"],"entity_ids":["lemonaid-spv","lemonaid-health","holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: The confirmation order of December 1, 2025 approved the Lemonaid sale to Lemonaid SPV, Inc. under a stock purchase agreement filed as Docket No. 1292: after the Lemonaid debtors' discharge, the Lemonaid interests vest in the purchaser free and clear of liens and claims in exchange for the purchase price, and the court found the purchaser to be a good-faith buyer."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-lem-closing","record":{"id":"c-lem-closing","kind":"fact","text":"A bankruptcy-data publisher reports that the Lemonaid sale closed on the plan's effective date, December 5, 2025, bringing total proceeds from the debtors' asset sales to about $312.5 million.","source_ids":["src-050"],"entity_ids":["lemonaid-spv","bambumeta","holdco"],"qualification":"Secondary summary; the closing notice was not retrieved.","response":"","outcome":""},"reading":"Fact: A bankruptcy-data publisher reports that the Lemonaid sale closed on the plan's effective date, December 5, 2025, bringing total proceeds from the debtors' asset sales to about $312.5 million."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ppl-awf","record":{"id":"c-ppl-awf","kind":"fact","text":"The Anne Wojcicki Foundation, a private grant-making foundation in Los Altos, California (EIN 47-1835703), has held a section 501(c)(3) tax exemption since February 2015. Its Form 990-PF for 2024, as reproduced by a nonprofit-data service, reports total assets of $593,310,267 and no liabilities, and lists Anne Wojcicki as President and Chair and Susan Wojcicki as Treasurer and Secretary, neither paid.","source_ids":["src-037"],"entity_ids":["aw-foundation","wojcicki","susan-wojcicki"],"qualification":"","response":"","outcome":""},"reading":"Fact: The Anne Wojcicki Foundation, a private grant-making foundation in Los Altos, California (EIN 47-1835703), has held a section 501(c)(3) tax exemption since February 2015. Its Form 990-PF for 2024, as reproduced by a nonprofit-data service, reports total assets of $593,310,267 and no liabilities, and lists Anne Wojcicki as President and Chair and Susan Wojcicki as Treasurer and Secretary, neither paid."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ppl-twf","record":{"id":"c-ppl-twf","kind":"fact","text":"The Troper Wojcicki Foundation of San Francisco (EIN 20-2777268), a private foundation, reports total assets of $339,320,002 in its Form 990-PF for 2024, as reproduced by a nonprofit-data service; the return lists Susan Wojcicki as its unpaid President until September 2024, after which other officers held the posts.","source_ids":["src-086"],"entity_ids":["twf","susan-wojcicki"],"qualification":"","response":"","outcome":""},"reading":"Fact: The Troper Wojcicki Foundation of San Francisco (EIN 20-2777268), a private foundation, reports total assets of $339,320,002 in its Form 990-PF for 2024, as reproduced by a nonprofit-data service; the return lists Susan Wojcicki as its unpaid President until September 2024, after which other officers held the posts."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ppl-wojcicki-zipline","record":{"id":"c-ppl-wojcicki-zipline","kind":"fact","text":"Zipline, the drone-delivery company, announced in September 2021 that Anne Wojcicki had joined its board of directors as it charted its next stage of growth after $250 million in new funding.","source_ids":["src-060"],"entity_ids":["wojcicki","zipline"],"qualification":"The company's announcement as carried by a trade publication.","response":"","outcome":""},"reading":"Fact: Zipline, the drone-delivery company, announced in September 2021 that Anne Wojcicki had joined its board of directors as it charted its next stage of growth after $250 million in new funding."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ppl-wojcicki-boards","record":{"id":"c-ppl-wojcicki-boards","kind":"fact","text":"A financial-data aggregator lists Anne Wojcicki on the boards of Ajax I, 23andMe Holding Co., 23andMe, Inc., Blok24, Inc., the Breakthrough Prize in Life Sciences, Capri Listco, the Foundation for the National Institutes of Health, the Kaiser Permanente Bernard J. Tyson School of Medicine and Zipline International, Inc. Sidecar Health, a health insurer, lists her on its board of advisors, describing her as the former chief executive of 23andMe, Inc., which she co-founded in 2006.","source_ids":["src-030","src-061"],"entity_ids":["wojcicki","ajax","blok24","breakthrough-prize","fnih","kp-school","zipline","sidecar","holdco","inc"],"qualification":"The aggregator mixes current and former seats; the advisory board is not a board of directors.","response":"","outcome":""},"reading":"Fact: A financial-data aggregator lists Anne Wojcicki on the boards of Ajax I, 23andMe Holding Co., 23andMe, Inc., Blok24, Inc., the Breakthrough Prize in Life Sciences, Capri Listco, the Foundation for the National Institutes of Health, the Kaiser Permanente Bernard J. Tyson School of Medicine and Zipline International, Inc. Sidecar Health, a health insurer, lists her on its board of advisors, describing her as the former chief executive of 23andMe, Inc., which she co-founded in 2006."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ppl-ajax","record":{"id":"c-ppl-ajax","kind":"fact","text":"The SEC's record for AJAX I (CIK 0001824963), a blank check company on whose board Wojcicki sat, shows a Cayman Islands company with a mailing address at 667 Madison Avenue, New York, no listed securities and the emerging growth company category.","source_ids":["src-082"],"entity_ids":["ajax"],"qualification":"","response":"","outcome":""},"reading":"Fact: The SEC's record for AJAX I (CIK 0001824963), a blank check company on whose board Wojcicki sat, shows a Cayman Islands company with a mailing address at 667 Madison Avenue, New York, no listed securities and the emerging growth company category."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ppl-cusenza","record":{"id":"c-ppl-cusenza","kind":"fact","text":"A financial-data aggregator describes Paul Cusenza as the founder of 23andMe, Inc. in 2006 and as chairman and chief executive officer of Nodal Exchange LLC since 2008 and of Nodal Exchange Holdings LLC, and chairman of Nodal Clear LLC since 2014; he was earlier SVP of marketing and public sector collaborations at Perlegen Sciences, Inc. from 2002 to 2010. It shows no position in the holding company.","source_ids":["src-103"],"entity_ids":["cusenza","inc","nodal-exchange","nodal-holdings","nodal-clear","perlegen"],"qualification":"","response":"","outcome":""},"reading":"Fact: A financial-data aggregator describes Paul Cusenza as the founder of 23andMe, Inc. in 2006 and as chairman and chief executive officer of Nodal Exchange LLC since 2008 and of Nodal Exchange Holdings LLC, and chairman of Nodal Clear LLC since 2014; he was earlier SVP of marketing and public sector collaborations at Perlegen Sciences, Inc. from 2002 to 2010. It shows no position in the holding company."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ppl-avey","record":{"id":"c-ppl-avey","kind":"fact","text":"The Human Immunome Project's board page, which spells her first name 'Linea', describes Linda Avey as the founder of 23andMe in 2006, a founding general partner of Humain Ventures, an Austin, Texas venture capital firm, a co-founder of Precisely, Inc., a member of the Board of Fellows at Stanford Medical Center and an adviser to Colossal Biosciences, and formerly the founding independent board director of Rock Health.","source_ids":["src-104"],"entity_ids":["avey","inc","humain","precisely","rock-health"],"qualification":"The organisation's own biography of a board member; it names no position in the holding company.","response":"","outcome":""},"reading":"Fact: The Human Immunome Project's board page, which spells her first name 'Linea', describes Linda Avey as the founder of 23andMe in 2006, a founding general partner of Humain Ventures, an Austin, Texas venture capital firm, a co-founder of Precisely, Inc., a member of the Board of Fellows at Stanford Medical Center and an adviser to Colossal Biosciences, and formerly the founding independent board director of Rock Health."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ppl-scheller-roles","record":{"id":"c-ppl-scheller-roles","kind":"fact","text":"GV's website describes Richard Scheller as an advisor who joined BridgeBio Pharma as chairman of R&D in 2019 after joining its board in 2018, sits on the boards of Alector, Maze Therapeutics, DiCE Molecules and Aarvik Therapeutics, and was executive vice president of research and early development at Genentech from 2001 to 2014; the page still lists him as a 23andMe director although he resigned with the other independent directors. A financial-data aggregator adds Oric Pharmaceuticals to his current boards. BridgeBio Pharma, Inc. is a Delaware corporation listed on Nasdaq (CIK 0001743881).","source_ids":["src-066","src-098"],"entity_ids":["scheller","bridgebio","alector","maze","dice","aarvik","genentech","oric","inc"],"qualification":"","response":"","outcome":""},"reading":"Fact: GV's website describes Richard Scheller as an advisor who joined BridgeBio Pharma as chairman of R&D in 2019 after joining its board in 2018, sits on the boards of Alector, Maze Therapeutics, DiCE Molecules and Aarvik Therapeutics, and was executive vice president of research and early development at Genentech from 2001 to 2014; the page still lists him as a 23andMe director although he resigned with the other independent directors. A financial-data aggregator adds Oric Pharmaceuticals to his current boards. BridgeBio Pharma, Inc. is a Delaware corporation listed on Nasdaq (CIK 0001743881)."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ppl-hernandez-roles","record":{"id":"c-ppl-hernandez-roles","kind":"fact","text":"On February 13, 2018 the California Health Care Foundation announced that Governor Jerry Brown had appointed its president and chief executive, Sandra R. Hernández, to the board of Covered California, the state's health insurance marketplace. A financial-data aggregator lists her other roles as director of Mills College and of The Center for Investigative Reporting, and earlier chief executive of The San Francisco Foundation (2010–2013) and director of Blackbaud, First Republic Bank (2010–2013) and Blue Shield of California.","source_ids":["src-067"],"entity_ids":["hernandez","chcf","covered-california","blackbaud","first-republic"],"qualification":"","response":"","outcome":""},"reading":"Fact: On February 13, 2018 the California Health Care Foundation announced that Governor Jerry Brown had appointed its president and chief executive, Sandra R. Hernández, to the board of Covered California, the state's health insurance marketplace. A financial-data aggregator lists her other roles as director of Mills College and of The Center for Investigative Reporting, and earlier chief executive of The San Francisco Foundation (2010–2013) and director of Blackbaud, First Republic Bank (2010–2013) and Blue Shield of California."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ppl-montgomery-rice-roles","record":{"id":"c-ppl-montgomery-rice-roles","kind":"fact","text":"Her inauguration biography describes Valerie Montgomery Rice as the founder and former director of the Center for Women's Health Research at Meharry Medical College, and an infertility specialist who served at Morehouse School of Medicine from 2011 as dean and executive vice president. An insider-filings aggregator shows her reporting as a director of UnitedHealth Group Inc. (transaction date August 4, 2017) and of the holding company (June 16, 2021).","source_ids":["src-101","src-070"],"entity_ids":["montgomery-rice","morehouse","meharry","unitedhealth","holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: Her inauguration biography describes Valerie Montgomery Rice as the founder and former director of the Center for Women's Health Research at Meharry Medical College, and an infertility specialist who served at Morehouse School of Medicine from 2011 as dean and executive vice president. An insider-filings aggregator shows her reporting as a director of UnitedHealth Group Inc. (transaction date August 4, 2017) and of the holding company (June 16, 2021)."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ppl-mohan-roles","record":{"id":"c-ppl-mohan-roles","kind":"fact","text":"A financial-data aggregator lists Neal Mohan as chief executive officer of YouTube since 2023, an independent director of Starbucks Corp. from 2024 and an advisor at CapitalG Management Co., and formerly an independent director of Stitch Fix, Inc. (2020–2023) and a director of 23andMe, Inc. from 2017.","source_ids":["src-097"],"entity_ids":["mohan","youtube","starbucks","stitch-fix","inc"],"qualification":"","response":"","outcome":""},"reading":"Fact: A financial-data aggregator lists Neal Mohan as chief executive officer of YouTube since 2023, an independent director of Starbucks Corp. from 2024 and an advisor at CapitalG Management Co., and formerly an independent director of Stitch Fix, Inc. (2020–2023) and a director of 23andMe, Inc. from 2017."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ppl-botha-spacex","record":{"id":"c-ppl-botha-spacex","kind":"fact","text":"According to a market-data summary published on June 17, 2026, the board of Space Exploration Technologies Corp. elected Roelof Botha, effective June 16, 2026, as an independent Common Stock Director and a member of its audit committee. A financial-data aggregator also lists him as a director of MongoDB, Block, Unity Software, Natera and Ethos Technologies.","source_ids":["src-089","src-111"],"entity_ids":["botha","spacex","mongodb","block","unity","natera"],"qualification":"The aggregator gives June 15, 2026 as the start of the SpaceX seat; the summary gives June 16.","response":"","outcome":""},"reading":"Fact: According to a market-data summary published on June 17, 2026, the board of Space Exploration Technologies Corp. elected Roelof Botha, effective June 16, 2026, as an independent Common Stock Director and a member of its audit committee. A financial-data aggregator also lists him as a director of MongoDB, Block, Unity Software, Natera and Ethos Technologies."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ppl-chung-roles","record":{"id":"c-ppl-chung-roles","kind":"fact","text":"A financial-data aggregator lists Patrick Chung as Managing General Partner of Xfund Management Co. LLC since 2012, a director of Philo, Inc. and founder of WRLD3D Ltd. in 2010, and as a director of 23andMe, Inc. from 2009 to 2024 and an independent director of the holding company from 2021 to 2024. In April 2019 he signed the Form D of the venture fund Xfund 3, L.P. as Managing Director of its general partner.","source_ids":["src-096","src-069"],"entity_ids":["chung","xfund","philo","wrld3d","xfund-3","inc","holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: A financial-data aggregator lists Patrick Chung as Managing General Partner of Xfund Management Co. LLC since 2012, a director of Philo, Inc. and founder of WRLD3D Ltd. in 2010, and as a director of 23andMe, Inc. from 2009 to 2024 and an independent director of the holding company from 2021 to 2024. In April 2019 he signed the Form D of the venture fund Xfund 3, L.P. as Managing Director of its general partner."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ppl-taylor-roles","record":{"id":"c-ppl-taylor-roles","kind":"fact","text":"A financial-data aggregator lists Peter J. Taylor, the former audit committee chair, as chairman of Southern California Edison Co. and independent non-executive chairman of Edison International since 2022 and a director of Pacific Mutual Holding Co. since 2016, and formerly president of the ECMC Foundation and chief financial officer of the University of California.","source_ids":["src-095"],"entity_ids":["taylor","sce","edison-intl","pacific-mutual","ecmc"],"qualification":"","response":"","outcome":""},"reading":"Fact: A financial-data aggregator lists Peter J. Taylor, the former audit committee chair, as chairman of Southern California Edison Co. and independent non-executive chairman of Edison International since 2022 and a director of Pacific Mutual Holding Co. since 2016, and formerly president of the ECMC Foundation and chief financial officer of the University of California."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ppl-fernandez-roles","record":{"id":"c-ppl-fernandez-roles","kind":"fact","text":"A financial-data aggregator lists Andre Fernandez as Vice Chairman of Froedtert Health System, Inc. and an independent director of Cardlytics, Inc. from 2024, and still shows his Chrome Holding Co. directorship, from October 27, 2024, as active although the board was dissolved on the plan's effective date. His amended Form 4 filed with Cardlytics in August 2026 confirms that he is a director of that company.","source_ids":["src-093","src-108"],"entity_ids":["fernandez","froedtert","cardlytics","holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: A financial-data aggregator lists Andre Fernandez as Vice Chairman of Froedtert Health System, Inc. and an independent director of Cardlytics, Inc. from 2024, and still shows his Chrome Holding Co. directorship, from October 27, 2024, as active although the board was dissolved on the plan's effective date. His amended Form 4 filed with Cardlytics in August 2026 confirms that he is a director of that company."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ppl-frankola-roles","record":{"id":"c-ppl-frankola-roles","kind":"fact","text":"IonQ, Inc. announced on August 28, 2025 that it had appointed Jim Frankola, the former chief financial officer of Ariba and Cloudera, to its board. A financial-data aggregator lists his directorships of Skillsoft and IonQ and of Chrome Holding Co. from October 27, 2024, and shows his Ansys seat ending on July 16, 2025; Ansys filed a Form 15-12G deregistering its securities in July 2025.","source_ids":["src-105","src-109","src-094"],"entity_ids":["frankola","ionq","skillsoft","ansys","ariba","cloudera","holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: IonQ, Inc. announced on August 28, 2025 that it had appointed Jim Frankola, the former chief financial officer of Ariba and Cloudera, to its board. A financial-data aggregator lists his directorships of Skillsoft and IonQ and of Chrome Holding Co. from October 27, 2024, and shows his Ansys seat ending on July 16, 2025; Ansys filed a Form 15-12G deregistering its securities in July 2025."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ppl-hibbs-roles","record":{"id":"c-ppl-hibbs-roles","kind":"fact","text":"An insider-filings aggregator describes Kathy L. Hibbs, the former Chief Administrative Officer, as a director of Sophia Genetics SA and earlier SVP and General Counsel of Genomic Health Inc.","source_ids":["src-100"],"entity_ids":["hibbs","sophia","genomic-health","holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: An insider-filings aggregator describes Kathy L. Hibbs, the former Chief Administrative Officer, as a director of Sophia Genetics SA and earlier SVP and General Counsel of Genomic Health Inc."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ppl-walper-bar","record":{"id":"c-ppl-walper-bar","kind":"fact","text":"The State Bar of California lists Thomas Bradley Walper (licence no. 96667) as an active attorney admitted on December 16, 1980, and its licence history shows no disciplinary or administrative actions; a financial-data aggregator gives Thomas B. Walper's law degree from Loyola Law School as conferred in 1980.","source_ids":["src-025"],"entity_ids":["walper"],"qualification":"The bar profile is matched to the director by name, practice and the year of the law degree; it does not itself name the company.","response":"","outcome":""},"reading":"Fact: The State Bar of California lists Thomas Bradley Walper (licence no. 96667) as an active attorney admitted on December 16, 1980, and its licence history shows no disciplinary or administrative actions; a financial-data aggregator gives Thomas B. Walper's law degree from Loyola Law School as conferred in 1980."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ppl-walper-declaration","record":{"id":"c-ppl-walper-declaration","kind":"fact","text":"In July 2026 the Plan Administration Trust filed a declaration of Thomas B. Walper in support of its motion to approve the stipulation among the trust, the Wind-Down Debtor and the signatory governmental claimants.","source_ids":["src-019"],"entity_ids":["walper","plan-trust","holdco"],"qualification":"","response":"","outcome":""},"reading":"Fact: In July 2026 the Plan Administration Trust filed a declaration of Thomas B. Walper in support of its motion to approve the stipulation among the trust, the Wind-Down Debtor and the signatory governmental claimants."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ppl-magides","record":{"id":"c-ppl-magides","kind":"fact","text":"A financial-data aggregator describes Richard Magides as the founder, in 2011, and chief executive officer of Zentree Investment Management Pte Ltd, and earlier a Managing Partner at Artradis Fund Management Pte Ltd.","source_ids":["src-046"],"entity_ids":["magides","zentree-im","artradis"],"qualification":"","response":"","outcome":""},"reading":"Fact: A financial-data aggregator describes Richard Magides as the founder, in 2011, and chief executive officer of Zentree Investment Management Pte Ltd, and earlier a Managing Partner at Artradis Fund Management Pte Ltd."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"c-ppl-virgin-2023","record":{"id":"c-ppl-virgin-2023","kind":"fact","text":"A Schedule 13D amendment filed on November 3, 2023 for Virgin Galactic Holdings, not for the company, describes the Virgin chain after Sir Richard Branson transferred all ordinary shares of Virgin Group Holdings Limited on November 1, 2023: Virgin Investments Limited is owned by Corvina Holdings Limited, which is owned by Virgin Group Holdings; BFT (PTC) Limited, as trustee of trusts for members of Branson's family and related philanthropic causes, holds all of Virgin Group Holdings' voting shares; BFT CLG (PTC) Limited may remove and replace the trustee's directors, and Branson, who owns all its 'A' membership interests, may be deemed to control it.","source_ids":["src-059"],"entity_ids":["virgin-galactic","virgin-investments","corvina","vghl","bft-ptc","bft-clg","branson"],"qualification":"This post-dates the business combination, after which the Virgin entities no longer held founder-share control of the company.","response":"","outcome":""},"reading":"Fact: A Schedule 13D amendment filed on November 3, 2023 for Virgin Galactic Holdings, not for the company, describes the Virgin chain after Sir Richard Branson transferred all ordinary shares of Virgin Group Holdings Limited on November 1, 2023: Virgin Investments Limited is owned by Corvina Holdings Limited, which is owned by Virgin Group Holdings; BFT (PTC) Limited, as trustee of trusts for members of Branson's family and related philanthropic causes, holds all of Virgin Group Holdings' voting shares; BFT CLG (PTC) Limited may remove and replace the trustee's directors, and Branson, who owns all its 'A' membership interests, may be deemed to control it."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-3dbb00fb237ef3fdf297efc9","record":{"id":"display-claim-3dbb00fb237ef3fdf297efc9","kind":"analysis","text":"Separates the SEC registrant, the former VG Acquisition Corp., from the operating company 23andMe, Inc. and from the buyer, and documents how Wojcicki's ten-vote shares gave her about half the vote until a June 2025 conversion. It sets the company's own account of the 2023 breach beside the Canadian and UK findings, the UK penalty and California's 2026 allegations, including the unanswered ransom allegation, and follows each breach claim to its settlement or open status. It reconstructs the Chapter 11 sale in which Wojcicki's non-profit outbid Regeneron, the states' objections and the court's reasons, and the plan's treatment of Wojcicki as a non-released party whose indemnification rights survive.","source_ids":["src-007","src-075","src-012","src-008","src-004","src-031","src-006","src-050","src-079","src-010","src-073","src-074","src-076","src-002","src-003","src-018","src-035","src-005","src-049","src-040","src-017","src-056","src-015","src-016","src-019","src-045","src-084","src-107","src-065"],"entity_ids":["holdco","inc","wojcicki","avey","cusenza","abeec","aw-trust","aw-foundation","botha","chung","hernandez","mohan","montgomery-rice","scheller","taylor","california","lemonaid-health","pharmacy-holdings","lemonaid-pharmacy-holdings","lemonaid-community-pharmacy","lpharm-ins","lpharm-cs","lpharm-rx","lprxone","lprxtwo","lprxthree","kvarda","ttam","regeneron","texas","biodata-trust","lemonaid-spv","bambumeta","plan-trust"],"premise_claim_ids":["c-spac-same-registrant","c-gov-founding","c-id-rename","c-ctl-2024-wojcicki","c-gov-special-committee","c-gov-go-private-2024","c-gov-resignations","c-gov-march-2025-final","c-br-company-account","c-br-regulator-safeguards","c-br-ico-penalty","c-br-ca-ransom","c-ch-filing","c-ch-causes","c-sale-ttam-origin","c-sale-regeneron","c-sale-ttam-wins","c-sale-newco","c-sale-opinion-price","c-sale-closing","c-sale-states-objection","c-sale-district-court","c-lem-acquisition","c-lem-spv-agreement","c-ch-confirmation","c-ch-plan-trust","c-ch-excluded-parties","c-ch-wojcicki-resolution","c-st-us-final","c-st-states-claims","c-st-states-allocation","c-st-ca-enforcement-order"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Separates the SEC registrant, the former VG Acquisition Corp., from the operating company 23andMe, Inc. and from the buyer, and documents how Wojcicki's ten-vote shares gave her about half the vote until a June 2025 conversion. It sets the company's own account of the 2023 breach beside the Canadian and UK findings, the UK penalty and California's 2026 allegations, including the unanswered ransom allegation, and follows each breach claim to its settlement or open status. It reconstructs the Chapter 11 sale in which Wojcicki's non-profit outbid Regeneron, the states' objections and the court's reasons, and the plan's treatment of Wojcicki as a non-released party whose indemnification rights survive."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-ca9f583806514dfc96a6fe0d","record":{"id":"display-claim-ca9f583806514dfc96a6fe0d","kind":"analysis","text":"The company that filed for bankruptcy as 23andMe Holding Co. is the former VG Acquisition Corp., a blank check company sponsored by the Virgin Group: its filings define it as \"23andMe Holding Co. (formerly known as VG Acquisition Corp.)\", while the genetic-testing business founded in 2006 by Anne Wojcicki, Linda Avey and Paul Cusenza is its subsidiary 23andMe, Inc. After selling the business the holding company renamed itself Chrome Holding Co. on August 14, 2025.","source_ids":["src-007","src-075","src-012","src-008"],"entity_ids":["holdco","inc","wojcicki","avey","cusenza"],"premise_claim_ids":["c-spac-same-registrant","c-gov-founding","c-id-rename"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The company that filed for bankruptcy as 23andMe Holding Co. is the former VG Acquisition Corp., a blank check company sponsored by the Virgin Group: its filings define it as \"23andMe Holding Co. (formerly known as VG Acquisition Corp.)\", while the genetic-testing business founded in 2006 by Anne Wojcicki, Linda Avey and Paul Cusenza is its subsidiary 23andMe, Inc. After selling the business the holding company renamed itself Chrome Holding Co. on August 14, 2025."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-d250027e5f6638ea80cc03da","record":{"id":"display-claim-d250027e5f6638ea80cc03da","kind":"analysis","text":"Through ten-vote Class B shares held by her company ABeeC 2.0, LLC, whose sole member is her revocable trust, and her own Class A shares, Wojcicki held 49.75% of the total vote on July 1, 2024 (share counts before the October 2024 reverse split). In March 2024 the board set up a Special Committee because her interests could differ from other stockholders'. It rejected her July 2024 proposal to take the company private at $0.40 a share ($8.00 after the reverse split), and on September 17, 2024 all seven independent directors resigned, saying they differed with her on strategy and, given her voting power, resigning was in stockholders' interest; she told employees she was surprised and disappointed, according to a case summary. Three new independent directors joined on October 28, 2024 and became the new Special Committee on November 2, which rejected her last offer, of $0.41 a share plus contingent value rights, in March 2025.","source_ids":["src-004","src-012","src-031","src-006","src-050","src-079","src-010"],"entity_ids":["abeec","aw-trust","wojcicki","aw-foundation","holdco","botha","chung","hernandez","mohan","montgomery-rice","scheller","taylor"],"premise_claim_ids":["c-ctl-2024-wojcicki","c-gov-special-committee","c-gov-go-private-2024","c-gov-resignations","c-gov-march-2025-final"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Through ten-vote Class B shares held by her company ABeeC 2.0, LLC, whose sole member is her revocable trust, and her own Class A shares, Wojcicki held 49.75% of the total vote on July 1, 2024 (share counts before the October 2024 reverse split). In March 2024 the board set up a Special Committee because her interests could differ from other stockholders'. It rejected her July 2024 proposal to take the company private at $0.40 a share ($8.00 after the reverse split), and on September 17, 2024 all seven independent directors resigned, saying they differed with her on strategy and, given her voting power, resigning was in stockholders' interest; she told employees she was surprised and disappointed, according to a case summary. Three new independent directors joined on October 28, 2024 and became the new Special Committee on November 2, which rejected her last offer, of $0.41 a share plus contingent value rights, in March 2025."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-59699c73ee07d76678aa4d74","record":{"id":"display-claim-59699c73ee07d76678aa4d74","kind":"analysis","text":"According to the company, an attacker logged into about 0.1% of accounts with passwords reused from other websites and reached information on about seven million customers through the DNA Relatives and Connections features. The Canadian and UK privacy commissioners found that 23andMe lacked safeguards suited to the sensitivity of the data; 23andMe told them of its later improvements, and the Canadian Commissioner treated the issue as resolved. The UK Information Commissioner fined 23andMe, Inc. £2,310,000 on June 5, 2025, after the company argued that a penalty would deplete funds for claimants; that was less than the £4,593,750 first proposed, and the record does not show whether the right of appeal was used.","source_ids":["src-012","src-073","src-074"],"entity_ids":["holdco","inc"],"premise_claim_ids":["c-br-company-account","c-br-regulator-safeguards","c-br-ico-penalty"],"qualification":"","response":"","outcome":""},"reading":"Analysis: According to the company, an attacker logged into about 0.1% of accounts with passwords reused from other websites and reached information on about seven million customers through the DNA Relatives and Connections features. The Canadian and UK privacy commissioners found that 23andMe lacked safeguards suited to the sensitivity of the data; 23andMe told them of its later improvements, and the Canadian Commissioner treated the issue as resolved. The UK Information Commissioner fined 23andMe, Inc. £2,310,000 on June 5, 2025, after the company argued that a penalty would deplete funds for claimants; that was less than the £4,593,750 first proposed, and the record does not show whether the right of appeal was used."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-80621e3667ae8b8c14f01b6d","record":{"id":"display-claim-80621e3667ae8b8c14f01b6d","kind":"analysis","text":"California's Attorney General alleges in a 2026 complaint that in October 2023 the company negotiated with the attacker and paid $400,000 in cryptocurrency for, among other things, deletion of posts about the breach and a cover story mitigating its severity. These are allegations no court has found proven, and no response to them by the company, the trust or Wojcicki was found in the record; the trust's motion in the bankruptcy court concerned whether California's claims were barred.","source_ids":["src-076","src-075"],"entity_ids":["holdco","wojcicki","california"],"premise_claim_ids":["c-br-ca-ransom"],"qualification":"","response":"","outcome":""},"reading":"Analysis: California's Attorney General alleges in a 2026 complaint that in October 2023 the company negotiated with the attacker and paid $400,000 in cryptocurrency for, among other things, deletion of posts about the breach and a cover story mitigating its severity. These are allegations no court has found proven, and no response to them by the company, the trust or Wojcicki was found in the record; the trust's motion in the bankruptcy court concerned whether California's claims were barred."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-15b12c70772ca392540b9d39","record":{"id":"display-claim-15b12c70772ca392540b9d39","kind":"analysis","text":"On March 23, 2025 the holding company and eleven subsidiaries filed for Chapter 11 in the Eastern District of Missouri. The chief restructuring officer said the business had never made a net profit despite more than $200 million of revenue a year, and the disclosure statement blames limited access to capital, the economy, the breach and the litigation. The court found that Wojcicki created TTAM Research Institute soon after the filing to buy the assets, a non-profit fully funded by her and her affiliates. Regeneron won the May auction with $256 million, but TTAM raised its offer to $305 million and was chosen on June 13, 2025; the business was moved into a new subsidiary whose shares were sold, so that no genetic data passed to TTAM directly.","source_ids":["src-002","src-003","src-012","src-031","src-018","src-035","src-005","src-049"],"entity_ids":["holdco","inc","lemonaid-health","pharmacy-holdings","lemonaid-pharmacy-holdings","lemonaid-community-pharmacy","lpharm-ins","lpharm-cs","lpharm-rx","lprxone","lprxtwo","lprxthree","kvarda","wojcicki","ttam","regeneron"],"premise_claim_ids":["c-ch-filing","c-ch-causes","c-sale-ttam-origin","c-sale-regeneron","c-sale-ttam-wins","c-sale-newco"],"qualification":"","response":"","outcome":""},"reading":"Analysis: On March 23, 2025 the holding company and eleven subsidiaries filed for Chapter 11 in the Eastern District of Missouri. The chief restructuring officer said the business had never made a net profit despite more than $200 million of revenue a year, and the disclosure statement blames limited access to capital, the economy, the breach and the litigation. The court found that Wojcicki created TTAM Research Institute soon after the filing to buy the assets, a non-profit fully funded by her and her affiliates. Regeneron won the May auction with $256 million, but TTAM raised its offer to $305 million and was chosen on June 13, 2025; the business was moved into a new subsidiary whose shares were sold, so that no genetic data passed to TTAM directly."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-ce5f8d7f2d32c970ac5240d8","record":{"id":"display-claim-ce5f8d7f2d32c970ac5240d8","kind":"analysis","text":"The court approved the sale on June 27, 2025, finding the price fair and that Wojcicki, investing more than $300 million of her own funds in a non-profit, would not benefit unfairly, and it closed on July 14, 2025 for $302.5 million in cash plus assumed liabilities. Some objecting states argued that the sale needed each customer's consent; the debtors said it complied with their policies and the law and restructured it as a share sale, which resolved most objections, and the court overruled the rest; an appeal by California and others was dismissed on September 29, 2026 as statutorily moot and for lack of standing. Lemonaid, bought for $400 million in 2021, was sold to Lemonaid SPV, Inc. for $10 million plus cure payments.","source_ids":["src-018","src-040","src-017","src-012","src-056","src-049","src-031","src-035","src-004"],"entity_ids":["holdco","ttam","wojcicki","lemonaid-health","regeneron","california","texas","biodata-trust","pharmacy-holdings","lemonaid-spv","bambumeta"],"premise_claim_ids":["c-sale-opinion-price","c-sale-closing","c-sale-states-objection","c-sale-district-court","c-lem-acquisition","c-lem-spv-agreement"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The court approved the sale on June 27, 2025, finding the price fair and that Wojcicki, investing more than $300 million of her own funds in a non-profit, would not benefit unfairly, and it closed on July 14, 2025 for $302.5 million in cash plus assumed liabilities. Some objecting states argued that the sale needed each customer's consent; the debtors said it complied with their policies and the law and restructured it as a share sale, which resolved most objections, and the court overruled the rest; an appeal by California and others was dismissed on September 29, 2026 as statutorily moot and for lack of standing. Lemonaid, bought for $400 million in 2021, was sold to Lemonaid SPV, Inc. for $10 million plus cure payments."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-ab68222edcc8c994e70c5736","record":{"id":"display-claim-ab68222edcc8c994e70c5736","kind":"analysis","text":"The liquidating plan, confirmed on December 1 and effective on December 5, 2025, cancelled the shares and moved the remaining assets into a Plan Administration Trust run by Thomas Walper. It names Wojcicki as an Excluded Party, not released and open to suit by the trust, which preserves possible claims and is not a finding of liability; her indemnification rights are preserved. The U.S. breach class settlement was finally approved at $46.75 million, and 41 states and the District of Columbia agreed in July 2026 to an $18 million payment and conduct limits, without admission of liability and subject to court approval at a hearing set for August 10, 2026, whose ruling the record does not include. The bankruptcy court held that the plan injunction bars the monetary claims of California's 2026 suit, which it found essentially similar to California's proof of claim, and ordered them dropped; California appealed.","source_ids":["src-015","src-016","src-019","src-045","src-084","src-107","src-076","src-065"],"entity_ids":["holdco","plan-trust","wojcicki","aw-foundation","abeec","ttam","inc","texas","california"],"premise_claim_ids":["c-ch-confirmation","c-ch-plan-trust","c-ch-excluded-parties","c-ch-wojcicki-resolution","c-st-us-final","c-st-states-claims","c-st-states-allocation","c-st-ca-enforcement-order"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The liquidating plan, confirmed on December 1 and effective on December 5, 2025, cancelled the shares and moved the remaining assets into a Plan Administration Trust run by Thomas Walper. It names Wojcicki as an Excluded Party, not released and open to suit by the trust, which preserves possible claims and is not a finding of liability; her indemnification rights are preserved. The U.S. breach class settlement was finally approved at $46.75 million, and 41 states and the District of Columbia agreed in July 2026 to an $18 million payment and conduct limits, without admission of liability and subject to court approval at a hearing set for August 10, 2026, whose ruling the record does not include. The bankruptcy court held that the plan injunction bars the monetary claims of California's 2026 suit, which it found essentially similar to California's proof of claim, and ordered them dropped; California appealed."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-4f3bfd7d652507767e3c7f21","record":{"id":"display-claim-4f3bfd7d652507767e3c7f21","kind":"analysis","text":"The SEC's EDGAR record for Central Index Key 0001804591 names the registrant Chrome Holding Co., a Delaware corporation with employer identification number 871240344, a fiscal year ending March 31 and the industry code 2834 (pharmaceutical preparations); when retrieved it listed no trading symbols or exchanges. EDGAR gives its earlier names as Bleecker Street Acquisition Corp. (March 6 to August 12, 2020), VG Acquisition Corp. (September 16, 2020 to June 17, 2021) and 23andMe Holding Co. (June 21, 2021 to August 4, 2025). EDGAR's end date for the 23andMe name is earlier than the August 14, 2025 effective date of the Delaware name change that the company itself reported.","source_ids":["src-001","src-008"],"entity_ids":["holdco"],"premise_claim_ids":["c-id-edgar","c-id-former-names"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The SEC's EDGAR record for Central Index Key 0001804591 names the registrant Chrome Holding Co., a Delaware corporation with employer identification number 871240344, a fiscal year ending March 31 and the industry code 2834 (pharmaceutical preparations); when retrieved it listed no trading symbols or exchanges. EDGAR gives its earlier names as Bleecker Street Acquisition Corp. (March 6 to August 12, 2020), VG Acquisition Corp. (September 16, 2020 to June 17, 2021) and 23andMe Holding Co. (June 21, 2021 to August 4, 2025). EDGAR's end date for the 23andMe name is earlier than the August 14, 2025 effective date of the Delaware name change that the company itself reported."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-51f789b15bdd5aca00261e57","record":{"id":"display-claim-51f789b15bdd5aca00261e57","kind":"analysis","text":"The listed company that filed for Chapter 11 as 23andMe Holding Co. is therefore the former VG Acquisition Corp.: its post-merger filings define it as \"23andMe Holding Co. (formerly known as VG Acquisition Corp.)\", while the genetic-testing business founded in 2006 is 23andMe, Inc., its subsidiary and accounting predecessor. On and effective August 14, 2025 the holding company filed a certificate of amendment in Delaware changing its name to Chrome Holding Co.; its Form 8-K said the change did not affect stockholders' rights. The disclosure statement of August 2025 explains that, in connection with the sale to TTAM and as the purchase agreement and sale order contemplated, the debtors stopped using the 23andMe trademark: 23andMe, Inc. became ChromeCo, Inc. and 23andMe Pharmacy Holdings, Inc. became Chrome Pharmacy Holdings, Inc.","source_ids":["src-007","src-075","src-012","src-008"],"entity_ids":["holdco","inc","pharmacy-holdings","ttam"],"premise_claim_ids":["c-spac-same-registrant","c-id-rename","c-id-trademark-names"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The listed company that filed for Chapter 11 as 23andMe Holding Co. is therefore the former VG Acquisition Corp.: its post-merger filings define it as \"23andMe Holding Co. (formerly known as VG Acquisition Corp.)\", while the genetic-testing business founded in 2006 is 23andMe, Inc., its subsidiary and accounting predecessor. On and effective August 14, 2025 the holding company filed a certificate of amendment in Delaware changing its name to Chrome Holding Co.; its Form 8-K said the change did not affect stockholders' rights. The disclosure statement of August 2025 explains that, in connection with the sale to TTAM and as the purchase agreement and sale order contemplated, the debtors stopped using the 23andMe trademark: 23andMe, Inc. became ChromeCo, Inc. and 23andMe Pharmacy Holdings, Inc. became Chrome Pharmacy Holdings, Inc."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-4ee3fdf104795448fe08122d","record":{"id":"display-claim-4ee3fdf104795448fe08122d","kind":"analysis","text":"VG Acquisition Corp. (VGAC) was incorporated in the Cayman Islands on February 19, 2020 as a blank check company to effect a business combination. It completed its initial public offering on October 6, 2020, selling 50,855,000 units at $10.00 each, including units sold to the underwriters on October 16, 2020 under their over-allotment option.","source_ids":["src-011"],"entity_ids":["holdco"],"premise_claim_ids":["c-spac-blank-check"],"qualification":"","response":"","outcome":""},"reading":"Analysis: VG Acquisition Corp. (VGAC) was incorporated in the Cayman Islands on February 19, 2020 as a blank check company to effect a business combination. It completed its initial public offering on October 6, 2020, selling 50,855,000 units at $10.00 each, including units sold to the underwriters on October 16, 2020 under their over-allotment option."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-18e817c904812bc9705549e7","record":{"id":"display-claim-18e817c904812bc9705549e7","kind":"analysis","text":"Its sponsor, VG Acquisition Sponsor LLC, held all 12,623,750 founder shares: 99.29% of the Class B ordinary shares and 19.86% of all ordinary shares, and before the business combination only founder-share holders could vote on directors. Corvina Holdings Limited, a British Virgin Islands company wholly owned by Virgin Group Holdings Limited, was the sponsor's sole managing member and manager; Virgin Group Holdings was owned by Sir Richard Branson, who could appoint and remove its management and may be deemed the indirect beneficial owner of the sponsor's shares. The sponsor, Corvina, Virgin Group Holdings and Branson reported the same 19.86% holding jointly on Schedule 13G for December 31, 2020.","source_ids":["src-011","src-055"],"entity_ids":["holdco","vgac-sponsor","corvina","vghl","branson"],"premise_claim_ids":["c-spac-sponsor-chain","c-spac-13g"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Its sponsor, VG Acquisition Sponsor LLC, held all 12,623,750 founder shares: 99.29% of the Class B ordinary shares and 19.86% of all ordinary shares, and before the business combination only founder-share holders could vote on directors. Corvina Holdings Limited, a British Virgin Islands company wholly owned by Virgin Group Holdings Limited, was the sponsor's sole managing member and manager; Virgin Group Holdings was owned by Sir Richard Branson, who could appoint and remove its management and may be deemed the indirect beneficial owner of the sponsor's shares. The sponsor, Corvina, Virgin Group Holdings and Branson reported the same 19.86% holding jointly on Schedule 13G for December 31, 2020."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-8704d28c60080387241db3e6","record":{"id":"display-claim-8704d28c60080387241db3e6","kind":"analysis","text":"The chain changed after the company's Virgin period. A Schedule 13D amendment filed on November 3, 2023 for Virgin Galactic Holdings, not for this company, records that on November 1, 2023 Branson transferred all ordinary shares of Virgin Group Holdings to BFT (PTC) Limited as trustee of trusts for members of his family and related philanthropic causes; BFT CLG (PTC) Limited may remove and replace the trustee's directors, and Branson, who owns all its 'A' membership interests, may be deemed to control it.","source_ids":["src-059"],"entity_ids":["virgin-galactic","virgin-investments","corvina","vghl","bft-ptc","bft-clg","branson"],"premise_claim_ids":["c-ppl-virgin-2023"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The chain changed after the company's Virgin period. A Schedule 13D amendment filed on November 3, 2023 for Virgin Galactic Holdings, not for this company, records that on November 1, 2023 Branson transferred all ordinary shares of Virgin Group Holdings to BFT (PTC) Limited as trustee of trusts for members of his family and related philanthropic causes; BFT CLG (PTC) Limited may remove and replace the trustee's directors, and Branson, who owns all its 'A' membership interests, may be deemed to control it."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-165fe0a4a256a71248c4382c","record":{"id":"display-claim-165fe0a4a256a71248c4382c","kind":"analysis","text":"Josh Bayliss, chief executive officer of the Virgin Group since 2011, was VGAC's chief executive officer and a director, and Evan Lovell, the group's chief investment officer since 2012, its chief financial officer and a director, both since February 2020; each held the same posts at the sister blank check companies VGAC II and VGAC III, and Lovell had been on Virgin Galactic's board since 2017. The other directors were Teresa Briggs, a former Vice Chair of Deloitte LLP who chaired the audit committee; James B. Lockhart III, former Vice Chairman of WL Ross & Co. and former Director of the Federal Housing Finance Agency; and Douglas R. Brown, founder of AquaVenture Holdings and former chief executive of Ionics. All of VGAC's officers and directors left when the business combination closed, except that Lovell was elected to the combined company's board.","source_ids":["src-011","src-007"],"entity_ids":["holdco","bayliss","lovell","briggs","lockhart","brown","vgac-ii","vgac-iii","vghl","corvina","virgin-investments","virgin-entertainment","virgin-red","virgin-green-fund","tpg","virgin-galactic","deloitte-llp","snowflake","servicenow","docusign","jand","wl-ross","virgin-money","aquaventure","seven-seas","ionics","advent","element-partners"],"premise_claim_ids":["c-spac-officers","c-spac-bayliss","c-spac-lovell","c-spac-briggs","c-spac-lockhart","c-spac-brown"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Josh Bayliss, chief executive officer of the Virgin Group since 2011, was VGAC's chief executive officer and a director, and Evan Lovell, the group's chief investment officer since 2012, its chief financial officer and a director, both since February 2020; each held the same posts at the sister blank check companies VGAC II and VGAC III, and Lovell had been on Virgin Galactic's board since 2017. The other directors were Teresa Briggs, a former Vice Chair of Deloitte LLP who chaired the audit committee; James B. Lockhart III, former Vice Chairman of WL Ross & Co. and former Director of the Federal Housing Finance Agency; and Douglas R. Brown, founder of AquaVenture Holdings and former chief executive of Ionics. All of VGAC's officers and directors left when the business combination closed, except that Lovell was elected to the combined company's board."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-b7ca15a0ed760dd218075e91","record":{"id":"display-claim-b7ca15a0ed760dd218075e91","kind":"analysis","text":"VGAC and 23andMe announced their merger agreement on February 4, 2021. The joint release valued 23andMe at an enterprise value of about $3.5 billion and expected up to $759 million of gross proceeds, from up to $509 million in VGAC's trust account and a $250 million private placement (PIPE) at $10.00 a share; Branson and Anne Wojcicki were each to invest $25 million in the PIPE, and existing 23andMe shareholders would own 81% of the combined company. These were the terms expected at signing. PIPE investors subscribed for 25,000,000 Class A shares, an affiliate of the sponsor taking 2,500,000 and the Anne Wojcicki Foundation buying 2,500,000; holders of 16,667,061 VGAC Class A shares redeemed them.","source_ids":["src-083","src-007"],"entity_ids":["holdco","inc","branson","wojcicki","vgac-sponsor","aw-foundation"],"premise_claim_ids":["c-spac-announcement","c-spac-pipe"],"qualification":"","response":"","outcome":""},"reading":"Analysis: VGAC and 23andMe announced their merger agreement on February 4, 2021. The joint release valued 23andMe at an enterprise value of about $3.5 billion and expected up to $759 million of gross proceeds, from up to $509 million in VGAC's trust account and a $250 million private placement (PIPE) at $10.00 a share; Branson and Anne Wojcicki were each to invest $25 million in the PIPE, and existing 23andMe shareholders would own 81% of the combined company. These were the terms expected at signing. PIPE investors subscribed for 25,000,000 Class A shares, an affiliate of the sponsor taking 2,500,000 and the Anne Wojcicki Foundation buying 2,500,000; holders of 16,667,061 VGAC Class A shares redeemed them."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-2e8e55c3f5f9fcb7069d76fc","record":{"id":"display-claim-2e8e55c3f5f9fcb7069d76fc","kind":"analysis","text":"At VGAC's extraordinary general meeting on June 10, 2021, with about 54.71% of the ordinary shares represented, shareholders approved the business combination (30,391,593 votes for, 3,265,415 against and 1,121,337 abstentions), the move to Delaware with the new name, and Class B common stock carrying ten votes per share. The holders of the 12,713,750 Class B ordinary shares elected Roelof Botha, Patrick Chung, Richard Scheller, Neal Mohan, Peter Taylor, Anne Wojcicki and Evan Lovell as directors of the combined company.","source_ids":["src-099"],"entity_ids":["holdco","inc","botha","chung","scheller","mohan","taylor","wojcicki","lovell"],"premise_claim_ids":["c-spac-vote","c-spac-board-elect"],"qualification":"","response":"","outcome":""},"reading":"Analysis: At VGAC's extraordinary general meeting on June 10, 2021, with about 54.71% of the ordinary shares represented, shareholders approved the business combination (30,391,593 votes for, 3,265,415 against and 1,121,337 abstentions), the move to Delaware with the new name, and Class B common stock carrying ten votes per share. The holders of the 12,713,750 Class B ordinary shares elected Roelof Botha, Patrick Chung, Richard Scheller, Neal Mohan, Peter Taylor, Anne Wojcicki and Evan Lovell as directors of the combined company."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-8c97dea19a371ff5844a0f72","record":{"id":"display-claim-8c97dea19a371ff5844a0f72","kind":"analysis","text":"On June 16, 2021 VGAC deregistered in the Cayman Islands, was domesticated in Delaware as 23andMe Holding Co., and its subsidiary Chrome Merger Sub, Inc. merged into 23andMe, Inc., which survived as a wholly owned subsidiary. Immediately afterwards 92,655,484 Class A shares, 313,759,355 Class B shares and 25,065,665 warrants were outstanding. The chief restructuring officer later put the merger's gross proceeds at about $592 million.","source_ids":["src-007","src-031"],"entity_ids":["holdco","inc","chrome-merger-sub","vgac-sponsor","aw-foundation"],"premise_claim_ids":["c-spac-closing","c-spac-pipe","c-spac-proceeds"],"qualification":"","response":"","outcome":""},"reading":"Analysis: On June 16, 2021 VGAC deregistered in the Cayman Islands, was domesticated in Delaware as 23andMe Holding Co., and its subsidiary Chrome Merger Sub, Inc. merged into 23andMe, Inc., which survived as a wholly owned subsidiary. Immediately afterwards 92,655,484 Class A shares, 313,759,355 Class B shares and 25,065,665 warrants were outstanding. The chief restructuring officer later put the merger's gross proceeds at about $592 million."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-a9006e8adf3531b8ad60504e","record":{"id":"display-claim-a9006e8adf3531b8ad60504e","kind":"analysis","text":"After the merger the Class A stock and warrants traded on The Nasdaq Global Select Market as ME and MEUSW; by March 2025 the Class A stock was registered on The Nasdaq Capital Market. On March 24, 2025 Nasdaq notified the company that, following the Chapter 11 filing, its securities would be delisted, which took effect on March 31, 2025; the stock then traded over the counter, and on July 25, 2025 about 25,431,244 Class A and 2,110,250 Class B shares were outstanding. The last filing in the EDGAR record is a Form 15-12G of December 4, 2025, the notice used to terminate the registration of a class of securities.","source_ids":["src-007","src-002","src-012","src-001"],"entity_ids":["holdco","nasdaq"],"premise_claim_ids":["c-id-listing","c-id-delisting","c-id-15-12g"],"qualification":"","response":"","outcome":""},"reading":"Analysis: After the merger the Class A stock and warrants traded on The Nasdaq Global Select Market as ME and MEUSW; by March 2025 the Class A stock was registered on The Nasdaq Capital Market. On March 24, 2025 Nasdaq notified the company that, following the Chapter 11 filing, its securities would be delisted, which took effect on March 31, 2025; the stock then traded over the counter, and on July 25, 2025 about 25,431,244 Class A and 2,110,250 Class B shares were outstanding. The last filing in the EDGAR record is a Form 15-12G of December 4, 2025, the notice used to terminate the registration of a class of securities."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-765afd6f1bfb97f2f6241223","record":{"id":"display-claim-765afd6f1bfb97f2f6241223","kind":"analysis","text":"The Form 8-K of March 24, 2025 moved the principal executive office from 223 N. Mathilda Avenue, Sunnyvale, to 870 Market Street, Room 415, San Francisco; in 2026 the Wind-Down Debtor's service address in the case was 490 Post St., Suite 500 PMB 2065, San Francisco. Colorado's Secretary of State records ChromeCo, Inc., registered there as a foreign corporation on March 24, 2016 (ID 20161206900), as withdrawn on August 6, 2026, with its principal office at the Post Street address.","source_ids":["src-002","src-019","src-087"],"entity_ids":["holdco","inc"],"premise_claim_ids":["c-id-addresses","c-id-colorado"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The Form 8-K of March 24, 2025 moved the principal executive office from 223 N. Mathilda Avenue, Sunnyvale, to 870 Market Street, Room 415, San Francisco; in 2026 the Wind-Down Debtor's service address in the case was 490 Post St., Suite 500 PMB 2065, San Francisco. Colorado's Secretary of State records ChromeCo, Inc., registered there as a foreign corporation on March 24, 2016 (ID 20161206900), as withdrawn on August 6, 2026, with its principal office at the Post Street address."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-f45949137000f473e943197d","record":{"id":"display-claim-f45949137000f473e943197d","kind":"analysis","text":"GLEIF's record for legal entity identifier 529900FU5IIBCXYHHX25 gives the legal name Chrome Holding Co., the previous name 23andMe Holding Co., Delaware registration number 6006171, a legal address care of Corporation Service Company in Wilmington and a headquarters address still recorded in Sunnyvale. GLEIF's recording timestamps (creation on June 15, 2021, name change effective September 11, 2025) do not match the dates in the SEC filings exactly. A GLEIF search for \"23andMe\" on October 16, 2026 returned only this record and an unrelated Italian company in liquidation; no record for 23andMe, Inc. appeared, which does not prove that none exists.","source_ids":["src-027","src-008","src-007","src-042"],"entity_ids":["holdco","csc","inc"],"premise_claim_ids":["c-id-gleif","c-id-gleif-search"],"qualification":"","response":"","outcome":""},"reading":"Analysis: GLEIF's record for legal entity identifier 529900FU5IIBCXYHHX25 gives the legal name Chrome Holding Co., the previous name 23andMe Holding Co., Delaware registration number 6006171, a legal address care of Corporation Service Company in Wilmington and a headquarters address still recorded in Sunnyvale. GLEIF's recording timestamps (creation on June 15, 2021, name change effective September 11, 2025) do not match the dates in the SEC filings exactly. A GLEIF search for \"23andMe\" on October 16, 2026 returned only this record and an unrelated Italian company in liquidation; no record for 23andMe, Inc. appeared, which does not prove that none exists."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-540fbd81e59d11100bcf5a70","record":{"id":"display-claim-540fbd81e59d11100bcf5a70","kind":"analysis","text":"A company-data aggregator's copy of the Delaware register, not the register itself, lists 23ANDME HOLDING CO. as company number 6006171, matching GLEIF, with Incorporating Services, Ltd as registered agent; it lists 23ANDME, INC. as number 4150436, with the holding company as parent and eight branch registrations in other states, some already under the ChromeCo name, and 23ANDME PHARMACY HOLDINGS, INC. as number 7632876.","source_ids":["src-013","src-014","src-024"],"entity_ids":["holdco","isl","inc","pharmacy-holdings"],"premise_claim_ids":["c-id-agg-holdco","c-id-agg-inc","c-id-agg-pharmacy"],"qualification":"","response":"","outcome":""},"reading":"Analysis: A company-data aggregator's copy of the Delaware register, not the register itself, lists 23ANDME HOLDING CO. as company number 6006171, matching GLEIF, with Incorporating Services, Ltd as registered agent; it lists 23ANDME, INC. as number 4150436, with the holding company as parent and eight branch registrations in other states, some already under the ChromeCo name, and 23ANDME PHARMACY HOLDINGS, INC. as number 7632876."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-90ef6d7e4e2185c202913069","record":{"id":"display-claim-90ef6d7e4e2185c202913069","kind":"analysis","text":"23andMe Holding Co. had two classes of common stock: Class A, with one vote per share and listed until March 2025, and Class B, with ten votes per share, which was unlisted, convertible into Class A one-for-one at the holder's option and converted automatically on most transfers.","source_ids":["src-004","src-012"],"entity_ids":["holdco"],"premise_claim_ids":["c-ctl-dual-class"],"qualification":"","response":"","outcome":""},"reading":"Analysis: 23andMe Holding Co. had two classes of common stock: Class A, with one vote per share and listed until March 2025, and Class B, with ten votes per share, which was unlisted, convertible into Class A one-for-one at the holder's option and converted automatically on most transfers."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-742c6822aaa531d408e9ee1b","record":{"id":"display-claim-742c6822aaa531d408e9ee1b","kind":"analysis","text":"Immediately after the June 16, 2021 merger the closing Form 8-K reported Wojcicki as beneficial owner of 102,453,219 Class A shares counting her convertible Class B stock (25.21%) and of the 98,702,638 Class B shares held through ABeeC 2.0, LLC (24.29%), together 30.67% of the total vote. ABeeC itself held 30.56% of the vote, Glaxo Group Limited 12.28%, funds affiliated with G Squared Equity Management 9.44% and funds affiliated with FMR LLC 7.79%.","source_ids":["src-007"],"entity_ids":["wojcicki","abeec","holdco","glaxo-group","g-squared","fmr"],"premise_claim_ids":["c-ctl-2021"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Immediately after the June 16, 2021 merger the closing Form 8-K reported Wojcicki as beneficial owner of 102,453,219 Class A shares counting her convertible Class B stock (25.21%) and of the 98,702,638 Class B shares held through ABeeC 2.0, LLC (24.29%), together 30.67% of the total vote. ABeeC itself held 30.56% of the vote, Glaxo Group Limited 12.28%, funds affiliated with G Squared Equity Management 9.44% and funds affiliated with FMR LLC 7.79%."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-530f39e61fe79e4f462ff906","record":{"id":"display-claim-530f39e61fe79e4f462ff906","kind":"analysis","text":"The 2024 proxy statement shows ABeeC with 98,633,827 Class B shares on July 1, 2024, 59.24% of the class and 49.20% of the vote. The Anne Wojcicki Revocable Trust U/A/D 9/2/09 was the LLC's sole member and Wojcicki its sole trustee, the three sharing voting and dispositive power; counting 10,880,319 Class A shares, including 2,500,000 held by her foundation, Wojcicki held 49.75% of the vote. The other holders of more than 5% were GSK plc, through Glaxo Group Limited (23.82% of Class B, 19.78% of the vote), entities affiliated with Sequoia Capital (8.89% of the vote), over which Douglas M. Leone and Roelof Botha exercised discretion as directors of SC US (TTGP), Ltd., The Vanguard Group (6.64% of Class A) and NewView Capital Fund I (5.73% of Class A). These share counts predate the 1-for-20 reverse split of October 16, 2024.","source_ids":["src-004"],"entity_ids":["abeec","aw-trust","wojcicki","aw-foundation","holdco","gsk","glaxo-group","sc-us-ttgp","botha","vanguard","newview"],"premise_claim_ids":["c-ctl-2024-wojcicki","c-ctl-2024-holders"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The 2024 proxy statement shows ABeeC with 98,633,827 Class B shares on July 1, 2024, 59.24% of the class and 49.20% of the vote. The Anne Wojcicki Revocable Trust U/A/D 9/2/09 was the LLC's sole member and Wojcicki its sole trustee, the three sharing voting and dispositive power; counting 10,880,319 Class A shares, including 2,500,000 held by her foundation, Wojcicki held 49.75% of the vote. The other holders of more than 5% were GSK plc, through Glaxo Group Limited (23.82% of Class B, 19.78% of the vote), entities affiliated with Sequoia Capital (8.89% of the vote), over which Douglas M. Leone and Roelof Botha exercised discretion as directors of SC US (TTGP), Ltd., The Vanguard Group (6.64% of Class A) and NewView Capital Fund I (5.73% of Class A). These share counts predate the 1-for-20 reverse split of October 16, 2024."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-e1fa136f82ab43a635793954","record":{"id":"display-claim-e1fa136f82ab43a635793954","kind":"analysis","text":"ABeeC, the trust and Wojcicki filed their first Schedule 13D on June 25, 2021 and twelve amendments between April 17, 2024 and March 11, 2025, then Amendment No. 13 on events of May and June 2025. The February and March 2025 amendments, signed for the manager-managed Delaware LLC by its manager Ryan Batenchuk, report 4,931,692 Class B shares, 69.4% of the class at January 31 and 69.5% at March 6, 2025, convertible into about 20% of the Class A stock, and total beneficial ownership for Wojcicki of 22.4% in February and 21.9% in March 2025; she disclaims beneficial ownership of the LLC's and the foundation's shares except to the extent of her pecuniary interest.","source_ids":["src-005","src-028","src-010"],"entity_ids":["abeec","aw-trust","wojcicki","holdco","batenchuk"],"premise_claim_ids":["c-ctl-13d-filings","c-ctl-2025-early"],"qualification":"","response":"","outcome":""},"reading":"Analysis: ABeeC, the trust and Wojcicki filed their first Schedule 13D on June 25, 2021 and twelve amendments between April 17, 2024 and March 11, 2025, then Amendment No. 13 on events of May and June 2025. The February and March 2025 amendments, signed for the manager-managed Delaware LLC by its manager Ryan Batenchuk, report 4,931,692 Class B shares, 69.4% of the class at January 31 and 69.5% at March 6, 2025, convertible into about 20% of the Class A stock, and total beneficial ownership for Wojcicki of 22.4% in February and 21.9% in March 2025; she disclaims beneficial ownership of the LLC's and the foundation's shares except to the extent of her pecuniary interest."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-8d79374faf655dd8fe5a99ad","record":{"id":"display-claim-8d79374faf655dd8fe5a99ad","kind":"analysis","text":"On June 9, 2025 ABeeC gave notice converting all 4,931,692 of its Class B shares into Class A, confirmed by the company on June 11. Amendment No. 13 then reported Wojcicki as beneficial owner of 5,722,832 Class A shares, 22% of the class, including 62,530 held directly, 603,610 options vesting within sixty days, the LLC's shares and 125,000 held by the Anne Wojcicki Foundation, a Los Altos non-profit of which she is President and Chairman and whose shares she votes; the percentages use the 25,431,244 Class A shares outstanding on June 11, and the same disclaimer applies. On July 1, 2025 she held 22.56% of Class A and 12.33% of the total vote, and no Class B shares; ABeeC held 19.39% of Class A, Zentree Investments Limited 14.55% (7.95% of the vote) and Farallon Capital Partners, L.P. 5.00% (2.73%), and the other directors held no shares.","source_ids":["src-005","src-057"],"entity_ids":["abeec","wojcicki","aw-foundation","holdco","zentree","farallon"],"premise_claim_ids":["c-ctl-conversion","c-ctl-awf-holding","c-ctl-2025-july"],"qualification":"","response":"","outcome":""},"reading":"Analysis: On June 9, 2025 ABeeC gave notice converting all 4,931,692 of its Class B shares into Class A, confirmed by the company on June 11. Amendment No. 13 then reported Wojcicki as beneficial owner of 5,722,832 Class A shares, 22% of the class, including 62,530 held directly, 603,610 options vesting within sixty days, the LLC's shares and 125,000 held by the Anne Wojcicki Foundation, a Los Altos non-profit of which she is President and Chairman and whose shares she votes; the percentages use the 25,431,244 Class A shares outstanding on June 11, and the same disclaimer applies. On July 1, 2025 she held 22.56% of Class A and 12.33% of the total vote, and no Class B shares; ABeeC held 19.39% of Class A, Zentree Investments Limited 14.55% (7.95% of the vote) and Farallon Capital Partners, L.P. 5.00% (2.73%), and the other directors held no shares."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-fa14ebbacff175332da47817","record":{"id":"display-claim-fa14ebbacff175332da47817","kind":"analysis","text":"Zentree Investments Limited, a Cayman Islands company with an address in Singapore care of its manager, and its director Richard Magides first reported a passive stake of 5.02% on November 8, 2024. A financial-data aggregator describes Magides as the founder in 2011 and chief executive of Zentree Investment Management Pte Ltd. On Schedule 13D they reported 13.0% on March 12, 2025, Magides having spent $9,340,639 of personal funds, and 18.2% on March 28, 2025; they said they sought a voice for minority investors, to prevent a sale at an unreasonable price, more prudent cost management and equal rights for the two share classes, purposes that are their own, with no agreements with others reported.","source_ids":["src-058","src-046","src-009","src-021"],"entity_ids":["zentree","magides","zentree-im","holdco","artradis"],"premise_claim_ids":["c-ctl-zentree-13g","c-ppl-magides","c-ctl-zentree-13d"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Zentree Investments Limited, a Cayman Islands company with an address in Singapore care of its manager, and its director Richard Magides first reported a passive stake of 5.02% on November 8, 2024. A financial-data aggregator describes Magides as the founder in 2011 and chief executive of Zentree Investment Management Pte Ltd. On Schedule 13D they reported 13.0% on March 12, 2025, Magides having spent $9,340,639 of personal funds, and 18.2% on March 28, 2025; they said they sought a voice for minority investors, to prevent a sale at an unreasonable price, more prudent cost management and equal rights for the two share classes, purposes that are their own, with no agreements with others reported."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-e7cc139bef134910996bfce0","record":{"id":"display-claim-e7cc139bef134910996bfce0","kind":"analysis","text":"Farallon Partners, L.L.C., general partner of funds including Farallon Capital Partners, L.P., reported as a passive investor shared power over 1,231,241 Class A shares, 6% of the class, for an event date of June 13, 2025.","source_ids":["src-020"],"entity_ids":["farallon","holdco"],"premise_claim_ids":["c-ctl-farallon"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Farallon Partners, L.L.C., general partner of funds including Farallon Capital Partners, L.P., reported as a passive investor shared power over 1,231,241 Class A shares, 6% of the class, for an event date of June 13, 2025."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-c42fb2da29a173181e379160","record":{"id":"display-claim-c42fb2da29a173181e379160","kind":"analysis","text":"23andMe, Inc. was founded in 2006 by Anne Wojcicki, Linda Avey and Paul Cusenza as the first direct-to-consumer genetic testing company. On March 26, 2025, as reported by a news outlet, Avey wrote on X that her time at the company was cut short in 2009 when Wojcicki convinced the board that she should run it, and that Wojcicki afterwards \"architected a majority vote for herself that eliminated board governance\". This is Avey's personal account, not a finding about the company's governance; the report said 23andMe did not immediately respond to a request for comment, and no response by Wojcicki was found in the retained record.","source_ids":["src-012","src-112"],"entity_ids":["inc","wojcicki","avey","cusenza"],"premise_claim_ids":["c-gov-founding","c-ctl-avey"],"qualification":"","response":"","outcome":""},"reading":"Analysis: 23andMe, Inc. was founded in 2006 by Anne Wojcicki, Linda Avey and Paul Cusenza as the first direct-to-consumer genetic testing company. On March 26, 2025, as reported by a news outlet, Avey wrote on X that her time at the company was cut short in 2009 when Wojcicki convinced the board that she should run it, and that Wojcicki afterwards \"architected a majority vote for herself that eliminated board governance\". This is Avey's personal account, not a finding about the company's governance; the report said 23andMe did not immediately respond to a request for comment, and no response by Wojcicki was found in the retained record."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-3e6ef6d9936af8cace84adf0","record":{"id":"display-claim-3e6ef6d9936af8cace84adf0","kind":"analysis","text":"Wojcicki, a co-founder and director of 23andMe, Inc. from 2006 and its chief executive from 2010, joined the holding company's board when the merger closed and became its chair effective June 16, 2021; in July 2024 she was chair and chief executive and a non-independent director. The board also appointed Valerie Montgomery Rice a Class II director and compensation committee chair from June 16, 2021. Evan Lovell served as a Class III director until his death in June 2023; the board had nine members until then and eight in July 2024: Roelof Botha, Patrick Chung, Sandra Hernández, Neal Mohan, Valerie Montgomery Rice, Richard Scheller, Peter Taylor and Wojcicki. Taylor, independent since 2021 and audit committee chair, and Wojcicki were nominated for re-election to 2027, and KPMG LLP for ratification as auditor.","source_ids":["src-004","src-057","src-007"],"entity_ids":["wojcicki","inc","holdco","montgomery-rice","lovell","botha","chung","hernandez","mohan","scheller","taylor","kpmg"],"premise_claim_ids":["c-gov-wojcicki-roles","c-gov-board-2021","c-gov-lovell-end","c-gov-board-2024"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Wojcicki, a co-founder and director of 23andMe, Inc. from 2006 and its chief executive from 2010, joined the holding company's board when the merger closed and became its chair effective June 16, 2021; in July 2024 she was chair and chief executive and a non-independent director. The board also appointed Valerie Montgomery Rice a Class II director and compensation committee chair from June 16, 2021. Evan Lovell served as a Class III director until his death in June 2023; the board had nine members until then and eight in July 2024: Roelof Botha, Patrick Chung, Sandra Hernández, Neal Mohan, Valerie Montgomery Rice, Richard Scheller, Peter Taylor and Wojcicki. Taylor, independent since 2021 and audit committee chair, and Wojcicki were nominated for re-election to 2027, and KPMG LLP for ratification as auditor."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-64fc2ab9ec200d48cd079447","record":{"id":"display-claim-64fc2ab9ec200d48cd079447","kind":"analysis","text":"The fiscal-2024 named executive officers were Wojcicki, Joseph Selsavage (chief financial and accounting officer, permanent from May 2024), William Richards (Head of Therapeutics Discovery, an executive officer from August 8, 2023 to August 23, 2024), Kathy Hibbs (former Chief Administrative Officer) and Kenneth Hillan (former Chief Therapeutics Officer); the ten directors and executive officers together held 59.44% of the vote on July 1, 2024. Wojcicki's base salary was raised from $64,480 to $66,560 on January 1, 2024 to meet California minimum salary rules, and her fiscal-2024 compensation was $7,363,723, almost all of it stock options; Selsavage received $2,133,227, Richards $1,461,868 and Hibbs $2,119,783.","source_ids":["src-004","src-057"],"entity_ids":["wojcicki","selsavage","richards","hibbs","hillan","holdco"],"premise_claim_ids":["c-gov-officers-2024","c-gov-wojcicki-pay","c-gov-officer-pay"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The fiscal-2024 named executive officers were Wojcicki, Joseph Selsavage (chief financial and accounting officer, permanent from May 2024), William Richards (Head of Therapeutics Discovery, an executive officer from August 8, 2023 to August 23, 2024), Kathy Hibbs (former Chief Administrative Officer) and Kenneth Hillan (former Chief Therapeutics Officer); the ten directors and executive officers together held 59.44% of the vote on July 1, 2024. Wojcicki's base salary was raised from $64,480 to $66,560 on January 1, 2024 to meet California minimum salary rules, and her fiscal-2024 compensation was $7,363,723, almost all of it stock options; Selsavage received $2,133,227, Richards $1,461,868 and Hibbs $2,119,783."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-0d00efae7e589dc027b007e5","record":{"id":"display-claim-0d00efae7e589dc027b007e5","kind":"analysis","text":"The 2024 proxy reported two related-party arrangements: Glaxo Group Limited was treated as a 5% holder because of an exclusive drug-discovery collaboration with a GSK affiliate from July 2018 to July 2023, amended in October 2023 into a non-exclusive licence to de-identified aggregate data, and 23andMe, Inc. paid director Richard Scheller $120,000 in fiscal 2024 under a consulting agreement in force from April 1, 2019 to March 31, 2024. In January 2024 the company also entered into a five-year research services agreement with the Troper Wojcicki Foundation, of which Anne Wojcicki's sister Susan Wojcicki was then a director and officer, to build lung-cancer research cohorts, with $5.4 million of fees under the first statement of work; revenue under it was $0.7 million in fiscal 2025, with $1.4 million deferred at March 31, 2025.","source_ids":["src-004","src-057"],"entity_ids":["holdco","glaxo-group","gsk","scheller","inc","twf","susan-wojcicki","wojcicki"],"premise_claim_ids":["c-gov-related-party","c-gov-twf"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The 2024 proxy reported two related-party arrangements: Glaxo Group Limited was treated as a 5% holder because of an exclusive drug-discovery collaboration with a GSK affiliate from July 2018 to July 2023, amended in October 2023 into a non-exclusive licence to de-identified aggregate data, and 23andMe, Inc. paid director Richard Scheller $120,000 in fiscal 2024 under a consulting agreement in force from April 1, 2019 to March 31, 2024. In January 2024 the company also entered into a five-year research services agreement with the Troper Wojcicki Foundation, of which Anne Wojcicki's sister Susan Wojcicki was then a director and officer, to build lung-cancer research cohorts, with $5.4 million of fees under the first statement of work; revenue under it was $0.7 million in fiscal 2025, with $1.4 million deferred at March 31, 2025."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-a2c36675aedd780dbfe74b96","record":{"id":"display-claim-a2c36675aedd780dbfe74b96","kind":"analysis","text":"In March 2024 the board formed a Special Committee of independent directors to review strategic transactions, including any proposal from Wojcicki, because she and her affiliates, with about 49% of the vote, could have interests different from other stockholders'; it hired Wells Fargo Securities and Dechert. In April 2024 Wojcicki disclosed that she was considering a take-private proposal, conditioned on approval by the committee and by a majority of unaffiliated shareholders, and that she wished to keep control and would not support an alternative. On July 29, 2024 she proposed $0.40 a share without committed financing ($8.00 after the October 2024 1-for-20 reverse split); on August 2 the committee rejected it as offering no premium, lacking financing and being conditional, and asked her to drop her opposition to third-party offers.","source_ids":["src-012","src-031"],"entity_ids":["holdco","wojcicki"],"premise_claim_ids":["c-gov-special-committee","c-gov-go-private-2024"],"qualification":"","response":"","outcome":""},"reading":"Analysis: In March 2024 the board formed a Special Committee of independent directors to review strategic transactions, including any proposal from Wojcicki, because she and her affiliates, with about 49% of the vote, could have interests different from other stockholders'; it hired Wells Fargo Securities and Dechert. In April 2024 Wojcicki disclosed that she was considering a take-private proposal, conditioned on approval by the committee and by a majority of unaffiliated shareholders, and that she wished to keep control and would not support an alternative. On July 29, 2024 she proposed $0.40 a share without committed financing ($8.00 after the October 2024 1-for-20 reverse split); on August 2 the committee rejected it as offering no premium, lacking financing and being conditional, and asked her to drop her opposition to third-party offers."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-9f4f0da1c27436cddc3c5bb0","record":{"id":"display-claim-9f4f0da1c27436cddc3c5bb0","kind":"analysis","text":"On September 17, 2024 all seven independent directors, who made up the audit, compensation and special committees, resigned with immediate effect. Their letter said they differed with Wojcicki on the company's strategic direction, that given that difference and her concentrated voting power resigning was in the stockholders' best interest, and that they had not received an actionable proposal from her and did not expect one. According to a bankruptcy-data summary, Wojcicki told employees she was surprised and disappointed. She was now the sole director; having said in early September that she was open to third-party proposals, she amended her 13D in late September to say she remained committed to acquiring the company and would not consider them, and Wells Fargo ended its engagement in October.","source_ids":["src-006","src-050","src-079","src-012"],"entity_ids":["botha","chung","hernandez","mohan","montgomery-rice","scheller","taylor","wojcicki","holdco"],"premise_claim_ids":["c-gov-resignations","c-gov-sole-director"],"qualification":"","response":"","outcome":""},"reading":"Analysis: On September 17, 2024 all seven independent directors, who made up the audit, compensation and special committees, resigned with immediate effect. Their letter said they differed with Wojcicki on the company's strategic direction, that given that difference and her concentrated voting power resigning was in the stockholders' best interest, and that they had not received an actionable proposal from her and did not expect one. According to a bankruptcy-data summary, Wojcicki told employees she was surprised and disappointed. She was now the sole director; having said in early September that she was open to third-party proposals, she amended her 13D in late September to say she remained committed to acquiring the company and would not consider them, and Wells Fargo ended its engagement in October."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-1d27202c7ca8e9eda2d1c7f4","record":{"id":"display-claim-1d27202c7ca8e9eda2d1c7f4","kind":"analysis","text":"On October 28, 2024 the board grew from one to four with three independent directors: Jim Frankola (Class I) and Andre Fernandez and Mark Jensen (Class II). All three joined the audit and compensation committees, Fernandez chairing audit and Jensen compensation as Lead Independent Director; on November 2, 2024 they became the new Special Committee, which engaged Moelis & Company and Goodwin Procter. Each was paid $1 million in cash for service to the 2025 annual meeting, $800,000 at once and $20,000 a month.","source_ids":["src-022","src-012","src-006","src-050","src-079"],"entity_ids":["frankola","fernandez","jensen","holdco","botha","chung","hernandez","mohan","montgomery-rice","scheller","taylor","wojcicki"],"premise_claim_ids":["c-gov-new-board","c-gov-resignations"],"qualification":"","response":"","outcome":""},"reading":"Analysis: On October 28, 2024 the board grew from one to four with three independent directors: Jim Frankola (Class I) and Andre Fernandez and Mark Jensen (Class II). All three joined the audit and compensation committees, Fernandez chairing audit and Jensen compensation as Lead Independent Director; on November 2, 2024 they became the new Special Committee, which engaged Moelis & Company and Goodwin Procter. Each was paid $1 million in cash for service to the 2025 annual meeting, $800,000 at once and $20,000 a month."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-474229c33e8a3e76be598313","record":{"id":"display-claim-474229c33e8a3e76be598313","kind":"analysis","text":"On January 28, 2025 the committee announced that it was exploring strategic alternatives. The company approached 103 potential counterparties, held 90 introductory calls and signed about 42 confidentiality agreements, and at the committee's request Wojcicki again said she would consider third-party proposals. On February 20 she and New Mountain Capital jointly proposed $2.53 a share, the only indication of interest that offered to acquire all the equity out of court; New Mountain withdrew, and on March 2 she proposed $0.41 a share plus $30 million of unsecured financing, which the committee rejected. Her offer of March 6 of $0.41 plus contingent value rights worth up to $2.53 in total, with interim financing at 7% and, from March 10, a $20 million operating commitment, was presented as best and final and was also rejected.","source_ids":["src-031","src-012","src-010"],"entity_ids":["holdco","wojcicki","new-mountain"],"premise_claim_ids":["c-gov-strategic-review","c-gov-feb-march-2025","c-gov-march-2025-final"],"qualification":"","response":"","outcome":""},"reading":"Analysis: On January 28, 2025 the committee announced that it was exploring strategic alternatives. The company approached 103 potential counterparties, held 90 introductory calls and signed about 42 confidentiality agreements, and at the committee's request Wojcicki again said she would consider third-party proposals. On February 20 she and New Mountain Capital jointly proposed $2.53 a share, the only indication of interest that offered to acquire all the equity out of court; New Mountain withdrew, and on March 2 she proposed $0.41 a share plus $30 million of unsecured financing, which the committee rejected. Her offer of March 6 of $0.41 plus contingent value rights worth up to $2.53 in total, with interim financing at 7% and, from March 10, a $20 million operating commitment, was presented as best and final and was also rejected."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-834c48f95d639afd9b1a7b94","record":{"id":"display-claim-834c48f95d639afd9b1a7b94","kind":"analysis","text":"On March 7, 2025 the board extended the committee's authority to all restructuring matters; on March 16 the committee had counsel review governance, transactions and operations for possible claims against insiders; and on March 21 it approved the Chapter 11 filing and the sale-procedures motion, having concluded that no indication of interest, Wojcicki's included, was actionable out of court or in the company's best interest. The same day Wojcicki resigned, by mutual agreement, as chief executive and president from 5:00 p.m. Eastern Time on March 23 and stepped down as chair, remaining a Class III director, and resigned her posts at 23andMe, Inc., Lemonaid Health and the pharmacy holding companies.","source_ids":["src-031","src-012","src-002"],"entity_ids":["holdco","wojcicki","inc","lemonaid-health","pharmacy-holdings","lemonaid-pharmacy-holdings"],"premise_claim_ids":["c-gov-restructuring-authority","c-gov-ceo-resignation"],"qualification":"","response":"","outcome":""},"reading":"Analysis: On March 7, 2025 the board extended the committee's authority to all restructuring matters; on March 16 the committee had counsel review governance, transactions and operations for possible claims against insiders; and on March 21 it approved the Chapter 11 filing and the sale-procedures motion, having concluded that no indication of interest, Wojcicki's included, was actionable out of court or in the company's best interest. The same day Wojcicki resigned, by mutual agreement, as chief executive and president from 5:00 p.m. Eastern Time on March 23 and stepped down as chair, remaining a Class III director, and resigned her posts at 23andMe, Inc., Lemonaid Health and the pharmacy holding companies."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-85c0b07f2ed17f474b917d5f","record":{"id":"display-claim-85c0b07f2ed17f474b917d5f","kind":"analysis","text":"The board made Mark Jensen chairman, Selsavage interim chief executive and president, and Matthew Kvarda of Alvarez & Marsal, the financial adviser since January 2025, chief restructuring officer; it appointed Thomas B. Walper an independent Class III director and committee member for $35,000 a month. On March 23 the committee gave Walper sole authority to investigate possible claims against insiders; with Goodwin and Paul, Weiss until mid-May he reviewed documents and interviewed management, directors and Wojcicki, and at the committee's insistence TTAM dropped from its bid the purchase of the estate's claims, including those against Wojcicki and former directors and officers. The committee also approved guidelines on communications between Wojcicki and management. In July 2025 the board's five directors were Frankola, Fernandez, Jensen, Walper and Wojcicki, who sat on no committee.","source_ids":["src-002","src-031","src-012","src-057"],"entity_ids":["jensen","selsavage","kvarda","alvarez-marsal","walper","holdco","wojcicki","ttam","frankola","fernandez"],"premise_claim_ids":["c-gov-march-2025-appointments","c-gov-investigation","c-gov-guidelines","c-gov-board-2025"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The board made Mark Jensen chairman, Selsavage interim chief executive and president, and Matthew Kvarda of Alvarez & Marsal, the financial adviser since January 2025, chief restructuring officer; it appointed Thomas B. Walper an independent Class III director and committee member for $35,000 a month. On March 23 the committee gave Walper sole authority to investigate possible claims against insiders; with Goodwin and Paul, Weiss until mid-May he reviewed documents and interviewed management, directors and Wojcicki, and at the committee's insistence TTAM dropped from its bid the purchase of the estate's claims, including those against Wojcicki and former directors and officers. The committee also approved guidelines on communications between Wojcicki and management. In July 2025 the board's five directors were Frankola, Fernandez, Jensen, Walper and Wojcicki, who sat on no committee."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-6d8c70f435199f7c99571bee","record":{"id":"display-claim-6d8c70f435199f7c99571bee","kind":"analysis","text":"According to the company's August 2025 disclosure statement, on October 1, 2023 a threat actor posted online a claim to hold users' profile information. The investigation with outside incident-response experts found that the actor had logged into about 0.1% of accounts whose usernames and passwords had been reused from other, previously compromised websites and, through them, reached information users had chosen to share in the DNA Relatives and Connections features: personal information of about seven million customers, generally ancestry information and, for a subset, genetics-based health information. Testifying to the Senate Judiciary Committee on June 11, 2025, interim chief executive Joseph Selsavage put the directly accessed accounts at about 14,000 and the affected DNA Relatives users at more than 6 million; he said the company disabled the affected accounts and the feature, forced password resets, engaged cybersecurity firms, notified authorities and customers, made two-step verification mandatory and regretted the incident, one of the causes of the bankruptcy.","source_ids":["src-012","src-029"],"entity_ids":["holdco","selsavage"],"premise_claim_ids":["c-br-company-account","c-br-senate"],"qualification":"","response":"","outcome":""},"reading":"Analysis: According to the company's August 2025 disclosure statement, on October 1, 2023 a threat actor posted online a claim to hold users' profile information. The investigation with outside incident-response experts found that the actor had logged into about 0.1% of accounts whose usernames and passwords had been reused from other, previously compromised websites and, through them, reached information users had chosen to share in the DNA Relatives and Connections features: personal information of about seven million customers, generally ancestry information and, for a subset, genetics-based health information. Testifying to the Senate Judiciary Committee on June 11, 2025, interim chief executive Joseph Selsavage put the directly accessed accounts at about 14,000 and the affected DNA Relatives users at more than 6 million; he said the company disabled the affected accounts and the feature, forced password resets, engaged cybersecurity firms, notified authorities and customers, made two-step verification mandatory and regretted the incident, one of the causes of the bankruptcy."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-af5a0ae42a8743d308b66a49","record":{"id":"display-claim-af5a0ae42a8743d308b66a49","kind":"analysis","text":"The Privacy Commissioner of Canada and the UK Information Commissioner, investigating jointly, found that the attack began on April 29, 2023 and gave the hacker access to more than 18,000 accounts over five months. 23andMe told them that almost 7 million customers were affected worldwide, including almost 320,000 in Canada and 155,600 in the UK; the data reachable included health, ethnicity, relatives, date of birth and sex, much of it derived from DNA. Their chronology records that in July 2023 the hacker logged into one free account more than a million times in a day and later tried to start profile transfers in 400 accounts, which 23andMe investigated without recognising a wider breach; that in August 2023 a claim of stolen data on more than 10 million users, sent through the support portal and repeated on Reddit, was dismissed as a hoax; and that in October 2023 the data was advertised for sale and the breach confirmed.","source_ids":["src-073"],"entity_ids":["inc"],"premise_claim_ids":["c-br-regulator-scope","c-br-regulator-chronology"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The Privacy Commissioner of Canada and the UK Information Commissioner, investigating jointly, found that the attack began on April 29, 2023 and gave the hacker access to more than 18,000 accounts over five months. 23andMe told them that almost 7 million customers were affected worldwide, including almost 320,000 in Canada and 155,600 in the UK; the data reachable included health, ethnicity, relatives, date of birth and sex, much of it derived from DNA. Their chronology records that in July 2023 the hacker logged into one free account more than a million times in a day and later tried to start profile transfers in 400 accounts, which 23andMe investigated without recognising a wider breach; that in August 2023 a claim of stolen data on more than 10 million users, sent through the support portal and repeated on Reddit, was dismissed as a hoax; and that in October 2023 the data was advertised for sale and the breach confirmed."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-c59d309cfa0b4afb06c0d7d4","record":{"id":"display-claim-c59d309cfa0b4afb06c0d7d4","kind":"analysis","text":"The commissioners found that 23andMe lacked safeguards suited to the sensitivity of the data. Multi-factor authentication was optional and used, with single sign-on, by fewer than 22% of customers, which the company said it had chosen to avoid friction; passwords needed only eight characters, compromised passwords were not checked, raw DNA data had no extra protection and monitoring did not flag the attack; after the breach it took four days to end all sessions and about a month to disable raw DNA downloads and make multi-factor authentication mandatory. Canada held that 23andMe contravened Principle 4.7 of PIPEDA and the UK that it infringed Articles 5(1)(f) and 32(1) of the UK GDPR. 23andMe told both offices of the improvements made since, and the Canadian Commissioner found the issue well-founded and resolved in light of them.","source_ids":["src-073"],"entity_ids":["inc"],"premise_claim_ids":["c-br-regulator-safeguards"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The commissioners found that 23andMe lacked safeguards suited to the sensitivity of the data. Multi-factor authentication was optional and used, with single sign-on, by fewer than 22% of customers, which the company said it had chosen to avoid friction; passwords needed only eight characters, compromised passwords were not checked, raw DNA data had no extra protection and monitoring did not flag the attack; after the breach it took four days to end all sessions and about a month to disable raw DNA downloads and make multi-factor authentication mandatory. Canada held that 23andMe contravened Principle 4.7 of PIPEDA and the UK that it infringed Articles 5(1)(f) and 32(1) of the UK GDPR. 23andMe told both offices of the improvements made since, and the Canadian Commissioner found the issue well-founded and resolved in light of them."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-404540892fcab9f7fe625c1a","record":{"id":"display-claim-404540892fcab9f7fe625c1a","kind":"analysis","text":"They also found the breach notifications incomplete: reports to the regulators omitted known information, notably about raw DNA data, notices to individuals did not fully describe the data or say that some of it had been posted for sale, and holders of directly accessed accounts were told only in January 2024. Canada found contraventions of section 10.1 of PIPEDA and the UK breaches of Articles 33(3) and 34 of the UK GDPR, although on timing both accepted that the report to them was made as soon as feasible or for an accepted reason. 23andMe told them of improvements to its notification process, and the Canadian Commissioner found this issue too well-founded and resolved.","source_ids":["src-073"],"entity_ids":["inc"],"premise_claim_ids":["c-br-regulator-notice"],"qualification":"","response":"","outcome":""},"reading":"Analysis: They also found the breach notifications incomplete: reports to the regulators omitted known information, notably about raw DNA data, notices to individuals did not fully describe the data or say that some of it had been posted for sale, and holders of directly accessed accounts were told only in January 2024. Canada found contraventions of section 10.1 of PIPEDA and the UK breaches of Articles 33(3) and 34 of the UK GDPR, although on timing both accepted that the report to them was made as soon as feasible or for an accepted reason. 23andMe told them of improvements to its notification process, and the Canadian Commissioner found this issue too well-founded and resolved."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-42fed79449ab534a3ad6a33f","record":{"id":"display-claim-42fed79449ab534a3ad6a33f","kind":"analysis","text":"On June 5, 2025 the UK Information Commissioner served a penalty notice, addressed to 23andMe, Inc. and 23andMe Holding Co., requiring 23andMe, Inc. to pay £2,310,000 for infringing Articles 5(1)(f) and 32(1) of the UK GDPR between May 25, 2018 and December 31, 2024. It found that the attacker obtained data on 155,592 UK customers, including health and genetic data, that the data was offered for sale in August and October 2023 in posts suggesting customers were targeted by ethnic background, and that the late detection and incomplete notices aggravated the infringement. 23andMe argued in April 2025 that, given its finances, no penalty should be imposed because it would deplete funds for claimants.","source_ids":["src-074"],"entity_ids":["inc","holdco"],"premise_claim_ids":["c-br-ico-penalty"],"qualification":"","response":"","outcome":""},"reading":"Analysis: On June 5, 2025 the UK Information Commissioner served a penalty notice, addressed to 23andMe, Inc. and 23andMe Holding Co., requiring 23andMe, Inc. to pay £2,310,000 for infringing Articles 5(1)(f) and 32(1) of the UK GDPR between May 25, 2018 and December 31, 2024. It found that the attacker obtained data on 155,592 UK customers, including health and genetic data, that the data was offered for sale in August and October 2023 in posts suggesting customers were targeted by ethnic background, and that the late detection and incomplete notices aggravated the infringement. 23andMe argued in April 2025 that, given its finances, no penalty should be imposed because it would deplete funds for claimants."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-009ee45f9571487e4d2a65fe","record":{"id":"display-claim-009ee45f9571487e4d2a65fe","kind":"analysis","text":"The Commissioner started from the higher statutory maximum of £17.5 million, applied a 20% turnover adjustment, because the holding company's projected 2025 turnover was near the lower end of the £100–250 million band, and a 60% seriousness adjustment, giving £2,100,000, then added 10% for aggravating factors to reach £2,310,000, about 2.3% of projected turnover. Noting the parent's accumulated deficit of $2.4 billion and $79.4 million of unrestricted cash at December 31, 2024, he made no further reduction because the company was selling its business through Chapter 11 and intended to keep operating. The penalty was lower than the £4,593,750 proposed in the notice of intent; the notice allowed an appeal to the First-tier Tribunal within 28 days, and the record does not show whether one was brought.","source_ids":["src-074"],"entity_ids":["inc","holdco"],"premise_claim_ids":["c-br-ico-amount","c-br-ico-penalty"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The Commissioner started from the higher statutory maximum of £17.5 million, applied a 20% turnover adjustment, because the holding company's projected 2025 turnover was near the lower end of the £100–250 million band, and a 60% seriousness adjustment, giving £2,100,000, then added 10% for aggravating factors to reach £2,310,000, about 2.3% of projected turnover. Noting the parent's accumulated deficit of $2.4 billion and $79.4 million of unrestricted cash at December 31, 2024, he made no further reduction because the company was selling its business through Chapter 11 and intended to keep operating. The penalty was lower than the £4,593,750 proposed in the notice of intent; the notice allowed an appeal to the First-tier Tribunal within 28 days, and the record does not show whether one was brought."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-a968ea578f04782986327dd1","record":{"id":"display-claim-a968ea578f04782986327dd1","kind":"analysis","text":"Before the bankruptcy, according to the disclosure statement, the Federal Trade Commission served a civil investigative demand in March 2024, attorneys general of 42 states and the District of Columbia opened a multistate investigation and 12 foreign regulators made inquiries; a UK firm also made a pre-arbitration demand for 3,720 UK customers. After the filing the debtors reported, besides the UK penalty, a letter of July 21, 2025 from the Spanish Data Protection Authority imposing a fine of 2,400,000 (about $2.8 million; the disclosure statement prints it with a pound sign and the Spanish decision was not retrieved), a civil investigative demand from the South Dakota Attorney General and shareholder demand letters about pre-bankruptcy conduct.","source_ids":["src-012"],"entity_ids":["holdco"],"premise_claim_ids":["c-br-regulatory-inquiries","c-br-postpetition-regulators"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Before the bankruptcy, according to the disclosure statement, the Federal Trade Commission served a civil investigative demand in March 2024, attorneys general of 42 states and the District of Columbia opened a multistate investigation and 12 foreign regulators made inquiries; a UK firm also made a pre-arbitration demand for 3,720 UK customers. After the filing the debtors reported, besides the UK penalty, a letter of July 21, 2025 from the Spanish Data Protection Authority imposing a fine of 2,400,000 (about $2.8 million; the disclosure statement prints it with a pound sign and the Spanish decision was not retrieved), a civil investigative demand from the South Dakota Attorney General and shareholder demand letters about pre-bankruptcy conduct."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-b62fbc04e4e9a37fba670c39","record":{"id":"display-claim-b62fbc04e4e9a37fba670c39","kind":"analysis","text":"In a suit announced on May 28, 2026, California's Attorney General alleges that a threat actor went undetected for five months, using about 14,000 accounts accessed with credentials stolen in earlier breaches, including that of the partner genealogy site MyHeritage, and a coding error in DNA Relatives to obtain data on nearly 7 million customers, 855,541 of them Californians; that data on one million people was offered for sale advertised as belonging to Asian American and Pacific Islander and Jewish users; and that 23andMe told the public there was no security incident, downplayed the stolen data and blamed customers. The complaint further alleges that engineers saw a spike of 1,300 log-in requests a minute from one IP address on July 6, 2023, that the security team knew of the August 2023 Reddit post two months before the October 1 discovery date the company gives, and that multi-factor authentication became mandatory only on November 6, 2023. These are allegations in a pending suit; the company's own account attributes the access to reused passwords and describes the resets, the disabling of DNA Relatives and the mandatory two-step verification.","source_ids":["src-072","src-075"],"entity_ids":["holdco","california"],"premise_claim_ids":["c-br-ca-allegations","c-br-ca-warnings"],"qualification":"","response":"","outcome":""},"reading":"Analysis: In a suit announced on May 28, 2026, California's Attorney General alleges that a threat actor went undetected for five months, using about 14,000 accounts accessed with credentials stolen in earlier breaches, including that of the partner genealogy site MyHeritage, and a coding error in DNA Relatives to obtain data on nearly 7 million customers, 855,541 of them Californians; that data on one million people was offered for sale advertised as belonging to Asian American and Pacific Islander and Jewish users; and that 23andMe told the public there was no security incident, downplayed the stolen data and blamed customers. The complaint further alleges that engineers saw a spike of 1,300 log-in requests a minute from one IP address on July 6, 2023, that the security team knew of the August 2023 Reddit post two months before the October 1 discovery date the company gives, and that multi-factor authentication became mandatory only on November 6, 2023. These are allegations in a pending suit; the company's own account attributes the access to reused passwords and describes the resets, the disabling of DNA Relatives and the mandatory two-step verification."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-78752a7cb76b1e2fd920d512","record":{"id":"display-claim-78752a7cb76b1e2fd920d512","kind":"analysis","text":"The complaint also alleges that on October 7 and 8, 2023 the actor messaged three people, including Anne Wojcicki, then chief executive, and that between October 8 and 25 the company negotiated with the actor and paid $400,000 in cryptocurrency for a report on the vulnerabilities used and two more, destruction of the data, deletion of posts about the breach and a cover story mitigating its severity, while its blog of October 6 said it had no indication of an incident in its systems; it says it is unknown whether any data was deleted. No court has found these allegations proven, and no response to them by the company, the trust or Wojcicki was found in the record; the trust's May 31, 2026 motion in the bankruptcy court concerned whether California's claims were barred.","source_ids":["src-076","src-075"],"entity_ids":["holdco","wojcicki","california"],"premise_claim_ids":["c-br-ca-ransom"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The complaint also alleges that on October 7 and 8, 2023 the actor messaged three people, including Anne Wojcicki, then chief executive, and that between October 8 and 25 the company negotiated with the actor and paid $400,000 in cryptocurrency for a report on the vulnerabilities used and two more, destruction of the data, deletion of posts about the breach and a cover story mitigating its severity, while its blog of October 6 said it had no indication of an incident in its systems; it says it is unknown whether any data was deleted. No court has found these allegations proven, and no response to them by the company, the trust or Wojcicki was found in the record; the trust's May 31, 2026 motion in the bankruptcy court concerned whether California's claims were barred."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-e0f38bfdf5a29d76df0175ba","record":{"id":"display-claim-e0f38bfdf5a29d76df0175ba","kind":"analysis","text":"After the October 2023 disclosure the company faced more than 40 putative class actions, arbitration claims by about 35,000 claimants and class actions in Canada, as well as government investigations. On April 11, 2024 the federal cases were centralised as MDL No. 3098 before Judge Edward M. Chen in the Northern District of California; on July 29, 2024 the parties agreed a $30.0 million settlement with security measures and three years of monitoring, which received preliminary conditional approval on December 4, 2024, excluding customers who had chosen arbitration. On March 21, 2025 the company also settled with the plaintiffs of the California state actions and with arbitration claimants, bringing its agreed payments to U.S. customers, subject to conditions, to $37.5 million.","source_ids":["src-012","src-002"],"entity_ids":["holdco"],"premise_claim_ids":["c-st-litigation-scale","c-st-mdl","c-st-march-2025"],"qualification":"","response":"","outcome":""},"reading":"Analysis: After the October 2023 disclosure the company faced more than 40 putative class actions, arbitration claims by about 35,000 claimants and class actions in Canada, as well as government investigations. On April 11, 2024 the federal cases were centralised as MDL No. 3098 before Judge Edward M. Chen in the Northern District of California; on July 29, 2024 the parties agreed a $30.0 million settlement with security measures and three years of monitoring, which received preliminary conditional approval on December 4, 2024, excluding customers who had chosen arbitration. On March 21, 2025 the company also settled with the plaintiffs of the California state actions and with arbitration claimants, bringing its agreed payments to U.S. customers, subject to conditions, to $37.5 million."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-ffef8009037e158978cc7c4d","record":{"id":"display-claim-ffef8009037e158978cc7c4d","kind":"analysis","text":"In the bankruptcy the debtors signed a U.S. class settlement on August 4, 2025 allowing one class claim of at least $30 million, with distributions capped at $50 million, and a Canadian agreement later replaced by an amended version. On October 2, 2025 the court preliminarily approved the Canadian, U.S. and Lemonaid pixel settlements together, and on November 19, 2025 it approved the U.S. Data Breach Arbitration Agreement of November 17 resolving about 32,000 arbitration claims. The settlement website states that the court granted final approval on January 30, 2026, approved a final amount of $46.75 million on July 7, 2026 and that payments were issued on September 29 and 30, 2026, to a class of about 6.4 million U.S. residents. A news agency reported the same day that the amount would be reduced by $14.29 million already disbursed, leaving $32.46 million; the order itself was not retrieved.","source_ids":["src-012","src-032","src-084","src-043"],"entity_ids":["holdco","inc"],"premise_claim_ids":["c-st-class-agreements","c-st-prelim-approvals","c-st-arbitration","c-st-us-final","c-st-news-july-2026"],"qualification":"","response":"","outcome":""},"reading":"Analysis: In the bankruptcy the debtors signed a U.S. class settlement on August 4, 2025 allowing one class claim of at least $30 million, with distributions capped at $50 million, and a Canadian agreement later replaced by an amended version. On October 2, 2025 the court preliminarily approved the Canadian, U.S. and Lemonaid pixel settlements together, and on November 19, 2025 it approved the U.S. Data Breach Arbitration Agreement of November 17 resolving about 32,000 arbitration claims. The settlement website states that the court granted final approval on January 30, 2026, approved a final amount of $46.75 million on July 7, 2026 and that payments were issued on September 29 and 30, 2026, to a class of about 6.4 million U.S. residents. A news agency reported the same day that the amount would be reduced by $14.29 million already disbursed, leaving $32.46 million; the order itself was not retrieved."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-48ddcc950c9d0af340733b57","record":{"id":"display-claim-48ddcc950c9d0af340733b57","kind":"analysis","text":"Plaintiffs sued 23andMe Holding Co. and 23andMe, Inc. in the Supreme Court of British Columbia on October 20, 2023 and again on September 18, 2024, adding directors and officers and the auditor KPMG LLP (United States); a proposed Ontario class action of November 24, 2023 was stayed by agreement in favour of the British Columbia actions. The disclosure statement counts three Canadian class actions and the chief restructuring officer two, one per province. On June 5, 2025 the bankruptcy court extended the stay to the directors, officers and KPMG. The U.S. cases were recognised in Canada under the Companies' Creditors Arrangement Act on May 26, 2025, with Matthew Kvarda as foreign representative, and on November 27, 2025 the British Columbia court recognised the U.S. order preliminarily approving the Canadian settlement.","source_ids":["src-012","src-039","src-038"],"entity_ids":["holdco","inc","kpmg","kvarda"],"premise_claim_ids":["c-st-canada-suits","c-st-canada-stay","c-st-ccaa"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Plaintiffs sued 23andMe Holding Co. and 23andMe, Inc. in the Supreme Court of British Columbia on October 20, 2023 and again on September 18, 2024, adding directors and officers and the auditor KPMG LLP (United States); a proposed Ontario class action of November 24, 2023 was stayed by agreement in favour of the British Columbia actions. The disclosure statement counts three Canadian class actions and the chief restructuring officer two, one per province. On June 5, 2025 the bankruptcy court extended the stay to the directors, officers and KPMG. The U.S. cases were recognised in Canada under the Companies' Creditors Arrangement Act on May 26, 2025, with Matthew Kvarda as foreign representative, and on November 27, 2025 the British Columbia court recognised the U.S. order preliminarily approving the Canadian settlement."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-f7feeb7115e17ac02169ad7a","record":{"id":"display-claim-f7feeb7115e17ac02169ad7a","kind":"analysis","text":"Under the amended Canadian settlement of September 5, 2025 the class of Canadian residents notified of the breach has a single claim allowed at US$3,250,000, with distributions capped at that amount, in full settlement of the claims against 23andMe; the claims against the former directors and officers and KPMG are to be dismissed once the plan takes effect and the fund is paid. The settlement is not an admission of liability. Class counsel's fee is 33%, and counsel expected about 64,000 eligible claimants to receive about CA$17.77 each; the final approval hearing was set for February 17, 2026.","source_ids":["src-039"],"entity_ids":["holdco","kpmg"],"premise_claim_ids":["c-st-canada-settlement"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Under the amended Canadian settlement of September 5, 2025 the class of Canadian residents notified of the breach has a single claim allowed at US$3,250,000, with distributions capped at that amount, in full settlement of the claims against 23andMe; the claims against the former directors and officers and KPMG are to be dismissed once the plan takes effect and the fund is paid. The settlement is not an admission of liability. Class counsel's fee is 33%, and counsel expected about 64,000 eligible claimants to receive about CA$17.77 each; the final approval hearing was set for February 17, 2026."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-b3ba586b7a82587d72347c2d","record":{"id":"display-claim-b3ba586b7a82587d72347c2d","kind":"analysis","text":"The company's cyber and liability cover for May 1, 2023 to May 1, 2024 totalled $25 million in eroding limits: $15,000,000 from underwriters at Lloyd's, $5,000,000 from Allied World Specialty Insurance Company and $2,500,000 each from Houston Casualty Company and Landmark American Insurance Company. Under a buyback motion of December 1, 2025 the insurers were to pay $16,525,759.63, the limits left after about $8,474,240.37 of defence costs, and take back the policies; the money was reserved for the breach and pixel settlements, and the insurers became released parties.","source_ids":["src-032","src-016"],"entity_ids":["holdco","allied-world","houston-casualty","landmark"],"premise_claim_ids":["c-st-cyber-insurers"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The company's cyber and liability cover for May 1, 2023 to May 1, 2024 totalled $25 million in eroding limits: $15,000,000 from underwriters at Lloyd's, $5,000,000 from Allied World Specialty Insurance Company and $2,500,000 each from Houston Casualty Company and Landmark American Insurance Company. Under a buyback motion of December 1, 2025 the insurers were to pay $16,525,759.63, the limits left after about $8,474,240.37 of defence costs, and take back the policies; the money was reserved for the breach and pixel settlements, and the insurers became released parties."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-5738e48a6216bd9025401c2c","record":{"id":"display-claim-5738e48a6216bd9025401c2c","kind":"analysis","text":"By the September 19, 2025 bar date 42 state and District of Columbia claimants had filed proofs of claim seeking at least about $100 billion. On July 14, 2026 they signed a stipulation with the Plan Administration Trust and the Wind-Down Debtor allowing their claims at $150 million but limiting payment to $18 million, and barring the debtors for five years from direct consumer sales and from collecting or keeping personal information beyond what the trust needs. The parties settled to avoid the cost and risk of litigation, preserving all defences and without admission of liability. The stipulation takes effect only on a final approval order; the hearing was set for August 10, 2026, and the record does not include the ruling.","source_ids":["src-019","src-107"],"entity_ids":["holdco","plan-trust"],"premise_claim_ids":["c-st-states-claims"],"qualification":"","response":"","outcome":""},"reading":"Analysis: By the September 19, 2025 bar date 42 state and District of Columbia claimants had filed proofs of claim seeking at least about $100 billion. On July 14, 2026 they signed a stipulation with the Plan Administration Trust and the Wind-Down Debtor allowing their claims at $150 million but limiting payment to $18 million, and barring the debtors for five years from direct consumer sales and from collecting or keeping personal information beyond what the trust needs. The parties settled to avoid the cost and risk of litigation, preserving all defences and without admission of liability. The stipulation takes effect only on a final approval order; the hearing was set for August 10, 2026, and the record does not include the ruling."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-e0ff45cb471cfd9c8f160a90","record":{"id":"display-claim-e0ff45cb471cfd9c8f160a90","kind":"analysis","text":"Appendix A allots the $18 million among 41 states and the District of Columbia, the largest shares going to Texas ($1,266,860), Florida ($1,111,206) and Indiana ($979,424) and the smallest to South Dakota ($149,339); California is not a signatory. The mutual release covers the debtors, the trust and their officers, directors and affiliates, but expressly not the asset buyer, 23andMe Research Institute. Announcing the settlement, the attorneys general of Colorado and Minnesota said their investigation found the company's data security unreasonable, that it learned of the breach months after the data was public, first denied it and then blamed consumers, and that recovery was limited by the estate's finite funds; they noted that the buyer had accepted strengthened protections. These are the states' conclusions announced with a negotiated settlement, not findings of a court.","source_ids":["src-019","src-107","src-044"],"entity_ids":["holdco","texas","ttam","plan-trust"],"premise_claim_ids":["c-st-states-allocation","c-st-states-release","c-st-states-findings"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Appendix A allots the $18 million among 41 states and the District of Columbia, the largest shares going to Texas ($1,266,860), Florida ($1,111,206) and Indiana ($979,424) and the smallest to South Dakota ($149,339); California is not a signatory. The mutual release covers the debtors, the trust and their officers, directors and affiliates, but expressly not the asset buyer, 23andMe Research Institute. Announcing the settlement, the attorneys general of Colorado and Minnesota said their investigation found the company's data security unreasonable, that it learned of the breach months after the data was public, first denied it and then blamed consumers, and that recovery was limited by the estate's finite funds; they noted that the buyer had accepted strengthened protections. These are the states' conclusions announced with a negotiated settlement, not findings of a court."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-8dc5c7efab430c3576592c45","record":{"id":"display-claim-8dc5c7efab430c3576592c45","kind":"analysis","text":"California said in the bankruptcy court that it might assert an administrative claim for violations of its Genetic Information Privacy Act when the sale to TTAM closed, and its representatives spoke of civil penalties of more than $1 billion; the debtors disputed it, obtained estimation procedures and reserved all rights, and the confirmation order of December 1, 2025 barred California from asserting that administrative claim against the debtors or their estates.","source_ids":["src-012","src-079","src-016"],"entity_ids":["holdco","california","ttam"],"premise_claim_ids":["c-st-ca-admin-claim"],"qualification":"","response":"","outcome":""},"reading":"Analysis: California said in the bankruptcy court that it might assert an administrative claim for violations of its Genetic Information Privacy Act when the sale to TTAM closed, and its representatives spoke of civil penalties of more than $1 billion; the debtors disputed it, obtained estimation procedures and reserved all rights, and the confirmation order of December 1, 2025 barred California from asserting that administrative claim against the debtors or their estates."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-ea990784908c81bef65f1965","record":{"id":"display-claim-ea990784908c81bef65f1965","kind":"analysis","text":"On May 27, 2026 the People of the State of California sued Chrome Holding Co., ChromeCo, Inc. and Doe defendants in San Francisco Superior Court (No. CGC-26-636891) over the breach, seeking injunctive relief and civil penalties under four state laws. The trust moved to enforce the plan, relying on its exclusive-jurisdiction provision and injunction; on July 10, 2026 the bankruptcy court held that the jurisdiction provision did not support the motion but that the plan injunction bars the monetary claims, and ordered California within 14 days to dismiss the suit or drop its monetary claims against the two companies. The order leaves the claims against the Doe defendants and non-monetary relief untouched, and the trust's objection to California's proof of claim of September 4, 2025, whose monetary claims the court found essentially similar to the suit's, remained pending. California filed a notice of appeal, transmitted to the Court of Appeals as No. 26-3083 on October 14, 2026; the docket entry does not name the order appealed.","source_ids":["src-075","src-076","src-065"],"entity_ids":["california","holdco","inc","plan-trust"],"premise_claim_ids":["c-st-ca-suit","c-st-ca-enforcement-order","c-st-ca-appeal-2026"],"qualification":"","response":"","outcome":""},"reading":"Analysis: On May 27, 2026 the People of the State of California sued Chrome Holding Co., ChromeCo, Inc. and Doe defendants in San Francisco Superior Court (No. CGC-26-636891) over the breach, seeking injunctive relief and civil penalties under four state laws. The trust moved to enforce the plan, relying on its exclusive-jurisdiction provision and injunction; on July 10, 2026 the bankruptcy court held that the jurisdiction provision did not support the motion but that the plan injunction bars the monetary claims, and ordered California within 14 days to dismiss the suit or drop its monetary claims against the two companies. The order leaves the claims against the Doe defendants and non-monetary relief untouched, and the trust's objection to California's proof of claim of September 4, 2025, whose monetary claims the court found essentially similar to the suit's, remained pending. California filed a notice of appeal, transmitted to the Court of Appeals as No. 26-3083 on October 14, 2026; the docket entry does not name the order appealed."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-3ba5e5089156249b07f05899","record":{"id":"display-claim-3ba5e5089156249b07f05899","kind":"analysis","text":"Revenue fell from $299.5 million in fiscal 2023 to $219.6 million in fiscal 2024 and $189.9 million in fiscal 2025, with net losses of $311.7 million, $666.7 million (including a $351.7 million goodwill impairment) and $280.9 million; revenue from GSK as a related party was $47.4 million, $12.0 million and $20.4 million (amounts rounded from thousands). Fiscal-2025 revenue fell 14%, mainly on lower sales and prices of Personal Genome Service kits, and included $19.3 million recognised on a GSK data use notice; telehealth revenue also fell, partly after the UK Lemonaid subsidiary was sold. In November 2024 the company stopped all therapeutics programmes and cut about 200 employees, roughly 40% of its staff.","source_ids":["src-035","src-012"],"entity_ids":["holdco","gsk","lemonaid-uk"],"premise_claim_ids":["c-ch-finances","c-ch-revenue-fy25","c-ch-cutbacks"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Revenue fell from $299.5 million in fiscal 2023 to $219.6 million in fiscal 2024 and $189.9 million in fiscal 2025, with net losses of $311.7 million, $666.7 million (including a $351.7 million goodwill impairment) and $280.9 million; revenue from GSK as a related party was $47.4 million, $12.0 million and $20.4 million (amounts rounded from thousands). Fiscal-2025 revenue fell 14%, mainly on lower sales and prices of Personal Genome Service kits, and included $19.3 million recognised on a GSK data use notice; telehealth revenue also fell, partly after the UK Lemonaid subsidiary was sold. In November 2024 the company stopped all therapeutics programmes and cut about 200 employees, roughly 40% of its staff."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-84015fbe14ad1d6e954a72d9","record":{"id":"display-claim-84015fbe14ad1d6e954a72d9","kind":"analysis","text":"At March 31, 2025 it had $38.2 million of unrestricted cash, down from $216.5 million, total assets of $159.9 million against liabilities of $186.6 million, an accumulated deficit of $2.5 billion and negative equity of $26.7 million (rounded), and management disclosed substantial doubt about its ability to continue as a going concern. KPMG LLP of Santa Clara, auditor since 2020, signed its report on June 11, 2025 and billed $3,398,206 for fiscal 2025. In April 2025 the Sunnyvale landlord drew $7.3 million of letters of credit. The chief restructuring officer said the business had never made a net profit despite more than $200 million of revenue a year for five years; the disclosure statement adds constrained access to capital after the merger, the economy, the breach and the litigation that followed. The debtors had no funded debt, and the court protected more than $1 billion of federal net operating losses with stock-transfer procedures.","source_ids":["src-035","src-057","src-031","src-012"],"entity_ids":["holdco","kpmg","kvarda"],"premise_claim_ids":["c-ch-balance-sheet","c-ch-kpmg-fees","c-ch-letters-of-credit","c-ch-causes","c-ch-nol"],"qualification":"","response":"","outcome":""},"reading":"Analysis: At March 31, 2025 it had $38.2 million of unrestricted cash, down from $216.5 million, total assets of $159.9 million against liabilities of $186.6 million, an accumulated deficit of $2.5 billion and negative equity of $26.7 million (rounded), and management disclosed substantial doubt about its ability to continue as a going concern. KPMG LLP of Santa Clara, auditor since 2020, signed its report on June 11, 2025 and billed $3,398,206 for fiscal 2025. In April 2025 the Sunnyvale landlord drew $7.3 million of letters of credit. The chief restructuring officer said the business had never made a net profit despite more than $200 million of revenue a year for five years; the disclosure statement adds constrained access to capital after the merger, the economy, the breach and the litigation that followed. The debtors had no funded debt, and the court protected more than $1 billion of federal net operating losses with stock-transfer procedures."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-a78b140861fbaf460bf20f63","record":{"id":"display-claim-a78b140861fbaf460bf20f63","kind":"analysis","text":"On March 23, 2025 23andMe Holding Co. and eleven subsidiaries filed voluntary petitions in the U.S. Bankruptcy Court for the Eastern District of Missouri, jointly administered as Case No. 25-40976-357, and moved for a sale through a competitive auction under section 363, advised by Moelis & Company. ChromeCo, Inc. (formerly 23andMe, Inc.), Lemonaid Health, Inc. and Chrome Pharmacy Holdings, Inc. were wholly owned by the holding company; the pharmacy holding company owned Lemonaid Pharmacy Holdings Inc. and, through it, the community pharmacy and the LPharm and LPRX companies, each with its own case number from 25-40975 to 25-40986. The confirmation order identifies the twelve debtors by the last four digits of their tax numbers, Chrome Holding Co. ending 0344.","source_ids":["src-002","src-003","src-012","src-036","src-016"],"entity_ids":["holdco","inc","lemonaid-health","pharmacy-holdings","lemonaid-pharmacy-holdings","lemonaid-community-pharmacy","lpharm-ins","lpharm-cs","lpharm-rx","lprxone","lprxtwo","lprxthree"],"premise_claim_ids":["c-ch-filing","c-ch-debtor-structure","c-ch-related-cases","c-ch-tax-ids"],"qualification":"","response":"","outcome":""},"reading":"Analysis: On March 23, 2025 23andMe Holding Co. and eleven subsidiaries filed voluntary petitions in the U.S. Bankruptcy Court for the Eastern District of Missouri, jointly administered as Case No. 25-40976-357, and moved for a sale through a competitive auction under section 363, advised by Moelis & Company. ChromeCo, Inc. (formerly 23andMe, Inc.), Lemonaid Health, Inc. and Chrome Pharmacy Holdings, Inc. were wholly owned by the holding company; the pharmacy holding company owned Lemonaid Pharmacy Holdings Inc. and, through it, the community pharmacy and the LPharm and LPRX companies, each with its own case number from 25-40975 to 25-40986. The confirmation order identifies the twelve debtors by the last four digits of their tax numbers, Chrome Holding Co. ending 0344."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-24f0959f7193c779fc4a29b4","record":{"id":"display-claim-24f0959f7193c779fc4a29b4","kind":"analysis","text":"According to an aggregator's copy of the docket, the community pharmacy is listed at 7580 Watson Road, Shrewsbury, Missouri, and the other pharmacy companies at 1701 Macklind Ave., Suite 300, St. Louis; the NPI registry lists the pharmacy as active since July 22, 2020. The same docket copy lists adversary proceedings including a suit by the debtors against J.R. and others of April 14, 2025, the multistate and Texas suits of June 9, 2025, a self-represented suit of July 17, 2025 and a 2026 suit by self-represented plaintiffs against 23andMe, Inc.","source_ids":["src-080","src-102","src-065"],"entity_ids":["lemonaid-community-pharmacy","lemonaid-pharmacy-holdings","lpharm-rx","lpharm-ins","lprxone","lprxthree","holdco","inc","texas"],"premise_claim_ids":["c-ch-addresses-pharmacy","c-ch-adversaries"],"qualification":"","response":"","outcome":""},"reading":"Analysis: According to an aggregator's copy of the docket, the community pharmacy is listed at 7580 Watson Road, Shrewsbury, Missouri, and the other pharmacy companies at 1701 Macklind Ave., Suite 300, St. Louis; the NPI registry lists the pharmacy as active since July 22, 2020. The same docket copy lists adversary proceedings including a suit by the debtors against J.R. and others of April 14, 2025, the multistate and Texas suits of June 9, 2025, a self-represented suit of July 17, 2025 and a 2026 suit by self-represented plaintiffs against 23andMe, Inc."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-c9e8690887a6a52091090812","record":{"id":"display-claim-c9e8690887a6a52091090812","kind":"analysis","text":"On the petition date the company signed a term sheet with JMB Capital Partners Lending, LLC for a super-priority debtor-in-possession loan of up to $35 million, authorised on March 26, 2025; the loan agreement of April 28, with all debtors as joint borrowers, was secured on substantially all assets at 14.0% interest. The company drew $10.0 million on May 5, the commitments were later raised to $60 million, and the loan was repaid in full at the closing of the TTAM sale on July 14, 2025. The court approved Paul, Weiss and Carmody MacDonald as counsel, Moelis as investment banker, Alvarez & Marsal and Matthew Kvarda as chief restructuring officer and Kroll as claims agent.","source_ids":["src-002","src-012","src-035"],"entity_ids":["holdco","jmb","alvarez-marsal","kvarda","kroll"],"premise_claim_ids":["c-ch-dip","c-ch-advisers"],"qualification":"","response":"","outcome":""},"reading":"Analysis: On the petition date the company signed a term sheet with JMB Capital Partners Lending, LLC for a super-priority debtor-in-possession loan of up to $35 million, authorised on March 26, 2025; the loan agreement of April 28, with all debtors as joint borrowers, was secured on substantially all assets at 14.0% interest. The company drew $10.0 million on May 5, the commitments were later raised to $60 million, and the loan was repaid in full at the closing of the TTAM sale on July 14, 2025. The court approved Paul, Weiss and Carmody MacDonald as counsel, Moelis as investment banker, Alvarez & Marsal and Matthew Kvarda as chief restructuring officer and Kroll as claims agent."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-153787a848ef0de4df50a744","record":{"id":"display-claim-153787a848ef0de4df50a744","kind":"analysis","text":"On April 3, 2025 the U.S. Trustee appointed a creditors' committee of LabCorp, Workday, Telus International, Jellyfish US and three individual creditors, which retained Kelley Drye & Warren, Stinson and FTI Consulting; on July 15, 2025 it appointed an equity committee of seven shareholders, four of them individuals not named here. The general bar date was July 14, 2025 and the governmental bar date September 19, 2025; about 170,800 timely claims and 46,530 late ones were filed, asserting more than $7 trillion in total. An aggregator's docket copy lists creditors including Converge Technology Solutions, CoreWeave, a GSK intellectual-property company, the landlord KR OP Tech, LabCorp and Oracle. A bankruptcy-data summary reports an ending cash balance of about $256.6 million in November 2025 and about $59.3 million of final fee requests, the largest approved amounts going to Paul, Weiss, Alvarez & Marsal and Kelley Drye & Warren; the operating reports and fee orders were not retrieved.","source_ids":["src-012","src-065","src-050"],"entity_ids":["holdco","labcorp","workday","telus","jellyfish","converge","kr-op-tech","jmb","alvarez-marsal"],"premise_claim_ids":["c-ch-creditors-committee","c-ch-equity-committee","c-ch-bar-dates","c-ch-creditors-list","c-ch-cash-fees"],"qualification":"","response":"","outcome":""},"reading":"Analysis: On April 3, 2025 the U.S. Trustee appointed a creditors' committee of LabCorp, Workday, Telus International, Jellyfish US and three individual creditors, which retained Kelley Drye & Warren, Stinson and FTI Consulting; on July 15, 2025 it appointed an equity committee of seven shareholders, four of them individuals not named here. The general bar date was July 14, 2025 and the governmental bar date September 19, 2025; about 170,800 timely claims and 46,530 late ones were filed, asserting more than $7 trillion in total. An aggregator's docket copy lists creditors including Converge Technology Solutions, CoreWeave, a GSK intellectual-property company, the landlord KR OP Tech, LabCorp and Oracle. A bankruptcy-data summary reports an ending cash balance of about $256.6 million in November 2025 and about $59.3 million of final fee requests, the largest approved amounts going to Paul, Weiss, Alvarez & Marsal and Kelley Drye & Warren; the operating reports and fee orders were not retrieved."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-4a001e8af647750587b25296","record":{"id":"display-claim-4a001e8af647750587b25296","kind":"analysis","text":"The debtors filed their joint plan on August 15, 2025 with a disclosure statement signed by Kvarda: a Plan Administrator would wind down the debtors, a Plan Administration Trust would hold the remaining assets for unsecured creditors and shareholders, and shareholders (Class 12) would receive a share of the trust's Class B interests, with no estimate of their recovery. The court approved the disclosure statement on October 1, 2025; the third amended plan of November 14 modified the arbitration settlement and dropped an alternative equity-sale structure. On November 26, 2025 Judge Brian C. Walsh capped the landlord KR OP Tech's lease-rejection claim at about $5.6 million, noting claims with a face value in the trillions against about $200 million to distribute; the landlord appealed the confirmation order on December 23, 2025, according to a case-tracking service.","source_ids":["src-012","src-045","src-034"],"entity_ids":["holdco","kvarda","plan-trust","california","inc","kr-op-tech"],"premise_claim_ids":["c-ch-plan-august","c-ch-ds-order","c-ch-landlord-opinion"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The debtors filed their joint plan on August 15, 2025 with a disclosure statement signed by Kvarda: a Plan Administrator would wind down the debtors, a Plan Administration Trust would hold the remaining assets for unsecured creditors and shareholders, and shareholders (Class 12) would receive a share of the trust's Class B interests, with no estimate of their recovery. The court approved the disclosure statement on October 1, 2025; the third amended plan of November 14 modified the arbitration settlement and dropped an alternative equity-sale structure. On November 26, 2025 Judge Brian C. Walsh capped the landlord KR OP Tech's lease-rejection claim at about $5.6 million, noting claims with a face value in the trillions against about $200 million to distribute; the landlord appealed the confirmation order on December 23, 2025, according to a case-tracking service."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-d42af154b50912f1a238f12d","record":{"id":"display-claim-d42af154b50912f1a238f12d","kind":"analysis","text":"The court confirmed the Modified Fifth Amended Joint Plan on December 1, 2025 (Docket No. 1662, amended December 5); the breach and pixel classes voted to accept, the unsecured classes 6 and 7 and the shareholders to reject, and the plan became effective on December 5, 2025. The debtors' assets other than the Lemonaid interests vested in the trust, whose distributions go first to reserves and administrative and priority claims, then to the breach and pixel settlements, then to unsecured claims. The 25,489,590 Class A and 2,110,250 Class B shares were cancelled, the boards dissolved and the directors and officers dismissed. Thomas Walper became the Plan Administrator, disclosed as an insider of the debtors, with Matthew Dundon representing unsecured creditors and Alan Halperin the shareholders.","source_ids":["src-015","src-016","src-019"],"entity_ids":["holdco","plan-trust","walper"],"premise_claim_ids":["c-ch-confirmation","c-ch-plan-trust","c-ch-shares-cancelled","c-ch-board-dissolved","c-ch-plan-administrator"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The court confirmed the Modified Fifth Amended Joint Plan on December 1, 2025 (Docket No. 1662, amended December 5); the breach and pixel classes voted to accept, the unsecured classes 6 and 7 and the shareholders to reject, and the plan became effective on December 5, 2025. The debtors' assets other than the Lemonaid interests vested in the trust, whose distributions go first to reserves and administrative and priority claims, then to the breach and pixel settlements, then to unsecured claims. The 25,489,590 Class A and 2,110,250 Class B shares were cancelled, the boards dissolved and the directors and officers dismissed. Thomas Walper became the Plan Administrator, disclosed as an insider of the debtors, with Matthew Dundon representing unsecured creditors and Alan Halperin the shareholders."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-27dcd26709a6afd7d151eb3d","record":{"id":"display-claim-27dcd26709a6afd7d151eb3d","kind":"analysis","text":"The plan names as Excluded Parties, who are not released and whom the trust may sue, the Former CEO, Anne Wojcicki in her capacity as director, shareholder and former chief executive, together with former directors and officers not in office on the petition date and a former Chief Security Officer; it states that she is not an affiliate of the debtors. Exclusion preserves possible claims and is not a finding of liability. The third amended plan had named ABeeC 2.0 and her foundation as released parties of the buyer, but paragraph 133 of the confirmation order treats Wojcicki, the foundation and ABeeC as having opted out of the releases, preserves their indemnification, advancement and exculpation rights, lets them raise counterclaims in any trust suit and does not limit their Class 12 distributions because of a disputed claim.","source_ids":["src-016","src-045"],"entity_ids":["wojcicki","holdco","ttam","abeec","aw-foundation","plan-trust"],"premise_claim_ids":["c-ch-excluded-parties","c-ch-third-plan-buyer","c-ch-wojcicki-resolution"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The plan names as Excluded Parties, who are not released and whom the trust may sue, the Former CEO, Anne Wojcicki in her capacity as director, shareholder and former chief executive, together with former directors and officers not in office on the petition date and a former Chief Security Officer; it states that she is not an affiliate of the debtors. Exclusion preserves possible claims and is not a finding of liability. The third amended plan had named ABeeC 2.0 and her foundation as released parties of the buyer, but paragraph 133 of the confirmation order treats Wojcicki, the foundation and ABeeC as having opted out of the releases, preserves their indemnification, advancement and exculpation rights, lets them raise counterclaims in any trust suit and does not limit their Class 12 distributions because of a disputed claim."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-24db7908b9ccc466280cc558","record":{"id":"display-claim-24db7908b9ccc466280cc558","kind":"analysis","text":"On January 3, 2026 Wojcicki applied, through Bryan Cave Leighton Paisner, for payment of her unliquidated indemnification expenses as an administrative expense, citing the British Columbia actions, the Special Committee's investigation, requests from the House Oversight Committee and a self-represented adversary proceeding. That suit, filed on July 17, 2025 against the debtors, TTAM, Wojcicki and others, was dismissed on October 15, 2025; the docket summary does not say what it alleged. A bankruptcy-data summary reports two other administrative applications that day, by 23andMe Research Institute and by a former executive. The record does not show how the court ruled on any of them.","source_ids":["src-051","src-016","src-052","src-050"],"entity_ids":["wojcicki","holdco","inc","ttam"],"premise_claim_ids":["c-ch-wojcicki-application","c-ch-pro-se-adversary","c-ch-admin-claims-2026"],"qualification":"","response":"","outcome":""},"reading":"Analysis: On January 3, 2026 Wojcicki applied, through Bryan Cave Leighton Paisner, for payment of her unliquidated indemnification expenses as an administrative expense, citing the British Columbia actions, the Special Committee's investigation, requests from the House Oversight Committee and a self-represented adversary proceeding. That suit, filed on July 17, 2025 against the debtors, TTAM, Wojcicki and others, was dismissed on October 15, 2025; the docket summary does not say what it alleged. A bankruptcy-data summary reports two other administrative applications that day, by 23andMe Research Institute and by a former executive. The record does not show how the court ruled on any of them."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-eb4f288d98578134a0c1a3fc","record":{"id":"display-claim-eb4f288d98578134a0c1a3fc","kind":"analysis","text":"The confirmation order reserved $4,061,000 for Converge Technology Solutions' claim for unpaid cloud invoices and left the landlord's lease claim undischarged until distributions are made. According to a case summary, the wind-down debtors argued that the Converge invoices were liabilities assumed by TTAM, which replied disputing any preclusive effect, and on March 4, 2026 the trust settled with Converge for $6.11 million while keeping a right to seek reimbursement from 23andMe Research Institute; the settlement papers were not retrieved.","source_ids":["src-016","src-050"],"entity_ids":["holdco","converge","kr-op-tech","ttam","plan-trust"],"premise_claim_ids":["c-ch-converge-reserve","c-ch-converge-settlement"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The confirmation order reserved $4,061,000 for Converge Technology Solutions' claim for unpaid cloud invoices and left the landlord's lease claim undischarged until distributions are made. According to a case summary, the wind-down debtors argued that the Converge invoices were liabilities assumed by TTAM, which replied disputing any preclusive effect, and on March 4, 2026 the trust settled with Converge for $6.11 million while keeping a right to seek reimbursement from 23andMe Research Institute; the settlement papers were not retrieved."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-1fd12155f2f44a54d9db898d","record":{"id":"display-claim-1fd12155f2f44a54d9db898d","kind":"analysis","text":"On January 21, 2026 the court closed all the cases except Chrome Holding Co.'s. In January 2026 the Northern District of California denied a temporary restraining order in a self-represented suit against 23andMe, Inc. and Regeneron, which the plaintiffs wrongly called the successor to the genomic assets. The court's calendar retrieved in October 2026 lists a claims-objection hearing on October 27, a status conference on November 3 and an estimation hearing on November 10, 2026, and an aggregator's docket copy shows the trust pursuing its twenty-third omnibus objection with a declaration of Joseph Selsavage.","source_ids":["src-019","src-078","src-048","src-047","src-065"],"entity_ids":["holdco","inc","regeneron","kroll","plan-trust","selsavage"],"premise_claim_ids":["c-ch-case-closing","c-ch-reyna","c-ch-hearing-calendar","c-ch-docket-oct-2026"],"qualification":"","response":"","outcome":""},"reading":"Analysis: On January 21, 2026 the court closed all the cases except Chrome Holding Co.'s. In January 2026 the Northern District of California denied a temporary restraining order in a self-represented suit against 23andMe, Inc. and Regeneron, which the plaintiffs wrongly called the successor to the genomic assets. The court's calendar retrieved in October 2026 lists a claims-objection hearing on October 27, a status conference on November 3 and an estimation hearing on November 10, 2026, and an aggregator's docket copy shows the trust pursuing its twenty-third omnibus objection with a declaration of Joseph Selsavage."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-4be232c4abcbfbd236b864ae","record":{"id":"display-claim-4be232c4abcbfbd236b864ae","kind":"analysis","text":"According to the court, the debtors held data on about 13 million customers at the sale hearing, more than 80% of whom had consented to research; the assets were saliva samples in biobanks and electronic data such as DNA results, names and email addresses, and about 1.9 million customers had deleted their accounts since the filing. The objecting states, citing the purchase agreement, described the data as biological samples, genotype data and personal information, and gave counts of 10,397,824 biobank-consented customers and genetic information for over 15 million consumers as of May 3, 2025. The court found that every privacy statement since 2007 had warned that personal information could be sold with the business; the states noted that on June 8, 2022 the company removed an assurance that data would not be sold for research without explicit consent.","source_ids":["src-018","src-056"],"entity_ids":["holdco"],"premise_claim_ids":["c-sale-customer-data","c-sale-data-categories","c-sale-privacy-history"],"qualification":"","response":"","outcome":""},"reading":"Analysis: According to the court, the debtors held data on about 13 million customers at the sale hearing, more than 80% of whom had consented to research; the assets were saliva samples in biobanks and electronic data such as DNA results, names and email addresses, and about 1.9 million customers had deleted their accounts since the filing. The objecting states, citing the purchase agreement, described the data as biological samples, genotype data and personal information, and gave counts of 10,397,824 biobank-consented customers and genetic information for over 15 million consumers as of May 3, 2025. The court found that every privacy statement since 2007 had warned that personal information could be sold with the business; the states noted that on June 8, 2022 the company removed an assurance that data would not be sold for research without explicit consent."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-be74a7c2665ae500a2623c03","record":{"id":"display-claim-be74a7c2665ae500a2623c03","kind":"analysis","text":"On March 31, 2025 FTC Chairman Andrew N. Ferguson wrote to the U.S. Trustee that any sale of users' personal information and samples, including those of 23andMe, Inc. and Lemonaid Health, would be subject to the company's privacy representations and that any buyer should agree to be bound by them, noting Wojcicki's September 2024 pledge to keep the privacy policy after any acquisition by her. The Canadian and UK commissioners wrote in April that their laws would apply. On April 29 the parties agreed to a Consumer Privacy Ombudsman, without prejudice to the debtors' view that one was not needed; Neil M. Richards filed his non-binding report on June 11, 2025. Selsavage told the Senate committee that bids from countries of concern were barred, that bidders had to follow the privacy policies and that genetic data was stored apart from identifiers; Regeneron and TTAM were then the two remaining bidders.","source_ids":["src-077","src-073","src-012","src-029"],"entity_ids":["holdco","inc","lemonaid-health","wojcicki","selsavage","regeneron","ttam"],"premise_claim_ids":["c-sale-ftc-letter","c-sale-regulators-letter","c-sale-cpo","c-sale-senate-safeguards"],"qualification":"","response":"","outcome":""},"reading":"Analysis: On March 31, 2025 FTC Chairman Andrew N. Ferguson wrote to the U.S. Trustee that any sale of users' personal information and samples, including those of 23andMe, Inc. and Lemonaid Health, would be subject to the company's privacy representations and that any buyer should agree to be bound by them, noting Wojcicki's September 2024 pledge to keep the privacy policy after any acquisition by her. The Canadian and UK commissioners wrote in April that their laws would apply. On April 29 the parties agreed to a Consumer Privacy Ombudsman, without prejudice to the debtors' view that one was not needed; Neil M. Richards filed his non-binding report on June 11, 2025. Selsavage told the Senate committee that bids from countries of concern were barred, that bidders had to follow the privacy policies and that genetic data was stored apart from identifiers; Regeneron and TTAM were then the two remaining bidders."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-48d66a7fef7632bea0dffa3b","record":{"id":"display-claim-48d66a7fef7632bea0dffa3b","kind":"analysis","text":"Bidding procedures were entered on March 28, 2025; Moelis contacted about 57 potential buyers, 32 indications of interest arrived, no stalking horse was named, and seven qualified bidders took part in an auction opened at $52 million from May 14 to 16. The debtors chose Regeneron's $256 million bid for everything except Lemonaid, signed with it on May 17 and named TTAM, at $146 million, as backup. The court found that Wojcicki created TTAM Research Institute soon after the filing to buy the assets: a non-profit public-benefit corporation, fully funded by her and her affiliates, of which she is chief executive, president and one of three directors.","source_ids":["src-012","src-018","src-035"],"entity_ids":["holdco","regeneron","ttam","wojcicki"],"premise_claim_ids":["c-sale-bidding-procedures","c-sale-regeneron","c-sale-ttam-origin"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Bidding procedures were entered on March 28, 2025; Moelis contacted about 57 potential buyers, 32 indications of interest arrived, no stalking horse was named, and seven qualified bidders took part in an auction opened at $52 million from May 14 to 16. The debtors chose Regeneron's $256 million bid for everything except Lemonaid, signed with it on May 17 and named TTAM, at $146 million, as backup. The court found that Wojcicki created TTAM Research Institute soon after the filing to buy the assets: a non-profit public-benefit corporation, fully funded by her and her affiliates, of which she is chief executive, president and one of three directors."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-42d2819efa42c160c1b9c569","record":{"id":"display-claim-42d2819efa42c160c1b9c569","kind":"analysis","text":"TTAM then raised its offer to $305 million; after final-round procedures approved on June 6, the debtors chose it on June 13, 2025, with Regeneron as backup at $151 million. Under the Chrome Purchase Agreement TTAM agreed to buy substantially all the Chrome debtors' assets for $302.5 million and to sponsor a plan to acquire the Lemonaid debtors for $2.5 million. On June 14 the debtors elected an equity sale: the assets would move to a new wholly owned subsidiary, NewCo, and its shares would be sold to TTAM, so that no genetic data passed to TTAM directly. TTAM undertook to keep the business, staff, data access and petition-date privacy policy, including deletion and opt-out rights, not to share data with insurers, to follow privacy laws even where its non-profit status might excuse it, to form an independent privacy advisory board within ninety days and to provide two years of identity-theft monitoring.","source_ids":["src-012","src-005","src-049","src-018"],"entity_ids":["ttam","holdco","regeneron","lemonaid-health"],"premise_claim_ids":["c-sale-ttam-wins","c-sale-newco","c-sale-ttam-terms"],"qualification":"","response":"","outcome":""},"reading":"Analysis: TTAM then raised its offer to $305 million; after final-round procedures approved on June 6, the debtors chose it on June 13, 2025, with Regeneron as backup at $151 million. Under the Chrome Purchase Agreement TTAM agreed to buy substantially all the Chrome debtors' assets for $302.5 million and to sponsor a plan to acquire the Lemonaid debtors for $2.5 million. On June 14 the debtors elected an equity sale: the assets would move to a new wholly owned subsidiary, NewCo, and its shares would be sold to TTAM, so that no genetic data passed to TTAM directly. TTAM undertook to keep the business, staff, data access and petition-date privacy policy, including deletion and opt-out rights, not to share data with insurers, to follow privacy laws even where its non-profit status might excuse it, to form an independent privacy advisory board within ninety days and to provide two years of identity-theft monitoring."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-e336bc56569d3ff85b9c0878","record":{"id":"display-claim-e336bc56569d3ff85b9c0878","kind":"analysis","text":"Attorneys general of more than 30 states and the District of Columbia objected. Some argued that selling the genetic data of more than 13 million customers needed each customer's new opt-in consent, while accepting that a purchase structured as a change of ownership might be lawful without it; they also argued that the agreements in effect sold the data free and clear, and that a non-profit buyer should stay subject to state privacy laws. On June 9, 2025 twenty-eight states and the District of Columbia, led by Arizona, sued for a declaration, and Texas filed its own suit, in which a preliminary injunction was denied on June 18. The debtors maintained that the transaction complied with their policies and the law and restructured it as the NewCo sale, which resolved the objections of 29 of 34 objecting jurisdictions; the court overruled the remaining objectors. The Global BioData Trust (CAVEAT) asked the court to treat the data as held in trust.","source_ids":["src-012","src-056","src-049","src-080","src-064"],"entity_ids":["holdco","ttam","regeneron","california","texas","inc","biodata-trust"],"premise_claim_ids":["c-sale-states-objection","c-sale-states-suits","c-sale-biodata-trust"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Attorneys general of more than 30 states and the District of Columbia objected. Some argued that selling the genetic data of more than 13 million customers needed each customer's new opt-in consent, while accepting that a purchase structured as a change of ownership might be lawful without it; they also argued that the agreements in effect sold the data free and clear, and that a non-profit buyer should stay subject to state privacy laws. On June 9, 2025 twenty-eight states and the District of Columbia, led by Arizona, sued for a declaration, and Texas filed its own suit, in which a preliminary injunction was denied on June 18. The debtors maintained that the transaction complied with their policies and the law and restructured it as the NewCo sale, which resolved the objections of 29 of 34 objecting jurisdictions; the court overruled the remaining objectors. The Global BioData Trust (CAVEAT) asked the court to treat the data as held in trust."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-a4708e8e5ef18db8258ded6e","record":{"id":"display-claim-a4708e8e5ef18db8258ded6e","kind":"analysis","text":"On June 30, 2025 Pennsylvania Attorney General Dave Sunday announced that a group of attorneys general who had sued and objected supported the sale to TTAM on the agreed conditions, while still objecting to consumer DNA ever being part of a bankruptcy auction. After the sale closed Texas dismissed its suit on July 21 and the multistate plaintiffs theirs on July 30, 2025.","source_ids":["src-041","src-056","src-080","src-064"],"entity_ids":["ttam","holdco","wojcicki","inc","texas"],"premise_claim_ids":["c-sale-pa-ag","c-sale-states-suits"],"qualification":"","response":"","outcome":""},"reading":"Analysis: On June 30, 2025 Pennsylvania Attorney General Dave Sunday announced that a group of attorneys general who had sued and objected supported the sale to TTAM on the agreed conditions, while still objecting to consumer DNA ever being part of a bankruptcy auction. After the sale closed Texas dismissed its suit on July 21 and the multistate plaintiffs theirs on July 30, 2025."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-02042ab29284fc2090969f80","record":{"id":"display-claim-02042ab29284fc2090969f80","kind":"analysis","text":"After a contested hearing on June 18 and 20, Judge Brian C. Walsh approved the sale on June 27, 2025 (Docket No. 908). He held that the debtors had to comply with state law, rejecting the argument that section 363(b)(1) pre-empts it, but found that their privacy policies authorised or did not prohibit a sale with the business, subject to customers' right to opt out. Moving the data to a wholly owned NewCo was not a transfer to a third party under California's statute or to a person under the Kentucky, Tennessee, Texas and Utah statutes, and selling NewCo's shares needed no consent because those laws do not regulate a change of ownership. He rejected Texas's property-right argument, Utah's purpose-limitation argument, and the sub rosa plan, fraudulent-transfer and 28 U.S.C. § 959(b) arguments, and found NewCo and TTAM good-faith purchasers.","source_ids":["src-018","src-012"],"entity_ids":["holdco","ttam","texas","california"],"premise_claim_ids":["c-sale-opinion","c-sale-opinion-newco"],"qualification":"","response":"","outcome":""},"reading":"Analysis: After a contested hearing on June 18 and 20, Judge Brian C. Walsh approved the sale on June 27, 2025 (Docket No. 908). He held that the debtors had to comply with state law, rejecting the argument that section 363(b)(1) pre-empts it, but found that their privacy policies authorised or did not prohibit a sale with the business, subject to customers' right to opt out. Moving the data to a wholly owned NewCo was not a transfer to a third party under California's statute or to a person under the Kentucky, Tennessee, Texas and Utah statutes, and selling NewCo's shares needed no consent because those laws do not regulate a change of ownership. He rejected Texas's property-right argument, Utah's purpose-limitation argument, and the sub rosa plan, fraudulent-transfer and 28 U.S.C. § 959(b) arguments, and found NewCo and TTAM good-faith purchasers."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-9e340582d90d1cafc5af1857","record":{"id":"display-claim-9e340582d90d1cafc5af1857","kind":"analysis","text":"The court found that the $305 million price, including $302.5 million in cash, was nearly six times the opening bid, set by a process run by independent directors, and that even treating Wojcicki as an insider she would not benefit unfairly, because she was investing more than $300 million of her own funds and would own a non-profit; TTAM would remain subject to state genetic-privacy laws. It declined the ombudsman's recommended conditions, including separate consent from each customer, although the ombudsman had been unable to conclude that the sale would not violate state laws, shortened the stays to 10 days and summed up the transaction as Wojcicki's repurchase of a business she co-founded and ran, involving a sale of customer data only in a technical sense.","source_ids":["src-018"],"entity_ids":["holdco","ttam","wojcicki"],"premise_claim_ids":["c-sale-opinion-price","c-sale-opinion-cpo"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The court found that the $305 million price, including $302.5 million in cash, was nearly six times the opening bid, set by a process run by independent directors, and that even treating Wojcicki as an insider she would not benefit unfairly, because she was investing more than $300 million of her own funds and would own a non-profit; TTAM would remain subject to state genetic-privacy laws. It declined the ombudsman's recommended conditions, including separate consent from each customer, although the ombudsman had been unable to conclude that the sale would not violate state laws, shortened the stays to 10 days and summed up the transaction as Wojcicki's repurchase of a business she co-founded and ran, involving a sale of customer data only in a technical sense."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-dba297e1fc008be4b586377c","record":{"id":"display-claim-dba297e1fc008be4b586377c","kind":"analysis","text":"California and CAVEAT appealed on July 3, 2025; the bankruptcy court, the district court and, on July 11, the Eighth Circuit all refused a stay, California's emergency motion having sought to stop the transfer of the data and samples of about 1.8 million Californians; California withdrew its Eighth Circuit appeal on August 11, 2025, according to the disclosure statement. The sale closed at about 8:00 a.m. Eastern Time on July 14, 2025: substantially all assets went to 23andMe Research Institute, formerly TTAM, for $302.5 million in cash plus assumed liabilities, the debtors keeping Lemonaid. On September 29, 2026 Judge Cristian M. Stevens dismissed the district-court appeal for lack of appellate standing and as statutorily moot under section 363(m), the findings of good faith not being clearly erroneous.","source_ids":["src-012","src-085","src-040","src-017","src-049"],"entity_ids":["california","biodata-trust","holdco","ttam","lemonaid-health"],"premise_claim_ids":["c-sale-appeals-stay","c-sale-closing","c-sale-district-court"],"qualification":"","response":"","outcome":""},"reading":"Analysis: California and CAVEAT appealed on July 3, 2025; the bankruptcy court, the district court and, on July 11, the Eighth Circuit all refused a stay, California's emergency motion having sought to stop the transfer of the data and samples of about 1.8 million Californians; California withdrew its Eighth Circuit appeal on August 11, 2025, according to the disclosure statement. The sale closed at about 8:00 a.m. Eastern Time on July 14, 2025: substantially all assets went to 23andMe Research Institute, formerly TTAM, for $302.5 million in cash plus assumed liabilities, the debtors keeping Lemonaid. On September 29, 2026 Judge Cristian M. Stevens dismissed the district-court appeal for lack of appellate standing and as statutorily moot under section 363(m), the findings of good faith not being clearly erroneous."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-cf20b53e3030e01ecf6d17ee","record":{"id":"display-claim-cf20b53e3030e01ecf6d17ee","kind":"analysis","text":"On the buyer's side the case lists 23andMe Research Institute, TTAM 2.0, LLC, 23andMe Employees LLC, 23andMe Genomics LLC and 23andMe Research LLC, represented by the same firm as Wojcicki, ABeeC 2.0, her trust and her foundation; the ownership of the four LLCs is not stated in the record. A 2026 conference profile describes Wojcicki as the Institute's founder and chief executive, consistent with the court's finding that she created and leads it.","source_ids":["src-065","src-088","src-068"],"entity_ids":["ttam","ttam-2","ttam-employees","ttam-genomics","ttam-research-llc","wojcicki","abeec","aw-trust","aw-foundation","holdco"],"premise_claim_ids":["c-sale-buyer-entities","c-sale-wojcicki-ttam-ceo"],"qualification":"","response":"","outcome":""},"reading":"Analysis: On the buyer's side the case lists 23andMe Research Institute, TTAM 2.0, LLC, 23andMe Employees LLC, 23andMe Genomics LLC and 23andMe Research LLC, represented by the same firm as Wojcicki, ABeeC 2.0, her trust and her foundation; the ownership of the four LLCs is not stated in the record. A 2026 conference profile describes Wojcicki as the Institute's founder and chief executive, consistent with the court's finding that she created and leads it."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-4a4c0e9bcf0651d1f32ebc10","record":{"id":"display-claim-4a4c0e9bcf0651d1f32ebc10","kind":"analysis","text":"In November 2021 23andMe acquired Lemonaid Health, Inc., an online platform offering telemedicine, laboratory and pharmacy fulfilment in all 50 states and the District of Columbia, for $400 million in cash ($88.6 million) and Class A shares, under a merger agreement of October 21, 2021 with Fortis Advisors LLC representing Lemonaid's shareholders.","source_ids":["src-031","src-035","src-004"],"entity_ids":["holdco","lemonaid-health"],"premise_claim_ids":["c-lem-acquisition"],"qualification":"","response":"","outcome":""},"reading":"Analysis: In November 2021 23andMe acquired Lemonaid Health, Inc., an online platform offering telemedicine, laboratory and pharmacy fulfilment in all 50 states and the District of Columbia, for $400 million in cash ($88.6 million) and Class A shares, under a merger agreement of October 21, 2021 with Fortis Advisors LLC representing Lemonaid's shareholders."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-af3f3e125f3f6fcdb3241546","record":{"id":"display-claim-af3f3e125f3f6fcdb3241546","kind":"analysis","text":"The company disposed of its only foreign subsidiary, the UK company Lemonaid Health Limited, on August 1, 2023. The UK register shows the company (No. 12561320), now Boots Digital Health Limited, controlled from that date by Boots UK Limited, itself controlled by Alliance Boots Holdings Limited; it does not name the U.S. group as owner for June 2021 to July 2023, when the company stated that it had no registrable person. Its directors in the group's time were Ian Alexander Van Every, from April 17, 2020 to December 21, 2022 (also registered as a person with significant control from December 30, 2020 to June 4, 2021), and Joseph Selsavage, the group's chief financial officer, until August 1, 2023.","source_ids":["src-035","src-053","src-054","src-081","src-071"],"entity_ids":["holdco","lemonaid-uk","boots-uk","alliance-boots","van-every","selsavage"],"premise_claim_ids":["c-lem-uk-disposal","c-lem-uk-officers"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The company disposed of its only foreign subsidiary, the UK company Lemonaid Health Limited, on August 1, 2023. The UK register shows the company (No. 12561320), now Boots Digital Health Limited, controlled from that date by Boots UK Limited, itself controlled by Alliance Boots Holdings Limited; it does not name the U.S. group as owner for June 2021 to July 2023, when the company stated that it had no registrable person. Its directors in the group's time were Ian Alexander Van Every, from April 17, 2020 to December 21, 2022 (also registered as a person with significant control from December 30, 2020 to June 4, 2021), and Joseph Selsavage, the group's chief financial officer, until August 1, 2023."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-6c92eee09469d694209823f7","record":{"id":"display-claim-6c92eee09469d694209823f7","kind":"analysis","text":"A class action filed on June 30, 2023 in the Northern District of California, A.J., et al. v. Lemonaid Health Inc. and LMND Medical Group, Inc. (No. 3:23-cv-03288), on behalf of visitors to the Lemonaid website between June 30, 2019 and July 14, 2025, alleges damages and seeks injunctive relief over the use of tracking pixels on the site; LMND Medical Group is a non-debtor California professional corporation. These are the plaintiffs' allegations, and no court ruled on their merits. Under a settlement of September 16, 2025 the class has a claim allowed at $3.25 million against Lemonaid Health, Chrome Holding Co. and ChromeCo, capped at that amount in total; the plan treats it as Class 14, paid from a pixel settlement fund on final approval. The class voted to accept the plan, and the court preliminarily approved the settlement on October 2, 2025.","source_ids":["src-032","src-012","src-016","src-015"],"entity_ids":["lemonaid-health","lmnd-medical","holdco","inc"],"premise_claim_ids":["c-lem-pixel-suit","c-lem-pixel-settlement"],"qualification":"","response":"","outcome":""},"reading":"Analysis: A class action filed on June 30, 2023 in the Northern District of California, A.J., et al. v. Lemonaid Health Inc. and LMND Medical Group, Inc. (No. 3:23-cv-03288), on behalf of visitors to the Lemonaid website between June 30, 2019 and July 14, 2025, alleges damages and seeks injunctive relief over the use of tracking pixels on the site; LMND Medical Group is a non-debtor California professional corporation. These are the plaintiffs' allegations, and no court ruled on their merits. Under a settlement of September 16, 2025 the class has a claim allowed at $3.25 million against Lemonaid Health, Chrome Holding Co. and ChromeCo, capped at that amount in total; the plan treats it as Class 14, paid from a pixel settlement fund on final approval. The class voted to accept the plan, and the court preliminarily approved the settlement on October 2, 2025."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-fe44d5a0f89d20fd7c1931b6","record":{"id":"display-claim-fe44d5a0f89d20fd7c1931b6","kind":"analysis","text":"TTAM's purchase agreement obliged it to sponsor a plan to buy the reorganised Lemonaid equity for $2.5 million, subject to higher offers; after the TTAM sale closed the debtors marketed Lemonaid separately. On September 10, 2025 Chrome Holding Co., Lemonaid Health and Chrome Pharmacy Holdings agreed to sell all the shares of Lemonaid Health and Chrome Pharmacy Holdings to Lemonaid SPV, Inc., a Delaware corporation, for $10 million in cash plus cure payments, with Bambumeta Ventures guaranteeing the price and a $2.5 million deposit; closing required an effective plan and approval of the transfer of pharmacy licences.","source_ids":["src-012","src-017"],"entity_ids":["ttam","lemonaid-health","holdco","pharmacy-holdings","lemonaid-spv","bambumeta"],"premise_claim_ids":["c-lem-ttam-stalking-horse","c-lem-spv-agreement"],"qualification":"","response":"","outcome":""},"reading":"Analysis: TTAM's purchase agreement obliged it to sponsor a plan to buy the reorganised Lemonaid equity for $2.5 million, subject to higher offers; after the TTAM sale closed the debtors marketed Lemonaid separately. On September 10, 2025 Chrome Holding Co., Lemonaid Health and Chrome Pharmacy Holdings agreed to sell all the shares of Lemonaid Health and Chrome Pharmacy Holdings to Lemonaid SPV, Inc., a Delaware corporation, for $10 million in cash plus cure payments, with Bambumeta Ventures guaranteeing the price and a $2.5 million deposit; closing required an effective plan and approval of the transfer of pharmacy licences."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-ea0d321349aa047b807a6919","record":{"id":"display-claim-ea0d321349aa047b807a6919","kind":"analysis","text":"The September 16, 2025 press release announcing the agreement says the SPV was formed with Innova Capital Partners, with BambuMeta Ventures as lead sponsor and guarantor, eGateway Capital as a lead sponsor and other investors in support, and that Bambu's general partners Richard Hearn and Kyle Pretsch would lead it; the SPV's ownership is not documented in a register. In an October 2025 interview Pretsch, the SPV's chief operating officer, said it had its own capital table, with Bambu as guarantor; the report compared the price of about $10 million with the $400 million paid in 2021.","source_ids":["src-063","src-033"],"entity_ids":["lemonaid-spv","bambumeta","innova","egateway","broadview","auctus","day-break","hearn","pretsch","runne","lemonaid-health"],"premise_claim_ids":["c-lem-spv-investors","c-lem-buyer-interview"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The September 16, 2025 press release announcing the agreement says the SPV was formed with Innova Capital Partners, with BambuMeta Ventures as lead sponsor and guarantor, eGateway Capital as a lead sponsor and other investors in support, and that Bambu's general partners Richard Hearn and Kyle Pretsch would lead it; the SPV's ownership is not documented in a register. In an October 2025 interview Pretsch, the SPV's chief operating officer, said it had its own capital table, with Bambu as guarantor; the report compared the price of about $10 million with the $400 million paid in 2021."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-97522f9b175961eda35c63d4","record":{"id":"display-claim-97522f9b175961eda35c63d4","kind":"analysis","text":"The confirmation order of December 1, 2025 approved the sale: after the Lemonaid debtors' discharge their interests vest in the buyer free and clear, and the buyer is a good-faith purchaser. A bankruptcy-data publisher reports that it closed on December 5, 2025, bringing the debtors' asset sales to about $312.5 million; the closing notice was not retrieved.","source_ids":["src-016","src-050"],"entity_ids":["lemonaid-spv","lemonaid-health","holdco","bambumeta"],"premise_claim_ids":["c-lem-sale-approved","c-lem-closing"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The confirmation order of December 1, 2025 approved the sale: after the Lemonaid debtors' discharge their interests vest in the buyer free and clear, and the buyer is a good-faith purchaser. A bankruptcy-data publisher reports that it closed on December 5, 2025, bringing the debtors' asset sales to about $312.5 million; the closing notice was not retrieved."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-8b48445e86a064953ec11559","record":{"id":"display-claim-8b48445e86a064953ec11559","kind":"analysis","text":"Company filings describe Wojcicki's earlier work as a healthcare analyst at Passport Capital (2004–2006), Andor Capital Management (2001–2002), Ardsley Partners (1999–2000) and Investor AB (1996–1999), and list her as a board member of Zipline and the Kaiser Permanente Bernard J. Tyson School of Medicine, co-founder and board member of the Breakthrough Prize in Life Sciences, a board member of the Foundation for the National Institutes of Health from 2008 to 2016, a director of the blank check company AJAX I from 2020 to 2021 and of Cazoo Group Ltd. until 2022 (an aggregator dates the end of the Cazoo seat to February 27, 2023). Zipline announced in September 2021 that she had joined its board, as carried by a trade publication. A financial-data aggregator lists further boards, mixing current and former seats, and Sidecar Health lists her on its board of advisors, which is not a board of directors. The SEC's record shows AJAX I as a Cayman Islands company with no listed securities.","source_ids":["src-057","src-030","src-060","src-061","src-082"],"entity_ids":["wojcicki","passport","andor","ardsley","investor-ab","zipline","kp-school","breakthrough-prize","fnih","ajax","cazoo","blok24","sidecar","holdco","inc"],"premise_claim_ids":["c-gov-wojcicki-background","c-ppl-wojcicki-zipline","c-ppl-wojcicki-boards","c-ppl-ajax"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Company filings describe Wojcicki's earlier work as a healthcare analyst at Passport Capital (2004–2006), Andor Capital Management (2001–2002), Ardsley Partners (1999–2000) and Investor AB (1996–1999), and list her as a board member of Zipline and the Kaiser Permanente Bernard J. Tyson School of Medicine, co-founder and board member of the Breakthrough Prize in Life Sciences, a board member of the Foundation for the National Institutes of Health from 2008 to 2016, a director of the blank check company AJAX I from 2020 to 2021 and of Cazoo Group Ltd. until 2022 (an aggregator dates the end of the Cazoo seat to February 27, 2023). Zipline announced in September 2021 that she had joined its board, as carried by a trade publication. A financial-data aggregator lists further boards, mixing current and former seats, and Sidecar Health lists her on its board of advisors, which is not a board of directors. The SEC's record shows AJAX I as a Cayman Islands company with no listed securities."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-0d684820d846c54490d87791","record":{"id":"display-claim-0d684820d846c54490d87791","kind":"analysis","text":"The Anne Wojcicki Foundation, a private grant-making foundation in Los Altos with a 501(c)(3) exemption since February 2015, reports total assets of $593,310,267 for 2024 in its Form 990-PF, as reproduced by a nonprofit-data service, with Anne Wojcicki as unpaid President and Chair and Susan Wojcicki as Treasurer and Secretary. The Troper Wojcicki Foundation of San Francisco, the counterparty of the January 2024 research agreement, reports $339,320,002 of assets, with Susan Wojcicki as its unpaid President until September 2024.","source_ids":["src-037","src-086","src-057"],"entity_ids":["aw-foundation","wojcicki","susan-wojcicki","twf","holdco"],"premise_claim_ids":["c-ppl-awf","c-ppl-twf","c-gov-twf"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The Anne Wojcicki Foundation, a private grant-making foundation in Los Altos with a 501(c)(3) exemption since February 2015, reports total assets of $593,310,267 for 2024 in its Form 990-PF, as reproduced by a nonprofit-data service, with Anne Wojcicki as unpaid President and Chair and Susan Wojcicki as Treasurer and Secretary. The Troper Wojcicki Foundation of San Francisco, the counterparty of the January 2024 research agreement, reports $339,320,002 of assets, with Susan Wojcicki as its unpaid President until September 2024."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-8adcb6a2b55ebfa543bcedee","record":{"id":"display-claim-8adcb6a2b55ebfa543bcedee","kind":"analysis","text":"A financial-data aggregator describes Paul Cusenza as chairman and chief executive of Nodal Exchange since 2008 and earlier an executive of Perlegen Sciences, with no position in the holding company. The Human Immunome Project's board page, the organisation's own biography, describes Linda Avey as a founding general partner of Humain Ventures in Austin, a co-founder of Precisely, Inc. and formerly the founding independent board director of Rock Health.","source_ids":["src-103","src-104"],"entity_ids":["cusenza","inc","nodal-exchange","nodal-holdings","nodal-clear","perlegen","avey","humain","precisely","rock-health"],"premise_claim_ids":["c-ppl-cusenza","c-ppl-avey"],"qualification":"","response":"","outcome":""},"reading":"Analysis: A financial-data aggregator describes Paul Cusenza as chairman and chief executive of Nodal Exchange since 2008 and earlier an executive of Perlegen Sciences, with no position in the holding company. The Human Immunome Project's board page, the organisation's own biography, describes Linda Avey as a founding general partner of Humain Ventures in Austin, a co-founder of Precisely, Inc. and formerly the founding independent board director of Rock Health."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-242f113ce1444ac80214d6ce","record":{"id":"display-claim-242f113ce1444ac80214d6ce","kind":"analysis","text":"Roelof Botha joined the 23andMe, Inc. board in 2017 and was at Sequoia Capital from 2003, a Managing Member of Sequoia Capital Operations from 2007; according to a market-data summary, SpaceX's board elected him an independent director and audit committee member effective June 16, 2026 (an aggregator gives June 15). Patrick Chung joined the 23andMe, Inc. board in 2009 and was Managing General Partner of Xfund from 2015 according to the proxy (an aggregator says 2012); in 2019 he signed Xfund 3's Form D. Richard Scheller was 23andMe's chief scientific officer and head of therapeutics from 2015 to 2019 and chairman of R&D of BridgeBio Pharma; GV's website, which still lists him as a 23andMe director, names his other boards, and he was executive vice president of research and early development at Genentech from 2001 to 2014.","source_ids":["src-004","src-089","src-111","src-096","src-069","src-066","src-098"],"entity_ids":["botha","inc","holdco","sequoia-ops","spacex","mongodb","block","unity","natera","chung","xfund","philo","wrld3d","xfund-3","scheller","bridgebio","alector","maze","dice","aarvik","genentech","oric"],"premise_claim_ids":["c-gov-botha","c-ppl-botha-spacex","c-gov-chung","c-ppl-chung-roles","c-gov-scheller","c-ppl-scheller-roles"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Roelof Botha joined the 23andMe, Inc. board in 2017 and was at Sequoia Capital from 2003, a Managing Member of Sequoia Capital Operations from 2007; according to a market-data summary, SpaceX's board elected him an independent director and audit committee member effective June 16, 2026 (an aggregator gives June 15). Patrick Chung joined the 23andMe, Inc. board in 2009 and was Managing General Partner of Xfund from 2015 according to the proxy (an aggregator says 2012); in 2019 he signed Xfund 3's Form D. Richard Scheller was 23andMe's chief scientific officer and head of therapeutics from 2015 to 2019 and chairman of R&D of BridgeBio Pharma; GV's website, which still lists him as a 23andMe director, names his other boards, and he was executive vice president of research and early development at Genentech from 2001 to 2014."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-a287c83868b441bfbcdd9dda","record":{"id":"display-claim-a287c83868b441bfbcdd9dda","kind":"analysis","text":"Neal Mohan joined the 23andMe, Inc. board in 2017 and is chief executive of YouTube; an aggregator lists him as a Starbucks director from 2024. Sandra Hernández, appointed in November 2021, has been president and chief executive of the California Health Care Foundation since 2014; the foundation announced in 2018 that Governor Jerry Brown had appointed her to the board of Covered California. Valerie Montgomery Rice, appointed in June 2021, is the sixth president and dean of Morehouse School of Medicine and the first woman to lead it; her inauguration biography describes her as founder of a women's health research centre at Meharry Medical College, and an insider-filings aggregator shows her as a UnitedHealth Group director. An aggregator lists Peter J. Taylor, the former audit committee chair, as chairman of Southern California Edison and Edison International since 2022.","source_ids":["src-004","src-097","src-067","src-101","src-070","src-095"],"entity_ids":["mohan","inc","holdco","youtube","starbucks","stitch-fix","hernandez","chcf","covered-california","blackbaud","first-republic","montgomery-rice","morehouse","meharry","unitedhealth","taylor","sce","edison-intl","pacific-mutual","ecmc"],"premise_claim_ids":["c-gov-mohan","c-ppl-mohan-roles","c-gov-hernandez","c-ppl-hernandez-roles","c-gov-montgomery-rice","c-ppl-montgomery-rice-roles","c-ppl-taylor-roles"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Neal Mohan joined the 23andMe, Inc. board in 2017 and is chief executive of YouTube; an aggregator lists him as a Starbucks director from 2024. Sandra Hernández, appointed in November 2021, has been president and chief executive of the California Health Care Foundation since 2014; the foundation announced in 2018 that Governor Jerry Brown had appointed her to the board of Covered California. Valerie Montgomery Rice, appointed in June 2021, is the sixth president and dean of Morehouse School of Medicine and the first woman to lead it; her inauguration biography describes her as founder of a women's health research centre at Meharry Medical College, and an insider-filings aggregator shows her as a UnitedHealth Group director. An aggregator lists Peter J. Taylor, the former audit committee chair, as chairman of Southern California Edison and Edison International since 2022."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-ce62a8b20532876433c03fb4","record":{"id":"display-claim-ce62a8b20532876433c03fb4","kind":"analysis","text":"Mark Jensen retired in 2012 from Deloitte & Touche, where he led audit and enterprise risk services in technology and the venture capital services group, and was earlier chief financial officer of Redleaf Group and Managing Partner of Arthur Andersen's Silicon Valley office; Lattice Semiconductor's 2026 proxy says he has been its director since June 2013 and a Wolfspeed director since May 2025, and sat on the Chrome Holding board from October 2024 to December 2025.","source_ids":["src-023","src-062"],"entity_ids":["jensen","deloitte-touche","redleaf","arthur-andersen","lattice","wolfspeed","holdco","exabeam","unwired-planet","control4","forescout"],"premise_claim_ids":["c-gov-jensen","c-gov-jensen-lattice"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Mark Jensen retired in 2012 from Deloitte & Touche, where he led audit and enterprise risk services in technology and the venture capital services group, and was earlier chief financial officer of Redleaf Group and Managing Partner of Arthur Andersen's Silicon Valley office; Lattice Semiconductor's 2026 proxy says he has been its director since June 2013 and a Wolfspeed director since May 2025, and sat on the Chrome Holding board from October 2024 to December 2025."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-9d5e847a8a4782bf939e0fd8","record":{"id":"display-claim-9d5e847a8a4782bf939e0fd8","kind":"analysis","text":"Andre Fernandez was chief financial officer of WeWork from 2022 to 2023 (WeWork filed for Chapter 11 in November 2023, five months after he left), of NCR from 2018 to 2020 and chief executive of CBS Radio from 2015 to 2017, and in 2025 was a director of Cardlytics; an aggregator still shows his Chrome Holding seat as active although the board was dissolved. Jim Frankola was chief financial officer of Cloudera from 2012 to 2021, of Yodlee and earlier of Ariba, and a director of Ansys and Skillsoft; IonQ appointed him to its board in August 2025, and an aggregator ends his Ansys seat on July 16, 2025, the month Ansys deregistered its securities.","source_ids":["src-057","src-023","src-093","src-108","src-106","src-105","src-109","src-094"],"entity_ids":["fernandez","wework","ncr","cbs-radio","domain-americas","cardlytics","blackstone-bis","faze","sachem","froedtert","holdco","frankola","cloudera","yodlee","ariba","ansys","skillsoft","ionq"],"premise_claim_ids":["c-gov-fernandez","c-ppl-fernandez-roles","c-gov-frankola","c-ppl-frankola-roles"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Andre Fernandez was chief financial officer of WeWork from 2022 to 2023 (WeWork filed for Chapter 11 in November 2023, five months after he left), of NCR from 2018 to 2020 and chief executive of CBS Radio from 2015 to 2017, and in 2025 was a director of Cardlytics; an aggregator still shows his Chrome Holding seat as active although the board was dissolved. Jim Frankola was chief financial officer of Cloudera from 2012 to 2021, of Yodlee and earlier of Ariba, and a director of Ansys and Skillsoft; IonQ appointed him to its board in August 2025, and an aggregator ends his Ansys seat on July 16, 2025, the month Ansys deregistered its securities."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-53cfbebb538d7462a44f06ea","record":{"id":"display-claim-53cfbebb538d7462a44f06ea","kind":"analysis","text":"Joseph Selsavage was chief financial and accounting officer from August 2022, interim chief executive from March 2025 and signed the December 4, 2025 Form 8-K as chief executive; he was earlier chief financial officer of Lemonaid Health from 2020 (an aggregator also calls him its chief executive and ends those posts in 2025), of Metromile and of Hotwire.com. Kathy L. Hibbs, General Counsel of 23andMe in a 2019 directory and later Chief Administrative Officer, is described by an insider-filings aggregator as a director of Sophia Genetics. Matthew Kvarda, the chief restructuring officer, is a Managing Director of Alvarez & Marsal, which was paid $1,300 an hour for his service with a $750,000 incentive on a plan or sale; he had been interim chief financial officer of Revlon, TEAM and Jacuzzi Brands.","source_ids":["src-057","src-008","src-015","src-110","src-100","src-026"],"entity_ids":["selsavage","holdco","lemonaid-health","red-eclipse","metromile","hotwire","hibbs","inc","sophia","genomic-health","kvarda","alvarez-marsal","revlon","team-inc","jacuzzi"],"premise_claim_ids":["c-gov-selsavage","c-gov-selsavage-titles","c-gov-hibbs-gc","c-ppl-hibbs-roles","c-gov-kvarda"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Joseph Selsavage was chief financial and accounting officer from August 2022, interim chief executive from March 2025 and signed the December 4, 2025 Form 8-K as chief executive; he was earlier chief financial officer of Lemonaid Health from 2020 (an aggregator also calls him its chief executive and ends those posts in 2025), of Metromile and of Hotwire.com. Kathy L. Hibbs, General Counsel of 23andMe in a 2019 directory and later Chief Administrative Officer, is described by an insider-filings aggregator as a director of Sophia Genetics. Matthew Kvarda, the chief restructuring officer, is a Managing Director of Alvarez & Marsal, which was paid $1,300 an hour for his service with a $750,000 incentive on a plan or sale; he had been interim chief financial officer of Revlon, TEAM and Jacuzzi Brands."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-8a4cda094baafd75909ef287","record":{"id":"display-claim-8a4cda094baafd75909ef287","kind":"analysis","text":"Thomas Walper is a bankruptcy and restructuring lawyer, a partner of Munger, Tolles & Olson until 2025 and earlier head of corporate restructuring at Plainfield Asset Management; his Form 3 shows him as a director from March 23, 2025 with no securities. The State Bar of California lists Thomas Bradley Walper as an active attorney admitted on December 16, 1980, with no disciplinary actions, matched to him by name, practice and the year of his law degree. On July 20, 2026 Getty Images Holdings appointed him a Class I director, and in July 2026 the Plan Administration Trust filed his declaration supporting the states' stipulation.","source_ids":["src-057","src-092","src-025","src-090","src-091","src-019"],"entity_ids":["walper","munger","plainfield","holdco","getty","plan-trust"],"premise_claim_ids":["c-gov-walper","c-ppl-walper-bar","c-gov-walper-getty","c-ppl-walper-declaration"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Thomas Walper is a bankruptcy and restructuring lawyer, a partner of Munger, Tolles & Olson until 2025 and earlier head of corporate restructuring at Plainfield Asset Management; his Form 3 shows him as a director from March 23, 2025 with no securities. The State Bar of California lists Thomas Bradley Walper as an active attorney admitted on December 16, 1980, with no disciplinary actions, matched to him by name, practice and the year of his law degree. On July 20, 2026 Getty Images Holdings appointed him a Class I director, and in July 2026 the Plan Administration Trust filed his declaration supporting the states' stipulation."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-7be0e6dc1fcf753799736b72","record":{"id":"display-claim-7be0e6dc1fcf753799736b72","kind":"analysis","text":"Wojcicki joined the board of 23andMe, Inc. and co-founded it in 2006 and was its chief executive from 2010; she became chair of the holding company effective June 16, 2021 and in July 2024 was its chair and chief executive. On March 21, 2025, by agreement with the Special Committee, she resigned as chief executive and president from March 23 and as chair, remaining a director, and left her posts at the subsidiaries. Her fiscal-2024 compensation was $7,363,723, almost all stock options. Company filings list her earlier work as a healthcare analyst and her other boards, including Zipline and, until 2022, Cazoo, whose seat an aggregator ends on February 27, 2023.","source_ids":["src-004","src-057","src-007","src-002","src-012","src-031","src-030"],"entity_ids":["wojcicki","inc","holdco","lemonaid-health","pharmacy-holdings","lemonaid-pharmacy-holdings","passport","andor","ardsley","investor-ab","zipline","kp-school","breakthrough-prize","fnih","ajax","cazoo"],"premise_claim_ids":["c-gov-wojcicki-roles","c-gov-ceo-resignation","c-gov-wojcicki-pay","c-gov-wojcicki-background"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Wojcicki joined the board of 23andMe, Inc. and co-founded it in 2006 and was its chief executive from 2010; she became chair of the holding company effective June 16, 2021 and in July 2024 was its chair and chief executive. On March 21, 2025, by agreement with the Special Committee, she resigned as chief executive and president from March 23 and as chair, remaining a director, and left her posts at the subsidiaries. Her fiscal-2024 compensation was $7,363,723, almost all stock options. Company filings list her earlier work as a healthcare analyst and her other boards, including Zipline and, until 2022, Cazoo, whose seat an aggregator ends on February 27, 2023."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-dedd97f6b0697194116fecf2","record":{"id":"display-claim-dedd97f6b0697194116fecf2","kind":"analysis","text":"Through ABeeC 2.0, LLC, of which her revocable trust is the sole member and she the sole trustee, Wojcicki held 30.67% of the vote after the 2021 merger and 49.75% on July 1, 2024, before the 1-for-20 reverse split. In June 2025 ABeeC converted its Class B shares, and on July 1, 2025 she held 22.56% of the Class A stock and 12.33% of the vote. Co-founder Linda Avey wrote in March 2025 that Wojcicki had \"architected a majority vote for herself\"; that is Avey's personal account, and the company did not immediately respond to the outlet that reported it.","source_ids":["src-007","src-004","src-057","src-112"],"entity_ids":["wojcicki","abeec","holdco","glaxo-group","g-squared","fmr","aw-trust","aw-foundation","zentree","farallon","avey","inc"],"premise_claim_ids":["c-ctl-2021","c-ctl-2024-wojcicki","c-ctl-2025-july","c-ctl-avey"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Through ABeeC 2.0, LLC, of which her revocable trust is the sole member and she the sole trustee, Wojcicki held 30.67% of the vote after the 2021 merger and 49.75% on July 1, 2024, before the 1-for-20 reverse split. In June 2025 ABeeC converted its Class B shares, and on July 1, 2025 she held 22.56% of the Class A stock and 12.33% of the vote. Co-founder Linda Avey wrote in March 2025 that Wojcicki had \"architected a majority vote for herself\"; that is Avey's personal account, and the company did not immediately respond to the outlet that reported it."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-82fb58bab25349c4a7bc6a88","record":{"id":"display-claim-82fb58bab25349c4a7bc6a88","kind":"analysis","text":"In April 2024 she said she was considering taking the company private and would not support an alternative transaction; the Special Committee rejected her $0.40-a-share proposal of July 29, 2024 ($8.00 after the reverse split) as offering no premium and lacking financing. After the independent directors resigned in September 2024 she was briefly the sole director. In 2025 her joint $2.53 proposal with New Mountain Capital lapsed when New Mountain withdrew, and the committee rejected her offers of $0.41 a share, the last with contingent value rights.","source_ids":["src-031","src-012","src-010"],"entity_ids":["wojcicki","holdco","new-mountain"],"premise_claim_ids":["c-gov-go-private-2024","c-gov-sole-director","c-gov-feb-march-2025","c-gov-march-2025-final"],"qualification":"","response":"","outcome":""},"reading":"Analysis: In April 2024 she said she was considering taking the company private and would not support an alternative transaction; the Special Committee rejected her $0.40-a-share proposal of July 29, 2024 ($8.00 after the reverse split) as offering no premium and lacking financing. After the independent directors resigned in September 2024 she was briefly the sole director. In 2025 her joint $2.53 proposal with New Mountain Capital lapsed when New Mountain withdrew, and the committee rejected her offers of $0.41 a share, the last with contingent value rights."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-f0129b55b0ac975431335a9e","record":{"id":"display-claim-f0129b55b0ac975431335a9e","kind":"analysis","text":"The court found that she created TTAM Research Institute soon after the filing to buy the assets, a non-profit public-benefit corporation fully funded by her and her affiliates, of which she is chief executive, president and one of three directors. Approving the sale, it found that even treating her as an insider she would not benefit unfairly because she was investing more than $300 million of her own funds and would own a non-profit, and it described the deal as her repurchase of a business she co-founded and ran. A 2026 conference profile calls her the Institute's founder and chief executive.","source_ids":["src-018","src-068"],"entity_ids":["wojcicki","ttam","holdco"],"premise_claim_ids":["c-sale-ttam-origin","c-sale-opinion-price","c-sale-opinion-cpo","c-sale-wojcicki-ttam-ceo"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The court found that she created TTAM Research Institute soon after the filing to buy the assets, a non-profit public-benefit corporation fully funded by her and her affiliates, of which she is chief executive, president and one of three directors. Approving the sale, it found that even treating her as an insider she would not benefit unfairly because she was investing more than $300 million of her own funds and would own a non-profit, and it described the deal as her repurchase of a business she co-founded and ran. A 2026 conference profile calls her the Institute's founder and chief executive."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-c69c2b409e69aa6feccfd558","record":{"id":"display-claim-c69c2b409e69aa6feccfd558","kind":"analysis","text":"The plan names her as an Excluded Party, not released and open to suit by the trust, and states that she is not an affiliate of the debtors; exclusion is not a finding of liability. The confirmation order treats her, her foundation and ABeeC as having opted out of the releases while preserving their indemnification and exculpation rights. On January 3, 2026 she applied for payment of her unliquidated indemnification expenses as an administrative expense; the record does not show the ruling.","source_ids":["src-016","src-045","src-051"],"entity_ids":["wojcicki","holdco","aw-foundation","abeec","ttam","plan-trust"],"premise_claim_ids":["c-ch-excluded-parties","c-ch-wojcicki-resolution","c-ch-wojcicki-application"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The plan names her as an Excluded Party, not released and open to suit by the trust, and states that she is not an affiliate of the debtors; exclusion is not a finding of liability. The confirmation order treats her, her foundation and ABeeC as having opted out of the releases while preserving their indemnification and exculpation rights. On January 3, 2026 she applied for payment of her unliquidated indemnification expenses as an administrative expense; the record does not show the ruling."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-11c6a7c364711fc8d49531ed","record":{"id":"display-claim-11c6a7c364711fc8d49531ed","kind":"analysis","text":"The court found that Wojcicki created TTAM soon after the Chapter 11 filing to buy the debtors' assets; it is a non-profit public-benefit corporation fully funded by her and her affiliates, with her as chief executive, president and one of three directors. It was named backup bidder when Regeneron won the auction in May 2025, then raised its offer to $305 million and was chosen on June 13, 2025, agreeing to buy substantially all the Chrome debtors' assets for $302.5 million and to sponsor a $2.5 million plan for Lemonaid, which was later sold to another buyer.","source_ids":["src-018","src-012","src-035","src-005","src-017"],"entity_ids":["wojcicki","ttam","holdco","regeneron","lemonaid-health","pharmacy-holdings","lemonaid-spv","bambumeta"],"premise_claim_ids":["c-sale-ttam-origin","c-sale-regeneron","c-sale-ttam-wins","c-lem-ttam-stalking-horse","c-lem-spv-agreement"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The court found that Wojcicki created TTAM soon after the Chapter 11 filing to buy the debtors' assets; it is a non-profit public-benefit corporation fully funded by her and her affiliates, with her as chief executive, president and one of three directors. It was named backup bidder when Regeneron won the auction in May 2025, then raised its offer to $305 million and was chosen on June 13, 2025, agreeing to buy substantially all the Chrome debtors' assets for $302.5 million and to sponsor a $2.5 million plan for Lemonaid, which was later sold to another buyer."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-6492f53e008c5d56dcda455a","record":{"id":"display-claim-6492f53e008c5d56dcda455a","kind":"analysis","text":"The debtors sold it the shares of NewCo, a subsidiary holding the business, so that no data passed directly. TTAM undertook to keep operations, staff, data access and the petition-date privacy policy, including deletion and opt-out rights, to follow privacy laws even where its non-profit status might excuse it, not to share data with insurers and to form an independent privacy advisory board. The court approved the sale on June 27, 2025, finding the price fair and TTAM a good-faith purchaser and adding that it would remain subject to state genetic-privacy laws; it closed on July 14, 2025, and the debtors stopped using the 23andMe name.","source_ids":["src-012","src-049","src-018","src-040","src-017"],"entity_ids":["holdco","ttam","wojcicki","lemonaid-health","inc","pharmacy-holdings"],"premise_claim_ids":["c-sale-newco","c-sale-ttam-terms","c-sale-opinion-price","c-sale-closing","c-id-trademark-names"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The debtors sold it the shares of NewCo, a subsidiary holding the business, so that no data passed directly. TTAM undertook to keep operations, staff, data access and the petition-date privacy policy, including deletion and opt-out rights, to follow privacy laws even where its non-profit status might excuse it, not to share data with insurers and to form an independent privacy advisory board. The court approved the sale on June 27, 2025, finding the price fair and TTAM a good-faith purchaser and adding that it would remain subject to state genetic-privacy laws; it closed on July 14, 2025, and the debtors stopped using the 23andMe name."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"claims","id":"display-claim-7fa6d4a7c8cc214c644e56fc","record":{"id":"display-claim-7fa6d4a7c8cc214c644e56fc","kind":"analysis","text":"The states' stipulation of July 2026 expressly excludes the Institute from its release, and the states noted that it had accepted strengthened protections, an advisory board and deletion rights. In January 2026 it applied for administrative payments under the purchase agreement, according to a case summary; the trust argued that it had assumed the Converge invoices, it replied disputing any preclusive effect, and on March 4, 2026 the trust settled with Converge for $6.11 million while keeping a right to seek reimbursement from it. California's appeal against the sale order was dismissed on September 29, 2026, the court finding no clear error in the finding that TTAM bought in good faith. Its group includes TTAM 2.0, LLC and three other LLCs represented by the same firm as Wojcicki.","source_ids":["src-019","src-107","src-044","src-050","src-049","src-065","src-088"],"entity_ids":["holdco","ttam","plan-trust","wojcicki","converge","california","biodata-trust","ttam-2","ttam-employees","ttam-genomics","ttam-research-llc","abeec","aw-trust","aw-foundation"],"premise_claim_ids":["c-st-states-release","c-st-states-findings","c-ch-admin-claims-2026","c-ch-converge-settlement","c-sale-district-court","c-sale-buyer-entities"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The states' stipulation of July 2026 expressly excludes the Institute from its release, and the states noted that it had accepted strengthened protections, an advisory board and deletion rights. In January 2026 it applied for administrative payments under the purchase agreement, according to a case summary; the trust argued that it had assumed the Converge invoices, it replied disputing any preclusive effect, and on March 4, 2026 the trust settled with Converge for $6.11 million while keeping a right to seek reimbursement from it. California's appeal against the sale order was dismissed on September 29, 2026, the court finding no clear error in the finding that TTAM bought in good faith. Its group includes TTAM 2.0, LLC and three other LLCs represented by the same firm as Wojcicki."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"holdco","record":{"id":"holdco","name":"Chrome Holding Co. (formerly 23andMe Holding Co.)","type":"organization","group":"subject","claim_ids":["c-id-edgar","c-id-former-names","c-id-rename","c-id-trademark-names","c-id-addresses","c-id-listing","c-id-delisting","c-id-15-12g","c-id-gleif","c-id-gleif-search","c-id-agg-holdco","c-id-agg-inc","c-id-agg-pharmacy","c-spac-blank-check","c-spac-sponsor-chain","c-spac-13g","c-spac-officers","c-spac-bayliss","c-spac-lovell","c-spac-briggs","c-spac-lockhart","c-spac-brown","c-spac-announcement","c-spac-vote","c-spac-board-elect","c-spac-closing","c-spac-same-registrant","c-spac-pipe","c-spac-proceeds","c-ctl-dual-class","c-ctl-2021","c-ctl-2024-wojcicki","c-ctl-2024-holders","c-ctl-13d-filings","c-ctl-2025-early","c-ctl-awf-holding","c-ctl-conversion","c-ctl-2025-july","c-ctl-zentree-13g","c-ctl-zentree-13d","c-ctl-farallon","c-gov-wojcicki-roles","c-gov-wojcicki-pay","c-gov-board-2021","c-gov-lovell-end","c-gov-board-2024","c-gov-botha","c-gov-chung","c-gov-scheller","c-gov-mohan","c-gov-hernandez","c-gov-montgomery-rice","c-gov-officers-2024","c-gov-officer-pay","c-gov-related-party","c-gov-twf","c-gov-special-committee","c-gov-go-private-2024","c-gov-resignations","c-gov-sole-director","c-gov-new-board","c-gov-jensen-lattice","c-gov-frankola","c-gov-strategic-review","c-gov-feb-march-2025","c-gov-march-2025-final","c-gov-restructuring-authority","c-gov-ceo-resignation","c-gov-march-2025-appointments","c-gov-investigation","c-gov-guidelines","c-gov-board-2025","c-gov-walper","c-gov-walper-getty","c-gov-selsavage","c-gov-selsavage-titles","c-gov-kvarda","c-br-company-account","c-br-senate","c-br-ico-penalty","c-br-ico-amount","c-br-regulatory-inquiries","c-br-postpetition-regulators","c-br-ca-allegations","c-br-ca-ransom","c-br-ca-warnings","c-st-litigation-scale","c-st-mdl","c-st-march-2025","c-st-class-agreements","c-st-prelim-approvals","c-st-arbitration","c-st-us-final","c-st-news-july-2026","c-st-canada-suits","c-st-canada-stay","c-st-ccaa","c-st-canada-settlement","c-st-cyber-insurers","c-st-states-claims","c-st-states-allocation","c-st-states-release","c-st-states-findings","c-st-ca-admin-claim","c-st-ca-suit","c-st-ca-enforcement-order","c-st-ca-appeal-2026","c-ch-finances","c-ch-revenue-fy25","c-ch-balance-sheet","c-ch-kpmg-fees","c-ch-cutbacks","c-ch-causes","c-ch-nol","c-ch-filing","c-ch-debtor-structure","c-ch-related-cases","c-ch-tax-ids","c-ch-dip","c-ch-letters-of-credit","c-ch-advisers","c-ch-creditors-committee","c-ch-equity-committee","c-ch-bar-dates","c-ch-creditors-list","c-ch-plan-august","c-ch-ds-order","c-ch-landlord-opinion","c-ch-confirmation","c-ch-plan-trust","c-ch-shares-cancelled","c-ch-board-dissolved","c-ch-plan-administrator","c-ch-excluded-parties","c-ch-wojcicki-resolution","c-ch-third-plan-buyer","c-ch-converge-reserve","c-ch-case-closing","c-ch-cash-fees","c-ch-admin-claims-2026","c-ch-wojcicki-application","c-ch-pro-se-adversary","c-ch-converge-settlement","c-ch-adversaries","c-ch-hearing-calendar","c-ch-docket-oct-2026","c-sale-customer-data","c-sale-data-categories","c-sale-privacy-history","c-sale-ftc-letter","c-sale-regulators-letter","c-sale-cpo","c-sale-senate-safeguards","c-sale-bidding-procedures","c-sale-regeneron","c-sale-ttam-origin","c-sale-ttam-wins","c-sale-newco","c-sale-ttam-terms","c-sale-states-objection","c-sale-states-suits","c-sale-biodata-trust","c-sale-opinion","c-sale-opinion-newco","c-sale-opinion-price","c-sale-opinion-cpo","c-sale-pa-ag","c-sale-appeals-stay","c-sale-closing","c-sale-district-court","c-sale-buyer-entities","c-lem-acquisition","c-lem-uk-disposal","c-lem-pixel-settlement","c-lem-ttam-stalking-horse","c-lem-spv-agreement","c-lem-sale-approved","c-lem-closing","c-ppl-wojcicki-boards","c-ppl-montgomery-rice-roles","c-ppl-chung-roles","c-ppl-fernandez-roles","c-ppl-frankola-roles","c-ppl-hibbs-roles","c-ppl-walper-declaration"],"badges":[{"label":"Chapter 11 filing (March 2025); liquidating plan effective December 5, 2025","claim_ids":["c-ch-filing"],"code":"A1","category":"FINANCIAL_DISTRESS","subject_id":"holdco"},{"label":"FTC demand, multistate and foreign regulators' inquiries into the 2023 breach (2024)","claim_ids":["c-br-regulatory-inquiries"],"code":"A4","category":"REGULATORY_ACTION","subject_id":"holdco"},{"label":"U.S. data-breach class actions, centralised and settled (2023–2026)","claim_ids":["c-st-litigation-scale","c-st-mdl"],"code":"A5","category":"CIVIL_LITIGATION","subject_id":"holdco"},{"label":"Canadian data-breach class actions (2023–2024; settled 2025)","claim_ids":["c-st-canada-suits"],"code":"A6","category":"CIVIL_LITIGATION","subject_id":"holdco"},{"label":"Proofs of claim of 42 state and D.C. governmental claimants settled for $18 million with conduct limits (2026)","claim_ids":["c-st-states-claims"],"code":"A7","category":"ENFORCEMENT","subject_id":"holdco"},{"label":"California Attorney General suit over the 2023 breach (2026; monetary claims barred by the plan injunction)","claim_ids":["c-st-ca-suit","c-st-ca-enforcement-order"],"code":"A8","category":"ENFORCEMENT","subject_id":"holdco"},{"label":"States' adversary proceedings over the sale of genetic data (2025; injunction denied, sale approved)","claim_ids":["c-sale-states-suits"],"code":"A9","category":"CIVIL_LITIGATION","subject_id":"holdco"}],"subtype":"company","jurisdiction":"us","aliases":["23andMe Holding Co.","Chrome Holding Co.","VG Acquisition Corp.","VGAC","Bleecker Street Acquisition Corp."],"identifiers":[{"scheme":"other","value":"0001804591","issuer":"U.S. Securities and Exchange Commission (Central Index Key)"},{"scheme":"other","value":"87-1240344","issuer":"U.S. Internal Revenue Service (employer identification number)"},{"scheme":"lei","value":"529900FU5IIBCXYHHX25"},{"scheme":"company_register","value":"6006171","issuer":"Delaware Division of Corporations (as recorded by GLEIF)"}],"same_as":["https://data.sec.gov/submissions/CIK0001804591.json","https://api.gleif.org/api/v1/lei-records/529900FU5IIBCXYHHX25"],"role":"","period":""},"reading":"Chrome Holding Co. (formerly 23andMe Holding Co.) (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"inc","record":{"id":"inc","name":"ChromeCo, Inc. (formerly 23andMe, Inc.)","type":"organization","group":"group_companies","claim_ids":["c-id-trademark-names","c-id-gleif-search","c-id-agg-inc","c-id-colorado","c-spac-announcement","c-spac-vote","c-spac-closing","c-spac-same-registrant","c-ctl-avey","c-gov-founding","c-gov-wojcicki-roles","c-gov-botha","c-gov-chung","c-gov-scheller","c-gov-mohan","c-gov-hibbs-gc","c-gov-related-party","c-gov-ceo-resignation","c-br-regulator-scope","c-br-regulator-chronology","c-br-regulator-safeguards","c-br-regulator-notice","c-br-ico-penalty","c-br-ico-amount","c-st-us-final","c-st-canada-suits","c-st-ccaa","c-st-ca-suit","c-st-ca-enforcement-order","c-ch-filing","c-ch-debtor-structure","c-ch-related-cases","c-ch-tax-ids","c-ch-landlord-opinion","c-ch-pro-se-adversary","c-ch-adversaries","c-ch-reyna","c-sale-ftc-letter","c-sale-regulators-letter","c-sale-states-suits","c-lem-pixel-settlement","c-ppl-wojcicki-boards","c-ppl-cusenza","c-ppl-avey","c-ppl-scheller-roles","c-ppl-mohan-roles","c-ppl-chung-roles"],"badges":[{"label":"Chapter 11 filing (March 2025); liquidating plan effective December 5, 2025","claim_ids":["c-ch-filing"],"code":"A1","category":"FINANCIAL_DISTRESS","subject_id":"inc"},{"label":"UK Information Commissioner penalty of £2,310,000 (June 2025)","claim_ids":["c-br-ico-penalty"],"code":"A2","category":"REGULATORY_ACTION","subject_id":"inc"},{"label":"Canadian and UK privacy commissioners found inadequate safeguards (2025)","claim_ids":["c-br-regulator-safeguards"],"code":"A3","category":"REGULATORY_ACTION","subject_id":"inc"},{"label":"Canadian data-breach class actions (2023–2024; settled 2025)","claim_ids":["c-st-canada-suits"],"code":"A6","category":"CIVIL_LITIGATION","subject_id":"inc"},{"label":"California Attorney General suit over the 2023 breach (2026; monetary claims barred by the plan injunction)","claim_ids":["c-st-ca-suit","c-st-ca-enforcement-order"],"code":"A8","category":"ENFORCEMENT","subject_id":"inc"},{"label":"States' adversary proceedings over the sale of genetic data (2025; injunction denied, sale approved)","claim_ids":["c-sale-states-suits"],"code":"A9","category":"CIVIL_LITIGATION","subject_id":"inc"}],"subtype":"company","jurisdiction":"us","aliases":["23andMe, Inc.","ChromeCo, Inc.","ChromeCo"],"role":"","period":""},"reading":"ChromeCo, Inc. (formerly 23andMe, Inc.) (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"pharmacy-holdings","record":{"id":"pharmacy-holdings","name":"Chrome Pharmacy Holdings, Inc. (formerly 23andMe Pharmacy Holdings, Inc.)","type":"organization","group":"group_companies","claim_ids":["c-id-trademark-names","c-id-agg-pharmacy","c-gov-ceo-resignation","c-ch-filing","c-ch-debtor-structure","c-ch-related-cases","c-ch-tax-ids","c-lem-spv-agreement"],"badges":[{"label":"Chapter 11 filing (March 2025); liquidating plan effective December 5, 2025","claim_ids":["c-ch-filing"],"code":"A1","category":"FINANCIAL_DISTRESS","subject_id":"pharmacy-holdings"}],"subtype":"company","jurisdiction":"us","aliases":["23andMe Pharmacy Holdings, Inc."],"role":"","period":""},"reading":"Chrome Pharmacy Holdings, Inc. (formerly 23andMe Pharmacy Holdings, Inc.) (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"lemonaid-health","record":{"id":"lemonaid-health","name":"Lemonaid Health, Inc.","type":"organization","group":"group_companies","claim_ids":["c-gov-ceo-resignation","c-gov-selsavage","c-ch-filing","c-ch-debtor-structure","c-ch-related-cases","c-ch-tax-ids","c-sale-ftc-letter","c-sale-ttam-wins","c-sale-closing","c-lem-acquisition","c-lem-pixel-suit","c-lem-pixel-settlement","c-lem-ttam-stalking-horse","c-lem-spv-agreement","c-lem-spv-investors","c-lem-sale-approved"],"badges":[{"label":"Chapter 11 filing (March 2025); liquidating plan effective December 5, 2025","claim_ids":["c-ch-filing"],"code":"A1","category":"FINANCIAL_DISTRESS","subject_id":"lemonaid-health"},{"label":"Tracking-pixel class action against Lemonaid (2023; settled 2025)","claim_ids":["c-lem-pixel-suit","c-lem-pixel-settlement"],"code":"A10","category":"CIVIL_LITIGATION","subject_id":"lemonaid-health"}],"subtype":"company","jurisdiction":"us","role":"","period":""},"reading":"Lemonaid Health, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"lemonaid-pharmacy-holdings","record":{"id":"lemonaid-pharmacy-holdings","name":"Lemonaid Pharmacy Holdings Inc.","type":"organization","group":"group_companies","claim_ids":["c-gov-ceo-resignation","c-ch-filing","c-ch-debtor-structure","c-ch-related-cases","c-ch-tax-ids","c-ch-addresses-pharmacy"],"subtype":"company","jurisdiction":"us","role":"","period":""},"reading":"Lemonaid Pharmacy Holdings Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"lemonaid-community-pharmacy","record":{"id":"lemonaid-community-pharmacy","name":"Lemonaid Community Pharmacy, Inc.","type":"organization","group":"group_companies","claim_ids":["c-ch-filing","c-ch-debtor-structure","c-ch-related-cases","c-ch-tax-ids","c-ch-addresses-pharmacy"],"subtype":"company","jurisdiction":"us","role":"","period":""},"reading":"Lemonaid Community Pharmacy, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"lpharm-ins","record":{"id":"lpharm-ins","name":"LPharm INS LLC","type":"organization","group":"group_companies","claim_ids":["c-ch-filing","c-ch-debtor-structure","c-ch-related-cases","c-ch-tax-ids","c-ch-addresses-pharmacy"],"subtype":"company","jurisdiction":"us","role":"","period":""},"reading":"LPharm INS LLC (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"lpharm-cs","record":{"id":"lpharm-cs","name":"LPharm CS LLC","type":"organization","group":"group_companies","claim_ids":["c-ch-filing","c-ch-debtor-structure","c-ch-related-cases","c-ch-tax-ids"],"subtype":"company","jurisdiction":"us","role":"","period":""},"reading":"LPharm CS LLC (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"lpharm-rx","record":{"id":"lpharm-rx","name":"LPharm RX LLC","type":"organization","group":"group_companies","claim_ids":["c-ch-filing","c-ch-debtor-structure","c-ch-related-cases","c-ch-tax-ids","c-ch-addresses-pharmacy"],"subtype":"company","jurisdiction":"us","role":"","period":""},"reading":"LPharm RX LLC (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"lprxone","record":{"id":"lprxone","name":"LPRXOne LLC","type":"organization","group":"group_companies","claim_ids":["c-ch-filing","c-ch-debtor-structure","c-ch-related-cases","c-ch-tax-ids","c-ch-addresses-pharmacy"],"subtype":"company","jurisdiction":"us","role":"","period":""},"reading":"LPRXOne LLC (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"lprxtwo","record":{"id":"lprxtwo","name":"LPRXTwo LLC","type":"organization","group":"group_companies","claim_ids":["c-ch-filing","c-ch-debtor-structure","c-ch-related-cases","c-ch-tax-ids"],"subtype":"company","jurisdiction":"us","role":"","period":""},"reading":"LPRXTwo LLC (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"lprxthree","record":{"id":"lprxthree","name":"LPRXThree LLC","type":"organization","group":"group_companies","claim_ids":["c-ch-filing","c-ch-debtor-structure","c-ch-related-cases","c-ch-tax-ids","c-ch-addresses-pharmacy"],"subtype":"company","jurisdiction":"us","role":"","period":""},"reading":"LPRXThree LLC (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"chrome-merger-sub","record":{"id":"chrome-merger-sub","name":"Chrome Merger Sub, Inc.","type":"organization","group":"group_companies","claim_ids":["c-spac-closing"],"subtype":"company","jurisdiction":"us","role":"","period":""},"reading":"Chrome Merger Sub, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"lemonaid-uk","record":{"id":"lemonaid-uk","name":"Lemonaid Health Limited (now Boots Digital Health Limited)","type":"organization","group":"historical","claim_ids":["c-ch-revenue-fy25","c-lem-uk-disposal","c-lem-uk-officers"],"subtype":"company","jurisdiction":"gb","aliases":["Boots Digital Health Limited"],"identifiers":[{"scheme":"company_register","value":"12561320","issuer":"Companies House (England and Wales)"}],"same_as":["https://find-and-update.company-information.service.gov.uk/company/12561320"],"role":"","period":""},"reading":"Lemonaid Health Limited (now Boots Digital Health Limited) (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"lmnd-medical","record":{"id":"lmnd-medical","name":"LMND Medical Group, Inc.","type":"organization","group":"other","claim_ids":["c-lem-pixel-suit"],"subtype":"company","jurisdiction":"us","role":"","period":""},"reading":"LMND Medical Group, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"plan-trust","record":{"id":"plan-trust","name":"Chrome Holding Co. Plan Administration Trust","type":"other","group":"group_companies","claim_ids":["c-st-states-claims","c-st-states-release","c-st-ca-enforcement-order","c-ch-plan-august","c-ch-plan-trust","c-ch-shares-cancelled","c-ch-board-dissolved","c-ch-plan-administrator","c-ch-wojcicki-resolution","c-ch-converge-settlement","c-ch-docket-oct-2026","c-ppl-walper-declaration"],"subtype":"other","role":"","period":""},"reading":"Chrome Holding Co. Plan Administration Trust (other)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"wojcicki","record":{"id":"wojcicki","name":"Anne Wojcicki","type":"person","group":"leadership","claim_ids":["c-spac-announcement","c-spac-board-elect","c-ctl-2021","c-ctl-2024-wojcicki","c-ctl-13d-filings","c-ctl-2025-early","c-ctl-awf-holding","c-ctl-conversion","c-ctl-2025-july","c-ctl-avey","c-gov-founding","c-gov-wojcicki-roles","c-gov-wojcicki-background","c-gov-wojcicki-pay","c-gov-board-2024","c-gov-officers-2024","c-gov-twf","c-gov-special-committee","c-gov-go-private-2024","c-gov-resignations","c-gov-sole-director","c-gov-strategic-review","c-gov-feb-march-2025","c-gov-march-2025-final","c-gov-ceo-resignation","c-gov-march-2025-appointments","c-gov-investigation","c-gov-guidelines","c-gov-board-2025","c-br-ca-ransom","c-ch-excluded-parties","c-ch-wojcicki-resolution","c-ch-admin-claims-2026","c-ch-wojcicki-application","c-ch-pro-se-adversary","c-sale-ftc-letter","c-sale-ttam-origin","c-sale-opinion-price","c-sale-opinion-cpo","c-sale-pa-ag","c-sale-buyer-entities","c-sale-wojcicki-ttam-ceo","c-ppl-awf","c-ppl-wojcicki-zipline","c-ppl-wojcicki-boards"],"subtype":"person","aliases":["Anne E. Wojcicki"],"role":"","period":""},"reading":"Anne Wojcicki (person)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"abeec","record":{"id":"abeec","name":"ABeeC 2.0, LLC","type":"organization","group":"leadership","claim_ids":["c-ctl-2021","c-ctl-2024-wojcicki","c-ctl-13d-filings","c-ctl-2025-early","c-ctl-conversion","c-ctl-2025-july","c-ch-wojcicki-resolution","c-ch-third-plan-buyer","c-sale-buyer-entities"],"subtype":"company","jurisdiction":"us","role":"","period":""},"reading":"ABeeC 2.0, LLC (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"aw-trust","record":{"id":"aw-trust","name":"The Anne Wojcicki Revocable Trust U/A/D 9/2/09","type":"other","group":"leadership","claim_ids":["c-ctl-2024-wojcicki","c-ctl-13d-filings","c-ctl-2025-early","c-sale-buyer-entities"],"subtype":"other","aliases":["Anne Wojcicki Revocable Trust"],"role":"","period":""},"reading":"The Anne Wojcicki Revocable Trust U/A/D 9/2/09 (other)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"aw-foundation","record":{"id":"aw-foundation","name":"Anne Wojcicki Foundation","type":"organization","group":"leadership","claim_ids":["c-spac-pipe","c-ctl-2024-wojcicki","c-ctl-awf-holding","c-ctl-conversion","c-ch-wojcicki-resolution","c-ch-third-plan-buyer","c-sale-buyer-entities","c-ppl-awf"],"subtype":"other","jurisdiction":"us","identifiers":[{"scheme":"other","value":"47-1835703","issuer":"U.S. Internal Revenue Service (employer identification number)"}],"role":"","period":""},"reading":"Anne Wojcicki Foundation (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"twf","record":{"id":"twf","name":"Troper Wojcicki Foundation","type":"organization","group":"counterparties","claim_ids":["c-gov-twf","c-ppl-twf"],"subtype":"other","jurisdiction":"us","identifiers":[{"scheme":"other","value":"20-2777268","issuer":"U.S. Internal Revenue Service (employer identification number)"}],"role":"","period":""},"reading":"Troper Wojcicki Foundation (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"susan-wojcicki","record":{"id":"susan-wojcicki","name":"Susan Wojcicki","type":"person","group":"other","claim_ids":["c-gov-twf","c-ppl-awf","c-ppl-twf"],"subtype":"person","role":"","period":""},"reading":"Susan Wojcicki (person)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"batenchuk","record":{"id":"batenchuk","name":"Ryan Batenchuk","type":"person","group":"other","claim_ids":["c-ctl-2025-early"],"subtype":"person","role":"","period":""},"reading":"Ryan Batenchuk (person)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"avey","record":{"id":"avey","name":"Linda Avey","type":"person","group":"historical","claim_ids":["c-ctl-avey","c-gov-founding","c-ppl-avey"],"subtype":"person","aliases":["Linea Avey"],"role":"","period":""},"reading":"Linda Avey (person)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"cusenza","record":{"id":"cusenza","name":"Paul Cusenza","type":"person","group":"historical","claim_ids":["c-gov-founding","c-ppl-cusenza"],"subtype":"person","aliases":["Paul J. Cusenza"],"role":"","period":""},"reading":"Paul Cusenza (person)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"botha","record":{"id":"botha","name":"Roelof Botha","type":"person","group":"leadership","claim_ids":["c-spac-board-elect","c-ctl-2024-holders","c-gov-board-2024","c-gov-botha","c-gov-resignations","c-ppl-botha-spacex"],"subtype":"person","aliases":["Roelof F. Botha"],"role":"","period":""},"reading":"Roelof Botha (person)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"chung","record":{"id":"chung","name":"Patrick Chung","type":"person","group":"leadership","claim_ids":["c-spac-board-elect","c-gov-board-2024","c-gov-chung","c-gov-resignations","c-ppl-chung-roles"],"subtype":"person","aliases":["Patrick Shuao-Fong Chung"],"role":"","period":""},"reading":"Patrick Chung (person)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"hernandez","record":{"id":"hernandez","name":"Sandra Hernández","type":"person","group":"leadership","claim_ids":["c-gov-board-2024","c-gov-hernandez","c-gov-resignations","c-ppl-hernandez-roles"],"subtype":"person","aliases":["Sandra R. Hernández","Sandra Rae Hernández"],"role":"","period":""},"reading":"Sandra Hernández (person)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"mohan","record":{"id":"mohan","name":"Neal Mohan","type":"person","group":"leadership","claim_ids":["c-spac-board-elect","c-gov-board-2024","c-gov-mohan","c-gov-resignations","c-ppl-mohan-roles"],"subtype":"person","role":"","period":""},"reading":"Neal Mohan (person)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"montgomery-rice","record":{"id":"montgomery-rice","name":"Valerie Montgomery Rice","type":"person","group":"leadership","claim_ids":["c-gov-board-2021","c-gov-board-2024","c-gov-montgomery-rice","c-gov-resignations","c-ppl-montgomery-rice-roles"],"subtype":"person","role":"","period":""},"reading":"Valerie Montgomery Rice (person)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"scheller","record":{"id":"scheller","name":"Richard Scheller","type":"person","group":"leadership","claim_ids":["c-spac-board-elect","c-gov-board-2024","c-gov-scheller","c-gov-related-party","c-gov-resignations","c-ppl-scheller-roles"],"subtype":"person","aliases":["Richard H. Scheller"],"role":"","period":""},"reading":"Richard Scheller (person)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"taylor","record":{"id":"taylor","name":"Peter J. Taylor","type":"person","group":"leadership","claim_ids":["c-spac-board-elect","c-gov-board-2024","c-gov-resignations","c-ppl-taylor-roles"],"subtype":"person","aliases":["Peter Taylor"],"role":"","period":""},"reading":"Peter J. Taylor (person)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"lovell","record":{"id":"lovell","name":"Evan Lovell","type":"person","group":"historical","claim_ids":["c-spac-officers","c-spac-lovell","c-spac-board-elect","c-gov-lovell-end"],"subtype":"person","role":"","period":""},"reading":"Evan Lovell (person)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"richards","record":{"id":"richards","name":"William G. Richards","type":"person","group":"leadership","claim_ids":["c-gov-officers-2024","c-gov-officer-pay"],"subtype":"person","aliases":["William Richards"],"role":"","period":""},"reading":"William G. Richards (person)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"hibbs","record":{"id":"hibbs","name":"Kathy L. Hibbs","type":"person","group":"leadership","claim_ids":["c-gov-officers-2024","c-gov-officer-pay","c-gov-hibbs-gc","c-ppl-hibbs-roles"],"subtype":"person","aliases":["Kathy Hibbs"],"role":"","period":""},"reading":"Kathy L. Hibbs (person)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"hillan","record":{"id":"hillan","name":"Kenneth Hillan","type":"person","group":"leadership","claim_ids":["c-gov-officers-2024"],"subtype":"person","role":"","period":""},"reading":"Kenneth Hillan (person)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"selsavage","record":{"id":"selsavage","name":"Joseph Selsavage","type":"person","group":"leadership","claim_ids":["c-gov-officers-2024","c-gov-officer-pay","c-gov-march-2025-appointments","c-gov-selsavage","c-gov-selsavage-titles","c-br-senate","c-ch-docket-oct-2026","c-sale-senate-safeguards","c-lem-uk-officers"],"subtype":"person","aliases":["Joseph Anthony Selsavage","Joe Selsavage"],"role":"","period":""},"reading":"Joseph Selsavage (person)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"jensen","record":{"id":"jensen","name":"Mark Jensen","type":"person","group":"leadership","claim_ids":["c-gov-new-board","c-gov-jensen","c-gov-jensen-lattice","c-gov-march-2025-appointments","c-gov-board-2025"],"subtype":"person","role":"","period":""},"reading":"Mark Jensen (person)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"fernandez","record":{"id":"fernandez","name":"Andre Fernandez","type":"person","group":"leadership","claim_ids":["c-gov-new-board","c-gov-fernandez","c-gov-board-2025","c-ppl-fernandez-roles"],"subtype":"person","aliases":["Andre J. Fernandez","Andre John Fernandez"],"role":"","period":""},"reading":"Andre Fernandez (person)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"frankola","record":{"id":"frankola","name":"Jim Frankola","type":"person","group":"leadership","claim_ids":["c-gov-new-board","c-gov-frankola","c-gov-board-2025","c-ppl-frankola-roles"],"subtype":"person","aliases":["James W. Frankola"],"role":"","period":""},"reading":"Jim Frankola (person)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"walper","record":{"id":"walper","name":"Thomas B. Walper","type":"person","group":"leadership","claim_ids":["c-gov-march-2025-appointments","c-gov-investigation","c-gov-board-2025","c-gov-walper","c-gov-walper-getty","c-ch-plan-administrator","c-ppl-walper-bar","c-ppl-walper-declaration"],"subtype":"person","aliases":["Thomas Walper","Thomas Bradley Walper"],"role":"","period":""},"reading":"Thomas B. Walper (person)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"kvarda","record":{"id":"kvarda","name":"Matthew Kvarda","type":"person","group":"leadership","claim_ids":["c-gov-march-2025-appointments","c-gov-kvarda","c-st-ccaa","c-ch-causes","c-ch-advisers","c-ch-plan-august"],"subtype":"person","aliases":["Matthew E. Kvarda"],"role":"","period":""},"reading":"Matthew Kvarda (person)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"van-every","record":{"id":"van-every","name":"Ian Alexander Van Every","type":"person","group":"historical","claim_ids":["c-lem-uk-officers"],"subtype":"person","role":"","period":""},"reading":"Ian Alexander Van Every (person)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"vgac-sponsor","record":{"id":"vgac-sponsor","name":"VG Acquisition Sponsor LLC","type":"organization","group":"historical","claim_ids":["c-spac-sponsor-chain","c-spac-13g","c-spac-pipe"],"subtype":"company","jurisdiction":"us","role":"","period":""},"reading":"VG Acquisition Sponsor LLC (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"corvina","record":{"id":"corvina","name":"Corvina Holdings Limited","type":"organization","group":"historical","claim_ids":["c-spac-sponsor-chain","c-spac-13g","c-spac-bayliss","c-ppl-virgin-2023"],"subtype":"company","jurisdiction":"vg","role":"","period":""},"reading":"Corvina Holdings Limited (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"vghl","record":{"id":"vghl","name":"Virgin Group Holdings Limited","type":"organization","group":"historical","claim_ids":["c-spac-sponsor-chain","c-spac-13g","c-spac-bayliss","c-ppl-virgin-2023"],"subtype":"company","jurisdiction":"vg","role":"","period":""},"reading":"Virgin Group Holdings Limited (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"virgin-investments","record":{"id":"virgin-investments","name":"Virgin Investments Limited","type":"organization","group":"historical","claim_ids":["c-spac-bayliss","c-ppl-virgin-2023"],"subtype":"company","role":"","period":""},"reading":"Virgin Investments Limited (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"bft-ptc","record":{"id":"bft-ptc","name":"BFT (PTC) Limited","type":"organization","group":"historical","claim_ids":["c-ppl-virgin-2023"],"subtype":"company","role":"","period":""},"reading":"BFT (PTC) Limited (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"bft-clg","record":{"id":"bft-clg","name":"BFT CLG (PTC) Limited","type":"organization","group":"historical","claim_ids":["c-ppl-virgin-2023"],"subtype":"company","role":"","period":""},"reading":"BFT CLG (PTC) Limited (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"branson","record":{"id":"branson","name":"Sir Richard Branson","type":"person","group":"historical","claim_ids":["c-spac-sponsor-chain","c-spac-13g","c-spac-announcement","c-ppl-virgin-2023"],"subtype":"person","aliases":["Richard Branson"],"role":"","period":""},"reading":"Sir Richard Branson (person)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"bayliss","record":{"id":"bayliss","name":"Josh Bayliss","type":"person","group":"historical","claim_ids":["c-spac-officers","c-spac-bayliss"],"subtype":"person","aliases":["Joshua Bayliss"],"role":"","period":""},"reading":"Josh Bayliss (person)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"briggs","record":{"id":"briggs","name":"Teresa Briggs","type":"person","group":"historical","claim_ids":["c-spac-officers","c-spac-briggs"],"subtype":"person","role":"","period":""},"reading":"Teresa Briggs (person)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"lockhart","record":{"id":"lockhart","name":"James B. Lockhart III","type":"person","group":"historical","claim_ids":["c-spac-officers","c-spac-lockhart"],"subtype":"person","role":"","period":""},"reading":"James B. Lockhart III (person)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"brown","record":{"id":"brown","name":"Douglas R. Brown","type":"person","group":"historical","claim_ids":["c-spac-officers","c-spac-brown"],"subtype":"person","role":"","period":""},"reading":"Douglas R. Brown (person)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"vgac-ii","record":{"id":"vgac-ii","name":"VG Acquisition Corp. II (VGAC II)","type":"organization","group":"historical","claim_ids":["c-spac-bayliss","c-spac-lovell"],"subtype":"company","role":"","period":""},"reading":"VG Acquisition Corp. II (VGAC II) (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"vgac-iii","record":{"id":"vgac-iii","name":"VG Acquisition Corp. III (VGAC III)","type":"organization","group":"historical","claim_ids":["c-spac-bayliss","c-spac-lovell"],"subtype":"company","role":"","period":""},"reading":"VG Acquisition Corp. III (VGAC III) (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"virgin-entertainment","record":{"id":"virgin-entertainment","name":"Virgin Entertainment Holdings, Inc.","type":"organization","group":"other","claim_ids":["c-spac-bayliss"],"subtype":"company","role":"","period":""},"reading":"Virgin Entertainment Holdings, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"virgin-red","record":{"id":"virgin-red","name":"Virgin Red Limited","type":"organization","group":"other","claim_ids":["c-spac-bayliss"],"subtype":"company","role":"","period":""},"reading":"Virgin Red Limited (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"virgin-galactic","record":{"id":"virgin-galactic","name":"Virgin Galactic Holdings, Inc.","type":"organization","group":"other","claim_ids":["c-spac-lovell","c-ppl-virgin-2023"],"subtype":"company","jurisdiction":"us","identifiers":[{"scheme":"other","value":"0001706946","issuer":"U.S. Securities and Exchange Commission (Central Index Key)"}],"role":"","period":""},"reading":"Virgin Galactic Holdings, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"virgin-green-fund","record":{"id":"virgin-green-fund","name":"Virgin Green Fund","type":"organization","group":"other","claim_ids":["c-spac-lovell"],"subtype":"other","role":"","period":""},"reading":"Virgin Green Fund (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"virgin-money","record":{"id":"virgin-money","name":"Virgin Money Holdings (UK)","type":"organization","group":"other","claim_ids":["c-spac-lockhart"],"subtype":"company","role":"","period":""},"reading":"Virgin Money Holdings (UK) (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"tpg","record":{"id":"tpg","name":"TPG Capital","type":"organization","group":"other","claim_ids":["c-spac-lovell"],"subtype":"company","role":"","period":""},"reading":"TPG Capital (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"wl-ross","record":{"id":"wl-ross","name":"WL Ross & Co. LLC","type":"organization","group":"other","claim_ids":["c-spac-lockhart"],"subtype":"company","role":"","period":""},"reading":"WL Ross & Co. LLC (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"aquaventure","record":{"id":"aquaventure","name":"AquaVenture Holdings","type":"organization","group":"other","claim_ids":["c-spac-brown"],"subtype":"company","role":"","period":""},"reading":"AquaVenture Holdings (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"seven-seas","record":{"id":"seven-seas","name":"Seven Seas Water Corporation","type":"organization","group":"other","claim_ids":["c-spac-brown"],"subtype":"company","role":"","period":""},"reading":"Seven Seas Water Corporation (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"ionics","record":{"id":"ionics","name":"Ionics, Incorporated","type":"organization","group":"other","claim_ids":["c-spac-brown"],"subtype":"company","role":"","period":""},"reading":"Ionics, Incorporated (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"advent","record":{"id":"advent","name":"Advent International","type":"organization","group":"other","claim_ids":["c-spac-brown"],"subtype":"company","role":"","period":""},"reading":"Advent International (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"element-partners","record":{"id":"element-partners","name":"Element Partners","type":"organization","group":"other","claim_ids":["c-spac-brown"],"subtype":"company","role":"","period":""},"reading":"Element Partners (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"deloitte-llp","record":{"id":"deloitte-llp","name":"Deloitte LLP","type":"organization","group":"other","claim_ids":["c-spac-briggs"],"subtype":"company","role":"","period":""},"reading":"Deloitte LLP (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"snowflake","record":{"id":"snowflake","name":"Snowflake, Inc.","type":"organization","group":"other","claim_ids":["c-spac-briggs"],"subtype":"company","role":"","period":""},"reading":"Snowflake, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"servicenow","record":{"id":"servicenow","name":"ServiceNow, Inc.","type":"organization","group":"other","claim_ids":["c-spac-briggs"],"subtype":"company","role":"","period":""},"reading":"ServiceNow, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"docusign","record":{"id":"docusign","name":"DocuSign, Inc.","type":"organization","group":"other","claim_ids":["c-spac-briggs"],"subtype":"company","role":"","period":""},"reading":"DocuSign, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"jand","record":{"id":"jand","name":"JAND, Inc. (Warby Parker)","type":"organization","group":"other","claim_ids":["c-spac-briggs"],"subtype":"company","role":"","period":""},"reading":"JAND, Inc. (Warby Parker) (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"gsk","record":{"id":"gsk","name":"GSK plc","type":"organization","group":"counterparties","claim_ids":["c-ctl-2024-holders","c-gov-related-party","c-ch-finances","c-ch-revenue-fy25"],"subtype":"company","role":"","period":""},"reading":"GSK plc (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"glaxo-group","record":{"id":"glaxo-group","name":"Glaxo Group Limited","type":"organization","group":"counterparties","claim_ids":["c-ctl-2021","c-ctl-2024-holders","c-gov-related-party"],"subtype":"company","role":"","period":""},"reading":"Glaxo Group Limited (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"sc-us-ttgp","record":{"id":"sc-us-ttgp","name":"SC US (TTGP), Ltd.","type":"organization","group":"other","claim_ids":["c-ctl-2024-holders"],"subtype":"company","role":"","period":""},"reading":"SC US (TTGP), Ltd. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"newview","record":{"id":"newview","name":"NewView Capital Fund I, L.P.","type":"organization","group":"other","claim_ids":["c-ctl-2024-holders"],"subtype":"company","role":"","period":""},"reading":"NewView Capital Fund I, L.P. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"vanguard","record":{"id":"vanguard","name":"The Vanguard Group","type":"organization","group":"other","claim_ids":["c-ctl-2024-holders"],"subtype":"company","role":"","period":""},"reading":"The Vanguard Group (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"g-squared","record":{"id":"g-squared","name":"G Squared Equity Management LP","type":"organization","group":"other","claim_ids":["c-ctl-2021"],"subtype":"company","role":"","period":""},"reading":"G Squared Equity Management LP (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"fmr","record":{"id":"fmr","name":"FMR LLC","type":"organization","group":"other","claim_ids":["c-ctl-2021"],"subtype":"company","role":"","period":""},"reading":"FMR LLC (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"zentree","record":{"id":"zentree","name":"Zentree Investments Limited","type":"organization","group":"other","claim_ids":["c-ctl-2025-july","c-ctl-zentree-13g","c-ctl-zentree-13d"],"subtype":"company","jurisdiction":"ky","role":"","period":""},"reading":"Zentree Investments Limited (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"magides","record":{"id":"magides","name":"Richard Magides","type":"person","group":"other","claim_ids":["c-ctl-zentree-13g","c-ctl-zentree-13d","c-ppl-magides"],"subtype":"person","aliases":["Richard Anthony Magides"],"role":"","period":""},"reading":"Richard Magides (person)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"zentree-im","record":{"id":"zentree-im","name":"Zentree Investment Management Pte Ltd","type":"organization","group":"other","claim_ids":["c-ctl-zentree-13g","c-ppl-magides"],"subtype":"company","jurisdiction":"sg","role":"","period":""},"reading":"Zentree Investment Management Pte Ltd (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"farallon","record":{"id":"farallon","name":"Farallon Partners, L.L.C.","type":"organization","group":"other","claim_ids":["c-ctl-2025-july","c-ctl-farallon"],"subtype":"company","role":"","period":""},"reading":"Farallon Partners, L.L.C. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"nasdaq","record":{"id":"nasdaq","name":"The Nasdaq Capital Market","type":"organization","group":"other","claim_ids":["c-id-listing","c-id-delisting"],"subtype":"other","role":"","period":""},"reading":"The Nasdaq Capital Market (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"ttam","record":{"id":"ttam","name":"23andMe Research Institute (formerly TTAM Research Institute)","type":"organization","group":"counterparties","claim_ids":["c-id-trademark-names","c-gov-investigation","c-st-states-release","c-st-states-findings","c-st-ca-admin-claim","c-ch-wojcicki-resolution","c-ch-third-plan-buyer","c-ch-admin-claims-2026","c-ch-pro-se-adversary","c-ch-converge-settlement","c-sale-senate-safeguards","c-sale-regeneron","c-sale-ttam-origin","c-sale-ttam-wins","c-sale-newco","c-sale-ttam-terms","c-sale-states-objection","c-sale-opinion","c-sale-opinion-newco","c-sale-opinion-price","c-sale-opinion-cpo","c-sale-pa-ag","c-sale-appeals-stay","c-sale-closing","c-sale-district-court","c-sale-buyer-entities","c-sale-wojcicki-ttam-ceo","c-lem-ttam-stalking-horse"],"subtype":"other","aliases":["TTAM Research Institute","TTAM"],"role":"","period":""},"reading":"23andMe Research Institute (formerly TTAM Research Institute) (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"ttam-2","record":{"id":"ttam-2","name":"TTAM 2.0, LLC","type":"organization","group":"counterparties","claim_ids":["c-sale-buyer-entities"],"subtype":"company","role":"","period":""},"reading":"TTAM 2.0, LLC (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"ttam-employees","record":{"id":"ttam-employees","name":"23andMe Employees LLC","type":"organization","group":"counterparties","claim_ids":["c-sale-buyer-entities"],"subtype":"company","role":"","period":""},"reading":"23andMe Employees LLC (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"ttam-genomics","record":{"id":"ttam-genomics","name":"23andMe Genomics LLC","type":"organization","group":"counterparties","claim_ids":["c-sale-buyer-entities"],"subtype":"company","role":"","period":""},"reading":"23andMe Genomics LLC (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"ttam-research-llc","record":{"id":"ttam-research-llc","name":"23andMe Research LLC","type":"organization","group":"counterparties","claim_ids":["c-sale-buyer-entities"],"subtype":"company","role":"","period":""},"reading":"23andMe Research LLC (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"regeneron","record":{"id":"regeneron","name":"Regeneron Pharmaceuticals, Inc.","type":"organization","group":"counterparties","claim_ids":["c-ch-reyna","c-sale-senate-safeguards","c-sale-regeneron","c-sale-ttam-wins","c-sale-states-objection"],"subtype":"company","role":"","period":""},"reading":"Regeneron Pharmaceuticals, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"new-mountain","record":{"id":"new-mountain","name":"New Mountain Capital L.L.C.","type":"organization","group":"other","claim_ids":["c-gov-feb-march-2025"],"subtype":"company","role":"","period":""},"reading":"New Mountain Capital L.L.C. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"lemonaid-spv","record":{"id":"lemonaid-spv","name":"Lemonaid SPV, Inc.","type":"organization","group":"counterparties","claim_ids":["c-lem-spv-agreement","c-lem-spv-investors","c-lem-buyer-interview","c-lem-sale-approved","c-lem-closing"],"subtype":"company","jurisdiction":"us","role":"","period":""},"reading":"Lemonaid SPV, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"bambumeta","record":{"id":"bambumeta","name":"Bambumeta Ventures, LLC","type":"organization","group":"counterparties","claim_ids":["c-lem-spv-agreement","c-lem-spv-investors","c-lem-buyer-interview","c-lem-closing"],"subtype":"company","aliases":["Bambu Ventures","BambuMeta Ventures"],"role":"","period":""},"reading":"Bambumeta Ventures, LLC (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"innova","record":{"id":"innova","name":"Innova Capital Partners","type":"organization","group":"other","claim_ids":["c-lem-spv-investors"],"subtype":"company","role":"","period":""},"reading":"Innova Capital Partners (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"egateway","record":{"id":"egateway","name":"eGateway Capital","type":"organization","group":"other","claim_ids":["c-lem-spv-investors"],"subtype":"company","role":"","period":""},"reading":"eGateway Capital (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"broadview","record":{"id":"broadview","name":"Broadview Capital","type":"organization","group":"other","claim_ids":["c-lem-spv-investors"],"subtype":"company","role":"","period":""},"reading":"Broadview Capital (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"auctus","record":{"id":"auctus","name":"Auctus Holding Ltd.","type":"organization","group":"other","claim_ids":["c-lem-spv-investors"],"subtype":"company","role":"","period":""},"reading":"Auctus Holding Ltd. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"day-break","record":{"id":"day-break","name":"Day Break Partners","type":"organization","group":"other","claim_ids":["c-lem-spv-investors"],"subtype":"company","role":"","period":""},"reading":"Day Break Partners (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"pretsch","record":{"id":"pretsch","name":"Kyle Pretsch","type":"person","group":"other","claim_ids":["c-lem-spv-investors","c-lem-buyer-interview"],"subtype":"person","role":"","period":""},"reading":"Kyle Pretsch (person)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"hearn","record":{"id":"hearn","name":"Richard Hearn","type":"person","group":"other","claim_ids":["c-lem-spv-investors"],"subtype":"person","role":"","period":""},"reading":"Richard Hearn (person)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"runne","record":{"id":"runne","name":"Dylan Runne","type":"person","group":"other","claim_ids":["c-lem-spv-investors"],"subtype":"person","role":"","period":""},"reading":"Dylan Runne (person)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"boots-uk","record":{"id":"boots-uk","name":"Boots UK Limited","type":"organization","group":"other","claim_ids":["c-lem-uk-disposal","c-lem-uk-officers"],"subtype":"company","jurisdiction":"gb","identifiers":[{"scheme":"company_register","value":"00928555","issuer":"Companies House (England and Wales)"}],"role":"","period":""},"reading":"Boots UK Limited (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"alliance-boots","record":{"id":"alliance-boots","name":"Alliance Boots Holdings Limited","type":"organization","group":"other","claim_ids":["c-lem-uk-disposal"],"subtype":"company","jurisdiction":"gb","identifiers":[{"scheme":"company_register","value":"04452715","issuer":"Companies House (England and Wales)"}],"role":"","period":""},"reading":"Alliance Boots Holdings Limited (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"jmb","record":{"id":"jmb","name":"JMB Capital Partners Lending, LLC","type":"organization","group":"counterparties","claim_ids":["c-ch-dip","c-ch-creditors-list"],"subtype":"company","role":"","period":""},"reading":"JMB Capital Partners Lending, LLC (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"alvarez-marsal","record":{"id":"alvarez-marsal","name":"Alvarez & Marsal North America, LLC","type":"organization","group":"counterparties","claim_ids":["c-gov-march-2025-appointments","c-gov-kvarda","c-ch-advisers","c-ch-cash-fees"],"subtype":"company","role":"","period":""},"reading":"Alvarez & Marsal North America, LLC (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"kroll","record":{"id":"kroll","name":"Kroll Restructuring Administration LLC","type":"organization","group":"counterparties","claim_ids":["c-ch-advisers","c-ch-hearing-calendar"],"subtype":"company","role":"","period":""},"reading":"Kroll Restructuring Administration LLC (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"kpmg","record":{"id":"kpmg","name":"KPMG LLP","type":"organization","group":"counterparties","claim_ids":["c-gov-board-2024","c-st-canada-suits","c-st-canada-stay","c-st-canada-settlement","c-ch-balance-sheet","c-ch-kpmg-fees"],"subtype":"company","role":"","period":""},"reading":"KPMG LLP (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"csc","record":{"id":"csc","name":"Corporation Service Company","type":"organization","group":"other","claim_ids":["c-id-gleif"],"subtype":"company","role":"","period":""},"reading":"Corporation Service Company (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"isl","record":{"id":"isl","name":"Incorporating Services, Ltd","type":"organization","group":"other","claim_ids":["c-id-agg-holdco","c-id-agg-inc","c-id-agg-pharmacy"],"subtype":"company","role":"","period":""},"reading":"Incorporating Services, Ltd (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"labcorp","record":{"id":"labcorp","name":"Laboratory Corporation of America Holdings","type":"organization","group":"counterparties","claim_ids":["c-ch-creditors-committee","c-ch-creditors-list"],"subtype":"company","role":"","period":""},"reading":"Laboratory Corporation of America Holdings (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"workday","record":{"id":"workday","name":"Workday, Inc.","type":"organization","group":"counterparties","claim_ids":["c-ch-creditors-committee"],"subtype":"company","role":"","period":""},"reading":"Workday, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"telus","record":{"id":"telus","name":"Telus International Services Limited","type":"organization","group":"counterparties","claim_ids":["c-ch-creditors-committee"],"subtype":"company","role":"","period":""},"reading":"Telus International Services Limited (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"jellyfish","record":{"id":"jellyfish","name":"Jellyfish US Limited","type":"organization","group":"counterparties","claim_ids":["c-ch-creditors-committee"],"subtype":"company","role":"","period":""},"reading":"Jellyfish US Limited (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"kr-op-tech","record":{"id":"kr-op-tech","name":"KR OP Tech, LLC","type":"organization","group":"counterparties","claim_ids":["c-ch-creditors-list","c-ch-landlord-opinion","c-ch-converge-reserve"],"subtype":"company","role":"","period":""},"reading":"KR OP Tech, LLC (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"converge","record":{"id":"converge","name":"Converge Technology Solutions US LLC","type":"organization","group":"counterparties","claim_ids":["c-ch-creditors-list","c-ch-converge-reserve","c-ch-converge-settlement"],"subtype":"company","role":"","period":""},"reading":"Converge Technology Solutions US LLC (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"allied-world","record":{"id":"allied-world","name":"Allied World Specialty Insurance Company","type":"organization","group":"counterparties","claim_ids":["c-st-cyber-insurers"],"subtype":"company","role":"","period":""},"reading":"Allied World Specialty Insurance Company (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"houston-casualty","record":{"id":"houston-casualty","name":"Houston Casualty Company","type":"organization","group":"counterparties","claim_ids":["c-st-cyber-insurers"],"subtype":"company","role":"","period":""},"reading":"Houston Casualty Company (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"landmark","record":{"id":"landmark","name":"Landmark American Insurance Company","type":"organization","group":"counterparties","claim_ids":["c-st-cyber-insurers"],"subtype":"company","role":"","period":""},"reading":"Landmark American Insurance Company (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"biodata-trust","record":{"id":"biodata-trust","name":"Global BioData Trust","type":"organization","group":"other","claim_ids":["c-sale-biodata-trust","c-sale-appeals-stay","c-sale-district-court"],"subtype":"other","role":"","period":""},"reading":"Global BioData Trust (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"california","record":{"id":"california","name":"State of California","type":"organization","group":"counterparties","claim_ids":["c-br-ca-allegations","c-br-ca-ransom","c-br-ca-warnings","c-st-ca-admin-claim","c-st-ca-suit","c-st-ca-enforcement-order","c-st-ca-appeal-2026","c-ch-ds-order","c-sale-states-objection","c-sale-opinion-newco","c-sale-appeals-stay","c-sale-district-court"],"subtype":"other","jurisdiction":"us","role":"","period":""},"reading":"State of California (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"texas","record":{"id":"texas","name":"State of Texas","type":"organization","group":"counterparties","claim_ids":["c-st-states-allocation","c-ch-adversaries","c-sale-states-objection","c-sale-states-suits","c-sale-opinion-newco"],"subtype":"other","jurisdiction":"us","role":"","period":""},"reading":"State of Texas (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"sequoia-ops","record":{"id":"sequoia-ops","name":"Sequoia Capital Operations, LLC","type":"organization","group":"other","claim_ids":["c-gov-botha"],"subtype":"company","role":"","period":""},"reading":"Sequoia Capital Operations, LLC (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"xfund","record":{"id":"xfund","name":"Xfund","type":"organization","group":"other","claim_ids":["c-gov-chung","c-ppl-chung-roles"],"subtype":"other","role":"","period":""},"reading":"Xfund (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"xfund-3","record":{"id":"xfund-3","name":"Xfund 3, L.P.","type":"organization","group":"other","claim_ids":["c-ppl-chung-roles"],"subtype":"company","jurisdiction":"us","identifiers":[{"scheme":"other","value":"0001763789","issuer":"U.S. Securities and Exchange Commission (Central Index Key)"}],"role":"","period":""},"reading":"Xfund 3, L.P. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"philo","record":{"id":"philo","name":"Philo, Inc.","type":"organization","group":"other","claim_ids":["c-ppl-chung-roles"],"subtype":"company","role":"","period":""},"reading":"Philo, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"wrld3d","record":{"id":"wrld3d","name":"WRLD3D Ltd.","type":"organization","group":"other","claim_ids":["c-ppl-chung-roles"],"subtype":"company","role":"","period":""},"reading":"WRLD3D Ltd. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"bridgebio","record":{"id":"bridgebio","name":"BridgeBio Pharma, Inc.","type":"organization","group":"other","claim_ids":["c-gov-scheller","c-ppl-scheller-roles"],"subtype":"company","jurisdiction":"us","identifiers":[{"scheme":"other","value":"0001743881","issuer":"U.S. Securities and Exchange Commission (Central Index Key)"}],"role":"","period":""},"reading":"BridgeBio Pharma, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"alector","record":{"id":"alector","name":"Alector, Inc.","type":"organization","group":"other","claim_ids":["c-ppl-scheller-roles"],"subtype":"company","role":"","period":""},"reading":"Alector, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"maze","record":{"id":"maze","name":"Maze Therapeutics, Inc.","type":"organization","group":"other","claim_ids":["c-ppl-scheller-roles"],"subtype":"company","role":"","period":""},"reading":"Maze Therapeutics, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"dice","record":{"id":"dice","name":"DiCE Molecules","type":"organization","group":"other","claim_ids":["c-ppl-scheller-roles"],"subtype":"company","role":"","period":""},"reading":"DiCE Molecules (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"aarvik","record":{"id":"aarvik","name":"Aarvik Therapeutics","type":"organization","group":"other","claim_ids":["c-ppl-scheller-roles"],"subtype":"company","role":"","period":""},"reading":"Aarvik Therapeutics (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"genentech","record":{"id":"genentech","name":"Genentech, Inc.","type":"organization","group":"other","claim_ids":["c-ppl-scheller-roles"],"subtype":"company","role":"","period":""},"reading":"Genentech, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"oric","record":{"id":"oric","name":"Oric Pharmaceuticals, Inc.","type":"organization","group":"other","claim_ids":["c-ppl-scheller-roles"],"subtype":"company","role":"","period":""},"reading":"Oric Pharmaceuticals, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"youtube","record":{"id":"youtube","name":"YouTube, Inc.","type":"organization","group":"other","claim_ids":["c-gov-mohan","c-ppl-mohan-roles"],"subtype":"company","role":"","period":""},"reading":"YouTube, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"starbucks","record":{"id":"starbucks","name":"Starbucks Corp.","type":"organization","group":"other","claim_ids":["c-ppl-mohan-roles"],"subtype":"company","role":"","period":""},"reading":"Starbucks Corp. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"stitch-fix","record":{"id":"stitch-fix","name":"Stitch Fix, Inc.","type":"organization","group":"other","claim_ids":["c-ppl-mohan-roles"],"subtype":"company","role":"","period":""},"reading":"Stitch Fix, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"chcf","record":{"id":"chcf","name":"California Health Care Foundation","type":"organization","group":"other","claim_ids":["c-gov-hernandez","c-ppl-hernandez-roles"],"subtype":"other","role":"","period":""},"reading":"California Health Care Foundation (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"covered-california","record":{"id":"covered-california","name":"Covered California","type":"organization","group":"other","claim_ids":["c-ppl-hernandez-roles"],"subtype":"other","role":"","period":""},"reading":"Covered California (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"blackbaud","record":{"id":"blackbaud","name":"Blackbaud, Inc.","type":"organization","group":"other","claim_ids":["c-ppl-hernandez-roles"],"subtype":"company","role":"","period":""},"reading":"Blackbaud, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"first-republic","record":{"id":"first-republic","name":"First Republic Bank","type":"organization","group":"other","claim_ids":["c-ppl-hernandez-roles"],"subtype":"company","role":"","period":""},"reading":"First Republic Bank (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"morehouse","record":{"id":"morehouse","name":"Morehouse School of Medicine","type":"organization","group":"other","claim_ids":["c-gov-montgomery-rice","c-ppl-montgomery-rice-roles"],"subtype":"other","role":"","period":""},"reading":"Morehouse School of Medicine (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"meharry","record":{"id":"meharry","name":"Meharry Medical College","type":"organization","group":"other","claim_ids":["c-ppl-montgomery-rice-roles"],"subtype":"other","role":"","period":""},"reading":"Meharry Medical College (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"unitedhealth","record":{"id":"unitedhealth","name":"UnitedHealth Group Inc.","type":"organization","group":"other","claim_ids":["c-ppl-montgomery-rice-roles"],"subtype":"company","role":"","period":""},"reading":"UnitedHealth Group Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"spacex","record":{"id":"spacex","name":"Space Exploration Technologies Corp.","type":"organization","group":"other","claim_ids":["c-ppl-botha-spacex"],"subtype":"company","role":"","period":""},"reading":"Space Exploration Technologies Corp. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"mongodb","record":{"id":"mongodb","name":"MongoDB, Inc.","type":"organization","group":"other","claim_ids":["c-ppl-botha-spacex"],"subtype":"company","role":"","period":""},"reading":"MongoDB, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"block","record":{"id":"block","name":"Block, Inc.","type":"organization","group":"other","claim_ids":["c-ppl-botha-spacex"],"subtype":"company","role":"","period":""},"reading":"Block, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"natera","record":{"id":"natera","name":"Natera, Inc.","type":"organization","group":"other","claim_ids":["c-ppl-botha-spacex"],"subtype":"company","role":"","period":""},"reading":"Natera, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"unity","record":{"id":"unity","name":"Unity Software Inc.","type":"organization","group":"other","claim_ids":["c-ppl-botha-spacex"],"subtype":"company","role":"","period":""},"reading":"Unity Software Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"sce","record":{"id":"sce","name":"Southern California Edison Co.","type":"organization","group":"other","claim_ids":["c-ppl-taylor-roles"],"subtype":"company","role":"","period":""},"reading":"Southern California Edison Co. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"edison-intl","record":{"id":"edison-intl","name":"Edison International","type":"organization","group":"other","claim_ids":["c-ppl-taylor-roles"],"subtype":"company","role":"","period":""},"reading":"Edison International (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"pacific-mutual","record":{"id":"pacific-mutual","name":"Pacific Mutual Holding Co.","type":"organization","group":"other","claim_ids":["c-ppl-taylor-roles"],"subtype":"company","role":"","period":""},"reading":"Pacific Mutual Holding Co. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"ecmc","record":{"id":"ecmc","name":"ECMC Foundation","type":"organization","group":"other","claim_ids":["c-ppl-taylor-roles"],"subtype":"other","role":"","period":""},"reading":"ECMC Foundation (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"deloitte-touche","record":{"id":"deloitte-touche","name":"Deloitte & Touche LLP","type":"organization","group":"other","claim_ids":["c-gov-jensen"],"subtype":"company","role":"","period":""},"reading":"Deloitte & Touche LLP (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"redleaf","record":{"id":"redleaf","name":"Redleaf Group","type":"organization","group":"other","claim_ids":["c-gov-jensen"],"subtype":"company","role":"","period":""},"reading":"Redleaf Group (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"arthur-andersen","record":{"id":"arthur-andersen","name":"Arthur Andersen LLP","type":"organization","group":"other","claim_ids":["c-gov-jensen"],"subtype":"company","role":"","period":""},"reading":"Arthur Andersen LLP (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"lattice","record":{"id":"lattice","name":"Lattice Semiconductor Corporation","type":"organization","group":"other","claim_ids":["c-gov-jensen","c-gov-jensen-lattice"],"subtype":"company","role":"","period":""},"reading":"Lattice Semiconductor Corporation (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"wolfspeed","record":{"id":"wolfspeed","name":"Wolfspeed, Inc.","type":"organization","group":"other","claim_ids":["c-gov-jensen-lattice"],"subtype":"company","role":"","period":""},"reading":"Wolfspeed, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"exabeam","record":{"id":"exabeam","name":"Exabeam, Inc.","type":"organization","group":"other","claim_ids":["c-gov-jensen-lattice"],"subtype":"company","role":"","period":""},"reading":"Exabeam, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"unwired-planet","record":{"id":"unwired-planet","name":"Unwired Planet, Inc.","type":"organization","group":"other","claim_ids":["c-gov-jensen-lattice"],"subtype":"company","role":"","period":""},"reading":"Unwired Planet, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"control4","record":{"id":"control4","name":"Control4 Corporation","type":"organization","group":"other","claim_ids":["c-gov-jensen-lattice"],"subtype":"company","role":"","period":""},"reading":"Control4 Corporation (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"forescout","record":{"id":"forescout","name":"ForeScout Technologies, Inc.","type":"organization","group":"other","claim_ids":["c-gov-jensen-lattice"],"subtype":"company","role":"","period":""},"reading":"ForeScout Technologies, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"wework","record":{"id":"wework","name":"WeWork, Inc.","type":"organization","group":"other","claim_ids":["c-gov-fernandez"],"subtype":"company","role":"","period":""},"reading":"WeWork, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"ncr","record":{"id":"ncr","name":"NCR Corporation","type":"organization","group":"other","claim_ids":["c-gov-fernandez"],"subtype":"company","role":"","period":""},"reading":"NCR Corporation (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"cbs-radio","record":{"id":"cbs-radio","name":"CBS Radio Inc.","type":"organization","group":"other","claim_ids":["c-gov-fernandez"],"subtype":"company","role":"","period":""},"reading":"CBS Radio Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"domain-americas","record":{"id":"domain-americas","name":"Domain Americas LLC","type":"organization","group":"other","claim_ids":["c-gov-fernandez"],"subtype":"company","role":"","period":""},"reading":"Domain Americas LLC (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"cardlytics","record":{"id":"cardlytics","name":"Cardlytics, Inc.","type":"organization","group":"other","claim_ids":["c-gov-fernandez","c-ppl-fernandez-roles"],"subtype":"company","jurisdiction":"us","identifiers":[{"scheme":"other","value":"0001666071","issuer":"U.S. Securities and Exchange Commission (Central Index Key)"}],"role":"","period":""},"reading":"Cardlytics, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"blackstone-bis","record":{"id":"blackstone-bis","name":"Blackstone Infrastructure Strategies L.P.","type":"organization","group":"other","claim_ids":["c-gov-fernandez"],"subtype":"company","role":"","period":""},"reading":"Blackstone Infrastructure Strategies L.P. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"faze","record":{"id":"faze","name":"FaZe Holdings, Inc.","type":"organization","group":"other","claim_ids":["c-gov-fernandez"],"subtype":"company","role":"","period":""},"reading":"FaZe Holdings, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"sachem","record":{"id":"sachem","name":"Sachem Acquisition Corp.","type":"organization","group":"other","claim_ids":["c-gov-fernandez"],"subtype":"company","role":"","period":""},"reading":"Sachem Acquisition Corp. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"froedtert","record":{"id":"froedtert","name":"Froedtert Health System, Inc.","type":"organization","group":"other","claim_ids":["c-ppl-fernandez-roles"],"subtype":"company","role":"","period":""},"reading":"Froedtert Health System, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"cloudera","record":{"id":"cloudera","name":"Cloudera, Inc.","type":"organization","group":"other","claim_ids":["c-gov-frankola","c-ppl-frankola-roles"],"subtype":"company","role":"","period":""},"reading":"Cloudera, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"yodlee","record":{"id":"yodlee","name":"Yodlee, Inc.","type":"organization","group":"other","claim_ids":["c-gov-frankola"],"subtype":"company","role":"","period":""},"reading":"Yodlee, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"ariba","record":{"id":"ariba","name":"Ariba, Inc.","type":"organization","group":"other","claim_ids":["c-gov-frankola","c-ppl-frankola-roles"],"subtype":"company","role":"","period":""},"reading":"Ariba, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"ansys","record":{"id":"ansys","name":"Ansys, Inc.","type":"organization","group":"other","claim_ids":["c-gov-frankola","c-ppl-frankola-roles"],"subtype":"company","jurisdiction":"us","identifiers":[{"scheme":"other","value":"0001013462","issuer":"U.S. Securities and Exchange Commission (Central Index Key)"}],"role":"","period":""},"reading":"Ansys, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"skillsoft","record":{"id":"skillsoft","name":"Skillsoft Corp.","type":"organization","group":"other","claim_ids":["c-gov-frankola","c-ppl-frankola-roles"],"subtype":"company","role":"","period":""},"reading":"Skillsoft Corp. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"ionq","record":{"id":"ionq","name":"IonQ, Inc.","type":"organization","group":"other","claim_ids":["c-ppl-frankola-roles"],"subtype":"company","role":"","period":""},"reading":"IonQ, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"getty","record":{"id":"getty","name":"Getty Images Holdings, Inc.","type":"organization","group":"other","claim_ids":["c-gov-walper-getty"],"subtype":"company","role":"","period":""},"reading":"Getty Images Holdings, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"munger","record":{"id":"munger","name":"Munger, Tolles & Olson LLP","type":"organization","group":"other","claim_ids":["c-gov-walper"],"subtype":"company","role":"","period":""},"reading":"Munger, Tolles & Olson LLP (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"plainfield","record":{"id":"plainfield","name":"Plainfield Asset Management LLC","type":"organization","group":"other","claim_ids":["c-gov-walper"],"subtype":"company","role":"","period":""},"reading":"Plainfield Asset Management LLC (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"revlon","record":{"id":"revlon","name":"Revlon, Inc.","type":"organization","group":"other","claim_ids":["c-gov-kvarda"],"subtype":"company","role":"","period":""},"reading":"Revlon, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"team-inc","record":{"id":"team-inc","name":"TEAM, Inc.","type":"organization","group":"other","claim_ids":["c-gov-kvarda"],"subtype":"company","role":"","period":""},"reading":"TEAM, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"jacuzzi","record":{"id":"jacuzzi","name":"Jacuzzi Brands","type":"organization","group":"other","claim_ids":["c-gov-kvarda"],"subtype":"company","role":"","period":""},"reading":"Jacuzzi Brands (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"metromile","record":{"id":"metromile","name":"Metromile Operating Co.","type":"organization","group":"other","claim_ids":["c-gov-selsavage"],"subtype":"company","role":"","period":""},"reading":"Metromile Operating Co. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"hotwire","record":{"id":"hotwire","name":"Hotwire, Inc.","type":"organization","group":"other","claim_ids":["c-gov-selsavage"],"subtype":"company","role":"","period":""},"reading":"Hotwire, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"red-eclipse","record":{"id":"red-eclipse","name":"Red Eclipse Consulting","type":"organization","group":"other","claim_ids":["c-gov-selsavage"],"subtype":"company","role":"","period":""},"reading":"Red Eclipse Consulting (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"sophia","record":{"id":"sophia","name":"Sophia Genetics SA","type":"organization","group":"other","claim_ids":["c-ppl-hibbs-roles"],"subtype":"company","role":"","period":""},"reading":"Sophia Genetics SA (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"genomic-health","record":{"id":"genomic-health","name":"Genomic Health Inc.","type":"organization","group":"other","claim_ids":["c-ppl-hibbs-roles"],"subtype":"company","role":"","period":""},"reading":"Genomic Health Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"passport","record":{"id":"passport","name":"Passport Capital, LLC","type":"organization","group":"other","claim_ids":["c-gov-wojcicki-background"],"subtype":"company","role":"","period":""},"reading":"Passport Capital, LLC (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"andor","record":{"id":"andor","name":"Andor Capital Management","type":"organization","group":"other","claim_ids":["c-gov-wojcicki-background"],"subtype":"company","role":"","period":""},"reading":"Andor Capital Management (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"ardsley","record":{"id":"ardsley","name":"Ardsley Partners","type":"organization","group":"other","claim_ids":["c-gov-wojcicki-background"],"subtype":"company","role":"","period":""},"reading":"Ardsley Partners (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"investor-ab","record":{"id":"investor-ab","name":"Investor AB","type":"organization","group":"other","claim_ids":["c-gov-wojcicki-background"],"subtype":"company","role":"","period":""},"reading":"Investor AB (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"zipline","record":{"id":"zipline","name":"Zipline International, Inc.","type":"organization","group":"other","claim_ids":["c-gov-wojcicki-background","c-ppl-wojcicki-zipline","c-ppl-wojcicki-boards"],"subtype":"company","aliases":["Zipline, Inc."],"role":"","period":""},"reading":"Zipline International, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"ajax","record":{"id":"ajax","name":"AJAX I","type":"organization","group":"other","claim_ids":["c-gov-wojcicki-background","c-ppl-wojcicki-boards","c-ppl-ajax"],"subtype":"company","jurisdiction":"ky","identifiers":[{"scheme":"other","value":"0001824963","issuer":"U.S. Securities and Exchange Commission (Central Index Key)"}],"role":"","period":""},"reading":"AJAX I (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"cazoo","record":{"id":"cazoo","name":"Cazoo Group Ltd.","type":"organization","group":"other","claim_ids":["c-gov-wojcicki-background"],"subtype":"company","role":"","period":""},"reading":"Cazoo Group Ltd. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"kp-school","record":{"id":"kp-school","name":"Kaiser Permanente Bernard J. Tyson School of Medicine","type":"organization","group":"other","claim_ids":["c-gov-wojcicki-background","c-ppl-wojcicki-boards"],"subtype":"other","role":"","period":""},"reading":"Kaiser Permanente Bernard J. Tyson School of Medicine (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"breakthrough-prize","record":{"id":"breakthrough-prize","name":"Breakthrough Prize in Life Sciences","type":"organization","group":"other","claim_ids":["c-gov-wojcicki-background","c-ppl-wojcicki-boards"],"subtype":"other","role":"","period":""},"reading":"Breakthrough Prize in Life Sciences (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"blok24","record":{"id":"blok24","name":"Blok24, Inc.","type":"organization","group":"other","claim_ids":["c-ppl-wojcicki-boards"],"subtype":"company","role":"","period":""},"reading":"Blok24, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"fnih","record":{"id":"fnih","name":"Foundation for the National Institutes of Health, Inc.","type":"organization","group":"other","claim_ids":["c-gov-wojcicki-background","c-ppl-wojcicki-boards"],"subtype":"other","role":"","period":""},"reading":"Foundation for the National Institutes of Health, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"sidecar","record":{"id":"sidecar","name":"Sidecar Health, Inc.","type":"organization","group":"other","claim_ids":["c-ppl-wojcicki-boards"],"subtype":"company","role":"","period":""},"reading":"Sidecar Health, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"nodal-exchange","record":{"id":"nodal-exchange","name":"Nodal Exchange LLC","type":"organization","group":"other","claim_ids":["c-ppl-cusenza"],"subtype":"company","role":"","period":""},"reading":"Nodal Exchange LLC (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"nodal-holdings","record":{"id":"nodal-holdings","name":"Nodal Exchange Holdings LLC","type":"organization","group":"other","claim_ids":["c-ppl-cusenza"],"subtype":"company","role":"","period":""},"reading":"Nodal Exchange Holdings LLC (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"nodal-clear","record":{"id":"nodal-clear","name":"Nodal Clear LLC","type":"organization","group":"other","claim_ids":["c-ppl-cusenza"],"subtype":"company","role":"","period":""},"reading":"Nodal Clear LLC (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"perlegen","record":{"id":"perlegen","name":"Perlegen Sciences, Inc.","type":"organization","group":"other","claim_ids":["c-ppl-cusenza"],"subtype":"company","role":"","period":""},"reading":"Perlegen Sciences, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"humain","record":{"id":"humain","name":"Humain Ventures","type":"organization","group":"other","claim_ids":["c-ppl-avey"],"subtype":"company","role":"","period":""},"reading":"Humain Ventures (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"precisely","record":{"id":"precisely","name":"Precisely, Inc.","type":"organization","group":"other","claim_ids":["c-ppl-avey"],"subtype":"company","role":"","period":""},"reading":"Precisely, Inc. (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"rock-health","record":{"id":"rock-health","name":"Rock Health","type":"organization","group":"other","claim_ids":["c-ppl-avey"],"subtype":"company","role":"","period":""},"reading":"Rock Health (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"entities","id":"artradis","record":{"id":"artradis","name":"Artradis Fund Management Pte Ltd","type":"organization","group":"other","claim_ids":["c-ppl-magides"],"subtype":"company","role":"","period":""},"reading":"Artradis Fund Management Pte Ltd (organization)"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-wojcicki-holdco-ceo","record":{"id":"r-wojcicki-holdco-ceo","from":"wojcicki","to":"holdco","status":"documented","role":"Chief executive officer and president","period":"From the June 16, 2021 closing until 5:00 p.m. ET on March 23, 2025","claim_ids":["c-gov-wojcicki-roles","c-gov-ceo-resignation","c-gov-wojcicki-pay"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"wojcicki → holdco: Chief executive officer and president [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-wojcicki-holdco-director","record":{"id":"r-wojcicki-holdco-director","from":"wojcicki","to":"holdco","status":"documented","role":"Director (chair from June 16, 2021 until March 21, 2025; sole director from September 17 to October 28, 2024; non-independent Class III director)","period":"Elected at the June 10, 2021 VGAC meeting, effective at the June 16, 2021 closing; sole director September 17 – October 28, 2024; still a director in July 2025","claim_ids":["c-spac-board-elect","c-gov-wojcicki-roles","c-gov-sole-director","c-gov-ceo-resignation","c-gov-board-2025","c-ch-excluded-parties"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"wojcicki → holdco: Director (chair from June 16, 2021 until March 21, 2025; sole director from September 17 to October 28, 2024; non-independent Class III director) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-wojcicki-holdco-vote","record":{"id":"r-wojcicki-holdco-vote","from":"wojcicki","to":"holdco","status":"documented","role":"Beneficial owner of shares carrying a large share of the vote, directly and through ABeeC 2.0, LLC, her revocable trust and her foundation (30.67% of the vote after the merger, 49.75% on July 1, 2024, 12.33% on July 1, 2025)","period":"From June 16, 2021; about 49% with affiliates when the Special Committee was formed in March 2024; reduced after the June 2025 conversion of the Class B shares","claim_ids":["c-ctl-2021","c-ctl-2024-wojcicki","c-gov-special-committee","c-ctl-2025-early","c-ctl-conversion","c-ctl-2025-july","c-gov-resignations"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"wojcicki → holdco: Beneficial owner of shares carrying a large share of the vote, directly and through ABeeC 2.0, LLC, her revocable trust and her foundation (30.67% of the vote after the merger, 49.75% on July 1, 2024, 12.33% on July 1, 2025) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-wojcicki-holdco-bids","record":{"id":"r-wojcicki-holdco-bids","from":"wojcicki","to":"holdco","status":"documented","role":"Bidder in take-private proposals for the company, which the Special Committee did not accept","period":"April 2024 – March 2025","claim_ids":["c-gov-go-private-2024","c-gov-feb-march-2025","c-gov-march-2025-final","c-gov-strategic-review","c-gov-guidelines"],"kind":"business","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"wojcicki → holdco: Bidder in take-private proposals for the company, which the Special Committee did not accept [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-wojcicki-holdco-pipe","record":{"id":"r-wojcicki-holdco-pipe","from":"wojcicki","to":"holdco","status":"documented","role":"Announced $25 million investment in the PIPE accompanying the merger","period":"Announced February 4, 2021","claim_ids":["c-spac-announcement"],"kind":"business","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"wojcicki → holdco: Announced $25 million investment in the PIPE accompanying the merger [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-wojcicki-holdco-excluded","record":{"id":"r-wojcicki-holdco-excluded","from":"wojcicki","to":"holdco","status":"documented","role":"Excluded Party under the plan (not released; the trust may bring claims); holder of Class 12 equity interests whose indemnification rights are preserved","period":"Plan confirmed December 1, 2025","claim_ids":["c-ch-excluded-parties","c-ch-wojcicki-resolution"],"kind":"legal","direction":"directed","role_group":"legal","temporal_status":"unknown"},"reading":"wojcicki → holdco: Excluded Party under the plan (not released; the trust may bring claims); holder of Class 12 equity interests whose indemnification rights are preserved [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-wojcicki-holdco-admin","record":{"id":"r-wojcicki-holdco-admin","from":"wojcicki","to":"holdco","status":"documented","role":"Applicant for payment of her indemnification expenses as an administrative expense of the estates","period":"Application of January 3, 2026","claim_ids":["c-ch-wojcicki-application","c-ch-admin-claims-2026"],"kind":"legal","direction":"directed","role_group":"business","temporal_status":"unknown"},"reading":"wojcicki → holdco: Applicant for payment of her indemnification expenses as an administrative expense of the estates [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-selsavage-holdco","record":{"id":"r-selsavage-holdco","from":"selsavage","to":"holdco","status":"documented","role":"Chief financial and accounting officer from August 2022; interim chief executive officer and president from March 23, 2025; chief executive officer by December 2025","period":"From August 2022; interim CEO from March 23, 2025; titled chief executive officer in a December 4, 2025 filing","claim_ids":["c-gov-selsavage","c-gov-march-2025-appointments","c-gov-selsavage-titles","c-br-senate","c-gov-officers-2024"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"selsavage → holdco: Chief financial and accounting officer from August 2022; interim chief executive officer and president from March 23, 2025; chief executive officer by December 2025 [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-walper-holdco","record":{"id":"r-walper-holdco","from":"walper","to":"holdco","status":"documented","role":"Independent Class III director and member of the Special Committee; led the independent investigation","period":"From March 23, 2025; on the board in July 2025","claim_ids":["c-gov-march-2025-appointments","c-gov-investigation","c-gov-walper","c-gov-walper-getty","c-gov-board-2025"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"walper → holdco: Independent Class III director and member of the Special Committee; led the independent investigation [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-walper-holdco-pa","record":{"id":"r-walper-holdco-pa","from":"walper","to":"holdco","status":"documented","role":"Initial Plan Administrator, representing the estates","period":"From the effective date, December 5, 2025","claim_ids":["c-ch-plan-administrator"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"current"},"reading":"walper → holdco: Initial Plan Administrator, representing the estates [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-kvarda-holdco","record":{"id":"r-kvarda-holdco","from":"kvarda","to":"holdco","status":"documented","role":"Chief restructuring officer, provided by Alvarez & Marsal; foreign representative in the Canadian recognition proceedings","period":"From March 23, 2025","claim_ids":["c-gov-march-2025-appointments","c-ch-advisers","c-gov-kvarda","c-ch-plan-august","c-st-ccaa"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"kvarda → holdco: Chief restructuring officer, provided by Alvarez & Marsal; foreign representative in the Canadian recognition proceedings [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-holdco-alvarez-marsal","record":{"id":"r-holdco-alvarez-marsal","from":"holdco","to":"alvarez-marsal","status":"documented","role":"Client of the restructuring adviser, which provided the chief restructuring officer","period":"Engaged January 2025; CRO from March 23, 2025","claim_ids":["c-gov-march-2025-appointments","c-ch-advisers","c-gov-kvarda","c-ch-cash-fees"],"kind":"business","direction":"directed","role_group":"business","temporal_status":"unknown"},"reading":"holdco → alvarez-marsal: Client of the restructuring adviser, which provided the chief restructuring officer [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-holdco-jmb","record":{"id":"r-holdco-jmb","from":"holdco","to":"jmb","status":"documented","role":"Borrower and grantor of security under the debtor-in-possession financing","period":"From March 2025 until repaid at the July 14, 2025 sale closing","claim_ids":["c-ch-dip"],"kind":"business","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"holdco → jmb: Borrower and grantor of security under the debtor-in-possession financing [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-holdco-nasdaq","record":{"id":"r-holdco-nasdaq","from":"holdco","to":"nasdaq","status":"documented","role":"Listed issuer of Class A common stock (ticker ME)","period":"From June 17, 2021 until delisting effective March 31, 2025","claim_ids":["c-id-listing","c-id-delisting"],"kind":"other","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"holdco → nasdaq: Listed issuer of Class A common stock (ticker ME) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-holdco-inc","record":{"id":"r-holdco-inc","from":"holdco","to":"inc","status":"documented","role":"Sole shareholder of the operating company (renamed ChromeCo, Inc. in 2025)","period":"From the June 16, 2021 merger","claim_ids":["c-spac-closing","c-spac-same-registrant","c-ch-debtor-structure","c-ch-filing","c-id-trademark-names","c-id-agg-inc","c-ch-tax-ids","c-br-ico-penalty","c-br-ico-amount","c-sale-ftc-letter"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"unknown"},"reading":"holdco → inc: Sole shareholder of the operating company (renamed ChromeCo, Inc. in 2025) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-holdco-inc-merger","record":{"id":"r-holdco-inc-merger","from":"holdco","to":"inc","status":"documented","role":"Acquirer of 23andMe, Inc. under the merger agreement of February 4, 2021 (through Chrome Merger Sub, Inc.)","period":"Signed February 4, 2021; closed June 16, 2021","claim_ids":["c-spac-announcement","c-spac-vote"],"kind":"business","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"holdco → inc: Acquirer of 23andMe, Inc. under the merger agreement of February 4, 2021 (through Chrome Merger Sub, Inc.) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-holdco-lemonaid","record":{"id":"r-holdco-lemonaid","from":"holdco","to":"lemonaid-health","status":"documented","role":"Sole shareholder of Lemonaid Health, Inc. after its acquisition","period":"From November 2021 until the sale to Lemonaid SPV, Inc. under the confirmed plan","claim_ids":["c-lem-acquisition","c-ch-debtor-structure","c-ch-filing","c-ch-tax-ids","c-lem-pixel-settlement","c-sale-ftc-letter"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"holdco → lemonaid-health: Sole shareholder of Lemonaid Health, Inc. after its acquisition [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-holdco-lemonaid-merger","record":{"id":"r-holdco-lemonaid-merger","from":"holdco","to":"lemonaid-health","status":"documented","role":"Acquirer under the merger agreement of October 21, 2021 ($400 million in cash and Class A shares)","period":"Signed October 21, 2021; closed November 2021","claim_ids":["c-lem-acquisition"],"kind":"business","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"holdco → lemonaid-health: Acquirer under the merger agreement of October 21, 2021 ($400 million in cash and Class A shares) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-holdco-pharmacy","record":{"id":"r-holdco-pharmacy","from":"holdco","to":"pharmacy-holdings","status":"documented","role":"Parent company of 23andMe Pharmacy Holdings, Inc. (renamed Chrome Pharmacy Holdings, Inc.)","period":"As of the March 2025 petitions","claim_ids":["c-ch-debtor-structure","c-ch-filing","c-id-trademark-names","c-ch-tax-ids","c-id-agg-pharmacy"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"unknown"},"reading":"holdco → pharmacy-holdings: Parent company of 23andMe Pharmacy Holdings, Inc. (renamed Chrome Pharmacy Holdings, Inc.) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-holdco-lph","record":{"id":"r-holdco-lph","from":"holdco","to":"lemonaid-pharmacy-holdings","status":"documented","role":"Group parent of a debtor subsidiary","period":"As of the March 2025 petitions","claim_ids":["c-ch-filing"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"unknown"},"reading":"holdco → lemonaid-pharmacy-holdings: Group parent of a debtor subsidiary [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-holdco-lcp","record":{"id":"r-holdco-lcp","from":"holdco","to":"lemonaid-community-pharmacy","status":"documented","role":"Group parent of a debtor subsidiary","period":"As of the March 2025 petitions","claim_ids":["c-ch-filing"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"unknown"},"reading":"holdco → lemonaid-community-pharmacy: Group parent of a debtor subsidiary [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-holdco-lpharm-ins","record":{"id":"r-holdco-lpharm-ins","from":"holdco","to":"lpharm-ins","status":"documented","role":"Group parent of a debtor subsidiary","period":"As of the March 2025 petitions","claim_ids":["c-ch-filing"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"unknown"},"reading":"holdco → lpharm-ins: Group parent of a debtor subsidiary [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-holdco-lpharm-cs","record":{"id":"r-holdco-lpharm-cs","from":"holdco","to":"lpharm-cs","status":"documented","role":"Group parent of a debtor subsidiary","period":"As of the March 2025 petitions","claim_ids":["c-ch-filing"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"unknown"},"reading":"holdco → lpharm-cs: Group parent of a debtor subsidiary [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-holdco-lpharm-rx","record":{"id":"r-holdco-lpharm-rx","from":"holdco","to":"lpharm-rx","status":"documented","role":"Group parent of a debtor subsidiary","period":"As of the March 2025 petitions","claim_ids":["c-ch-filing"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"unknown"},"reading":"holdco → lpharm-rx: Group parent of a debtor subsidiary [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-holdco-lprxone","record":{"id":"r-holdco-lprxone","from":"holdco","to":"lprxone","status":"documented","role":"Group parent of a debtor subsidiary","period":"As of the March 2025 petitions","claim_ids":["c-ch-filing","c-ch-related-cases"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"unknown"},"reading":"holdco → lprxone: Group parent of a debtor subsidiary [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-holdco-lprxtwo","record":{"id":"r-holdco-lprxtwo","from":"holdco","to":"lprxtwo","status":"documented","role":"Group parent of a debtor subsidiary","period":"As of the March 2025 petitions","claim_ids":["c-ch-filing"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"unknown"},"reading":"holdco → lprxtwo: Group parent of a debtor subsidiary [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-holdco-lprxthree","record":{"id":"r-holdco-lprxthree","from":"holdco","to":"lprxthree","status":"documented","role":"Group parent of a debtor subsidiary","period":"As of the March 2025 petitions","claim_ids":["c-ch-filing"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"unknown"},"reading":"holdco → lprxthree: Group parent of a debtor subsidiary [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-abeec-holdco","record":{"id":"r-abeec-holdco","from":"abeec","to":"holdco","status":"documented","role":"Holder of the Class B super-voting block (49.20% of the vote on July 1, 2024); converted its 4,931,692 Class B shares into Class A in June 2025","period":"From the June 16, 2021 merger; Class A holder after June 11, 2025","claim_ids":["c-ctl-2021","c-ctl-2024-wojcicki","c-ctl-13d-filings","c-ctl-2025-early","c-ctl-conversion","c-ctl-2025-july"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"unknown"},"reading":"abeec → holdco: Holder of the Class B super-voting block (49.20% of the vote on July 1, 2024); converted its 4,931,692 Class B shares into Class A in June 2025 [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-awtrust-abeec","record":{"id":"r-awtrust-abeec","from":"aw-trust","to":"abeec","status":"documented","role":"Sole member of ABeeC 2.0, LLC","period":"As of July 1, 2024","claim_ids":["c-ctl-2024-wojcicki"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"unknown"},"reading":"aw-trust → abeec: Sole member of ABeeC 2.0, LLC [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-awtrust-holdco","record":{"id":"r-awtrust-holdco","from":"aw-trust","to":"holdco","status":"documented","role":"Indirect holder of the Class B block as sole member of ABeeC 2.0, LLC, sharing voting and dispositive power","period":"As of July 1, 2024","claim_ids":["c-ctl-2024-wojcicki"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"unknown"},"reading":"aw-trust → holdco: Indirect holder of the Class B block as sole member of ABeeC 2.0, LLC, sharing voting and dispositive power [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-wojcicki-abeec","record":{"id":"r-wojcicki-abeec","from":"wojcicki","to":"abeec","status":"documented","role":"Controls the LLC as sole trustee of its sole member and votes and disposes of its shares","period":"From 2021","claim_ids":["c-ctl-2024-wojcicki","c-ctl-2025-early","c-ctl-2025-july","c-ch-wojcicki-resolution"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"unknown"},"reading":"wojcicki → abeec: Controls the LLC as sole trustee of its sole member and votes and disposes of its shares [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-wojcicki-awf","record":{"id":"r-wojcicki-awf","from":"wojcicki","to":"aw-foundation","status":"documented","role":"President and chair of the board; shares voting and dispositive power over the foundation's shares","period":"As of 2024–2025","claim_ids":["c-ctl-2024-wojcicki","c-ctl-conversion","c-ctl-awf-holding","c-ppl-awf","c-ch-wojcicki-resolution"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"wojcicki → aw-foundation: President and chair of the board; shares voting and dispositive power over the foundation's shares [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-gsk-holdco","record":{"id":"r-gsk-holdco","from":"gsk","to":"holdco","status":"documented","role":"Indirect holder, through Glaxo Group Limited, of 23.82% of the Class B shares and 19.78% of the vote","period":"As of July 1, 2024","claim_ids":["c-ctl-2024-holders"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"unknown"},"reading":"gsk → holdco: Indirect holder, through Glaxo Group Limited, of 23.82% of the Class B shares and 19.78% of the vote [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-glaxo-holdco","record":{"id":"r-glaxo-holdco","from":"glaxo-group","to":"holdco","status":"documented","role":"Direct holder of 39,660,487 Class B shares (12.28% of the vote after the merger)","period":"From June 16, 2021; as of July 1, 2024","claim_ids":["c-ctl-2021","c-ctl-2024-holders"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"unknown"},"reading":"glaxo-group → holdco: Direct holder of 39,660,487 Class B shares (12.28% of the vote after the merger) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-holdco-glaxo-collab","record":{"id":"r-holdco-glaxo-collab","from":"holdco","to":"glaxo-group","status":"documented","role":"Counterparty, with a GSK affiliate, to the exclusive drug-discovery collaboration (July 2018 – July 2023), amended into a non-exclusive data licence","period":"From July 2018; amended October 2023","claim_ids":["c-gov-related-party"],"kind":"business","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"holdco → glaxo-group: Counterparty, with a GSK affiliate, to the exclusive drug-discovery collaboration (July 2018 – July 2023), amended into a non-exclusive data licence [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-holdco-gsk-data","record":{"id":"r-holdco-gsk-data","from":"holdco","to":"gsk","status":"documented","role":"Licensor of data to GSK; recognised $19.3 million on GSK's data use notice in fiscal 2025","period":"Fiscal 2025 (under the 2023 amendment)","claim_ids":["c-ch-revenue-fy25","c-gov-related-party","c-ch-finances"],"kind":"business","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"holdco → gsk: Licensor of data to GSK; recognised $19.3 million on GSK's data use notice in fiscal 2025 [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-sequoia-holdco","record":{"id":"r-sequoia-holdco","from":"sc-us-ttgp","to":"holdco","status":"documented","role":"Entity of the Sequoia Capital group whose directors exercised voting and investment discretion over 10.70% of the Class B shares (8.89% of the vote)","period":"As of July 1, 2024","claim_ids":["c-ctl-2024-holders"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"unknown"},"reading":"sc-us-ttgp → holdco: Entity of the Sequoia Capital group whose directors exercised voting and investment discretion over 10.70% of the Class B shares (8.89% of the vote) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-newview-holdco","record":{"id":"r-newview-holdco","from":"newview","to":"holdco","status":"documented","role":"Holder of 5.73% of the Class A shares","period":"As of July 1, 2024","claim_ids":["c-ctl-2024-holders"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"unknown"},"reading":"newview → holdco: Holder of 5.73% of the Class A shares [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-vanguard-holdco","record":{"id":"r-vanguard-holdco","from":"vanguard","to":"holdco","status":"documented","role":"Holder of 6.64% of the Class A shares","period":"As of July 1, 2024","claim_ids":["c-ctl-2024-holders"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"unknown"},"reading":"vanguard → holdco: Holder of 6.64% of the Class A shares [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-gsquared-holdco","record":{"id":"r-gsquared-holdco","from":"g-squared","to":"holdco","status":"documented","role":"Adviser to funds holding 9.44% of the vote","period":"Immediately after the June 16, 2021 merger","claim_ids":["c-ctl-2021"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"unknown"},"reading":"g-squared → holdco: Adviser to funds holding 9.44% of the vote [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-fmr-holdco","record":{"id":"r-fmr-holdco","from":"fmr","to":"holdco","status":"documented","role":"Parent of funds holding 7.79% of the vote","period":"Immediately after the June 16, 2021 merger","claim_ids":["c-ctl-2021"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"unknown"},"reading":"fmr → holdco: Parent of funds holding 7.79% of the vote [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-botha-holdco","record":{"id":"r-botha-holdco","from":"botha","to":"holdco","status":"documented","role":"Independent director (audit committee)","period":"June 16, 2021 – September 17, 2024 (elected June 10, 2021)","claim_ids":["c-spac-board-elect","c-gov-botha","c-gov-board-2024","c-gov-resignations"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"botha → holdco: Independent director (audit committee) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-chung-holdco","record":{"id":"r-chung-holdco","from":"chung","to":"holdco","status":"documented","role":"Independent director (audit and compensation committees)","period":"June 16, 2021 – September 17, 2024 (elected June 10, 2021)","claim_ids":["c-spac-board-elect","c-gov-chung","c-gov-board-2024","c-gov-resignations","c-ppl-chung-roles"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"chung → holdco: Independent director (audit and compensation committees) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-hernandez-holdco","record":{"id":"r-hernandez-holdco","from":"hernandez","to":"holdco","status":"documented","role":"Independent director (Special Committee)","period":"November 2021 – September 17, 2024","claim_ids":["c-gov-hernandez","c-gov-board-2024","c-gov-resignations"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"hernandez → holdco: Independent director (Special Committee) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-mohan-holdco","record":{"id":"r-mohan-holdco","from":"mohan","to":"holdco","status":"documented","role":"Independent director (compensation committee)","period":"June 16, 2021 – September 17, 2024 (elected June 10, 2021)","claim_ids":["c-spac-board-elect","c-gov-mohan","c-gov-board-2024","c-gov-resignations"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"mohan → holdco: Independent director (compensation committee) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-montgomery-rice-holdco","record":{"id":"r-montgomery-rice-holdco","from":"montgomery-rice","to":"holdco","status":"documented","role":"Class II director and chair of the compensation committee","period":"June 16, 2021 – September 17, 2024","claim_ids":["c-gov-board-2021","c-gov-board-2024","c-gov-resignations","c-ppl-montgomery-rice-roles"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"montgomery-rice → holdco: Class II director and chair of the compensation committee [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-scheller-holdco","record":{"id":"r-scheller-holdco","from":"scheller","to":"holdco","status":"documented","role":"Non-independent director","period":"June 16, 2021 – September 17, 2024 (elected June 10, 2021)","claim_ids":["c-spac-board-elect","c-gov-scheller","c-gov-board-2024","c-gov-resignations"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"scheller → holdco: Non-independent director [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-taylor-holdco","record":{"id":"r-taylor-holdco","from":"taylor","to":"holdco","status":"documented","role":"Independent Class III director, chair of the audit committee and member of the Special Committee","period":"June 16, 2021 – September 17, 2024 (elected June 10, 2021)","claim_ids":["c-spac-board-elect","c-gov-board-2024","c-gov-resignations"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"taylor → holdco: Independent Class III director, chair of the audit committee and member of the Special Committee [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-inc-scheller-consulting","record":{"id":"r-inc-scheller-consulting","from":"inc","to":"scheller","status":"documented","role":"Engaged director Richard Scheller as a consultant ($10,000 a month at the start; $120,000 paid in fiscal 2024)","period":"April 1, 2019 – March 31, 2024","claim_ids":["c-gov-related-party"],"kind":"business","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"inc → scheller: Engaged director Richard Scheller as a consultant ($10,000 a month at the start; $120,000 paid in fiscal 2024) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-richards-holdco","record":{"id":"r-richards-holdco","from":"richards","to":"holdco","status":"documented","role":"Head of Therapeutics Discovery; executive officer from August 8, 2023 to August 23, 2024","period":"August 8, 2023 – August 23, 2024","claim_ids":["c-gov-officers-2024","c-gov-officer-pay"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"richards → holdco: Head of Therapeutics Discovery; executive officer from August 8, 2023 to August 23, 2024 [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-hibbs-holdco","record":{"id":"r-hibbs-holdco","from":"hibbs","to":"holdco","status":"documented","role":"Chief Administrative Officer (a named executive officer for fiscal 2024)","period":"Former officer by the 2024 proxy","claim_ids":["c-gov-officers-2024","c-ppl-hibbs-roles"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"hibbs → holdco: Chief Administrative Officer (a named executive officer for fiscal 2024) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-hillan-holdco","record":{"id":"r-hillan-holdco","from":"hillan","to":"holdco","status":"documented","role":"Chief Therapeutics Officer (a named executive officer for fiscal 2024)","period":"Former officer by the 2024 proxy","claim_ids":["c-gov-officers-2024"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"hillan → holdco: Chief Therapeutics Officer (a named executive officer for fiscal 2024) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-wojcicki-inc","record":{"id":"r-wojcicki-inc","from":"wojcicki","to":"inc","status":"documented","role":"Co-founder; director from 2006 and chief executive officer from 2010","period":"2006 – March 21, 2025 (resigned as director and officer)","claim_ids":["c-gov-wojcicki-roles","c-gov-founding","c-gov-ceo-resignation"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"wojcicki → inc: Co-founder; director from 2006 and chief executive officer from 2010 [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-wojcicki-zipline","record":{"id":"r-wojcicki-zipline","from":"wojcicki","to":"zipline","status":"documented","role":"Member of the board of directors","period":"From September 2021 (announcement)","claim_ids":["c-gov-wojcicki-background","c-ppl-wojcicki-boards","c-ppl-wojcicki-zipline"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"wojcicki → zipline: Member of the board of directors [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-wojcicki-ajax","record":{"id":"r-wojcicki-ajax","from":"wojcicki","to":"ajax","status":"documented","role":"Director of the blank check company","period":"2020 – 2021","claim_ids":["c-gov-wojcicki-background","c-ppl-wojcicki-boards"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"wojcicki → ajax: Director of the blank check company [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-wojcicki-cazoo","record":{"id":"r-wojcicki-cazoo","from":"wojcicki","to":"cazoo","status":"documented","role":"Director","period":"2021 – 2022","claim_ids":["c-gov-wojcicki-background"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"wojcicki → cazoo: Director [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-wojcicki-awtrust","record":{"id":"r-wojcicki-awtrust","from":"wojcicki","to":"aw-trust","status":"documented","role":"Sole trustee","period":"As of 2024–2025","claim_ids":["c-ctl-2024-wojcicki","c-ctl-2025-early","c-ctl-13d-filings"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"wojcicki → aw-trust: Sole trustee [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-kpmg-holdco","record":{"id":"r-kpmg-holdco","from":"kpmg","to":"holdco","status":"documented","role":"Independent registered public accounting firm (auditor since 2020)","period":"From 2020; audit report on fiscal 2025 dated June 11, 2025","claim_ids":["c-gov-board-2024","c-ch-balance-sheet","c-ch-kpmg-fees"],"kind":"other","direction":"directed","role_group":"business","temporal_status":"unknown"},"reading":"kpmg → holdco: Independent registered public accounting firm (auditor since 2020) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-botha-inc","record":{"id":"r-botha-inc","from":"botha","to":"inc","status":"documented","role":"Director of 23andMe, Inc.","period":"From 2017","claim_ids":["c-gov-botha"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"botha → inc: Director of 23andMe, Inc. [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-botha-sequoia","record":{"id":"r-botha-sequoia","from":"botha","to":"sequoia-ops","status":"documented","role":"Managing Member","period":"From 2007 (with Sequoia Capital since 2003); until 2025 according to a market-data summary","claim_ids":["c-gov-botha"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"botha → sequoia-ops: Managing Member [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-chung-inc","record":{"id":"r-chung-inc","from":"chung","to":"inc","status":"documented","role":"Director of 23andMe, Inc.","period":"2009 – 2024","claim_ids":["c-gov-chung","c-ppl-chung-roles"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"chung → inc: Director of 23andMe, Inc. [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-chung-xfund","record":{"id":"r-chung-xfund","from":"chung","to":"xfund","status":"documented","role":"Managing General Partner of Xfund (aggregator: of Xfund Management Co. LLC since 2012)","period":"From 2015 according to the 2024 proxy; from 2012 according to an aggregator","claim_ids":["c-gov-chung","c-ppl-chung-roles"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"chung → xfund: Managing General Partner of Xfund (aggregator: of Xfund Management Co. LLC since 2012) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-chung-xfund3","record":{"id":"r-chung-xfund3","from":"chung","to":"xfund-3","status":"documented","role":"Managing Director of the general partner; signed the fund's Form D","period":"April 17, 2019","claim_ids":["c-ppl-chung-roles"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"chung → xfund-3: Managing Director of the general partner; signed the fund's Form D [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-scheller-inc","record":{"id":"r-scheller-inc","from":"scheller","to":"inc","status":"documented","role":"Chief scientific officer and head of therapeutics (2015–2019); director from 2019","period":"2015 – 2019 (officer); director from 2019","claim_ids":["c-gov-scheller","c-ppl-scheller-roles"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"scheller → inc: Chief scientific officer and head of therapeutics (2015–2019); director from 2019 [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-scheller-bridgebio","record":{"id":"r-scheller-bridgebio","from":"scheller","to":"bridgebio","status":"documented","role":"Board member from 2018 and chairman of R&D from 2019 (senior advisor)","period":"From 2018","claim_ids":["c-gov-scheller","c-ppl-scheller-roles"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"current"},"reading":"scheller → bridgebio: Board member from 2018 and chairman of R&D from 2019 (senior advisor) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-mohan-inc","record":{"id":"r-mohan-inc","from":"mohan","to":"inc","status":"documented","role":"Director of 23andMe, Inc.","period":"From 2017 (aggregator: until 2024)","claim_ids":["c-gov-mohan","c-ppl-mohan-roles"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"mohan → inc: Director of 23andMe, Inc. [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-mohan-youtube","record":{"id":"r-mohan-youtube","from":"mohan","to":"youtube","status":"documented","role":"Chief executive officer","period":"From 2023","claim_ids":["c-gov-mohan","c-ppl-mohan-roles"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"current"},"reading":"mohan → youtube: Chief executive officer [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-hernandez-chcf","record":{"id":"r-hernandez-chcf","from":"hernandez","to":"chcf","status":"documented","role":"President and chief executive officer","period":"From 2014","claim_ids":["c-gov-hernandez","c-ppl-hernandez-roles"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"current"},"reading":"hernandez → chcf: President and chief executive officer [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-montgomery-rice-msm","record":{"id":"r-montgomery-rice-msm","from":"montgomery-rice","to":"morehouse","status":"documented","role":"President and dean (at the school since 2011)","period":"From 2011 (dean and executive vice president before the presidency)","claim_ids":["c-gov-montgomery-rice","c-ppl-montgomery-rice-roles"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"current"},"reading":"montgomery-rice → morehouse: President and dean (at the school since 2011) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-holdco-ttam-sale","record":{"id":"r-holdco-ttam-sale","from":"holdco","to":"ttam","status":"documented","role":"Seller to TTAM, through the NewCo equity sale, of substantially all the Chrome debtors' assets, including customers' genetic data, for $302.5 million in cash plus assumed liabilities","period":"Chosen as winning bidder June 13, 2025; sale order June 27, 2025; closed July 14, 2025","claim_ids":["c-sale-ttam-wins","c-sale-newco","c-sale-ttam-terms","c-sale-opinion","c-sale-opinion-price","c-sale-opinion-newco","c-sale-closing","c-sale-pa-ag","c-sale-district-court","c-sale-ttam-origin","c-sale-states-objection","c-sale-appeals-stay","c-st-states-findings","c-ch-third-plan-buyer","c-sale-opinion-cpo"],"kind":"business","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"holdco → ttam: Seller to TTAM, through the NewCo equity sale, of substantially all the Chrome debtors' assets, including customers' genetic data, for $302.5 million in cash plus assumed liabilities [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-ttam-holdco-appeal","record":{"id":"r-ttam-holdco-appeal","from":"ttam","to":"holdco","status":"documented","role":"Intervenor-appellee with the debtors in the appeal of California and others against the sale order","period":"Appeal dismissed September 29, 2026","claim_ids":["c-sale-district-court"],"kind":"legal","direction":"directed","role_group":"legal","temporal_status":"historical"},"reading":"ttam → holdco: Intervenor-appellee with the debtors in the appeal of California and others against the sale order [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-ttam-holdco-opinion","record":{"id":"r-ttam-holdco-opinion","from":"ttam","to":"holdco","status":"documented","role":"Buyer defending the sale with the debtors against the states' objections","period":"June 2025 sale hearing","claim_ids":["c-sale-opinion","c-sale-opinion-cpo"],"kind":"legal","direction":"directed","role_group":"legal","temporal_status":"historical"},"reading":"ttam → holdco: Buyer defending the sale with the debtors against the states' objections [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-ttam-holdco-converge","record":{"id":"r-ttam-holdco-converge","from":"ttam","to":"holdco","status":"reported","role":"Buyer said by the wind-down debtors to have assumed the Converge invoices under the purchase agreement (trust keeps a reimbursement right)","period":"Dispute settled with Converge on March 4, 2026","claim_ids":["c-ch-converge-settlement"],"kind":"business","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"ttam → holdco: Buyer said by the wind-down debtors to have assumed the Converge invoices under the purchase agreement (trust keeps a reimbursement right) [reported]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-wojcicki-ttam","record":{"id":"r-wojcicki-ttam","from":"wojcicki","to":"ttam","status":"documented","role":"Creator, funder with her affiliates, chief executive officer, president and one of three directors","period":"From 2025 (formed soon after the March 23, 2025 petitions)","claim_ids":["c-sale-ttam-origin","c-sale-opinion-price","c-sale-pa-ag","c-sale-wojcicki-ttam-ceo","c-ch-wojcicki-resolution"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"current"},"reading":"wojcicki → ttam: Creator, funder with her affiliates, chief executive officer, president and one of three directors [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-batenchuk-abeec","record":{"id":"r-batenchuk-abeec","from":"batenchuk","to":"abeec","status":"documented","role":"Manager who signed the LLC's Schedule 13D filings","period":"February – March 2025 filings","claim_ids":["c-ctl-2025-early"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"batenchuk → abeec: Manager who signed the LLC's Schedule 13D filings [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-holdco-mergersub","record":{"id":"r-holdco-mergersub","from":"holdco","to":"chrome-merger-sub","status":"documented","role":"Parent of the merger subsidiary that merged into 23andMe, Inc.","period":"Until the merger on June 16, 2021","claim_ids":["c-spac-closing"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"holdco → chrome-merger-sub: Parent of the merger subsidiary that merged into 23andMe, Inc. [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-sponsor-holdco","record":{"id":"r-sponsor-holdco","from":"vgac-sponsor","to":"holdco","status":"documented","role":"Sponsor of VGAC holding all 12,623,750 founder shares (99.29% of Class B, 19.86% of all ordinary shares) and the sole right to elect directors before the merger","period":"Until the June 16, 2021 business combination","claim_ids":["c-spac-sponsor-chain","c-spac-13g","c-spac-pipe"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"vgac-sponsor → holdco: Sponsor of VGAC holding all 12,623,750 founder shares (99.29% of Class B, 19.86% of all ordinary shares) and the sole right to elect directors before the merger [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-lovell-holdco","record":{"id":"r-lovell-holdco","from":"lovell","to":"holdco","status":"documented","role":"Chief financial officer and director of VGAC; then Class III director of the combined company","period":"From February 2020 (VGAC); director of the combined company from June 16, 2021 until his death in June 2023","claim_ids":["c-spac-officers","c-spac-lovell","c-spac-board-elect","c-gov-lovell-end"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"lovell → holdco: Chief financial officer and director of VGAC; then Class III director of the combined company [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-bayliss-holdco","record":{"id":"r-bayliss-holdco","from":"bayliss","to":"holdco","status":"documented","role":"Chief executive officer and director of VGAC","period":"February 2020 – June 16, 2021","claim_ids":["c-spac-officers","c-spac-bayliss"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"bayliss → holdco: Chief executive officer and director of VGAC [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-briggs-holdco","record":{"id":"r-briggs-holdco","from":"briggs","to":"holdco","status":"documented","role":"Independent director of VGAC and chair of its audit committee","period":"October 2020 (initial public offering) – June 16, 2021","claim_ids":["c-spac-officers","c-spac-briggs"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"briggs → holdco: Independent director of VGAC and chair of its audit committee [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-lockhart-holdco","record":{"id":"r-lockhart-holdco","from":"lockhart","to":"holdco","status":"documented","role":"Independent director of VGAC","period":"October 2020 (initial public offering) – June 16, 2021","claim_ids":["c-spac-officers","c-spac-lockhart"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"lockhart → holdco: Independent director of VGAC [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-brown-holdco","record":{"id":"r-brown-holdco","from":"brown","to":"holdco","status":"documented","role":"Independent director of VGAC","period":"October 2020 (initial public offering) – June 16, 2021","claim_ids":["c-spac-officers","c-spac-brown"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"brown → holdco: Independent director of VGAC [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-zentree-holdco","record":{"id":"r-zentree-holdco","from":"zentree","to":"holdco","status":"documented","role":"Holder of Class A shares, reporting jointly with Richard Magides (5.02% in November 2024, 18.2% in March 2025; 14.55% and 7.95% of the vote on July 1, 2025)","period":"From November 8, 2024 (Schedule 13G); Schedule 13D from March 2025","claim_ids":["c-ctl-zentree-13g","c-ctl-zentree-13d","c-ctl-2025-july"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"unknown"},"reading":"zentree → holdco: Holder of Class A shares, reporting jointly with Richard Magides (5.02% in November 2024, 18.2% in March 2025; 14.55% and 7.95% of the vote on July 1, 2025) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-magides-holdco","record":{"id":"r-magides-holdco","from":"magides","to":"holdco","status":"documented","role":"Personal holder of Class A shares reporting jointly with Zentree (858,813 shares in November 2024; 3,132,593 on March 28, 2025)","period":"From November 8, 2024; as of March 28, 2025","claim_ids":["c-ctl-zentree-13g","c-ctl-zentree-13d"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"unknown"},"reading":"magides → holdco: Personal holder of Class A shares reporting jointly with Zentree (858,813 shares in November 2024; 3,132,593 on March 28, 2025) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-magides-zentree","record":{"id":"r-magides-zentree","from":"magides","to":"zentree","status":"documented","role":"Director","period":"As of the 2024–2025 filings","claim_ids":["c-ctl-zentree-13g","c-ctl-zentree-13d"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"magides → zentree: Director [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-zentree-zentreeim","record":{"id":"r-zentree-zentreeim","from":"zentree","to":"zentree-im","status":"documented","role":"Uses the Singapore manager as its address for correspondence (c/o)","period":"As of the 2024 filing","claim_ids":["c-ctl-zentree-13g"],"kind":"other","direction":"undirected","role_group":"associations","temporal_status":"unknown"},"reading":"zentree → zentree-im: Uses the Singapore manager as its address for correspondence (c/o) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-farallon-holdco","record":{"id":"r-farallon-holdco","from":"farallon","to":"holdco","status":"documented","role":"General partner of funds sharing voting and dispositive power over 6% of the Class A shares (Farallon Capital Partners, L.P.: 5.00% on July 1, 2025)","period":"Event date June 13, 2025; as of July 1, 2025","claim_ids":["c-ctl-farallon","c-ctl-2025-july"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"unknown"},"reading":"farallon → holdco: General partner of funds sharing voting and dispositive power over 6% of the Class A shares (Farallon Capital Partners, L.P.: 5.00% on July 1, 2025) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-corvina-holdco","record":{"id":"r-corvina-holdco","from":"corvina","to":"holdco","status":"documented","role":"Sole managing member and manager of VGAC's sponsor","period":"Until the June 16, 2021 business combination","claim_ids":["c-spac-sponsor-chain"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"corvina → holdco: Sole managing member and manager of VGAC's sponsor [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-vghl-holdco","record":{"id":"r-vghl-holdco","from":"vghl","to":"holdco","status":"documented","role":"Owner of Corvina Holdings Limited, the sponsor's manager","period":"Until the June 16, 2021 business combination","claim_ids":["c-spac-sponsor-chain"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"vghl → holdco: Owner of Corvina Holdings Limited, the sponsor's manager [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-branson-holdco","record":{"id":"r-branson-holdco","from":"branson","to":"holdco","status":"documented","role":"Owner of Virgin Group Holdings and deemed indirect beneficial owner of the sponsor's founder shares","period":"Until the June 16, 2021 business combination","claim_ids":["c-spac-sponsor-chain"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"branson → holdco: Owner of Virgin Group Holdings and deemed indirect beneficial owner of the sponsor's founder shares [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-branson-holdco-pipe","record":{"id":"r-branson-holdco-pipe","from":"branson","to":"holdco","status":"documented","role":"Announced $25 million investment in the PIPE accompanying the merger","period":"Announced February 4, 2021","claim_ids":["c-spac-announcement"],"kind":"business","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"branson → holdco: Announced $25 million investment in the PIPE accompanying the merger [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-avey-inc","record":{"id":"r-avey-inc","from":"avey","to":"inc","status":"documented","role":"Co-founder","period":"2006","claim_ids":["c-gov-founding","c-ppl-avey"],"kind":"other","direction":"directed","role_group":"associations","temporal_status":"historical"},"reading":"avey → inc: Co-founder [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-cusenza-inc","record":{"id":"r-cusenza-inc","from":"cusenza","to":"inc","status":"documented","role":"Co-founder","period":"2006","claim_ids":["c-gov-founding","c-ppl-cusenza"],"kind":"other","direction":"directed","role_group":"associations","temporal_status":"historical"},"reading":"cusenza → inc: Co-founder [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-jensen-holdco","record":{"id":"r-jensen-holdco","from":"jensen","to":"holdco","status":"documented","role":"Independent Class II director, Lead Independent Director and compensation committee chair; chairman of the board from March 21, 2025; Special Committee member","period":"From October 28, 2024 until December 2025","claim_ids":["c-gov-new-board","c-gov-march-2025-appointments","c-gov-jensen-lattice","c-gov-board-2025"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"jensen → holdco: Independent Class II director, Lead Independent Director and compensation committee chair; chairman of the board from March 21, 2025; Special Committee member [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-fernandez-holdco","record":{"id":"r-fernandez-holdco","from":"fernandez","to":"holdco","status":"documented","role":"Independent Class II director, audit committee chair and Special Committee member","period":"From October 28, 2024 (an aggregator dates it from October 27, 2024)","claim_ids":["c-gov-new-board","c-gov-board-2025","c-ppl-fernandez-roles"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"fernandez → holdco: Independent Class II director, audit committee chair and Special Committee member [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-frankola-holdco","record":{"id":"r-frankola-holdco","from":"frankola","to":"holdco","status":"documented","role":"Independent Class I director and Special Committee member","period":"From October 28, 2024 (an aggregator dates it from October 27, 2024)","claim_ids":["c-gov-new-board","c-gov-board-2025","c-gov-frankola","c-ppl-frankola-roles"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"frankola → holdco: Independent Class I director and Special Committee member [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-wojcicki-lemonaid","record":{"id":"r-wojcicki-lemonaid","from":"wojcicki","to":"lemonaid-health","status":"documented","role":"Director and officer","period":"Until March 21, 2025","claim_ids":["c-gov-ceo-resignation"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"wojcicki → lemonaid-health: Director and officer [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-wojcicki-pharmacy","record":{"id":"r-wojcicki-pharmacy","from":"wojcicki","to":"pharmacy-holdings","status":"documented","role":"Officer","period":"Until March 21, 2025","claim_ids":["c-gov-ceo-resignation"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"wojcicki → pharmacy-holdings: Officer [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-wojcicki-lph","record":{"id":"r-wojcicki-lph","from":"wojcicki","to":"lemonaid-pharmacy-holdings","status":"documented","role":"Officer","period":"Until March 21, 2025","claim_ids":["c-gov-ceo-resignation"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"wojcicki → lemonaid-pharmacy-holdings: Officer [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-regeneron-ttam","record":{"id":"r-regeneron-ttam","from":"regeneron","to":"ttam","status":"documented","role":"Rival bidder for the genetic-testing business (Regeneron first chosen, TTAM backup; then TTAM winner and Regeneron backup at $151 million)","period":"May 19 – June 13, 2025","claim_ids":["c-sale-regeneron","c-sale-ttam-wins"],"kind":"other","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"regeneron → ttam: Rival bidder for the genetic-testing business (Regeneron first chosen, TTAM backup; then TTAM winner and Regeneron backup at $151 million) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-wojcicki-newmountain","record":{"id":"r-wojcicki-newmountain","from":"wojcicki","to":"new-mountain","status":"documented","role":"Joint bidder with New Mountain Capital at $2.53 a share; New Mountain withdrew","period":"February 20 – March 3, 2025","claim_ids":["c-gov-feb-march-2025"],"kind":"business","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"wojcicki → new-mountain: Joint bidder with New Mountain Capital at $2.53 a share; New Mountain withdrew [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-holdco-isl","record":{"id":"r-holdco-isl","from":"holdco","to":"isl","status":"documented","role":"Registered agent in Delaware (as shown by an aggregator)","period":"As retrieved in 2026","claim_ids":["c-id-agg-holdco"],"kind":"other","direction":"directed","role_group":"business","temporal_status":"unknown"},"reading":"holdco → isl: Registered agent in Delaware (as shown by an aggregator) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-inc-isl","record":{"id":"r-inc-isl","from":"inc","to":"isl","status":"documented","role":"Registered agent in Delaware (as shown by an aggregator)","period":"As retrieved in 2026","claim_ids":["c-id-agg-inc"],"kind":"other","direction":"directed","role_group":"business","temporal_status":"unknown"},"reading":"inc → isl: Registered agent in Delaware (as shown by an aggregator) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-labcorp-holdco","record":{"id":"r-labcorp-holdco","from":"labcorp","to":"holdco","status":"documented","role":"Unsecured creditor appointed to the official creditors' committee","period":"From April 3, 2025","claim_ids":["c-ch-creditors-committee","c-ch-creditors-list"],"kind":"legal","direction":"directed","role_group":"business","temporal_status":"unknown"},"reading":"labcorp → holdco: Unsecured creditor appointed to the official creditors' committee [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-workday-holdco","record":{"id":"r-workday-holdco","from":"workday","to":"holdco","status":"documented","role":"Unsecured creditor appointed to the official creditors' committee","period":"From April 3, 2025","claim_ids":["c-ch-creditors-committee"],"kind":"legal","direction":"directed","role_group":"business","temporal_status":"unknown"},"reading":"workday → holdco: Unsecured creditor appointed to the official creditors' committee [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-telus-holdco","record":{"id":"r-telus-holdco","from":"telus","to":"holdco","status":"documented","role":"Unsecured creditor appointed to the official creditors' committee","period":"From April 3, 2025","claim_ids":["c-ch-creditors-committee"],"kind":"legal","direction":"directed","role_group":"business","temporal_status":"unknown"},"reading":"telus → holdco: Unsecured creditor appointed to the official creditors' committee [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-jellyfish-holdco","record":{"id":"r-jellyfish-holdco","from":"jellyfish","to":"holdco","status":"documented","role":"Unsecured creditor appointed to the official creditors' committee","period":"From April 3, 2025","claim_ids":["c-ch-creditors-committee"],"kind":"legal","direction":"directed","role_group":"business","temporal_status":"unknown"},"reading":"jellyfish → holdco: Unsecured creditor appointed to the official creditors' committee [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-regeneron-holdco","record":{"id":"r-regeneron-holdco","from":"regeneron","to":"holdco","status":"documented","role":"Initial successful bidder ($256 million) under an asset purchase agreement, then outbid by TTAM and named backup bidder","period":"Agreement of May 17, 2025; backup from June 13, 2025","claim_ids":["c-sale-regeneron","c-sale-ttam-wins","c-sale-states-objection"],"kind":"business","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"regeneron → holdco: Initial successful bidder ($256 million) under an asset purchase agreement, then outbid by TTAM and named backup bidder [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-biodata-holdco","record":{"id":"r-biodata-holdco","from":"biodata-trust","to":"holdco","status":"documented","role":"Objector to the sale (amicus motion of June 18, 2025) and appellant against the sale order","period":"June 2025 – September 29, 2026 (appeal dismissed)","claim_ids":["c-sale-biodata-trust","c-sale-appeals-stay","c-sale-district-court"],"kind":"legal","direction":"directed","role_group":"legal","temporal_status":"historical"},"reading":"biodata-trust → holdco: Objector to the sale (amicus motion of June 18, 2025) and appellant against the sale order [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-ttam-lemonaid-stalking","record":{"id":"r-ttam-lemonaid-stalking","from":"ttam","to":"lemonaid-health","status":"documented","role":"Stalking-horse plan sponsor for the reorganised Lemonaid equity at $2.5 million","period":"Under the June 13, 2025 purchase agreement","claim_ids":["c-lem-ttam-stalking-horse","c-sale-ttam-wins"],"kind":"business","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"ttam → lemonaid-health: Stalking-horse plan sponsor for the reorganised Lemonaid equity at $2.5 million [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-holdco-kroll","record":{"id":"r-holdco-kroll","from":"holdco","to":"kroll","status":"documented","role":"Debtor retaining Kroll as claims and noticing agent","period":"From the 2025 retention","claim_ids":["c-ch-advisers","c-ch-hearing-calendar"],"kind":"business","direction":"directed","role_group":"business","temporal_status":"unknown"},"reading":"holdco → kroll: Debtor retaining Kroll as claims and noticing agent [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-spv-lemonaid","record":{"id":"r-spv-lemonaid","from":"lemonaid-spv","to":"lemonaid-health","status":"documented","role":"Buyer of all the shares of Lemonaid Health, Inc.","period":"Agreement of September 10, 2025; approved December 1, 2025","claim_ids":["c-lem-spv-agreement","c-lem-sale-approved","c-lem-spv-investors"],"kind":"business","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"lemonaid-spv → lemonaid-health: Buyer of all the shares of Lemonaid Health, Inc. [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-spv-holdco","record":{"id":"r-spv-holdco","from":"lemonaid-spv","to":"holdco","status":"documented","role":"Buyer from Chrome Holding Co. under the stock purchase agreement for the Lemonaid companies ($10 million plus cure payments)","period":"Agreement of September 10, 2025; closed December 5, 2025 (reported)","claim_ids":["c-lem-spv-agreement","c-lem-sale-approved","c-lem-closing"],"kind":"business","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"lemonaid-spv → holdco: Buyer from Chrome Holding Co. under the stock purchase agreement for the Lemonaid companies ($10 million plus cure payments) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-spv-pharmacy","record":{"id":"r-spv-pharmacy","from":"lemonaid-spv","to":"pharmacy-holdings","status":"documented","role":"Buyer of all the shares of Chrome Pharmacy Holdings, Inc.","period":"Agreement of September 10, 2025","claim_ids":["c-lem-spv-agreement"],"kind":"business","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"lemonaid-spv → pharmacy-holdings: Buyer of all the shares of Chrome Pharmacy Holdings, Inc. [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-bambumeta-spv","record":{"id":"r-bambumeta-spv","from":"bambumeta","to":"lemonaid-spv","status":"documented","role":"Guarantor of the purchase price and lead sponsor of the buyer","period":"From the September 10, 2025 agreement","claim_ids":["c-lem-spv-agreement","c-lem-buyer-interview","c-lem-spv-investors","c-lem-closing"],"kind":"legal","direction":"directed","role_group":"business","temporal_status":"unknown"},"reading":"bambumeta → lemonaid-spv: Guarantor of the purchase price and lead sponsor of the buyer [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-jensen-deloitte","record":{"id":"r-jensen-deloitte","from":"jensen","to":"deloitte-touche","status":"documented","role":"U.S. Managing Partner for audit and enterprise risk services in technology and for venture capital services","period":"Until his retirement in 2012","claim_ids":["c-gov-jensen"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"jensen → deloitte-touche: U.S. Managing Partner for audit and enterprise risk services in technology and for venture capital services [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-jensen-redleaf","record":{"id":"r-jensen-redleaf","from":"jensen","to":"redleaf","status":"documented","role":"Chief financial officer","period":"Before 2012","claim_ids":["c-gov-jensen"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"jensen → redleaf: Chief financial officer [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-jensen-andersen","record":{"id":"r-jensen-andersen","from":"jensen","to":"arthur-andersen","status":"documented","role":"Managing Partner of the Silicon Valley office","period":"Before 2012","claim_ids":["c-gov-jensen"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"jensen → arthur-andersen: Managing Partner of the Silicon Valley office [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-jensen-lattice","record":{"id":"r-jensen-lattice","from":"jensen","to":"lattice","status":"documented","role":"Director and audit committee chair","period":"From June 2013","claim_ids":["c-gov-jensen","c-gov-jensen-lattice"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"current"},"reading":"jensen → lattice: Director and audit committee chair [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-fernandez-wework","record":{"id":"r-fernandez-wework","from":"fernandez","to":"wework","status":"documented","role":"Chief financial officer","period":"2022 – 2023","claim_ids":["c-gov-fernandez"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"fernandez → wework: Chief financial officer [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-fernandez-ncr","record":{"id":"r-fernandez-ncr","from":"fernandez","to":"ncr","status":"documented","role":"Executive vice president and chief financial officer","period":"2018 – 2020","claim_ids":["c-gov-fernandez"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"fernandez → ncr: Executive vice president and chief financial officer [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-fernandez-cbs","record":{"id":"r-fernandez-cbs","from":"fernandez","to":"cbs-radio","status":"documented","role":"President and chief executive officer","period":"2015 – 2017","claim_ids":["c-gov-fernandez"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"fernandez → cbs-radio: President and chief executive officer [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-fernandez-cardlytics","record":{"id":"r-fernandez-cardlytics","from":"fernandez","to":"cardlytics","status":"documented","role":"Independent director and audit committee member","period":"From 2024; still a director in 2026","claim_ids":["c-gov-fernandez","c-ppl-fernandez-roles"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"current"},"reading":"fernandez → cardlytics: Independent director and audit committee member [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-frankola-cloudera","record":{"id":"r-frankola-cloudera","from":"frankola","to":"cloudera","status":"documented","role":"Chief financial officer","period":"2012 – 2021 (an aggregator gives September 30, 2021 as the end)","claim_ids":["c-gov-frankola","c-ppl-frankola-roles"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"frankola → cloudera: Chief financial officer [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-frankola-yodlee","record":{"id":"r-frankola-yodlee","from":"frankola","to":"yodlee","status":"documented","role":"Chief financial officer","period":"2010 – 2012","claim_ids":["c-gov-frankola"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"frankola → yodlee: Chief financial officer [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-frankola-ariba","record":{"id":"r-frankola-ariba","from":"frankola","to":"ariba","status":"documented","role":"Chief financial officer","period":"Before 2010","claim_ids":["c-gov-frankola","c-ppl-frankola-roles"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"frankola → ariba: Chief financial officer [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-frankola-ansys","record":{"id":"r-frankola-ansys","from":"frankola","to":"ansys","status":"documented","role":"Independent director and audit committee chair","period":"From 2021 until July 16, 2025 (Ansys deregistered its securities in July 2025)","claim_ids":["c-gov-frankola","c-ppl-frankola-roles"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"frankola → ansys: Independent director and audit committee chair [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-frankola-skillsoft","record":{"id":"r-frankola-skillsoft","from":"frankola","to":"skillsoft","status":"documented","role":"Director and audit committee chair","period":"From July 17, 2024 (aggregator); a director in October 2024","claim_ids":["c-gov-frankola","c-ppl-frankola-roles"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"current"},"reading":"frankola → skillsoft: Director and audit committee chair [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-pharmacy-isl","record":{"id":"r-pharmacy-isl","from":"pharmacy-holdings","to":"isl","status":"documented","role":"Registered agent in Delaware (as shown by an aggregator)","period":"As retrieved in 2026","claim_ids":["c-id-agg-pharmacy"],"kind":"other","direction":"directed","role_group":"business","temporal_status":"unknown"},"reading":"pharmacy-holdings → isl: Registered agent in Delaware (as shown by an aggregator) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-walper-getty","record":{"id":"r-walper-getty","from":"walper","to":"getty","status":"documented","role":"Independent Class I director","period":"From July 20, 2026","claim_ids":["c-gov-walper-getty"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"current"},"reading":"walper → getty: Independent Class I director [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-walper-munger","record":{"id":"r-walper-munger","from":"walper","to":"munger","status":"documented","role":"Partner (bankruptcy and restructuring practice)","period":"Until 2025 (an aggregator gives December 31, 2024)","claim_ids":["c-gov-walper"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"walper → munger: Partner (bankruptcy and restructuring practice) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-walper-plainfield","record":{"id":"r-walper-plainfield","from":"walper","to":"plainfield","status":"documented","role":"Head of corporate restructuring","period":"Between his partnership terms at Munger, Tolles & Olson","claim_ids":["c-gov-walper"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"walper → plainfield: Head of corporate restructuring [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-holdco-csc","record":{"id":"r-holdco-csc","from":"holdco","to":"csc","status":"documented","role":"Legal address care of Corporation Service Company in Wilmington, Delaware (GLEIF record)","period":"As recorded in October 2026","claim_ids":["c-id-gleif"],"kind":"other","direction":"directed","role_group":"business","temporal_status":"unknown"},"reading":"holdco → csc: Legal address care of Corporation Service Company in Wilmington, Delaware (GLEIF record) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-selsavage-lemonaid","record":{"id":"r-selsavage-lemonaid","from":"selsavage","to":"lemonaid-health","status":"documented","role":"Chief financial officer","period":"From 2020","claim_ids":["c-gov-selsavage"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"selsavage → lemonaid-health: Chief financial officer [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-selsavage-metromile","record":{"id":"r-selsavage-metromile","from":"selsavage","to":"metromile","status":"documented","role":"Chief financial officer","period":"2015 – 2018","claim_ids":["c-gov-selsavage"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"selsavage → metromile: Chief financial officer [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-selsavage-hotwire","record":{"id":"r-selsavage-hotwire","from":"selsavage","to":"hotwire","status":"documented","role":"Vice president and chief financial officer","period":"2001 – 2015","claim_ids":["c-gov-selsavage"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"selsavage → hotwire: Vice president and chief financial officer [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-selsavage-redeclipse","record":{"id":"r-selsavage-redeclipse","from":"selsavage","to":"red-eclipse","status":"documented","role":"Consultant","period":"2018 – 2020","claim_ids":["c-gov-selsavage"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"selsavage → red-eclipse: Consultant [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-kvarda-revlon","record":{"id":"r-kvarda-revlon","from":"kvarda","to":"revlon","status":"documented","role":"Interim chief financial officer (signed a Sarbanes-Oxley certification of the 2022 annual report)","period":"From October 1, 2022","claim_ids":["c-gov-kvarda"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"kvarda → revlon: Interim chief financial officer (signed a Sarbanes-Oxley certification of the 2022 annual report) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-kvarda-am","record":{"id":"r-kvarda-am","from":"kvarda","to":"alvarez-marsal","status":"documented","role":"Managing Director","period":"As of 2025","claim_ids":["c-gov-kvarda","c-gov-march-2025-appointments","c-ch-advisers"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"current"},"reading":"kvarda → alvarez-marsal: Managing Director [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-kvarda-team","record":{"id":"r-kvarda-team","from":"kvarda","to":"team-inc","status":"documented","role":"Interim chief financial officer","period":"Before 2025","claim_ids":["c-gov-kvarda"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"kvarda → team-inc: Interim chief financial officer [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-kvarda-jacuzzi","record":{"id":"r-kvarda-jacuzzi","from":"kvarda","to":"jacuzzi","status":"documented","role":"Interim chief financial officer","period":"Before 2025","claim_ids":["c-gov-kvarda"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"kvarda → jacuzzi: Interim chief financial officer [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-wojcicki-kpschool","record":{"id":"r-wojcicki-kpschool","from":"wojcicki","to":"kp-school","status":"documented","role":"Board member","period":"As listed in 2021–2025 filings","claim_ids":["c-gov-wojcicki-background","c-ppl-wojcicki-boards"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"wojcicki → kp-school: Board member [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-wojcicki-breakthrough","record":{"id":"r-wojcicki-breakthrough","from":"wojcicki","to":"breakthrough-prize","status":"documented","role":"Co-founder and board member","period":"As listed in 2021–2025 filings","claim_ids":["c-gov-wojcicki-background","c-ppl-wojcicki-boards"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"wojcicki → breakthrough-prize: Co-founder and board member [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-wojcicki-blok24","record":{"id":"r-wojcicki-blok24","from":"wojcicki","to":"blok24","status":"reported","role":"Board member (as listed by an aggregator)","period":"Undated aggregator listing","claim_ids":["c-ppl-wojcicki-boards"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"wojcicki → blok24: Board member (as listed by an aggregator) [reported]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-wojcicki-fnih","record":{"id":"r-wojcicki-fnih","from":"wojcicki","to":"fnih","status":"documented","role":"Board member","period":"2008 – 2016","claim_ids":["c-gov-wojcicki-background","c-ppl-wojcicki-boards"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"wojcicki → fnih: Board member [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-holdco-allied","record":{"id":"r-holdco-allied","from":"holdco","to":"allied-world","status":"documented","role":"Insured under a $5,000,000 layer of cyber and liability cover; party to the policy buyback settlement","period":"Policy period May 1, 2023 – May 1, 2024; buyback motion December 1, 2025","claim_ids":["c-st-cyber-insurers"],"kind":"business","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"holdco → allied-world: Insured under a $5,000,000 layer of cyber and liability cover; party to the policy buyback settlement [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-holdco-houston","record":{"id":"r-holdco-houston","from":"holdco","to":"houston-casualty","status":"documented","role":"Insured under a $2,500,000 layer of cyber and liability cover; party to the policy buyback settlement","period":"Policy period May 1, 2023 – May 1, 2024; buyback motion December 1, 2025","claim_ids":["c-st-cyber-insurers"],"kind":"business","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"holdco → houston-casualty: Insured under a $2,500,000 layer of cyber and liability cover; party to the policy buyback settlement [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-holdco-landmark","record":{"id":"r-holdco-landmark","from":"holdco","to":"landmark","status":"documented","role":"Insured under a $2,500,000 layer of cyber and liability cover; party to the policy buyback settlement","period":"Policy period May 1, 2023 – May 1, 2024; buyback motion December 1, 2025","claim_ids":["c-st-cyber-insurers"],"kind":"business","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"holdco → landmark: Insured under a $2,500,000 layer of cyber and liability cover; party to the policy buyback settlement [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-walper-trust","record":{"id":"r-walper-trust","from":"walper","to":"plan-trust","status":"documented","role":"Declarant for the trust in support of its motion to approve the states' stipulation","period":"July 2026","claim_ids":["c-ppl-walper-declaration"],"kind":"legal","direction":"directed","role_group":"business","temporal_status":"unknown"},"reading":"walper → plan-trust: Declarant for the trust in support of its motion to approve the states' stipulation [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-pretsch-spv","record":{"id":"r-pretsch-spv","from":"pretsch","to":"lemonaid-spv","status":"documented","role":"Chief operating officer; one of the Bambu general partners named to lead the buyer","period":"From 2025","claim_ids":["c-lem-buyer-interview","c-lem-spv-investors"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"current"},"reading":"pretsch → lemonaid-spv: Chief operating officer; one of the Bambu general partners named to lead the buyer [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-pretsch-bambu","record":{"id":"r-pretsch-bambu","from":"pretsch","to":"bambumeta","status":"documented","role":"General partner","period":"As of 2025","claim_ids":["c-lem-buyer-interview"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"current"},"reading":"pretsch → bambumeta: General partner [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-inc-landlord","record":{"id":"r-inc-landlord","from":"inc","to":"kr-op-tech","status":"documented","role":"Former tenant of the landlord's San Francisco building; rejected the lease after the asset sale","period":"Rejection after July 2025; claim ruled on November 26, 2025","claim_ids":["c-ch-landlord-opinion"],"kind":"business","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"inc → kr-op-tech: Former tenant of the landlord's San Francisco building; rejected the lease after the asset sale [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-landlord-holdco","record":{"id":"r-landlord-holdco","from":"kr-op-tech","to":"holdco","status":"documented","role":"Creditor objecting to the debtors' treatment of its lease-rejection claim and appellant against the confirmation order","period":"November 2025; appeal filed December 23, 2025","claim_ids":["c-ch-landlord-opinion"],"kind":"legal","direction":"directed","role_group":"legal","temporal_status":"historical"},"reading":"kr-op-tech → holdco: Creditor objecting to the debtors' treatment of its lease-rejection claim and appellant against the confirmation order [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-holdco-landlord-claim","record":{"id":"r-holdco-landlord-claim","from":"holdco","to":"kr-op-tech","status":"documented","role":"Debtor whose plan leaves the landlord's lease claim undischarged until distributions are made","period":"Confirmation order of December 1, 2025","claim_ids":["c-ch-converge-reserve"],"kind":"legal","direction":"directed","role_group":"business","temporal_status":"unknown"},"reading":"holdco → kr-op-tech: Debtor whose plan leaves the landlord's lease claim undischarged until distributions are made [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-holdco-lemonaid-uk","record":{"id":"r-holdco-lemonaid-uk","from":"holdco","to":"lemonaid-uk","status":"documented","role":"Parent of its only foreign subsidiary, disposed of on August 1, 2023","period":"Until August 1, 2023","claim_ids":["c-lem-uk-disposal","c-ch-revenue-fy25"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"holdco → lemonaid-uk: Parent of its only foreign subsidiary, disposed of on August 1, 2023 [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-susan-awf","record":{"id":"r-susan-awf","from":"susan-wojcicki","to":"aw-foundation","status":"documented","role":"Treasurer and secretary (unpaid)","period":"As listed in the 2024 return","claim_ids":["c-ppl-awf"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"susan-wojcicki → aw-foundation: Treasurer and secretary (unpaid) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-ttam-abeec-release","record":{"id":"r-ttam-abeec-release","from":"ttam","to":"abeec","status":"documented","role":"Buyer whose released parties under the third amended plan included ABeeC 2.0, LLC","period":"Third amended plan of November 14, 2025 (later treated as opted out)","claim_ids":["c-ch-third-plan-buyer"],"kind":"legal","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"ttam → abeec: Buyer whose released parties under the third amended plan included ABeeC 2.0, LLC [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-ttam-awf-release","record":{"id":"r-ttam-awf-release","from":"ttam","to":"aw-foundation","status":"documented","role":"Buyer whose released parties under the third amended plan included the Anne Wojcicki Foundation","period":"Third amended plan of November 14, 2025 (later treated as opted out)","claim_ids":["c-ch-third-plan-buyer"],"kind":"legal","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"ttam → aw-foundation: Buyer whose released parties under the third amended plan included the Anne Wojcicki Foundation [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-magides-zentreeim","record":{"id":"r-magides-zentreeim","from":"magides","to":"zentree-im","status":"documented","role":"Founder and chief executive officer","period":"From 2011 (aggregator: post from December 31, 2010)","claim_ids":["c-ppl-magides"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"current"},"reading":"magides → zentree-im: Founder and chief executive officer [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-magides-artradis","record":{"id":"r-magides-artradis","from":"magides","to":"artradis","status":"documented","role":"Managing Partner","period":"Before 2011","claim_ids":["c-ppl-magides"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"magides → artradis: Managing Partner [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-california-holdco","record":{"id":"r-california-holdco","from":"california","to":"holdco","status":"documented","role":"State objecting to the genetic-data sale, appellant against the sale order, claimant of an administrative penalty claim and plaintiff in an enforcement suit","period":"From June 2025; suit announced May 28, 2026; notice of appeal transmitted October 14, 2026","claim_ids":["c-sale-opinion-newco","c-sale-district-court","c-st-ca-admin-claim","c-br-ca-allegations","c-st-ca-appeal-2026","c-st-ca-suit","c-br-ca-warnings","c-br-ca-ransom","c-ch-ds-order","c-st-ca-enforcement-order"],"kind":"legal","direction":"directed","role_group":"legal","temporal_status":"unknown"},"reading":"california → holdco: State objecting to the genetic-data sale, appellant against the sale order, claimant of an administrative penalty claim and plaintiff in an enforcement suit [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-converge-holdco","record":{"id":"r-converge-holdco","from":"converge","to":"holdco","status":"documented","role":"Administrative claimant for unpaid cloud-service invoices ($4,061,000 reserved; settled with the trust for $6.11 million)","period":"Invoices of May 1 – August 20, 2025; reserve ordered December 1, 2025; settlement March 4, 2026 (reported)","claim_ids":["c-ch-converge-reserve","c-ch-converge-settlement","c-ch-creditors-list"],"kind":"legal","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"converge → holdco: Administrative claimant for unpaid cloud-service invoices ($4,061,000 reserved; settled with the trust for $6.11 million) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-ttam-converge","record":{"id":"r-ttam-converge","from":"ttam","to":"converge","status":"reported","role":"Buyer that the wind-down debtors said had assumed the Converge invoices","period":"Dispute of 2025–2026 (reported)","claim_ids":["c-ch-converge-settlement"],"kind":"business","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"ttam → converge: Buyer that the wind-down debtors said had assumed the Converge invoices [reported]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-boots-lemonaid-uk","record":{"id":"r-boots-lemonaid-uk","from":"boots-uk","to":"lemonaid-uk","status":"documented","role":"Holder of 75% or more of the shares and votes","period":"From August 1, 2023","claim_ids":["c-lem-uk-disposal","c-lem-uk-officers"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"current"},"reading":"boots-uk → lemonaid-uk: Holder of 75% or more of the shares and votes [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-alliance-boots-uk","record":{"id":"r-alliance-boots-uk","from":"alliance-boots","to":"boots-uk","status":"documented","role":"Person with significant control (75% or more of shares and votes)","period":"From April 6, 2016","claim_ids":["c-lem-uk-disposal"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"current"},"reading":"alliance-boots → boots-uk: Person with significant control (75% or more of shares and votes) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-vanevery-lemonaid-uk","record":{"id":"r-vanevery-lemonaid-uk","from":"van-every","to":"lemonaid-uk","status":"documented","role":"Registered person with significant control","period":"December 30, 2020 – June 4, 2021","claim_ids":["c-lem-uk-officers"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"van-every → lemonaid-uk: Registered person with significant control [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-vanevery-lemonaid-uk-dir","record":{"id":"r-vanevery-lemonaid-uk-dir","from":"van-every","to":"lemonaid-uk","status":"documented","role":"Director","period":"April 17, 2020 – December 21, 2022","claim_ids":["c-lem-uk-officers"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"van-every → lemonaid-uk: Director [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-selsavage-lemonaid-uk","record":{"id":"r-selsavage-lemonaid-uk","from":"selsavage","to":"lemonaid-uk","status":"documented","role":"Director","period":"December 21, 2022 – August 1, 2023","claim_ids":["c-lem-uk-officers"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"selsavage → lemonaid-uk: Director [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-corvina-sponsor","record":{"id":"r-corvina-sponsor","from":"corvina","to":"vgac-sponsor","status":"documented","role":"Sole managing member and manager","period":"As of December 31, 2020","claim_ids":["c-spac-13g","c-spac-sponsor-chain"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"corvina → vgac-sponsor: Sole managing member and manager [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-vghl-sponsor","record":{"id":"r-vghl-sponsor","from":"vghl","to":"vgac-sponsor","status":"documented","role":"Indirect owner through Corvina Holdings Limited","period":"As of December 31, 2020","claim_ids":["c-spac-13g","c-spac-sponsor-chain"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"vghl → vgac-sponsor: Indirect owner through Corvina Holdings Limited [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-branson-sponsor","record":{"id":"r-branson-sponsor","from":"branson","to":"vgac-sponsor","status":"documented","role":"Deemed indirect beneficial owner of the sponsor's shares","period":"As of December 31, 2020","claim_ids":["c-spac-13g","c-spac-sponsor-chain"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"branson → vgac-sponsor: Deemed indirect beneficial owner of the sponsor's shares [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-vghl-corvina","record":{"id":"r-vghl-corvina","from":"vghl","to":"corvina","status":"documented","role":"Sole shareholder","period":"As of November 2023 (also its owner in 2020)","claim_ids":["c-ppl-virgin-2023","c-spac-sponsor-chain"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"unknown"},"reading":"vghl → corvina: Sole shareholder [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-bftptc-vghl","record":{"id":"r-bftptc-vghl","from":"bft-ptc","to":"vghl","status":"documented","role":"Sole holder of the voting shares, as trustee of trusts for members of Branson's family and related philanthropic causes","period":"From November 1, 2023","claim_ids":["c-ppl-virgin-2023"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"current"},"reading":"bft-ptc → vghl: Sole holder of the voting shares, as trustee of trusts for members of Branson's family and related philanthropic causes [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-bftclg-vghl","record":{"id":"r-bftclg-vghl","from":"bft-clg","to":"vghl","status":"documented","role":"Holder of consent rights over the trustee's exercise of control of Virgin Group Holdings","period":"From November 2023","claim_ids":["c-ppl-virgin-2023"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"current"},"reading":"bft-clg → vghl: Holder of consent rights over the trustee's exercise of control of Virgin Group Holdings [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-branson-vghl","record":{"id":"r-branson-vghl","from":"branson","to":"vghl","status":"documented","role":"Former holder of all the ordinary shares (transferred to the trustee on November 1, 2023); keeps the indirect ability to appoint and remove management","period":"Owner until November 1, 2023","claim_ids":["c-ppl-virgin-2023","c-spac-sponsor-chain"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"unknown"},"reading":"branson → vghl: Former holder of all the ordinary shares (transferred to the trustee on November 1, 2023); keeps the indirect ability to appoint and remove management [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-wojcicki-sidecar","record":{"id":"r-wojcicki-sidecar","from":"wojcicki","to":"sidecar","status":"documented","role":"Member of the board of advisors (not the board of directors)","period":"Undated website listing","claim_ids":["c-ppl-wojcicki-boards"],"kind":"other","direction":"directed","role_group":"associations","temporal_status":"unknown"},"reading":"wojcicki → sidecar: Member of the board of advisors (not the board of directors) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-jensen-wolfspeed","record":{"id":"r-jensen-wolfspeed","from":"jensen","to":"wolfspeed","status":"documented","role":"Director","period":"From May 2025","claim_ids":["c-gov-jensen-lattice"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"current"},"reading":"jensen → wolfspeed: Director [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-jensen-exabeam","record":{"id":"r-jensen-exabeam","from":"jensen","to":"exabeam","status":"documented","role":"Director","period":"2022 – 2024 (earlier board)","claim_ids":["c-gov-jensen-lattice"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"jensen → exabeam: Director [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-jensen-unwired","record":{"id":"r-jensen-unwired","from":"jensen","to":"unwired-planet","status":"documented","role":"Director","period":"2012 – 2015 (earlier board)","claim_ids":["c-gov-jensen-lattice"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"jensen → unwired-planet: Director [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-jensen-control4","record":{"id":"r-jensen-control4","from":"jensen","to":"control4","status":"documented","role":"Director","period":"2015 – 2019 (earlier board)","claim_ids":["c-gov-jensen-lattice"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"jensen → control4: Director [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-jensen-forescout","record":{"id":"r-jensen-forescout","from":"jensen","to":"forescout","status":"documented","role":"Director","period":"2013 – 2020 (earlier board)","claim_ids":["c-gov-jensen-lattice"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"jensen → forescout: Director [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-innova-spv","record":{"id":"r-innova-spv","from":"innova","to":"lemonaid-spv","status":"reported","role":"Partner in forming the SPV; its principals sit on the board","period":"September 2025 announcement","claim_ids":["c-lem-spv-investors"],"kind":"other","direction":"directed","role_group":"business","temporal_status":"unknown"},"reading":"innova → lemonaid-spv: Partner in forming the SPV; its principals sit on the board [reported]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-egateway-spv","record":{"id":"r-egateway-spv","from":"egateway","to":"lemonaid-spv","status":"reported","role":"A lead sponsor of the SPV","period":"September 2025 announcement","claim_ids":["c-lem-spv-investors"],"kind":"other","direction":"directed","role_group":"business","temporal_status":"unknown"},"reading":"egateway → lemonaid-spv: A lead sponsor of the SPV [reported]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-broadview-spv","record":{"id":"r-broadview-spv","from":"broadview","to":"lemonaid-spv","status":"reported","role":"Supporting investor in the SPV","period":"September 2025 announcement","claim_ids":["c-lem-spv-investors"],"kind":"other","direction":"directed","role_group":"business","temporal_status":"unknown"},"reading":"broadview → lemonaid-spv: Supporting investor in the SPV [reported]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-auctus-spv","record":{"id":"r-auctus-spv","from":"auctus","to":"lemonaid-spv","status":"reported","role":"Supporting investor in the SPV","period":"September 2025 announcement","claim_ids":["c-lem-spv-investors"],"kind":"other","direction":"directed","role_group":"business","temporal_status":"unknown"},"reading":"auctus → lemonaid-spv: Supporting investor in the SPV [reported]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-daybreak-spv","record":{"id":"r-daybreak-spv","from":"day-break","to":"lemonaid-spv","status":"reported","role":"Supporting investor in the SPV","period":"September 2025 announcement","claim_ids":["c-lem-spv-investors"],"kind":"other","direction":"directed","role_group":"business","temporal_status":"unknown"},"reading":"day-break → lemonaid-spv: Supporting investor in the SPV [reported]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-hearn-spv","record":{"id":"r-hearn-spv","from":"hearn","to":"lemonaid-spv","status":"reported","role":"Executive leadership as a Bambu general partner, in an operational role","period":"September 2025 announcement","claim_ids":["c-lem-spv-investors"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"hearn → lemonaid-spv: Executive leadership as a Bambu general partner, in an operational role [reported]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-runne-spv","record":{"id":"r-runne-spv","from":"runne","to":"lemonaid-spv","status":"reported","role":"Board member alongside Innova's principals","period":"September 2025 announcement","claim_ids":["c-lem-spv-investors"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"runne → lemonaid-spv: Board member alongside Innova's principals [reported]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-corvina-vil","record":{"id":"r-corvina-vil","from":"corvina","to":"virgin-investments","status":"documented","role":"Sole shareholder","period":"As of November 2023","claim_ids":["c-ppl-virgin-2023"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"unknown"},"reading":"corvina → virgin-investments: Sole shareholder [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-bayliss-corvina","record":{"id":"r-bayliss-corvina","from":"bayliss","to":"corvina","status":"documented","role":"Director","period":"As of the 2020 annual report and the 2023 filing","claim_ids":["c-spac-bayliss"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"bayliss → corvina: Director [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-bayliss-vghl","record":{"id":"r-bayliss-vghl","from":"bayliss","to":"vghl","status":"documented","role":"Director","period":"As of the 2020 annual report and the 2023 filing","claim_ids":["c-spac-bayliss"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"bayliss → vghl: Director [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-bayliss-vil","record":{"id":"r-bayliss-vil","from":"bayliss","to":"virgin-investments","status":"documented","role":"Director","period":"As of the 2020 annual report and the 2023 filing","claim_ids":["c-spac-bayliss"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"bayliss → virgin-investments: Director [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-bftclg-bftptc","record":{"id":"r-bftclg-bftptc","from":"bft-clg","to":"bft-ptc","status":"documented","role":"May remove and replace the trustee's directors and so may be deemed to control it","period":"As of November 2023","claim_ids":["c-ppl-virgin-2023"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"unknown"},"reading":"bft-clg → bft-ptc: May remove and replace the trustee's directors and so may be deemed to control it [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-branson-bftclg","record":{"id":"r-branson-bftclg","from":"branson","to":"bft-clg","status":"documented","role":"Owner of all the 'A' membership interests, deemed to control it","period":"As of November 2023","claim_ids":["c-ppl-virgin-2023"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"unknown"},"reading":"branson → bft-clg: Owner of all the 'A' membership interests, deemed to control it [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-holdco-twf","record":{"id":"r-holdco-twf","from":"holdco","to":"twf","status":"documented","role":"Provider of research services under a five-year agreement to build lung-cancer research cohorts ($5.4 million under the first statement of work)","period":"January 2024 – December 21, 2028 (five-year term)","claim_ids":["c-gov-twf"],"kind":"business","direction":"directed","role_group":"business","temporal_status":"unknown"},"reading":"holdco → twf: Provider of research services under a five-year agreement to build lung-cancer research cohorts ($5.4 million under the first statement of work) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-susan-twf","record":{"id":"r-susan-twf","from":"susan-wojcicki","to":"twf","status":"documented","role":"Director and officer; President until September 2024","period":"In January 2024; until September 2024","claim_ids":["c-gov-twf","c-ppl-twf"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"susan-wojcicki → twf: Director and officer; President until September 2024 [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-susan-anne","record":{"id":"r-susan-anne","from":"susan-wojcicki","to":"wojcicki","status":"documented","role":"Sister","period":"Stated in the company filings","claim_ids":["c-gov-twf"],"kind":"family","direction":"undirected","role_group":"associations","temporal_status":"unknown"},"reading":"susan-wojcicki → wojcicki: Sister [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-wojcicki-passport","record":{"id":"r-wojcicki-passport","from":"wojcicki","to":"passport","status":"documented","role":"Healthcare analyst","period":"2004 – 2006","claim_ids":["c-gov-wojcicki-background"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"wojcicki → passport: Healthcare analyst [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-wojcicki-andor","record":{"id":"r-wojcicki-andor","from":"wojcicki","to":"andor","status":"documented","role":"Healthcare analyst","period":"2001 – 2002","claim_ids":["c-gov-wojcicki-background"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"wojcicki → andor: Healthcare analyst [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-wojcicki-ardsley","record":{"id":"r-wojcicki-ardsley","from":"wojcicki","to":"ardsley","status":"documented","role":"Healthcare analyst","period":"1999 – 2000","claim_ids":["c-gov-wojcicki-background"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"wojcicki → ardsley: Healthcare analyst [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-wojcicki-investorab","record":{"id":"r-wojcicki-investorab","from":"wojcicki","to":"investor-ab","status":"documented","role":"Healthcare analyst","period":"1996 – 1999","claim_ids":["c-gov-wojcicki-background"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"wojcicki → investor-ab: Healthcare analyst [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-fernandez-domain","record":{"id":"r-fernandez-domain","from":"fernandez","to":"domain-americas","status":"documented","role":"Principal of the consulting firm","period":"In 2025","claim_ids":["c-gov-fernandez"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"fernandez → domain-americas: Principal of the consulting firm [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-fernandez-blackstone","record":{"id":"r-fernandez-blackstone","from":"fernandez","to":"blackstone-bis","status":"documented","role":"Director","period":"In 2025","claim_ids":["c-gov-fernandez"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"fernandez → blackstone-bis: Director [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-fernandez-faze","record":{"id":"r-fernandez-faze","from":"fernandez","to":"faze","status":"documented","role":"Director","period":"2022 – 2024","claim_ids":["c-gov-fernandez"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"fernandez → faze: Director [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-fernandez-sachem","record":{"id":"r-fernandez-sachem","from":"fernandez","to":"sachem","status":"documented","role":"Director","period":"2021 – 2022","claim_ids":["c-gov-fernandez"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"fernandez → sachem: Director [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-bayliss-vgacii","record":{"id":"r-bayliss-vgacii","from":"bayliss","to":"vgac-ii","status":"documented","role":"Chief executive officer and director of the sister blank check company","period":"As of the 2020 annual report","claim_ids":["c-spac-bayliss"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"bayliss → vgac-ii: Chief executive officer and director of the sister blank check company [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-bayliss-vgaciii","record":{"id":"r-bayliss-vgaciii","from":"bayliss","to":"vgac-iii","status":"documented","role":"Chief executive officer and director of the sister blank check company","period":"As of the 2020 annual report","claim_ids":["c-spac-bayliss"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"bayliss → vgac-iii: Chief executive officer and director of the sister blank check company [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-bayliss-ventertainment","record":{"id":"r-bayliss-ventertainment","from":"bayliss","to":"virgin-entertainment","status":"documented","role":"Director","period":"As of the 2020 annual report","claim_ids":["c-spac-bayliss"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"bayliss → virgin-entertainment: Director [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-bayliss-vred","record":{"id":"r-bayliss-vred","from":"bayliss","to":"virgin-red","status":"documented","role":"Director","period":"As of the 2020 annual report (UK register: from 2018)","claim_ids":["c-spac-bayliss"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"bayliss → virgin-red: Director [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-lovell-vgacii","record":{"id":"r-lovell-vgacii","from":"lovell","to":"vgac-ii","status":"documented","role":"Chief financial officer and director of the sister blank check company","period":"As of the 2020 annual report","claim_ids":["c-spac-lovell"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"lovell → vgac-ii: Chief financial officer and director of the sister blank check company [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-lovell-vgalactic","record":{"id":"r-lovell-vgalactic","from":"lovell","to":"virgin-galactic","status":"documented","role":"Board member","period":"From 2017 (as of the 2020 annual report)","claim_ids":["c-spac-lovell"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"lovell → virgin-galactic: Board member [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-lovell-tpg","record":{"id":"r-lovell-tpg","from":"lovell","to":"tpg","status":"documented","role":"Investment professional","period":"1998 – 2008","claim_ids":["c-spac-lovell"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"lovell → tpg: Investment professional [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-lovell-vgf","record":{"id":"r-lovell-vgf","from":"lovell","to":"virgin-green-fund","status":"documented","role":"Founding partner","period":"2008 – 2012","claim_ids":["c-spac-lovell"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"lovell → virgin-green-fund: Founding partner [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-briggs-snowflake","record":{"id":"r-briggs-snowflake","from":"briggs","to":"snowflake","status":"documented","role":"Director","period":"As of the 2020 annual report","claim_ids":["c-spac-briggs"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"briggs → snowflake: Director [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-briggs-servicenow","record":{"id":"r-briggs-servicenow","from":"briggs","to":"servicenow","status":"documented","role":"Director (still a director in May 2026, according to an insider-trading report)","period":"From before 2021","claim_ids":["c-spac-briggs"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"current"},"reading":"briggs → servicenow: Director (still a director in May 2026, according to an insider-trading report) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-briggs-docusign","record":{"id":"r-briggs-docusign","from":"briggs","to":"docusign","status":"documented","role":"Director","period":"As of the 2020 annual report","claim_ids":["c-spac-briggs"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"briggs → docusign: Director [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-briggs-jand","record":{"id":"r-briggs-jand","from":"briggs","to":"jand","status":"documented","role":"Director","period":"As of the 2020 annual report","claim_ids":["c-spac-briggs"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"briggs → jand: Director [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-briggs-deloitte","record":{"id":"r-briggs-deloitte","from":"briggs","to":"deloitte-llp","status":"documented","role":"Vice Chair and West Region and San Francisco Managing Partner; earlier Managing Partner, Silicon Valley","period":"2006 – April 2019","claim_ids":["c-spac-briggs"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"briggs → deloitte-llp: Vice Chair and West Region and San Francisco Managing Partner; earlier Managing Partner, Silicon Valley [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-lockhart-wlross","record":{"id":"r-lockhart-wlross","from":"lockhart","to":"wl-ross","status":"documented","role":"Vice Chairman","period":"2009 – 2018","claim_ids":["c-spac-lockhart"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"lockhart → wl-ross: Vice Chairman [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-lockhart-vmoney","record":{"id":"r-lockhart-vmoney","from":"lockhart","to":"virgin-money","status":"documented","role":"Director","period":"Before 2020","claim_ids":["c-spac-lockhart"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"lockhart → virgin-money: Director [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-brown-aquaventure","record":{"id":"r-brown-aquaventure","from":"brown","to":"aquaventure","status":"documented","role":"Founder, chairman and chief executive officer","period":"December 2006 – March 2020","claim_ids":["c-spac-brown"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"brown → aquaventure: Founder, chairman and chief executive officer [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-brown-sevenseas","record":{"id":"r-brown-sevenseas","from":"brown","to":"seven-seas","status":"documented","role":"Chief executive officer","period":"Before 2020","claim_ids":["c-spac-brown"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"brown → seven-seas: Chief executive officer [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-brown-ionics","record":{"id":"r-brown-ionics","from":"brown","to":"ionics","status":"documented","role":"Chief executive officer","period":"2003 – 2005","claim_ids":["c-spac-brown"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"brown → ionics: Chief executive officer [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-brown-advent","record":{"id":"r-brown-advent","from":"brown","to":"advent","status":"documented","role":"Seventeen years at the firm","period":"Before 2003","claim_ids":["c-spac-brown"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"brown → advent: Seventeen years at the firm [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-brown-element","record":{"id":"r-brown-element","from":"brown","to":"element-partners","status":"documented","role":"Operating partner","period":"Before 2020","claim_ids":["c-spac-brown"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"brown → element-partners: Operating partner [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-ttam-ttam2","record":{"id":"r-ttam-ttam2","from":"ttam","to":"ttam-2","status":"documented","role":"Buyer-side party in the bankruptcy case, represented by the same law firm","period":"As of 2025–2026","claim_ids":["c-sale-buyer-entities"],"kind":"other","direction":"undirected","role_group":"associations","temporal_status":"unknown"},"reading":"ttam → ttam-2: Buyer-side party in the bankruptcy case, represented by the same law firm [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-ttam-employees","record":{"id":"r-ttam-employees","from":"ttam","to":"ttam-employees","status":"documented","role":"Buyer-side party in the bankruptcy case (formerly TTAM Employee Company)","period":"As of 2025–2026","claim_ids":["c-sale-buyer-entities"],"kind":"other","direction":"undirected","role_group":"associations","temporal_status":"unknown"},"reading":"ttam → ttam-employees: Buyer-side party in the bankruptcy case (formerly TTAM Employee Company) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-ttam-genomics","record":{"id":"r-ttam-genomics","from":"ttam","to":"ttam-genomics","status":"documented","role":"Buyer-side party in the bankruptcy case (formerly 23andMe PGS LLC)","period":"As of 2025–2026","claim_ids":["c-sale-buyer-entities"],"kind":"other","direction":"undirected","role_group":"associations","temporal_status":"unknown"},"reading":"ttam → ttam-genomics: Buyer-side party in the bankruptcy case (formerly 23andMe PGS LLC) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-ttam-researchllc","record":{"id":"r-ttam-researchllc","from":"ttam","to":"ttam-research-llc","status":"documented","role":"Buyer-side party in the bankruptcy case (formerly TTAM Research Company, LLC)","period":"As of 2025–2026","claim_ids":["c-sale-buyer-entities"],"kind":"other","direction":"undirected","role_group":"associations","temporal_status":"unknown"},"reading":"ttam → ttam-research-llc: Buyer-side party in the bankruptcy case (formerly TTAM Research Company, LLC) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-scheller-alector","record":{"id":"r-scheller-alector","from":"scheller","to":"alector","status":"documented","role":"Independent director","period":"From September 30, 2018 (aggregator)","claim_ids":["c-ppl-scheller-roles"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"current"},"reading":"scheller → alector: Independent director [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-scheller-maze","record":{"id":"r-scheller-maze","from":"scheller","to":"maze","status":"documented","role":"Director","period":"From May 31, 2019 (aggregator)","claim_ids":["c-ppl-scheller-roles"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"current"},"reading":"scheller → maze: Director [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-scheller-dice","record":{"id":"r-scheller-dice","from":"scheller","to":"dice","status":"documented","role":"Director","period":"As listed by GV","claim_ids":["c-ppl-scheller-roles"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"scheller → dice: Director [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-scheller-aarvik","record":{"id":"r-scheller-aarvik","from":"scheller","to":"aarvik","status":"documented","role":"Director","period":"As listed by GV","claim_ids":["c-ppl-scheller-roles"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"scheller → aarvik: Director [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-scheller-genentech","record":{"id":"r-scheller-genentech","from":"scheller","to":"genentech","status":"documented","role":"Executive vice president of research and early development","period":"2001 – 2014","claim_ids":["c-ppl-scheller-roles"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"scheller → genentech: Executive vice president of research and early development [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-scheller-oric","record":{"id":"r-scheller-oric","from":"scheller","to":"oric","status":"reported","role":"Independent director (as listed by an aggregator)","period":"Undated aggregator listing","claim_ids":["c-ppl-scheller-roles"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"scheller → oric: Independent director (as listed by an aggregator) [reported]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-hernandez-coveredca","record":{"id":"r-hernandez-coveredca","from":"hernandez","to":"covered-california","status":"documented","role":"Board member appointed by Governor Jerry Brown","period":"From February 13, 2018","claim_ids":["c-ppl-hernandez-roles"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"current"},"reading":"hernandez → covered-california: Board member appointed by Governor Jerry Brown [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-hernandez-blackbaud","record":{"id":"r-hernandez-blackbaud","from":"hernandez","to":"blackbaud","status":"documented","role":"Director (former)","period":"Until March 15, 2006 (aggregator)","claim_ids":["c-ppl-hernandez-roles"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"hernandez → blackbaud: Director (former) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-hernandez-frb","record":{"id":"r-hernandez-frb","from":"hernandez","to":"first-republic","status":"documented","role":"Director","period":"2010 – 2013","claim_ids":["c-ppl-hernandez-roles"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"hernandez → first-republic: Director [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-montgomery-rice-meharry","record":{"id":"r-montgomery-rice-meharry","from":"montgomery-rice","to":"meharry","status":"documented","role":"Founder and former director of the Center for Women's Health Research","period":"Before 2011","claim_ids":["c-ppl-montgomery-rice-roles"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"montgomery-rice → meharry: Founder and former director of the Center for Women's Health Research [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-montgomery-rice-unh","record":{"id":"r-montgomery-rice-unh","from":"montgomery-rice","to":"unitedhealth","status":"documented","role":"Director (reporting person in insider filings)","period":"Earliest listed transaction August 4, 2017","claim_ids":["c-ppl-montgomery-rice-roles"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"montgomery-rice → unitedhealth: Director (reporting person in insider filings) [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-texas-holdco","record":{"id":"r-texas-holdco","from":"texas","to":"holdco","status":"documented","role":"State objecting to the genetic-data sale, plaintiff in its own adversary proceeding (No. 25-04036) and signatory governmental claimant allotted $1,266,860 of the 2026 settlement","period":"June 2025 (preliminary injunction denied June 18, 2025); stipulation of July 14, 2026","claim_ids":["c-sale-states-suits","c-sale-opinion-newco","c-st-states-allocation","c-ch-adversaries"],"kind":"legal","direction":"directed","role_group":"legal","temporal_status":"historical"},"reading":"texas → holdco: State objecting to the genetic-data sale, plaintiff in its own adversary proceeding (No. 25-04036) and signatory governmental claimant allotted $1,266,860 of the 2026 settlement [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-botha-spacex","record":{"id":"r-botha-spacex","from":"botha","to":"spacex","status":"documented","role":"Independent director and audit committee member","period":"From June 16, 2026","claim_ids":["c-ppl-botha-spacex"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"current"},"reading":"botha → spacex: Independent director and audit committee member [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-botha-mongodb","record":{"id":"r-botha-mongodb","from":"botha","to":"mongodb","status":"reported","role":"Director (as listed by an aggregator)","period":"From 2013 (aggregator, listed in 2026)","claim_ids":["c-ppl-botha-spacex"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"botha → mongodb: Director (as listed by an aggregator) [reported]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-botha-block","record":{"id":"r-botha-block","from":"botha","to":"block","status":"reported","role":"Director (as listed by an aggregator)","period":"From 2010 (aggregator, listed in 2026)","claim_ids":["c-ppl-botha-spacex"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"botha → block: Director (as listed by an aggregator) [reported]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-botha-natera","record":{"id":"r-botha-natera","from":"botha","to":"natera","status":"reported","role":"Director (as listed by an aggregator)","period":"From 2006 (aggregator, listed in 2026)","claim_ids":["c-ppl-botha-spacex"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"botha → natera: Director (as listed by an aggregator) [reported]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-botha-unity","record":{"id":"r-botha-unity","from":"botha","to":"unity","status":"reported","role":"Director (as listed by an aggregator)","period":"From May 14, 2024 (aggregator, listed in 2026)","claim_ids":["c-ppl-botha-spacex"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"botha → unity: Director (as listed by an aggregator) [reported]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-fernandez-froedtert","record":{"id":"r-fernandez-froedtert","from":"fernandez","to":"froedtert","status":"reported","role":"Vice Chairman (as listed by an aggregator)","period":"As listed in 2026","claim_ids":["c-ppl-fernandez-roles"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"fernandez → froedtert: Vice Chairman (as listed by an aggregator) [reported]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-frankola-ionq","record":{"id":"r-frankola-ionq","from":"frankola","to":"ionq","status":"documented","role":"Director","period":"From August 2025 (announced August 28; aggregator: August 25, 2025)","claim_ids":["c-ppl-frankola-roles"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"current"},"reading":"frankola → ionq: Director [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-taylor-edison","record":{"id":"r-taylor-edison","from":"taylor","to":"edison-intl","status":"reported","role":"Independent non-executive chairman","period":"From 2022 (aggregator)","claim_ids":["c-ppl-taylor-roles"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"taylor → edison-intl: Independent non-executive chairman [reported]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-taylor-sce","record":{"id":"r-taylor-sce","from":"taylor","to":"sce","status":"reported","role":"Chairman","period":"From 2022 (aggregator)","claim_ids":["c-ppl-taylor-roles"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"taylor → sce: Chairman [reported]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-taylor-pacific","record":{"id":"r-taylor-pacific","from":"taylor","to":"pacific-mutual","status":"reported","role":"Director","period":"From 2016 (aggregator)","claim_ids":["c-ppl-taylor-roles"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"taylor → pacific-mutual: Director [reported]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-taylor-ecmc","record":{"id":"r-taylor-ecmc","from":"taylor","to":"ecmc","status":"reported","role":"President","period":"Former role (aggregator: 2016 – 2023)","claim_ids":["c-ppl-taylor-roles"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"taylor → ecmc: President [reported]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-chung-philo","record":{"id":"r-chung-philo","from":"chung","to":"philo","status":"reported","role":"Director (as listed by an aggregator)","period":"As listed in 2026","claim_ids":["c-ppl-chung-roles"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"chung → philo: Director (as listed by an aggregator) [reported]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-chung-wrld3d","record":{"id":"r-chung-wrld3d","from":"chung","to":"wrld3d","status":"reported","role":"Founder and director (as listed by an aggregator)","period":"Founded 2010","claim_ids":["c-ppl-chung-roles"],"kind":"other","direction":"directed","role_group":"associations","temporal_status":"unknown"},"reading":"chung → wrld3d: Founder and director (as listed by an aggregator) [reported]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-mohan-starbucks","record":{"id":"r-mohan-starbucks","from":"mohan","to":"starbucks","status":"reported","role":"Independent director","period":"From 2024 (aggregator)","claim_ids":["c-ppl-mohan-roles"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"current"},"reading":"mohan → starbucks: Independent director [reported]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-mohan-stitchfix","record":{"id":"r-mohan-stitchfix","from":"mohan","to":"stitch-fix","status":"reported","role":"Independent director","period":"2020 – 2023 (aggregator)","claim_ids":["c-ppl-mohan-roles"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"mohan → stitch-fix: Independent director [reported]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-hibbs-sophia","record":{"id":"r-hibbs-sophia","from":"hibbs","to":"sophia","status":"reported","role":"Director (as listed by an insider-filings aggregator)","period":"As listed in 2026","claim_ids":["c-ppl-hibbs-roles"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"hibbs → sophia: Director (as listed by an insider-filings aggregator) [reported]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-hibbs-genomic","record":{"id":"r-hibbs-genomic","from":"hibbs","to":"genomic-health","status":"reported","role":"Senior vice president and general counsel","period":"Earlier role (aggregator)","claim_ids":["c-ppl-hibbs-roles"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"hibbs → genomic-health: Senior vice president and general counsel [reported]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-hibbs-inc","record":{"id":"r-hibbs-inc","from":"hibbs","to":"inc","status":"reported","role":"General counsel","period":"As listed in a 2019 legal directory profile","claim_ids":["c-gov-hibbs-gc"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"hibbs → inc: General counsel [reported]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-cusenza-nodal","record":{"id":"r-cusenza-nodal","from":"cusenza","to":"nodal-exchange","status":"reported","role":"Chairman and chief executive officer","period":"From 2008 (aggregator)","claim_ids":["c-ppl-cusenza"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"current"},"reading":"cusenza → nodal-exchange: Chairman and chief executive officer [reported]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-cusenza-nodalh","record":{"id":"r-cusenza-nodalh","from":"cusenza","to":"nodal-holdings","status":"reported","role":"Chairman and chief executive officer","period":"As listed in 2026 (aggregator)","claim_ids":["c-ppl-cusenza"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"cusenza → nodal-holdings: Chairman and chief executive officer [reported]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-cusenza-nodalc","record":{"id":"r-cusenza-nodalc","from":"cusenza","to":"nodal-clear","status":"reported","role":"Chairman","period":"From 2014 (aggregator)","claim_ids":["c-ppl-cusenza"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"current"},"reading":"cusenza → nodal-clear: Chairman [reported]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-cusenza-perlegen","record":{"id":"r-cusenza-perlegen","from":"cusenza","to":"perlegen","status":"reported","role":"SVP of marketing and public sector collaborations","period":"2002 – 2010 (aggregator)","claim_ids":["c-ppl-cusenza"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"cusenza → perlegen: SVP of marketing and public sector collaborations [reported]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-avey-humain","record":{"id":"r-avey-humain","from":"avey","to":"humain","status":"reported","role":"Founding general partner","period":"As described in 2026","claim_ids":["c-ppl-avey"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"current"},"reading":"avey → humain: Founding general partner [reported]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-avey-precisely","record":{"id":"r-avey-precisely","from":"avey","to":"precisely","status":"reported","role":"Co-founder","period":"As described in 2026","claim_ids":["c-ppl-avey"],"kind":"other","direction":"directed","role_group":"associations","temporal_status":"unknown"},"reading":"avey → precisely: Co-founder [reported]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-avey-rockhealth","record":{"id":"r-avey-rockhealth","from":"avey","to":"rock-health","status":"reported","role":"Founding independent board director","period":"Former role","claim_ids":["c-ppl-avey"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"avey → rock-health: Founding independent board director [reported]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"relationships","id":"r-holdco-plantrust","record":{"id":"r-holdco-plantrust","from":"holdco","to":"plan-trust","status":"documented","role":"Wind-down debtor whose assets other than the Lemonaid interests vested in the trust; its shares were cancelled and its board dissolved, the Plan Administrator becoming its sole officer and director","period":"From the effective date, December 5, 2025","claim_ids":["c-ch-plan-trust","c-ch-shares-cancelled","c-ch-board-dissolved","c-st-states-claims","c-ch-docket-oct-2026"],"kind":"legal","direction":"directed","role_group":"business","temporal_status":"current"},"reading":"holdco → plan-trust: Wind-down debtor whose assets other than the Lemonaid interests vested in the trust; its shares were cancelled and its board dissolved, the Plan Administrator becoming its sole officer and director [documented]"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2006-founding","record":{"id":"e-2006-founding","date":"2006","title":"Anne Wojcicki, Linda Avey and Paul Cusenza found 23andMe, Inc.","claim_ids":["c-gov-founding"]},"reading":"2006 Anne Wojcicki, Linda Avey and Paul Cusenza found 23andMe, Inc."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2020-vgac","record":{"id":"e-2020-vgac","date":"2020-02-19","title":"VG Acquisition Corp. is incorporated in the Cayman Islands as a blank check company","claim_ids":["c-spac-blank-check"]},"reading":"2020-02-19 VG Acquisition Corp. is incorporated in the Cayman Islands as a blank check company"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2020-ipo","record":{"id":"e-2020-ipo","date":"2020-10-06","title":"VGAC completes its initial public offering","claim_ids":["c-spac-blank-check"]},"reading":"2020-10-06 VGAC completes its initial public offering"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2021-announce","record":{"id":"e-2021-announce","date":"2021-02-04","title":"VGAC and 23andMe announce their merger agreement","claim_ids":["c-spac-announcement"]},"reading":"2021-02-04 VGAC and 23andMe announce their merger agreement"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2021-vote","record":{"id":"e-2021-vote","date":"2021-06-10","title":"VGAC shareholders approve the business combination and ten-vote Class B stock","claim_ids":["c-spac-vote","c-spac-board-elect"]},"reading":"2021-06-10 VGAC shareholders approve the business combination and ten-vote Class B stock"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2021-closing","record":{"id":"e-2021-closing","date":"2021-06-16","title":"VGAC becomes 23andMe Holding Co. and acquires 23andMe, Inc.","claim_ids":["c-spac-closing","c-ctl-2021"]},"reading":"2021-06-16 VGAC becomes 23andMe Holding Co. and acquires 23andMe, Inc."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2021-lemonaid","record":{"id":"e-2021-lemonaid","date":"2021-11","title":"23andMe acquires Lemonaid Health for $400 million","claim_ids":["c-lem-acquisition"]},"reading":"2021-11 23andMe acquires Lemonaid Health for $400 million"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2023-attack","record":{"id":"e-2023-attack","date":"2023-04-29","title":"The credential-stuffing attack begins, according to the Canadian and UK regulators","claim_ids":["c-br-regulator-scope"]},"reading":"2023-04-29 The credential-stuffing attack begins, according to the Canadian and UK regulators"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2023-pixel","record":{"id":"e-2023-pixel","date":"2023-06-30","title":"Tracking-pixel class action filed against Lemonaid Health","claim_ids":["c-lem-pixel-suit"]},"reading":"2023-06-30 Tracking-pixel class action filed against Lemonaid Health"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2023-uk-disposal","record":{"id":"e-2023-uk-disposal","date":"2023-08-01","title":"The UK subsidiary Lemonaid Health Limited passes to Boots UK","claim_ids":["c-lem-uk-disposal"]},"reading":"2023-08-01 The UK subsidiary Lemonaid Health Limited passes to Boots UK"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2023-disclosure","record":{"id":"e-2023-disclosure","date":"2023-10","title":"The company discloses the data breach","claim_ids":["c-br-company-account","c-st-litigation-scale"]},"reading":"2023-10 The company discloses the data breach"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2024-committee","record":{"id":"e-2024-committee","date":"2024-03","title":"The board forms a Special Committee to review Wojcicki's proposals","claim_ids":["c-gov-special-committee"]},"reading":"2024-03 The board forms a Special Committee to review Wojcicki's proposals"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2024-mdl","record":{"id":"e-2024-mdl","date":"2024-04-11","title":"Federal breach class actions centralised as MDL No. 3098","claim_ids":["c-st-mdl"]},"reading":"2024-04-11 Federal breach class actions centralised as MDL No. 3098"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2024-proxy","record":{"id":"e-2024-proxy","date":"2024-07-01","title":"Wojcicki holds 49.75% of the vote, according to the 2024 proxy","claim_ids":["c-ctl-2024-wojcicki"]},"reading":"2024-07-01 Wojcicki holds 49.75% of the vote, according to the 2024 proxy"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2024-proposal","record":{"id":"e-2024-proposal","date":"2024-07-29","title":"Wojcicki proposes to take the company private at $0.40 a share","claim_ids":["c-gov-go-private-2024"]},"reading":"2024-07-29 Wojcicki proposes to take the company private at $0.40 a share"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2024-resignations","record":{"id":"e-2024-resignations","date":"2024-09-17","title":"All seven independent directors resign","claim_ids":["c-gov-resignations"]},"reading":"2024-09-17 All seven independent directors resign"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2024-new-board","record":{"id":"e-2024-new-board","date":"2024-10-28","title":"Three new independent directors join the board","claim_ids":["c-gov-new-board"]},"reading":"2024-10-28 Three new independent directors join the board"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2024-cutbacks","record":{"id":"e-2024-cutbacks","date":"2024-11","title":"Therapeutics programmes end and about 40% of staff are cut","claim_ids":["c-ch-cutbacks"]},"reading":"2024-11 Therapeutics programmes end and about 40% of staff are cut"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2025-strategic","record":{"id":"e-2025-strategic","date":"2025-01-28","title":"The Special Committee announces a review of strategic alternatives","claim_ids":["c-gov-strategic-review"]},"reading":"2025-01-28 The Special Committee announces a review of strategic alternatives"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2025-nm-bid","record":{"id":"e-2025-nm-bid","date":"2025-02-20","title":"Wojcicki and New Mountain Capital propose $2.53 a share","claim_ids":["c-gov-feb-march-2025"]},"reading":"2025-02-20 Wojcicki and New Mountain Capital propose $2.53 a share"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2025-ch11","record":{"id":"e-2025-ch11","date":"2025-03-23","title":"Chapter 11 filing; Wojcicki steps down as chief executive","claim_ids":["c-ch-filing","c-gov-ceo-resignation"]},"reading":"2025-03-23 Chapter 11 filing; Wojcicki steps down as chief executive"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2025-dip","record":{"id":"e-2025-dip","date":"2025-03-26","title":"Court authorises the JMB debtor-in-possession loan","claim_ids":["c-ch-dip"]},"reading":"2025-03-26 Court authorises the JMB debtor-in-possession loan"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2025-delisting","record":{"id":"e-2025-delisting","date":"2025-03-31","title":"Nasdaq delisting takes effect","claim_ids":["c-id-delisting"]},"reading":"2025-03-31 Nasdaq delisting takes effect"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2025-ftc","record":{"id":"e-2025-ftc","date":"2025-03-31","title":"FTC Chairman's letter on the sale of customer data","claim_ids":["c-sale-ftc-letter"]},"reading":"2025-03-31 FTC Chairman's letter on the sale of customer data"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2025-auction","record":{"id":"e-2025-auction","date":"2025-05-19","title":"Regeneron named successful bidder, TTAM backup","claim_ids":["c-sale-regeneron"]},"reading":"2025-05-19 Regeneron named successful bidder, TTAM backup"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2025-ico","record":{"id":"e-2025-ico","date":"2025-06-05","title":"UK Information Commissioner fines 23andMe, Inc. £2,310,000","claim_ids":["c-br-ico-penalty"]},"reading":"2025-06-05 UK Information Commissioner fines 23andMe, Inc. £2,310,000"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2025-states-suits","record":{"id":"e-2025-states-suits","date":"2025-06-09","title":"Twenty-eight states and D.C., and Texas, sue over the sale of genetic data","claim_ids":["c-sale-states-suits"]},"reading":"2025-06-09 Twenty-eight states and D.C., and Texas, sue over the sale of genetic data"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2025-conversion","record":{"id":"e-2025-conversion","date":"2025-06-11","title":"ABeeC 2.0 converts its Class B shares into Class A","claim_ids":["c-ctl-conversion"]},"reading":"2025-06-11 ABeeC 2.0 converts its Class B shares into Class A"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2025-ttam-wins","record":{"id":"e-2025-ttam-wins","date":"2025-06-13","title":"TTAM chosen as winning bidder at $305 million","claim_ids":["c-sale-ttam-wins"]},"reading":"2025-06-13 TTAM chosen as winning bidder at $305 million"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2025-sale-order","record":{"id":"e-2025-sale-order","date":"2025-06-27","title":"Court approves the sale to TTAM","claim_ids":["c-sale-opinion","c-sale-closing"]},"reading":"2025-06-27 Court approves the sale to TTAM"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2025-sale-closing","record":{"id":"e-2025-sale-closing","date":"2025-07-14","title":"Sale to TTAM closes for $302.5 million; DIP loan repaid","claim_ids":["c-sale-closing","c-ch-dip"]},"reading":"2025-07-14 Sale to TTAM closes for $302.5 million; DIP loan repaid"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2025-rename","record":{"id":"e-2025-rename","date":"2025-08-14","title":"23andMe Holding Co. renamed Chrome Holding Co.","claim_ids":["c-id-rename"]},"reading":"2025-08-14 23andMe Holding Co. renamed Chrome Holding Co."}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2025-plan","record":{"id":"e-2025-plan","date":"2025-08-15","title":"Debtors file their joint plan","claim_ids":["c-ch-plan-august"]},"reading":"2025-08-15 Debtors file their joint plan"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2025-lemonaid-spa","record":{"id":"e-2025-lemonaid-spa","date":"2025-09-10","title":"Agreement to sell Lemonaid to Lemonaid SPV, Inc. for $10 million","claim_ids":["c-lem-spv-agreement"]},"reading":"2025-09-10 Agreement to sell Lemonaid to Lemonaid SPV, Inc. for $10 million"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2025-arbitration","record":{"id":"e-2025-arbitration","date":"2025-11-19","title":"Court approves the arbitration settlement covering about 32,000 claims","claim_ids":["c-st-arbitration"]},"reading":"2025-11-19 Court approves the arbitration settlement covering about 32,000 claims"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2025-confirmation","record":{"id":"e-2025-confirmation","date":"2025-12-01","title":"Court confirms the liquidating plan","claim_ids":["c-ch-confirmation"]},"reading":"2025-12-01 Court confirms the liquidating plan"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2025-15-12g","record":{"id":"e-2025-15-12g","date":"2025-12-04","title":"Form 15-12G terminating the registration of the securities","claim_ids":["c-id-15-12g"]},"reading":"2025-12-04 Form 15-12G terminating the registration of the securities"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2025-effective","record":{"id":"e-2025-effective","date":"2025-12-05","title":"Plan effective: shares cancelled, Plan Administration Trust formed","claim_ids":["c-ch-confirmation","c-ch-plan-trust"]},"reading":"2025-12-05 Plan effective: shares cancelled, Plan Administration Trust formed"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2025-lemonaid-close","record":{"id":"e-2025-lemonaid-close","date":"2025-12-05","title":"Lemonaid sale reported closed","claim_ids":["c-lem-closing"]},"reading":"2025-12-05 Lemonaid sale reported closed"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2026-wojcicki-application","record":{"id":"e-2026-wojcicki-application","date":"2026-01-03","title":"Wojcicki applies for payment of her indemnification expenses","claim_ids":["c-ch-wojcicki-application"]},"reading":"2026-01-03 Wojcicki applies for payment of her indemnification expenses"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2026-case-closing","record":{"id":"e-2026-case-closing","date":"2026-01-21","title":"All cases closed except Chrome Holding Co.'s","claim_ids":["c-ch-case-closing"]},"reading":"2026-01-21 All cases closed except Chrome Holding Co.'s"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2026-us-final","record":{"id":"e-2026-us-final","date":"2026-01-30","title":"Final approval of the U.S. breach class settlement","claim_ids":["c-st-us-final"]},"reading":"2026-01-30 Final approval of the U.S. breach class settlement"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2026-ca-suit","record":{"id":"e-2026-ca-suit","date":"2026-05-27","title":"California's Attorney General sues over the breach","claim_ids":["c-st-ca-suit","c-br-ca-allegations"]},"reading":"2026-05-27 California's Attorney General sues over the breach"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2026-ca-order","record":{"id":"e-2026-ca-order","date":"2026-07-10","title":"Bankruptcy court bars the monetary claims of California's suit","claim_ids":["c-st-ca-enforcement-order"]},"reading":"2026-07-10 Bankruptcy court bars the monetary claims of California's suit"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2026-states","record":{"id":"e-2026-states","date":"2026-07-14","title":"Stipulation with 41 states and D.C.: $18 million and conduct limits","claim_ids":["c-st-states-claims"]},"reading":"2026-07-14 Stipulation with 41 states and D.C.: $18 million and conduct limits"}
{"case_id":"case-23andme-holding-co","version":"1.0","as_of":"2026-10-17","record_type":"events","id":"e-2026-appeal-dismissed","record":{"id":"e-2026-appeal-dismissed","date":"2026-09-29","title":"District court dismisses the appeal against the sale order","claim_ids":["c-sale-district-court"]},"reading":"2026-09-29 District court dismisses the appeal against the sale order"}